NCBI Home Page NCBI Site Search page NCBI Guide that lists and describes the NCBI resources
Conserved domains on  [gi|514698100|ref|XP_004996619|]
View 

uncharacterized protein PTSG_11840 [Salpingoeca rosetta]

Protein Classification

Graphical summary

 Zoom to residue level

show extra options »

Show site features     Horizontal zoom: ×

List of domain hits

Name Accession Description Interval E-value
FhaB COG3210
Large exoprotein involved in heme utilization or adhesion [Intracellular trafficking, ...
211-1927 1.62e-17

Large exoprotein involved in heme utilization or adhesion [Intracellular trafficking, secretion, and vesicular transport];


:

Pssm-ID: 442443 [Multi-domain]  Cd Length: 1698  Bit Score: 92.14  E-value: 1.62e-17
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  211 GGATGVASVTVAGVAATLRSPILDYFAVVELGSAPAGTSGAVVVVAESGARVVSSQTFTYAEPATIAAVSPSSGQVGTRV 290
Cdd:COG3210     3 GGLAGTTGNKTIGVDIAVTTTAATLGSNTAGTSGLNILGSGGVGTAGGIASNAGTTASTSGGSGTAGGVGNTSASTGGIG 82
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  291 TITGTNLLGGGAAVERVTLAGVEASLVAQSATQIVVVASPSRERAAGPVVVYSDTGAFARLESAFAYQIPGRISTLSPSS 370
Cdd:COG3210    83 AAAANTAGTLETGLTSNIGGGSVNGSNSTGNGTLTTTAASATTGNNTGGTTTSSTNTVTTLGGTTTGNTVLSTSGAGNNT 162
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  371 GQAGTVVELTGFNLLGGGSALSSLSVHGVEVEQVTFASDALIAFVVPLTSVQGLGDVRIVSASGATVEAGDAFTLLEPGR 450
Cdd:COG3210   163 NTNNSSSGTNIGNSIPTTGGSLNVVAANPTGVTGVGGALINATAGVLANAGGGTAGGVASANSTLTGGVVAAGTGAGVIS 242
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  451 IVGVAPERGQEGTFVTIVGERLLGGGETIARAVLGATAAEAVVSSSDARVVVRAGAAVTFGPVGVTLWADTGAVVNTSAG 530
Cdd:COG3210   243 TGGTDISSLSVAAGAGTGGAGGTGNAGNTTIGTTVTGTNATGSNTAGASSGDTTTNGTSSVTGAGGTGVLGGGTAAGITT 322
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  531 LFEYLAPGMVASVLPVSGQAGTQVVIEGMELLGHETALEAVTLGGVQAAAILSFNRTHVVVTAGDGPASTGPVVLTASNG 610
Cdd:COG3210   323 TNTVGGNGDGNNTTANSGAGLVSGGTGGNNGTTGTGAGSGLTGTGNGGGLTTAGAGTVASTVGTATASTGNASSTTVLGS 402
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  611 SRVTGGAVWTQLERGAIGSVQPSSGHGGTRVTITGQRLLGGGAALASVELGGVLATEIAWANDTVAVVSAGASGSALAGG 690
Cdd:COG3210   403 GSLATGNTGTTIAGNGGSANAGGFTTTGGVLGITGNGTVTGGTIGGLTGSGTTNGAGLSGNTDVSGTGTVTNSAGNTTSA 482
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  691 NVTLVADTGAVTTGSGLWAYVAPAVISSVAPTSGQAGTVVTIRGNNLSMGGAVREVFLAGIPAVSVSLVNDSFVVAHASG 770
Cdd:COG3210   483 TTLAGGGIGTVTTNATISNNAGGDANGIATGLTGITAGGGGGGNATSGGTGGDGTTLSGSGLTTTVSGGASGTTAASGSN 562
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  771 ALSGRSSPAVVRNNFGAFVSSSVNWTYVPAGAVDITRPARAQFGTRVTVTGSNLLQGGAIIASASMAGVPCTVLSSNDTT 850
Cdd:COG3210   563 TANTLGVLAATGGTSNATTAGNSTSATGGTGTNSGGTVLSIGTGSAGATGTITLGAGTSGAGANATGGGAGLTGSAVGAA 642
                         650       660       670       680       690       700       710       720
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  851 VVVSVAGNFAATVASPSMTLVSDSGAVITFTSSTTAEPSGVVTAISPS-SGQYGTFVTLSGTQLLAHASNLRTVSLAGTq 929
Cdd:COG3210   643 LSGTGSGTTGTASANGSNTTGVNTAGGTGGGTTGTVTSGATGGTTGTTlNAATGGTLNNAGNTLTISTGSITVTGQIGA- 721
                         730       740       750       760       770       780       790       800
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  930 vlsIESATESEVIVRAGLGVNGTAGSPRLRASSGGVVAAATGVNFTYVRQGRIDTVSPLFG--QLGTLVTISGEHLLSGG 1007
Cdd:COG3210   722 ---LANANGDTVTFGNLGTGATLTLNAGVTITSGNAGTLSIGLTANTTASGTTLTLANANGntSAGATLDNAGAEISIDI 798
                         810       820       830       840       850       860       870       880
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1008 SSASRVLLAGlpaavvssnssvvvaraPLSNSTSIRTGSVVVLANTGALSAESSTTFTFRPAGFIASVSPSFGQRGTYVE 1087
Cdd:COG3210   799 TADGTITAAG-----------------TTAINVTGSGGTITINTATTGLTGTGDTTSGAGGSNTTDTTTGTTSDGASGGG 861
                         890       900       910       920       930       940       950       960
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1088 IAGNRLLDGSGLREVLLADVPAEVLSANDTFALVRAQASLPRVGDVVVRSDSGYEVVSSQAFVYIAPQHPDTVVPASGQF 1167
Cdd:COG3210   862 TAGANSGSLAATAASITVGSGGVATSTGTANAGTLTNLGTTTNAASGNGAVLATVTATGTGGGGLTGGNAAAGGTGAGNG 941
                         970       980       990      1000      1010      1020      1030      1040
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1168 GTRVTINGTGLLGGGATVQTVQFDAVAGSDPRVTAAGIEVSAPGGAAGVRNITVVANTGAYFTVARAFTVIAEPNVTAIT 1247
Cdd:COG3210   942 TTALSGTQGNAGLSAASASDGAGDTGASSAAGSSAVGTSANSAGSTGGVIAATGILVAGNSGTTASTTGGSGAIVAGGNG 1021
                        1050      1060      1070      1080      1090      1100      1110      1120
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1248 PSSGQAGAYVTVSGTELLGGGAFAERVFLAGVEADVVTSSPSSVVVRAPVSVAKVGPTVIVADTGATTTSLLNFTFTPQL 1327
Cdd:COG3210  1022 VTGTTGTASATGTGTAATAGGQNGVGVNASGISGGNAAALTASGTAGTTGGTAASNGGGGTAQASGAGTTHTLGGITNGG 1101
                        1130      1140      1150      1160      1170      1180      1190      1200
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1328 SVTSVSPSSGQGGTRVTVLGANLRLGSSAVTGVLLGSAACSLISENDTAVVCAAGVASAGSVPVTVEASSGAFASVGGVL 1407
Cdd:COG3210  1102 ATGTSGGTTTSTGGVTASKVGGTTTVGATGTSTASTEAAGAGTLTGLVAVSAVAGGASSASAGDTTAVAAATTTTTGSAI 1181
                        1210      1220      1230      1240      1250      1260      1270      1280
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1408 AfeyldAGVINSVEPGSGQQGTRVVVSGLRLLGGGIRVDQAFLGGVEATIRSSSAFAVTLAAGNGSEPSSGDIVLIADTG 1487
Cdd:COG3210  1182 N-----GGADSAATEGTAGTDLKGGDSTGGSTTTIGTTNVTTTTTLTASDTGNTTATGGSSAGQTGSFVAAGSASGTGDA 1256
                        1290      1300      1310      1320      1330      1340      1350      1360
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1488 AVVSRSGMWTYTEPCGVTDVSPPSGQAGTLVTITGTGFPCTGSSVSTVSLGGVGASIRTQSATQIVVEAPSGSGQGDVVV 1567
Cdd:COG3210  1257 TTGATAGAVSNGATSTVAGNAGATATGSTVDIGSTSATSAGGSLDTTGNTAGANGATVGTGIGGTTATGTAVAAVNSGGV 1336
                        1370      1380      1390      1400      1410      1420      1430      1440
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1568 TADDGSFAVSRGGWEFSRISSVTPASGQFGTAVTVAGQGLRLGFSSVTQVRLGDVAATILSENNTHVVVRAGTGSLVGVP 1647
Cdd:COG3210  1337 NAGGGTINTTAANTGLNGGNGATDSAAGAGSGGAAGSLAATAGAGTVLTGAGNNTGAEGTNAGRDGGVTTSGTGVGNNGG 1416
                        1450      1460      1470      1480      1490      1500      1510      1520
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1648 VDVQVISSGATTVQQSVAWTYLRDGVVSSVVPVQGQRGTRVTVRGERLLGGGSRLERVLLGDIAVDRILSYNDTVVVVEA 1727
Cdd:COG3210  1417 VSGTTVAGTTGSSATTGTGGTGNTTGTSVAGAGGGNADASAINTGNASSLGAGGSTAGNAVGGAVIGGTTTGGNGAGVAG 1496
                        1530      1540      1550      1560      1570      1580      1590      1600
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1728 GLSNSSAVVDVTLVSDTLAGVTGENVFTYVEPMTLYGLTRATGQAGTETTLLGRSLLGGSLAVTEVLLAGTGAQVIGFND 1807
Cdd:COG3210  1497 ATASNGGTSTGAGGTAGGTTAEVAKASLEGGEGTYGGSSVAEAGTGGGILGAVSGAGSEGGAAGGVTGSVGVGGTDGAGG 1576
                        1610      1620      1630      1640      1650      1660      1670      1680
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1808 THVTVrALAGTPGQGNVVIRTSNGAYLVAINGWSFSTPGAIAAVEPVSGQAGTRVTIVGSRLLGGGSRVASVALGSVVHT 1887
Cdd:COG3210  1577 DTGGA-DDTGAQAPTAGNTATLTLSLAEGTNAEYGGTTNVTSGTAGNAGATGANSNTVVTTNGGEGVLALVAGGNTTNGT 1655
                        1690      1700      1710      1720
                  ....*....|....*....|....*....|....*....|
gi 514698100 1888 SSVISGNDTQVVLDALAGPPGLSDVIITSDTRATVTAENV 1927
Cdd:COG3210  1656 TLSGAVNGAGNGWAVDLTDATLAGLGGATTAAAGNVATGD 1695
TNFRSF super family cl22855
Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) ...
5597-5762 5.72e-17

Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) interactions with TNF superfamily (TNFSF) ligands (TNFL) control key cellular processes such as differentiation, proliferation, apoptosis, and cell growth. Dysregulation of these pathways has been shown to result in a wide range of pathological conditions, including autoimmune diseases, inflammation, cancer, and viral infection. There are 29 very diverse family members of TNFRSF reported in humans: 22 are type I transmembrane receptors (single pass with the N terminus on extracellular side of the cell membrane) and have a clear signal peptide; the remaining 7 members are either type III transmembrane receptors (single pass with the N terminus on extracellular side of the membrane but no signal sequence; TNFR13B, TNFR13C, TNFR17, and XEDAR), or attached to the membrane via a glycosylphosphatidylinositol (GPI) linker (TNFR10C), or secreted as soluble receptors (TNFR11B and TNFR6B). All TNFRs contain relatively short cysteine-rich domains (CRDs) in the ectodomain, and are involved in interaction with the TNF homology domain (THD) of their ligands. TNFRs often have multiple CRDs (between one and six), with the most frequent configurations of three or four copies; most CRDs possess three disulfide bridges, but could have between one and four. Localized or genome-wide duplication and evolution of the TNFRSF members appear to have paralleled the emergence of the adaptive immune system; teleosts (i.e. ray-finned, bony fish), which possess an immune system with B and T cells, possess primary and secondary lymphoid organs, and are capable of adaptive responses to pathogens also display several characteristics that are different from the mammalian immune system, making teleost TNFSF orthologs and paralogs of interest to better understand immune system evolution and the immunological pathways elicited to pathogens.


The actual alignment was detected with superfamily member cd10577:

Pssm-ID: 473981 [Multi-domain]  Cd Length: 163  Bit Score: 82.14  E-value: 5.72e-17
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5597 CDGTTTYQPSKGQeRCLSvkTCGAGEEETTSPSATRNRVCQPCQlGSTFKAQSGQSTRCISVTT-CGAGEEEIASPTLST 5675
Cdd:cd10577     1 CRNSKEYYDEKAQ-MCCS--KCPPGQHVKHSCTKTSDTVCAPCE-ESTYTQLWNWVPECLSCSSpCSSDQVETQACTRQQ 76
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5676 DRQCrTCASGTFKAAAGQSTT--CIAVSTCAAGFTEDVAPTPSSDRVCVECAPGTFKATAG-DGTCRAHRTCEDTeyeTV 5752
Cdd:cd10577    77 NRIC-SCKPGWYCVLKLQEGCrqCRPLKKCGPGFGVARPGTASSDVECKPCAPGTFSDTTSsTDTCRPHRICSSV---AI 152
                         170
                  ....*....|
gi 514698100 5753 APTSSSDRKC 5762
Cdd:cd10577   153 PGNASMDAVC 162
FhaB COG3210
Large exoprotein involved in heme utilization or adhesion [Intracellular trafficking, ...
2048-3743 1.07e-16

Large exoprotein involved in heme utilization or adhesion [Intracellular trafficking, secretion, and vesicular transport];


:

Pssm-ID: 442443 [Multi-domain]  Cd Length: 1698  Bit Score: 89.44  E-value: 1.07e-16
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2048 GGADRVVSATLAGAPGSARVVRENDTVVLVQVLVAMPVAFADLRLTASSGATVTFPSAFTALLPGTIASVLPLQGQAGTR 2127
Cdd:COG3210     2 SGGLAGTTGNKTIGVDIAVTTTAATLGSNTAGTSGLNILGSGGVGTAGGIASNAGTTASTSGGSGTAGGVGNTSASTGGI 81
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2128 VTVTGARLRGGSAAVTRATIAGVEATVVVESNDVVVLRATAAMAHPLQGPVVVVGEAGSLVSNAMINFTYLEQGVVTAAT 2207
Cdd:COG3210    82 GAAAANTAGTLETGLTSNIGGGSVNGSNSTGNGTLTTTAASATTGNNTGGTTTSSTNTVTTLGGTTTGNTVLSTSGAGNN 161
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2208 PAYGQRHTRVTVTGTNILGGGSRIVNASFGGVSALDVLASNNSMAVVIAPRLLPGQHSIQLVADSGAVVSSSNLFTARLE 2287
Cdd:COG3210   162 TNTNNSSSGTNIGNSIPTTGGSLNVVAANPTGVTGVGGALINATAGVLANAGGGTAGGVASANSTLTGGVVAAGTGAGVI 241
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2288 GNITSLMPGSGQRGTRITVNGNRLRGSGNEVVSAWVGNVPATVVSEGNSQVVIRPTSSGAAGTSVRIVLVADTGARVETA 2367
Cdd:COG3210   242 STGGTDISSLSVAAGAGTGGAGGTGNAGNTTIGTTVTGTNATGSNTAGASSGDTTTNGTSSVTGAGGTGVLGGGTAAGIT 321
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2368 TVQFDFVPPGDIQAVGPASGQEGTLVTIRGERLLGNGTALAYTYIGGVAAQIVSASNDEVVVVAGRSSNRFTLDqhpVIS 2447
Cdd:COG3210   322 TTNTVGGNGDGNNTTANSGAGLVSGGTGGNNGTTGTGAGSGLTGTGNGGGLTTAGAGTVASTVGTATASTGNAS---STT 398
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2448 DIVLVADNGAEVVAASSFTYLRPGVISSVFPLSGQAGTRVGISGVRLFGGGSRIVSVYLGATQAQVITQTVHAVVVTAKA 2527
Cdd:COG3210   399 VLGSGSLATGNTGTTIAGNGGSANAGGFTTTGGVLGITGNGTVTGGTIGGLTGSGTTNGAGLSGNTDVSGTGTVTNSAGN 478
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2528 GNVSASPEPIRIVADTGAVVTLNDTWSYVQAGRVASVNPASGHQGTLVTIQGTSLLGGGTTAVSVMLAGSSALVLSSNAT 2607
Cdd:COG3210   479 TTSATTLAGGGIGTVTTNATISNNAGGDANGIATGLTGITAGGGGGGNATSGGTGGDGTTLSGSGLTTTVSGGASGTTAA 558
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2608 DVVVTAGPGAQSSGDVVIVSETGATVARGAAWTYVEPGFIQRASPASGTAGTRVTITGASLLGGASTLARVTLAGVPVDS 2687
Cdd:COG3210   559 SGSNTANTLGVLAATGGTSNATTAGNSTSATGGTGTNSGGTVLSIGTGSAGATGTITLGAGTSGAGANATGGGAGLTGSA 638
                         650       660       670       680       690       700       710       720
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2688 IDHQSNEVVIVTAASGAQRMGAIVLTADTGAVVQRLNFWDYIATPVVGEIEPSSGQLGTVVTIRGSNLLAGGEALQLVTL 2767
Cdd:COG3210   639 VGAALSGTGSGTTGTASANGSNTTGVNTAGGTGGGTTGTVTSGATGGTTGTTLNAATGGTLNNAGNTLTISTGSITVTGQ 718
                         730       740       750       760       770       780       790       800
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2768 AGvpaeAILSSNNSVVTVSSAQGSGATGPAVLVAAETGGRAVGTPSVNYTYLAGSSIASVQPASG--QGGTFVDIVGERL 2845
Cdd:COG3210   719 IG----ALANANGDTVTFGNLGTGATLTLNAGVTITSGNAGTLSIGLTANTTASGTTLTLANANGntSAGATLDNAGAEI 794
                         810       820       830       840       850       860       870       880
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2846 LSGGSAVAAVSLAGVAAEVISGND---TFVRARAGPSAVTLTGDVVVTADTGGRAELVNAWAYNTAGVVDAVVPGSGQRG 2922
Cdd:COG3210   795 SIDITADGTITAAGTTAINVTGSGgtiTINTATTGLTGTGDTTSGAGGSNTTDTTTGTTSDGASGGGTAGANSGSLAATA 874
                         890       900       910       920       930       940       950       960
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2923 TRVTIQGTRLLGEGTRAVRVSLGDVRAHIVESTATAVVVVYPGRVT--LGVHDVEVESDTGSVVSAPAAWTALDNGVVHS 3000
Cdd:COG3210   875 ASITVGSGGVATSTGTANAGTLTNLGTTTNAASGNGAVLATVTATGtgGGGLTGGNAAAGGTGAGNGTTALSGTQGNAGL 954
                         970       980       990      1000      1010      1020      1030      1040
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3001 VNPDVGHGGTVVTIRGVRLLGGGDSVADVALAGVVTANVVSANNSVVVVVAELQAQAVTLGDVVVRADTNATVVSSTGLF 3080
Cdd:COG3210   955 SAASASDGAGDTGASSAAGSSAVGTSANSAGSTGGVIAATGILVAGNSGTTASTTGGSGAIVAGGNGVTGTTGTASATGT 1034
                        1050      1060      1070      1080      1090      1100      1110      1120
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3081 DYVAPGEIVSVSPSSGQLGTVVTIEGRSLRGGSSAVVDVVLGGVSALDVVSENDTRVVAVAGPSSGATGTESVQVVGQQG 3160
Cdd:COG3210  1035 GTAATAGGQNGVGVNASGISGGNAAALTASGTAGTTGGTAASNGGGGTAQASGAGTTHTLGGITNGGATGTSGGTTTSTG 1114
                        1130      1140      1150      1160      1170      1180      1190      1200
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3161 SVVARPSVWSYVAPAEVLDVAPQQGRAGTRVTVRGQGLLQGGGRIAQATVAGVTTARIVDSNDTTVVLEAEVAPAGVTPV 3240
Cdd:COG3210  1115 GVTASKVGGTTTVGATGTSTASTEAAGAGTLTGLVAVSAVAGGASSASAGDTTAVAAATTTTTGSAINGGADSAATEGTA 1194
                        1210      1220      1230      1240      1250      1260      1270      1280
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3241 GDVQLVSDTGARVNASVTWQYLAAAVIDSVQPTSGQEGVFVELRGQHLLGGGSAIVDASLAGVAVERVVQSNDTFVRVVA 3320
Cdd:COG3210  1195 GTDLKGGDSTGGSTTTIGTTNVTTTTTLTASDTGNTTATGGSSAGQTGSFVAAGSASGTGDATTGATAGAVSNGATSTVA 1274
                        1290      1300      1310      1320      1330      1340      1350      1360
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3321 GAKNASVVGDVVARGDTGALLRVVNGWQYAVPSVINSVVPASGQEGTLVTVSGVRLLGSLPGRITFVEVCGTEAEVVSES 3400
Cdd:COG3210  1275 GNAGATATGSTVDIGSTSATSAGGSLDTTGNTAGANGATVGTGIGGTTATGTAVAAVNSGGVNAGGGTINTTAANTGLNG 1354
                        1370      1380      1390      1400      1410      1420      1430      1440
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3401 DTLVVARLRSNGGASQLGDVVVRADNGARTRAVNGFTYLSTSMIAAVTPAEGQYGTRVTITGQRLLGGGAAVQAVELAGV 3480
Cdd:COG3210  1355 GNGATDSAAGAGSGGAAGSLAATAGAGTVLTGAGNNTGAEGTNAGRDGGVTTSGTGVGNNGGVSGTTVAGTTGSSATTGT 1434
                        1450      1460      1470      1480      1490      1500      1510      1520
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3481 AATVVSGSDTEVVVAAGNGTAGDVGDVVITSDSGAVSVDALAWRYLDASHITSVTPRHGQKGTVVTINGTLLRGHGSGVA 3560
Cdd:COG3210  1435 GGTGNTTGTSVAGAGGGNADASAINTGNASSLGAGGSTAGNAVGGAVIGGTTTGGNGAGVAGATASNGGTSTGAGGTAGG 1514
                        1530      1540      1550      1560      1570      1580      1590      1600
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3561 VVLLAGEAANVLSESDTSVVVAASAFGGSKSGPVTIIASNGATAVSTPTAFEYRAPGAVSAIVPNSGHRGTYVTIKGSNL 3640
Cdd:COG3210  1515 TTAEVAKASLEGGEGTYGGSSVAEAGTGGGILGAVSGAGSEGGAAGGVTGSVGVGGTDGAGGDTGGADDTGAQAPTAGNT 1594
                        1610      1620      1630      1640      1650      1660      1670      1680
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3641 RGHGPTVMSVTLGGVAGHIVSENSSSVVVRVERLSVAVATPVDVVLTSRSGAQVAAAGAFTYLVEGSVADLLPAQGQRGT 3720
Cdd:COG3210  1595 ATLTLSLAEGTNAEYGGTTNVTSGTAGNAGATGANSNTVVTTNGGEGVLALVAGGNTTNGTTLSGAVNGAGNGWAVDLTD 1674
                        1690      1700
                  ....*....|....*....|...
gi 514698100 3721 AVSLSGSNLCGGGTAIVAVTLGG 3743
Cdd:COG3210  1675 ATLAGLGGATTAAAGNVATGDTA 1697
TNFRSF super family cl22855
Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) ...
5804-5948 3.12e-14

Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) interactions with TNF superfamily (TNFSF) ligands (TNFL) control key cellular processes such as differentiation, proliferation, apoptosis, and cell growth. Dysregulation of these pathways has been shown to result in a wide range of pathological conditions, including autoimmune diseases, inflammation, cancer, and viral infection. There are 29 very diverse family members of TNFRSF reported in humans: 22 are type I transmembrane receptors (single pass with the N terminus on extracellular side of the cell membrane) and have a clear signal peptide; the remaining 7 members are either type III transmembrane receptors (single pass with the N terminus on extracellular side of the membrane but no signal sequence; TNFR13B, TNFR13C, TNFR17, and XEDAR), or attached to the membrane via a glycosylphosphatidylinositol (GPI) linker (TNFR10C), or secreted as soluble receptors (TNFR11B and TNFR6B). All TNFRs contain relatively short cysteine-rich domains (CRDs) in the ectodomain, and are involved in interaction with the TNF homology domain (THD) of their ligands. TNFRs often have multiple CRDs (between one and six), with the most frequent configurations of three or four copies; most CRDs possess three disulfide bridges, but could have between one and four. Localized or genome-wide duplication and evolution of the TNFRSF members appear to have paralleled the emergence of the adaptive immune system; teleosts (i.e. ray-finned, bony fish), which possess an immune system with B and T cells, possess primary and secondary lymphoid organs, and are capable of adaptive responses to pathogens also display several characteristics that are different from the mammalian immune system, making teleost TNFSF orthologs and paralogs of interest to better understand immune system evolution and the immunological pathways elicited to pathogens.


The actual alignment was detected with superfamily member cd10577:

Pssm-ID: 473981 [Multi-domain]  Cd Length: 163  Bit Score: 74.05  E-value: 3.12e-14
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5804 DTSPTKCvgCDECASDEYTLSSCTLSSQTQCRQC-----TTCGNDEYQTKACSvsqdtecatlTTCSSTQFEVEAPTATR 5878
Cdd:cd10577     9 DEKAQMC--CSKCPPGQHVKHSCTKTSDTVCAPCeestyTQLWNWVPECLSCS----------SPCSSDQVETQACTRQQ 76
                          90       100       110       120       130       140       150
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5879 DRRCkdltACQPGEYeCTAATLTTDRECCGVTQCVPGSEETSAPTATSDRECRQCVAGTTDADGSGTTPC 5948
Cdd:cd10577    77 NRIC----SCKPGWY-CVLKLQEGCRQCRPLKKCGPGFGVARPGTASSDVECKPCAPGTFSDTTSSTDTC 141
FhaB COG3210
Large exoprotein involved in heme utilization or adhesion [Intracellular trafficking, ...
3055-4665 4.30e-14

Large exoprotein involved in heme utilization or adhesion [Intracellular trafficking, secretion, and vesicular transport];


:

Pssm-ID: 442443 [Multi-domain]  Cd Length: 1698  Bit Score: 80.97  E-value: 4.30e-14
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3055 AQAVTLGDVVVRADTNATVVSSTGLFDYVAPGEIVSVSPSSGQLGTVVTIEGRSLRGGSSAVVDVVLGGVSALDVVSEND 3134
Cdd:COG3210    19 AVTTTAATLGSNTAGTSGLNILGSGGVGTAGGIASNAGTTASTSGGSGTAGGVGNTSASTGGIGAAAANTAGTLETGLTS 98
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3135 TRVVAVAGPSSGATGTESVQVVGQQGSVVARPSVWSYVAPAEVLDVAPQQGRAGTRVTVRGQGLLQGGGRIAQATVAGVT 3214
Cdd:COG3210    99 NIGGGSVNGSNSTGNGTLTTTAASATTGNNTGGTTTSSTNTVTTLGGTTTGNTVLSTSGAGNNTNTNNSSSGTNIGNSIP 178
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3215 TARIVDSNDTTVVLEAEVAPAGVTPVGDVQLVSDTGARVNASVTWQYLAAAVIDSVQPTSGQEGVFVELRGQHLLGGGSA 3294
Cdd:COG3210   179 TTGGSLNVVAANPTGVTGVGGALINATAGVLANAGGGTAGGVASANSTLTGGVVAAGTGAGVISTGGTDISSLSVAAGAG 258
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3295 IVDASLAGVAVERVVQSNDTFVRVVAGAKNASVVGDVVARGDTGALLRVVNGWQYAVPSVINSVVPASGQEGTLVTVSGV 3374
Cdd:COG3210   259 TGGAGGTGNAGNTTIGTTVTGTNATGSNTAGASSGDTTTNGTSSVTGAGGTGVLGGGTAAGITTTNTVGGNGDGNNTTAN 338
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3375 RLLGSLPGRITFVEVCGTEAEVVSESDTLVVARL--RSNGGASQLGDVVVRADNGARTRAVNGFTYLSTSMIAAVTPAEG 3452
Cdd:COG3210   339 SGAGLVSGGTGGNNGTTGTGAGSGLTGTGNGGGLttAGAGTVASTVGTATASTGNASSTTVLGSGSLATGNTGTTIAGNG 418
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3453 QYGTRVTITGQRLLGGGAAVQAVELAGVAATVVSGSDTEVVVAAGNGTAGDVGDVVITSDSGAVSVDALAWRYLDASHIT 3532
Cdd:COG3210   419 GSANAGGFTTTGGVLGITGNGTVTGGTIGGLTGSGTTNGAGLSGNTDVSGTGTVTNSAGNTTSATTLAGGGIGTVTTNAT 498
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3533 SVTPRHGQKGTVVTINGTL---LRGHGSGVAVVLLAGEAANVLSESDTSVVVAASAFGGSKSGPVTIIASNGATAVSTPT 3609
Cdd:COG3210   499 ISNNAGGDANGIATGLTGItagGGGGGNATSGGTGGDGTTLSGSGLTTTVSGGASGTTAASGSNTANTLGVLAATGGTSN 578
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3610 AFEYRAPGAVSAIVPNSGHRGTYVTIKGSNLRGHGPTVMSVTLGGVAGHIVSENSSSVVVRVERLSVAVATPVDVVLTSR 3689
Cdd:COG3210   579 ATTAGNSTSATGGTGTNSGGTVLSIGTGSAGATGTITLGAGTSGAGANATGGGAGLTGSAVGAALSGTGSGTTGTASANG 658
                         650       660       670       680       690       700       710       720
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3690 SGAQVAAAGAFTYLVEGSVADLLPAQGQRGTAVSLSGSNLCGGGTAIVAVTLGGVAASLKPTSTCNLVQFVAGSRNNTAA 3769
Cdd:COG3210   659 SNTTGVNTAGGTGGGTTGTVTSGATGGTTGTTLNAATGGTLNNAGNTLTISTGSITVTGQIGALANANGDTVTFGNLGTG 738
                         730       740       750       760       770       780       790       800
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3770 EAVDVVLESNTGALIEGTGRWTYVVEGAISsvlppgGVAGTLVTIRGSNLLGGGSTAAGVTLAGVSASVEQANATHVIVT 3849
Cdd:COG3210   739 ATLTLNAGVTITSGNAGTLSIGLTANTTAS------GTTLTLANANGNTSAGATLDNAGAEISIDITADGTITAAGTTAI 812
                         810       820       830       840       850       860       870       880
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3850 ANRGTTAGDVVVTSDTGSNVVLQDGFTYSRISSVSPAEGQEGTRVRLDGVGFFTGGASVDRVEICGVASSVTNQSDSRLD 3929
Cdd:COG3210   813 NVTGSGGTITINTATTGLTGTGDTTSGAGGSNTTDTTTGTTSDGASGGGTAGANSGSLAATAASITVGSGGVATSTGTAN 892
                         890       900       910       920       930       940       950       960
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3930 VVVPAATTLVPPLRCDVEVVSAFGVSIVAADAFDYLEPGEIAAVTPTSGHEGTVVTVSGARLLGGGSQVASVTFAGVEVH 4009
Cdd:COG3210   893 AGTLTNLGTTTNAASGNGAVLATVTATGTGGGGLTGGNAAAGGTGAGNGTTALSGTQGNAGLSAASASDGAGDTGASSAA 972
                         970       980       990      1000      1010      1020      1030      1040
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4010 DVLTQSDSEIVAVLRSGGAGGSGDVVVESDTGAVVRLAAGFRYVPQAQILHLTRASGQVGTETTIVGEGLQMGDVIVSVL 4089
Cdd:COG3210   973 GSSAVGTSANSAGSTGGVIAATGILVAGNSGTTASTTGGSGAIVAGGNGVTGTTGTASATGTGTAATAGGQNGVGVNASG 1052
                        1050      1060      1070      1080      1090      1100      1110      1120
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4090 LAGVPAQVLSQSDVNVTVRANTSTPATGDVMLVAGSGAFVELVNGWTYDDAGAIEDVQPAQGFAGNLVTISGRGLRGGSA 4169
Cdd:COG3210  1053 ISGGNAAALTASGTAGTTGGTAASNGGGGTAQASGAGTTHTLGGITNGGATGTSGGTTTSTGGVTASKVGGTTTVGATGT 1132
                        1130      1140      1150      1160      1170      1180      1190      1200
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4170 AVTRVTLVGVLATEIVHENDTVVVVRAGLPVDPFVMQTGRVVVMGSSGATITALDAFTYNVAGDITDVSPSFGRVGTRVR 4249
Cdd:COG3210  1133 STASTEAAGAGTLTGLVAVSAVAGGASSASAGDTTAVAAATTTTTGSAINGGADSAATEGTAGTDLKGGDSTGGSTTTIG 1212
                        1210      1220      1230      1240      1250      1260      1270      1280
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4250 LLGSNLLGGGTSAEVRFGGVTGAVTAVSETAIDVTVPAASGPSGLVNVSIVSDSGSHVLEVAGFRYTAPGSVAAVAPSSG 4329
Cdd:COG3210  1213 TTNVTTTTTLTASDTGNTTATGGSSAGQTGSFVAAGSASGTGDATTGATAGAVSNGATSTVAGNAGATATGSTVDIGSTS 1292
                        1290      1300      1310      1320      1330      1340      1350      1360
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4330 HEGTVVTISGASLLAEEADAARVTLGGVNATVVFANDTRLVVVAGASSTAGLGDVFIETVGGARLLAANAWMYVAQATIT 4409
Cdd:COG3210  1293 ATSAGGSLDTTGNTAGANGATVGTGIGGTTATGTAVAAVNSGGVNAGGGTINTTAANTGLNGGNGATDSAAGAGSGGAAG 1372
                        1370      1380      1390      1400      1410      1420      1430      1440
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4410 DVQPGSGQVGTRVTIRGTGLRCGGAAVTSVLLGSAVAPVVTEDDTTVIAEAPARAVGASPVDVTVVADTGAYVTADDAWT 4489
Cdd:COG3210  1373 SLAATAGAGTVLTGAGNNTGAEGTNAGRDGGVTTSGTGVGNNGGVSGTTVAGTTGSSATTGTGGTGNTTGTSVAGAGGGN 1452
                        1450      1460      1470      1480      1490      1500      1510      1520
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4490 FVTAGAVSSVVPSSGQEGTRVTLSGTNLLGSGSGVDQVLLAGVSATVVSAASSEVVVITSALPGGVVGPVTGNVTVVSTS 4569
Cdd:COG3210  1453 ADASAINTGNASSLGAGGSTAGNAVGGAVIGGTTTGGNGAGVAGATASNGGTSTGAGGTAGGTTAEVAKASLEGGEGTYG 1532
                        1530      1540      1550      1560      1570      1580      1590      1600
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4570 GALVHADTDSFTYVRAGAVTGVSPLAGVQGTRVTVTGERLLGGGSSIAAVQVAGVETRVIESSNNTHVVLRASNGTGSGD 4649
Cdd:COG3210  1533 GSSVAEAGTGGGILGAVSGAGSEGGAAGGVTGSVGVGGTDGAGGDTGGADDTGAQAPTAGNTATLTLSLAEGTNAEYGGT 1612
                        1610
                  ....*....|....*.
gi 514698100 4650 IELIADTGAKTVANVT 4665
Cdd:COG3210  1613 TNVTSGTAGNAGATGA 1628
TNFRSF super family cl22855
Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) ...
6098-6261 3.47e-13

Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) interactions with TNF superfamily (TNFSF) ligands (TNFL) control key cellular processes such as differentiation, proliferation, apoptosis, and cell growth. Dysregulation of these pathways has been shown to result in a wide range of pathological conditions, including autoimmune diseases, inflammation, cancer, and viral infection. There are 29 very diverse family members of TNFRSF reported in humans: 22 are type I transmembrane receptors (single pass with the N terminus on extracellular side of the cell membrane) and have a clear signal peptide; the remaining 7 members are either type III transmembrane receptors (single pass with the N terminus on extracellular side of the membrane but no signal sequence; TNFR13B, TNFR13C, TNFR17, and XEDAR), or attached to the membrane via a glycosylphosphatidylinositol (GPI) linker (TNFR10C), or secreted as soluble receptors (TNFR11B and TNFR6B). All TNFRs contain relatively short cysteine-rich domains (CRDs) in the ectodomain, and are involved in interaction with the TNF homology domain (THD) of their ligands. TNFRs often have multiple CRDs (between one and six), with the most frequent configurations of three or four copies; most CRDs possess three disulfide bridges, but could have between one and four. Localized or genome-wide duplication and evolution of the TNFRSF members appear to have paralleled the emergence of the adaptive immune system; teleosts (i.e. ray-finned, bony fish), which possess an immune system with B and T cells, possess primary and secondary lymphoid organs, and are capable of adaptive responses to pathogens also display several characteristics that are different from the mammalian immune system, making teleost TNFSF orthologs and paralogs of interest to better understand immune system evolution and the immunological pathways elicited to pathogens.


The actual alignment was detected with superfamily member cd13416:

Pssm-ID: 473981 [Multi-domain]  Cd Length: 159  Bit Score: 71.18  E-value: 3.47e-13
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6098 CGSGEYETRAPTATtDRKCAsvtQC-DSTQFvvSKPTATTDRdCAECDRCdSGTQYETATCTATTNRVCadltVCADTEY 6176
Cdd:cd13416    18 CPPGEGVARPCGDN-QTVCE---PClDGVTF--SDVVSHTEP-CQPCTRC-PGLMSMRAPCTATHDTVC----ECAYGYY 85
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6177 esvaaTDTSDRKCSSCRECTSSEYLVSGCSESANAVCKACtecPSGTFVSTActplADAE-CTECTRCGSGYFVQSPCTS 6255
Cdd:cd13416    86 -----LDEDSGTCEPCTVCPPGQGVVQSCGPNQDTVCEAC---PEGTYSDED----SSTDpCLPCTVCEDGEVELRECTP 153

                  ....*.
gi 514698100 6256 EADTTC 6261
Cdd:cd13416   154 VSDTVC 159
TMEM132 super family cl25648
Transmembrane protein family 132; This presumed domain is found in members of the TMEM132 ...
6687-6972 3.02e-10

Transmembrane protein family 132; This presumed domain is found in members of the TMEM132 family. TMEM132A may be involved in embryonic and postnatal brain development. TMEM132D may be a marker for oligodendrocyte differentiation.


The actual alignment was detected with superfamily member pfam16070:

Pssm-ID: 465003  Cd Length: 344  Bit Score: 66.16  E-value: 3.02e-10
                           10        20        30        40        50        60        70        80
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  6687 LVNTGLLTGIETSTQLVVTAYDEFGA-SSTATPTEC-SLDAGASGAALaavsaNCDAVtlssSASLPFSSPGGQAVVTVR 6764
Cdd:pfam16070    2 ILNTAILTGRTVAVPVKVVAVEADGTvTDVTESVSCsSTDEDVLKVSS-----SCDSV----YVNGKESRGSSNASVNFT 72
                           90       100       110       120       130       140       150       160
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  6765 QGQLEATTVVSVYVPASAPSVALDRTSLRALVPREVSLAFGVREPCAAAT--------------VFERTRVHVLANFTCT 6830
Cdd:pfam16070   73 YGTLSAQLEFTVWVPRLPLEIEVSDTELSQIKGWRVPIGSNKRRPARDSEdeeeddrkgrgcrlQYQHATVRVLARFVAE 152
                          170       180       190       200       210       220       230       240
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  6831 GVDGQACLPALPGQVQLDVAQLALE-LTVADDDVARVKDTYVV-GVADGTTEVRVEQPNSGVVLASTPVHVTrDEVVEID 6908
Cdd:pfam16070  153 DADTGQVSYLLGSDWQVDVTDLVADfLRVEDPRVARLQDGRVLqGREPGTTTVQVLSPLSDSVLGEKTITVL-DDKVTIT 231
                          250       260       270       280       290       300
                   ....*....|....*....|....*....|....*....|....*....|....*....|....
gi 514698100  6909 GLYAGSAESATLSLDHDAVHQLFDQVPVHVRlqsSPLRAEGDVTHVYAFVVLRDGTQFPIDVLD 6972
Cdd:pfam16070  232 DLGVQLVSGLSLSLQPSPGSNRAIVATTTAQ---ETLTAPKQEALLSAWLQFSDGSVTPLDLYD 292
TNFRSF super family cl22855
Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) ...
5950-6116 1.80e-08

Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) interactions with TNF superfamily (TNFSF) ligands (TNFL) control key cellular processes such as differentiation, proliferation, apoptosis, and cell growth. Dysregulation of these pathways has been shown to result in a wide range of pathological conditions, including autoimmune diseases, inflammation, cancer, and viral infection. There are 29 very diverse family members of TNFRSF reported in humans: 22 are type I transmembrane receptors (single pass with the N terminus on extracellular side of the cell membrane) and have a clear signal peptide; the remaining 7 members are either type III transmembrane receptors (single pass with the N terminus on extracellular side of the membrane but no signal sequence; TNFR13B, TNFR13C, TNFR17, and XEDAR), or attached to the membrane via a glycosylphosphatidylinositol (GPI) linker (TNFR10C), or secreted as soluble receptors (TNFR11B and TNFR6B). All TNFRs contain relatively short cysteine-rich domains (CRDs) in the ectodomain, and are involved in interaction with the TNF homology domain (THD) of their ligands. TNFRs often have multiple CRDs (between one and six), with the most frequent configurations of three or four copies; most CRDs possess three disulfide bridges, but could have between one and four. Localized or genome-wide duplication and evolution of the TNFRSF members appear to have paralleled the emergence of the adaptive immune system; teleosts (i.e. ray-finned, bony fish), which possess an immune system with B and T cells, possess primary and secondary lymphoid organs, and are capable of adaptive responses to pathogens also display several characteristics that are different from the mammalian immune system, making teleost TNFSF orthologs and paralogs of interest to better understand immune system evolution and the immunological pathways elicited to pathogens.


The actual alignment was detected with superfamily member cd13416:

Pssm-ID: 473981 [Multi-domain]  Cd Length: 159  Bit Score: 57.31  E-value: 1.80e-08
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5950 ACSAGHYVPRGRtggCAAFeCAAGH--VDQDEDAATACKLCEAGVNYAGSAGLT-RCTSVSECGAGEEETSAPTASTDRV 6026
Cdd:cd13416     2 ACPSGQYTSSGE---CCEQ-CPPGEgvARPCGDNQTVCEPCLDGVTFSDVVSHTePCQPCTRCPGLMSMRAPCTATHDTV 77
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6027 CStCASGKFKATTGQTpCEAVSTCEEDEYVYRAATVSTDTQCRaltACSDEQYETRAPTVNSDRECtglTTCGSGEYETR 6106
Cdd:cd13416    78 CE-CAYGYYLDEDSGT-CEPCTVCPPGQGVVQSCGPNQDTVCE---ACPEGTYSDEDSSTDPCLPC---TVCEDGEVELR 149
                         170
                  ....*....|
gi 514698100 6107 APTATTDRKC 6116
Cdd:cd13416   150 ECTPVSDTVC 159
IPT cd00102
Immunoglobulin-like fold, Plexins, Transcription factors (IPT). IPTs are also known as ...
1935-2021 1.09e-07

Immunoglobulin-like fold, Plexins, Transcription factors (IPT). IPTs are also known as Transcription factor ImmunoGlobin (TIG) domains. They are present in intracellular transcription factors, cell surface receptors (such as plexins and scatter factor receptors), as well as, cyclodextrin glycosyltransferase and similar enzymes. Although they are involved in DNA binding in transcription factors, their function in other proteins is unknown. In these transcription factors, IPTs form homo- or heterodimers with the exception of the nuclear factor of activated Tcells (NFAT) transcription factors which are mainly monomers.


:

Pssm-ID: 238050 [Multi-domain]  Cd Length: 89  Bit Score: 53.23  E-value: 1.09e-07
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1935 VIQSVDPQSGQV--GTRITIVGSGLlgGSAFAREVVMGNSVPCSVLRGNDSVVVCVL-ADAGSPAAAVDVTVVGARGSRV 2011
Cdd:cd00102     2 VITSISPSSGPVsgGTEVTITGSNF--GSGSNLRVTFGGGVPCSVLSVSSTAIVCTTpPYANPGPGPVEVTVDRGNGGIT 79
                          90
                  ....*....|
gi 514698100 2012 VASLAFEVLP 2021
Cdd:cd00102    80 SSPLTFTYVP 89
TNFRSF super family cl22855
Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) ...
5514-5576 2.79e-06

Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) interactions with TNF superfamily (TNFSF) ligands (TNFL) control key cellular processes such as differentiation, proliferation, apoptosis, and cell growth. Dysregulation of these pathways has been shown to result in a wide range of pathological conditions, including autoimmune diseases, inflammation, cancer, and viral infection. There are 29 very diverse family members of TNFRSF reported in humans: 22 are type I transmembrane receptors (single pass with the N terminus on extracellular side of the cell membrane) and have a clear signal peptide; the remaining 7 members are either type III transmembrane receptors (single pass with the N terminus on extracellular side of the membrane but no signal sequence; TNFR13B, TNFR13C, TNFR17, and XEDAR), or attached to the membrane via a glycosylphosphatidylinositol (GPI) linker (TNFR10C), or secreted as soluble receptors (TNFR11B and TNFR6B). All TNFRs contain relatively short cysteine-rich domains (CRDs) in the ectodomain, and are involved in interaction with the TNF homology domain (THD) of their ligands. TNFRs often have multiple CRDs (between one and six), with the most frequent configurations of three or four copies; most CRDs possess three disulfide bridges, but could have between one and four. Localized or genome-wide duplication and evolution of the TNFRSF members appear to have paralleled the emergence of the adaptive immune system; teleosts (i.e. ray-finned, bony fish), which possess an immune system with B and T cells, possess primary and secondary lymphoid organs, and are capable of adaptive responses to pathogens also display several characteristics that are different from the mammalian immune system, making teleost TNFSF orthologs and paralogs of interest to better understand immune system evolution and the immunological pathways elicited to pathogens.


The actual alignment was detected with superfamily member cd13422:

Pssm-ID: 473981 [Multi-domain]  Cd Length: 161  Bit Score: 51.27  E-value: 2.79e-06
                          10        20        30        40        50        60
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*.
gi 514698100 5514 VCRGLTTCGAGEQEKVAPTASSDRVCEACPAGTTDANSDGSDACVT---CGGGTYVPAGSTGTCSQ 5576
Cdd:cd13422    93 TCVPHTTCGPGQGVKSKGNHIRDTVCEECPDGTFSNNSSAEGVCKKwteCESGYKVEAAGTNTSDN 158
JmjC_2 super family cl46321
JmjC domain; This entry includes proteins with a JmjC domain that belong to the cupin ...
4920-5049 1.21e-05

JmjC domain; This entry includes proteins with a JmjC domain that belong to the cupin superfamily, including Bifunctional lysine-specific demethylase and histidyl-hydroxylase NO66, Ribosomal oxygenase 1/2, and 50S ribosomal protein L16 3-hydroxylase from Escherichia coli. Proteins are bifunctional, acting as histone lysine demethylases and ribosomal histidine hydroxylases.


The actual alignment was detected with superfamily member pfam08007:

Pssm-ID: 480661  Cd Length: 116  Bit Score: 48.02  E-value: 1.21e-05
                           10        20        30        40        50        60        70        80
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  4920 PHTDPYDVLVIQLQGSKRWT---TCVPDayvsdsndddddsANERSNANSTAADRPPSEAEvlagfnaaqlgqlqeirsq 4996
Cdd:pfam08007   30 PHYDDYDVFLLQGEGRKRWRvgaPKVPD-------------LEFYSDPPLRILDDFEPVHD------------------- 77
                           90       100       110       120       130
                   ....*....|....*....|....*....|....*....|....*....|...
gi 514698100  4997 rqqgctgyqdsmlrgmrctnFTLREGDTMYMPKGIIHFALTEEqGSSHITISL 5049
Cdd:pfam08007   78 --------------------FVLEPGDMLYLPRGFIHQGVALD-ESLHYSVGF 109
TNFRSF super family cl22855
Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) ...
7951-8021 5.92e-05

Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) interactions with TNF superfamily (TNFSF) ligands (TNFL) control key cellular processes such as differentiation, proliferation, apoptosis, and cell growth. Dysregulation of these pathways has been shown to result in a wide range of pathological conditions, including autoimmune diseases, inflammation, cancer, and viral infection. There are 29 very diverse family members of TNFRSF reported in humans: 22 are type I transmembrane receptors (single pass with the N terminus on extracellular side of the cell membrane) and have a clear signal peptide; the remaining 7 members are either type III transmembrane receptors (single pass with the N terminus on extracellular side of the membrane but no signal sequence; TNFR13B, TNFR13C, TNFR17, and XEDAR), or attached to the membrane via a glycosylphosphatidylinositol (GPI) linker (TNFR10C), or secreted as soluble receptors (TNFR11B and TNFR6B). All TNFRs contain relatively short cysteine-rich domains (CRDs) in the ectodomain, and are involved in interaction with the TNF homology domain (THD) of their ligands. TNFRs often have multiple CRDs (between one and six), with the most frequent configurations of three or four copies; most CRDs possess three disulfide bridges, but could have between one and four. Localized or genome-wide duplication and evolution of the TNFRSF members appear to have paralleled the emergence of the adaptive immune system; teleosts (i.e. ray-finned, bony fish), which possess an immune system with B and T cells, possess primary and secondary lymphoid organs, and are capable of adaptive responses to pathogens also display several characteristics that are different from the mammalian immune system, making teleost TNFSF orthologs and paralogs of interest to better understand immune system evolution and the immunological pathways elicited to pathogens.


The actual alignment was detected with superfamily member cd15834:

Pssm-ID: 473981 [Multi-domain]  Cd Length: 150  Bit Score: 47.10  E-value: 5.92e-05
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 7951 RNACTlSCGEGEYGDIDAWV--CRAVRPCDLSSEYMVAPETPTSNRVCETLT------------------VCRPSSKyET 8010
Cdd:cd15834    33 RSQCT-PCPEGTYLEQINYSpnCRRCTLCKVKNEEEVSPCKKSSNTVCRCKKgyyksridsetreclkckTCGPGEI-EI 110
                          90
                  ....*....|.
gi 514698100 8011 TAATPTSDRVC 8021
Cdd:cd15834   111 QPCTPESNTVC 121
IPT_PCSR cd00603
IPT domain of Plexins and Cell Surface Receptors (PCSR) and related proteins . This subgroup ...
104-184 1.19e-03

IPT domain of Plexins and Cell Surface Receptors (PCSR) and related proteins . This subgroup contains IPT domains of plexins, receptors, like the plasminogen-related growth factor receptors, the hepatocyte growth factor-scatter factors, and the macrophage-stimulating receptors and of fibrocystin. Plexins are involved in the regulation of cell proliferation and of cellular adhesion and repulsion receptors. In general, there are three copies of the IPT_PCSR domain present preceeded by SEMA (semaphorin) and PSI (plexin, semaphorin, integrin) domains.


:

Pssm-ID: 238337 [Multi-domain]  Cd Length: 90  Bit Score: 41.67  E-value: 1.19e-03
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  104 VITAVRPAIG--RVGTLVTIEGERLQSGGSAVaRVDLGGVPATLLHGNDSTVVviCSAGSGA----GAVRVTSDVGGFVE 177
Cdd:cd00603     2 VITSISPSSGplSGGTRLTITGSNLGSGSPRV-RVTVGGVPCKVLNVSSTEIV--CRTPAAAtpgeGPVEVTVDGANVSA 78

                  ....*..
gi 514698100  178 GLLWTFV 184
Cdd:cd00603    79 RVLSNTT 85
 
Name Accession Description Interval E-value
FhaB COG3210
Large exoprotein involved in heme utilization or adhesion [Intracellular trafficking, ...
211-1927 1.62e-17

Large exoprotein involved in heme utilization or adhesion [Intracellular trafficking, secretion, and vesicular transport];


Pssm-ID: 442443 [Multi-domain]  Cd Length: 1698  Bit Score: 92.14  E-value: 1.62e-17
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  211 GGATGVASVTVAGVAATLRSPILDYFAVVELGSAPAGTSGAVVVVAESGARVVSSQTFTYAEPATIAAVSPSSGQVGTRV 290
Cdd:COG3210     3 GGLAGTTGNKTIGVDIAVTTTAATLGSNTAGTSGLNILGSGGVGTAGGIASNAGTTASTSGGSGTAGGVGNTSASTGGIG 82
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  291 TITGTNLLGGGAAVERVTLAGVEASLVAQSATQIVVVASPSRERAAGPVVVYSDTGAFARLESAFAYQIPGRISTLSPSS 370
Cdd:COG3210    83 AAAANTAGTLETGLTSNIGGGSVNGSNSTGNGTLTTTAASATTGNNTGGTTTSSTNTVTTLGGTTTGNTVLSTSGAGNNT 162
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  371 GQAGTVVELTGFNLLGGGSALSSLSVHGVEVEQVTFASDALIAFVVPLTSVQGLGDVRIVSASGATVEAGDAFTLLEPGR 450
Cdd:COG3210   163 NTNNSSSGTNIGNSIPTTGGSLNVVAANPTGVTGVGGALINATAGVLANAGGGTAGGVASANSTLTGGVVAAGTGAGVIS 242
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  451 IVGVAPERGQEGTFVTIVGERLLGGGETIARAVLGATAAEAVVSSSDARVVVRAGAAVTFGPVGVTLWADTGAVVNTSAG 530
Cdd:COG3210   243 TGGTDISSLSVAAGAGTGGAGGTGNAGNTTIGTTVTGTNATGSNTAGASSGDTTTNGTSSVTGAGGTGVLGGGTAAGITT 322
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  531 LFEYLAPGMVASVLPVSGQAGTQVVIEGMELLGHETALEAVTLGGVQAAAILSFNRTHVVVTAGDGPASTGPVVLTASNG 610
Cdd:COG3210   323 TNTVGGNGDGNNTTANSGAGLVSGGTGGNNGTTGTGAGSGLTGTGNGGGLTTAGAGTVASTVGTATASTGNASSTTVLGS 402
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  611 SRVTGGAVWTQLERGAIGSVQPSSGHGGTRVTITGQRLLGGGAALASVELGGVLATEIAWANDTVAVVSAGASGSALAGG 690
Cdd:COG3210   403 GSLATGNTGTTIAGNGGSANAGGFTTTGGVLGITGNGTVTGGTIGGLTGSGTTNGAGLSGNTDVSGTGTVTNSAGNTTSA 482
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  691 NVTLVADTGAVTTGSGLWAYVAPAVISSVAPTSGQAGTVVTIRGNNLSMGGAVREVFLAGIPAVSVSLVNDSFVVAHASG 770
Cdd:COG3210   483 TTLAGGGIGTVTTNATISNNAGGDANGIATGLTGITAGGGGGGNATSGGTGGDGTTLSGSGLTTTVSGGASGTTAASGSN 562
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  771 ALSGRSSPAVVRNNFGAFVSSSVNWTYVPAGAVDITRPARAQFGTRVTVTGSNLLQGGAIIASASMAGVPCTVLSSNDTT 850
Cdd:COG3210   563 TANTLGVLAATGGTSNATTAGNSTSATGGTGTNSGGTVLSIGTGSAGATGTITLGAGTSGAGANATGGGAGLTGSAVGAA 642
                         650       660       670       680       690       700       710       720
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  851 VVVSVAGNFAATVASPSMTLVSDSGAVITFTSSTTAEPSGVVTAISPS-SGQYGTFVTLSGTQLLAHASNLRTVSLAGTq 929
Cdd:COG3210   643 LSGTGSGTTGTASANGSNTTGVNTAGGTGGGTTGTVTSGATGGTTGTTlNAATGGTLNNAGNTLTISTGSITVTGQIGA- 721
                         730       740       750       760       770       780       790       800
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  930 vlsIESATESEVIVRAGLGVNGTAGSPRLRASSGGVVAAATGVNFTYVRQGRIDTVSPLFG--QLGTLVTISGEHLLSGG 1007
Cdd:COG3210   722 ---LANANGDTVTFGNLGTGATLTLNAGVTITSGNAGTLSIGLTANTTASGTTLTLANANGntSAGATLDNAGAEISIDI 798
                         810       820       830       840       850       860       870       880
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1008 SSASRVLLAGlpaavvssnssvvvaraPLSNSTSIRTGSVVVLANTGALSAESSTTFTFRPAGFIASVSPSFGQRGTYVE 1087
Cdd:COG3210   799 TADGTITAAG-----------------TTAINVTGSGGTITINTATTGLTGTGDTTSGAGGSNTTDTTTGTTSDGASGGG 861
                         890       900       910       920       930       940       950       960
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1088 IAGNRLLDGSGLREVLLADVPAEVLSANDTFALVRAQASLPRVGDVVVRSDSGYEVVSSQAFVYIAPQHPDTVVPASGQF 1167
Cdd:COG3210   862 TAGANSGSLAATAASITVGSGGVATSTGTANAGTLTNLGTTTNAASGNGAVLATVTATGTGGGGLTGGNAAAGGTGAGNG 941
                         970       980       990      1000      1010      1020      1030      1040
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1168 GTRVTINGTGLLGGGATVQTVQFDAVAGSDPRVTAAGIEVSAPGGAAGVRNITVVANTGAYFTVARAFTVIAEPNVTAIT 1247
Cdd:COG3210   942 TTALSGTQGNAGLSAASASDGAGDTGASSAAGSSAVGTSANSAGSTGGVIAATGILVAGNSGTTASTTGGSGAIVAGGNG 1021
                        1050      1060      1070      1080      1090      1100      1110      1120
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1248 PSSGQAGAYVTVSGTELLGGGAFAERVFLAGVEADVVTSSPSSVVVRAPVSVAKVGPTVIVADTGATTTSLLNFTFTPQL 1327
Cdd:COG3210  1022 VTGTTGTASATGTGTAATAGGQNGVGVNASGISGGNAAALTASGTAGTTGGTAASNGGGGTAQASGAGTTHTLGGITNGG 1101
                        1130      1140      1150      1160      1170      1180      1190      1200
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1328 SVTSVSPSSGQGGTRVTVLGANLRLGSSAVTGVLLGSAACSLISENDTAVVCAAGVASAGSVPVTVEASSGAFASVGGVL 1407
Cdd:COG3210  1102 ATGTSGGTTTSTGGVTASKVGGTTTVGATGTSTASTEAAGAGTLTGLVAVSAVAGGASSASAGDTTAVAAATTTTTGSAI 1181
                        1210      1220      1230      1240      1250      1260      1270      1280
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1408 AfeyldAGVINSVEPGSGQQGTRVVVSGLRLLGGGIRVDQAFLGGVEATIRSSSAFAVTLAAGNGSEPSSGDIVLIADTG 1487
Cdd:COG3210  1182 N-----GGADSAATEGTAGTDLKGGDSTGGSTTTIGTTNVTTTTTLTASDTGNTTATGGSSAGQTGSFVAAGSASGTGDA 1256
                        1290      1300      1310      1320      1330      1340      1350      1360
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1488 AVVSRSGMWTYTEPCGVTDVSPPSGQAGTLVTITGTGFPCTGSSVSTVSLGGVGASIRTQSATQIVVEAPSGSGQGDVVV 1567
Cdd:COG3210  1257 TTGATAGAVSNGATSTVAGNAGATATGSTVDIGSTSATSAGGSLDTTGNTAGANGATVGTGIGGTTATGTAVAAVNSGGV 1336
                        1370      1380      1390      1400      1410      1420      1430      1440
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1568 TADDGSFAVSRGGWEFSRISSVTPASGQFGTAVTVAGQGLRLGFSSVTQVRLGDVAATILSENNTHVVVRAGTGSLVGVP 1647
Cdd:COG3210  1337 NAGGGTINTTAANTGLNGGNGATDSAAGAGSGGAAGSLAATAGAGTVLTGAGNNTGAEGTNAGRDGGVTTSGTGVGNNGG 1416
                        1450      1460      1470      1480      1490      1500      1510      1520
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1648 VDVQVISSGATTVQQSVAWTYLRDGVVSSVVPVQGQRGTRVTVRGERLLGGGSRLERVLLGDIAVDRILSYNDTVVVVEA 1727
Cdd:COG3210  1417 VSGTTVAGTTGSSATTGTGGTGNTTGTSVAGAGGGNADASAINTGNASSLGAGGSTAGNAVGGAVIGGTTTGGNGAGVAG 1496
                        1530      1540      1550      1560      1570      1580      1590      1600
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1728 GLSNSSAVVDVTLVSDTLAGVTGENVFTYVEPMTLYGLTRATGQAGTETTLLGRSLLGGSLAVTEVLLAGTGAQVIGFND 1807
Cdd:COG3210  1497 ATASNGGTSTGAGGTAGGTTAEVAKASLEGGEGTYGGSSVAEAGTGGGILGAVSGAGSEGGAAGGVTGSVGVGGTDGAGG 1576
                        1610      1620      1630      1640      1650      1660      1670      1680
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1808 THVTVrALAGTPGQGNVVIRTSNGAYLVAINGWSFSTPGAIAAVEPVSGQAGTRVTIVGSRLLGGGSRVASVALGSVVHT 1887
Cdd:COG3210  1577 DTGGA-DDTGAQAPTAGNTATLTLSLAEGTNAEYGGTTNVTSGTAGNAGATGANSNTVVTTNGGEGVLALVAGGNTTNGT 1655
                        1690      1700      1710      1720
                  ....*....|....*....|....*....|....*....|
gi 514698100 1888 SSVISGNDTQVVLDALAGPPGLSDVIITSDTRATVTAENV 1927
Cdd:COG3210  1656 TLSGAVNGAGNGWAVDLTDATLAGLGGATTAAAGNVATGD 1695
TNFRSF1B cd10577
Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B), also known as TNFR2; TNFRSF1B ...
5597-5762 5.72e-17

Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B), also known as TNFR2; TNFRSF1B (also known as TNFR2, type 2 TNFR, TNFBR, TNFR80, TNF-R75, TNF-R-II, p75, CD120b) binds TNF-alpha, but lacks the death domain (DD) that is associated with the cytoplasmic domain of TNFRSF1A (TNFR1). It is inducible and expressed exclusively by oligodendrocytes, astrocytes, T cells, thymocytes, myocytes, endothelial cells, and in human mesenchymal stem cells. TNFRSF1B protects oligodendrocyte progenitor cells (OLGs) against oxidative stress, and induces the up-regulation of cell survival genes. While pro-inflammatory and pathogen-clearing activities of TNF are mediated mainly through activation of TNFRSF1A, a strong activator of NF-kappaB, TNFRSF1B is more responsible for suppression of inflammation. Although the affinities of both receptors for soluble TNF are similar, TNFRSF1B is sometimes more abundantly expressed and thought to associate with TNF, thereby increasing its concentration near TNFRSF1A receptors, and making TNF available to activate TNFRSF1A (a ligand-passing mechanism).


Pssm-ID: 276903 [Multi-domain]  Cd Length: 163  Bit Score: 82.14  E-value: 5.72e-17
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5597 CDGTTTYQPSKGQeRCLSvkTCGAGEEETTSPSATRNRVCQPCQlGSTFKAQSGQSTRCISVTT-CGAGEEEIASPTLST 5675
Cdd:cd10577     1 CRNSKEYYDEKAQ-MCCS--KCPPGQHVKHSCTKTSDTVCAPCE-ESTYTQLWNWVPECLSCSSpCSSDQVETQACTRQQ 76
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5676 DRQCrTCASGTFKAAAGQSTT--CIAVSTCAAGFTEDVAPTPSSDRVCVECAPGTFKATAG-DGTCRAHRTCEDTeyeTV 5752
Cdd:cd10577    77 NRIC-SCKPGWYCVLKLQEGCrqCRPLKKCGPGFGVARPGTASSDVECKPCAPGTFSDTTSsTDTCRPHRICSSV---AI 152
                         170
                  ....*....|
gi 514698100 5753 APTSSSDRKC 5762
Cdd:cd10577   153 PGNASMDAVC 162
FhaB COG3210
Large exoprotein involved in heme utilization or adhesion [Intracellular trafficking, ...
2048-3743 1.07e-16

Large exoprotein involved in heme utilization or adhesion [Intracellular trafficking, secretion, and vesicular transport];


Pssm-ID: 442443 [Multi-domain]  Cd Length: 1698  Bit Score: 89.44  E-value: 1.07e-16
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2048 GGADRVVSATLAGAPGSARVVRENDTVVLVQVLVAMPVAFADLRLTASSGATVTFPSAFTALLPGTIASVLPLQGQAGTR 2127
Cdd:COG3210     2 SGGLAGTTGNKTIGVDIAVTTTAATLGSNTAGTSGLNILGSGGVGTAGGIASNAGTTASTSGGSGTAGGVGNTSASTGGI 81
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2128 VTVTGARLRGGSAAVTRATIAGVEATVVVESNDVVVLRATAAMAHPLQGPVVVVGEAGSLVSNAMINFTYLEQGVVTAAT 2207
Cdd:COG3210    82 GAAAANTAGTLETGLTSNIGGGSVNGSNSTGNGTLTTTAASATTGNNTGGTTTSSTNTVTTLGGTTTGNTVLSTSGAGNN 161
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2208 PAYGQRHTRVTVTGTNILGGGSRIVNASFGGVSALDVLASNNSMAVVIAPRLLPGQHSIQLVADSGAVVSSSNLFTARLE 2287
Cdd:COG3210   162 TNTNNSSSGTNIGNSIPTTGGSLNVVAANPTGVTGVGGALINATAGVLANAGGGTAGGVASANSTLTGGVVAAGTGAGVI 241
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2288 GNITSLMPGSGQRGTRITVNGNRLRGSGNEVVSAWVGNVPATVVSEGNSQVVIRPTSSGAAGTSVRIVLVADTGARVETA 2367
Cdd:COG3210   242 STGGTDISSLSVAAGAGTGGAGGTGNAGNTTIGTTVTGTNATGSNTAGASSGDTTTNGTSSVTGAGGTGVLGGGTAAGIT 321
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2368 TVQFDFVPPGDIQAVGPASGQEGTLVTIRGERLLGNGTALAYTYIGGVAAQIVSASNDEVVVVAGRSSNRFTLDqhpVIS 2447
Cdd:COG3210   322 TTNTVGGNGDGNNTTANSGAGLVSGGTGGNNGTTGTGAGSGLTGTGNGGGLTTAGAGTVASTVGTATASTGNAS---STT 398
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2448 DIVLVADNGAEVVAASSFTYLRPGVISSVFPLSGQAGTRVGISGVRLFGGGSRIVSVYLGATQAQVITQTVHAVVVTAKA 2527
Cdd:COG3210   399 VLGSGSLATGNTGTTIAGNGGSANAGGFTTTGGVLGITGNGTVTGGTIGGLTGSGTTNGAGLSGNTDVSGTGTVTNSAGN 478
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2528 GNVSASPEPIRIVADTGAVVTLNDTWSYVQAGRVASVNPASGHQGTLVTIQGTSLLGGGTTAVSVMLAGSSALVLSSNAT 2607
Cdd:COG3210   479 TTSATTLAGGGIGTVTTNATISNNAGGDANGIATGLTGITAGGGGGGNATSGGTGGDGTTLSGSGLTTTVSGGASGTTAA 558
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2608 DVVVTAGPGAQSSGDVVIVSETGATVARGAAWTYVEPGFIQRASPASGTAGTRVTITGASLLGGASTLARVTLAGVPVDS 2687
Cdd:COG3210   559 SGSNTANTLGVLAATGGTSNATTAGNSTSATGGTGTNSGGTVLSIGTGSAGATGTITLGAGTSGAGANATGGGAGLTGSA 638
                         650       660       670       680       690       700       710       720
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2688 IDHQSNEVVIVTAASGAQRMGAIVLTADTGAVVQRLNFWDYIATPVVGEIEPSSGQLGTVVTIRGSNLLAGGEALQLVTL 2767
Cdd:COG3210   639 VGAALSGTGSGTTGTASANGSNTTGVNTAGGTGGGTTGTVTSGATGGTTGTTLNAATGGTLNNAGNTLTISTGSITVTGQ 718
                         730       740       750       760       770       780       790       800
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2768 AGvpaeAILSSNNSVVTVSSAQGSGATGPAVLVAAETGGRAVGTPSVNYTYLAGSSIASVQPASG--QGGTFVDIVGERL 2845
Cdd:COG3210   719 IG----ALANANGDTVTFGNLGTGATLTLNAGVTITSGNAGTLSIGLTANTTASGTTLTLANANGntSAGATLDNAGAEI 794
                         810       820       830       840       850       860       870       880
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2846 LSGGSAVAAVSLAGVAAEVISGND---TFVRARAGPSAVTLTGDVVVTADTGGRAELVNAWAYNTAGVVDAVVPGSGQRG 2922
Cdd:COG3210   795 SIDITADGTITAAGTTAINVTGSGgtiTINTATTGLTGTGDTTSGAGGSNTTDTTTGTTSDGASGGGTAGANSGSLAATA 874
                         890       900       910       920       930       940       950       960
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2923 TRVTIQGTRLLGEGTRAVRVSLGDVRAHIVESTATAVVVVYPGRVT--LGVHDVEVESDTGSVVSAPAAWTALDNGVVHS 3000
Cdd:COG3210   875 ASITVGSGGVATSTGTANAGTLTNLGTTTNAASGNGAVLATVTATGtgGGGLTGGNAAAGGTGAGNGTTALSGTQGNAGL 954
                         970       980       990      1000      1010      1020      1030      1040
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3001 VNPDVGHGGTVVTIRGVRLLGGGDSVADVALAGVVTANVVSANNSVVVVVAELQAQAVTLGDVVVRADTNATVVSSTGLF 3080
Cdd:COG3210   955 SAASASDGAGDTGASSAAGSSAVGTSANSAGSTGGVIAATGILVAGNSGTTASTTGGSGAIVAGGNGVTGTTGTASATGT 1034
                        1050      1060      1070      1080      1090      1100      1110      1120
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3081 DYVAPGEIVSVSPSSGQLGTVVTIEGRSLRGGSSAVVDVVLGGVSALDVVSENDTRVVAVAGPSSGATGTESVQVVGQQG 3160
Cdd:COG3210  1035 GTAATAGGQNGVGVNASGISGGNAAALTASGTAGTTGGTAASNGGGGTAQASGAGTTHTLGGITNGGATGTSGGTTTSTG 1114
                        1130      1140      1150      1160      1170      1180      1190      1200
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3161 SVVARPSVWSYVAPAEVLDVAPQQGRAGTRVTVRGQGLLQGGGRIAQATVAGVTTARIVDSNDTTVVLEAEVAPAGVTPV 3240
Cdd:COG3210  1115 GVTASKVGGTTTVGATGTSTASTEAAGAGTLTGLVAVSAVAGGASSASAGDTTAVAAATTTTTGSAINGGADSAATEGTA 1194
                        1210      1220      1230      1240      1250      1260      1270      1280
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3241 GDVQLVSDTGARVNASVTWQYLAAAVIDSVQPTSGQEGVFVELRGQHLLGGGSAIVDASLAGVAVERVVQSNDTFVRVVA 3320
Cdd:COG3210  1195 GTDLKGGDSTGGSTTTIGTTNVTTTTTLTASDTGNTTATGGSSAGQTGSFVAAGSASGTGDATTGATAGAVSNGATSTVA 1274
                        1290      1300      1310      1320      1330      1340      1350      1360
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3321 GAKNASVVGDVVARGDTGALLRVVNGWQYAVPSVINSVVPASGQEGTLVTVSGVRLLGSLPGRITFVEVCGTEAEVVSES 3400
Cdd:COG3210  1275 GNAGATATGSTVDIGSTSATSAGGSLDTTGNTAGANGATVGTGIGGTTATGTAVAAVNSGGVNAGGGTINTTAANTGLNG 1354
                        1370      1380      1390      1400      1410      1420      1430      1440
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3401 DTLVVARLRSNGGASQLGDVVVRADNGARTRAVNGFTYLSTSMIAAVTPAEGQYGTRVTITGQRLLGGGAAVQAVELAGV 3480
Cdd:COG3210  1355 GNGATDSAAGAGSGGAAGSLAATAGAGTVLTGAGNNTGAEGTNAGRDGGVTTSGTGVGNNGGVSGTTVAGTTGSSATTGT 1434
                        1450      1460      1470      1480      1490      1500      1510      1520
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3481 AATVVSGSDTEVVVAAGNGTAGDVGDVVITSDSGAVSVDALAWRYLDASHITSVTPRHGQKGTVVTINGTLLRGHGSGVA 3560
Cdd:COG3210  1435 GGTGNTTGTSVAGAGGGNADASAINTGNASSLGAGGSTAGNAVGGAVIGGTTTGGNGAGVAGATASNGGTSTGAGGTAGG 1514
                        1530      1540      1550      1560      1570      1580      1590      1600
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3561 VVLLAGEAANVLSESDTSVVVAASAFGGSKSGPVTIIASNGATAVSTPTAFEYRAPGAVSAIVPNSGHRGTYVTIKGSNL 3640
Cdd:COG3210  1515 TTAEVAKASLEGGEGTYGGSSVAEAGTGGGILGAVSGAGSEGGAAGGVTGSVGVGGTDGAGGDTGGADDTGAQAPTAGNT 1594
                        1610      1620      1630      1640      1650      1660      1670      1680
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3641 RGHGPTVMSVTLGGVAGHIVSENSSSVVVRVERLSVAVATPVDVVLTSRSGAQVAAAGAFTYLVEGSVADLLPAQGQRGT 3720
Cdd:COG3210  1595 ATLTLSLAEGTNAEYGGTTNVTSGTAGNAGATGANSNTVVTTNGGEGVLALVAGGNTTNGTTLSGAVNGAGNGWAVDLTD 1674
                        1690      1700
                  ....*....|....*....|...
gi 514698100 3721 AVSLSGSNLCGGGTAIVAVTLGG 3743
Cdd:COG3210  1675 ATLAGLGGATTAAAGNVATGDTA 1697
TNFRSF1B cd10577
Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B), also known as TNFR2; TNFRSF1B ...
5804-5948 3.12e-14

Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B), also known as TNFR2; TNFRSF1B (also known as TNFR2, type 2 TNFR, TNFBR, TNFR80, TNF-R75, TNF-R-II, p75, CD120b) binds TNF-alpha, but lacks the death domain (DD) that is associated with the cytoplasmic domain of TNFRSF1A (TNFR1). It is inducible and expressed exclusively by oligodendrocytes, astrocytes, T cells, thymocytes, myocytes, endothelial cells, and in human mesenchymal stem cells. TNFRSF1B protects oligodendrocyte progenitor cells (OLGs) against oxidative stress, and induces the up-regulation of cell survival genes. While pro-inflammatory and pathogen-clearing activities of TNF are mediated mainly through activation of TNFRSF1A, a strong activator of NF-kappaB, TNFRSF1B is more responsible for suppression of inflammation. Although the affinities of both receptors for soluble TNF are similar, TNFRSF1B is sometimes more abundantly expressed and thought to associate with TNF, thereby increasing its concentration near TNFRSF1A receptors, and making TNF available to activate TNFRSF1A (a ligand-passing mechanism).


Pssm-ID: 276903 [Multi-domain]  Cd Length: 163  Bit Score: 74.05  E-value: 3.12e-14
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5804 DTSPTKCvgCDECASDEYTLSSCTLSSQTQCRQC-----TTCGNDEYQTKACSvsqdtecatlTTCSSTQFEVEAPTATR 5878
Cdd:cd10577     9 DEKAQMC--CSKCPPGQHVKHSCTKTSDTVCAPCeestyTQLWNWVPECLSCS----------SPCSSDQVETQACTRQQ 76
                          90       100       110       120       130       140       150
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5879 DRRCkdltACQPGEYeCTAATLTTDRECCGVTQCVPGSEETSAPTATSDRECRQCVAGTTDADGSGTTPC 5948
Cdd:cd10577    77 NRIC----SCKPGWY-CVLKLQEGCRQCRPLKKCGPGFGVARPGTASSDVECKPCAPGTFSDTTSSTDTC 141
FhaB COG3210
Large exoprotein involved in heme utilization or adhesion [Intracellular trafficking, ...
3055-4665 4.30e-14

Large exoprotein involved in heme utilization or adhesion [Intracellular trafficking, secretion, and vesicular transport];


Pssm-ID: 442443 [Multi-domain]  Cd Length: 1698  Bit Score: 80.97  E-value: 4.30e-14
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3055 AQAVTLGDVVVRADTNATVVSSTGLFDYVAPGEIVSVSPSSGQLGTVVTIEGRSLRGGSSAVVDVVLGGVSALDVVSEND 3134
Cdd:COG3210    19 AVTTTAATLGSNTAGTSGLNILGSGGVGTAGGIASNAGTTASTSGGSGTAGGVGNTSASTGGIGAAAANTAGTLETGLTS 98
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3135 TRVVAVAGPSSGATGTESVQVVGQQGSVVARPSVWSYVAPAEVLDVAPQQGRAGTRVTVRGQGLLQGGGRIAQATVAGVT 3214
Cdd:COG3210    99 NIGGGSVNGSNSTGNGTLTTTAASATTGNNTGGTTTSSTNTVTTLGGTTTGNTVLSTSGAGNNTNTNNSSSGTNIGNSIP 178
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3215 TARIVDSNDTTVVLEAEVAPAGVTPVGDVQLVSDTGARVNASVTWQYLAAAVIDSVQPTSGQEGVFVELRGQHLLGGGSA 3294
Cdd:COG3210   179 TTGGSLNVVAANPTGVTGVGGALINATAGVLANAGGGTAGGVASANSTLTGGVVAAGTGAGVISTGGTDISSLSVAAGAG 258
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3295 IVDASLAGVAVERVVQSNDTFVRVVAGAKNASVVGDVVARGDTGALLRVVNGWQYAVPSVINSVVPASGQEGTLVTVSGV 3374
Cdd:COG3210   259 TGGAGGTGNAGNTTIGTTVTGTNATGSNTAGASSGDTTTNGTSSVTGAGGTGVLGGGTAAGITTTNTVGGNGDGNNTTAN 338
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3375 RLLGSLPGRITFVEVCGTEAEVVSESDTLVVARL--RSNGGASQLGDVVVRADNGARTRAVNGFTYLSTSMIAAVTPAEG 3452
Cdd:COG3210   339 SGAGLVSGGTGGNNGTTGTGAGSGLTGTGNGGGLttAGAGTVASTVGTATASTGNASSTTVLGSGSLATGNTGTTIAGNG 418
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3453 QYGTRVTITGQRLLGGGAAVQAVELAGVAATVVSGSDTEVVVAAGNGTAGDVGDVVITSDSGAVSVDALAWRYLDASHIT 3532
Cdd:COG3210   419 GSANAGGFTTTGGVLGITGNGTVTGGTIGGLTGSGTTNGAGLSGNTDVSGTGTVTNSAGNTTSATTLAGGGIGTVTTNAT 498
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3533 SVTPRHGQKGTVVTINGTL---LRGHGSGVAVVLLAGEAANVLSESDTSVVVAASAFGGSKSGPVTIIASNGATAVSTPT 3609
Cdd:COG3210   499 ISNNAGGDANGIATGLTGItagGGGGGNATSGGTGGDGTTLSGSGLTTTVSGGASGTTAASGSNTANTLGVLAATGGTSN 578
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3610 AFEYRAPGAVSAIVPNSGHRGTYVTIKGSNLRGHGPTVMSVTLGGVAGHIVSENSSSVVVRVERLSVAVATPVDVVLTSR 3689
Cdd:COG3210   579 ATTAGNSTSATGGTGTNSGGTVLSIGTGSAGATGTITLGAGTSGAGANATGGGAGLTGSAVGAALSGTGSGTTGTASANG 658
                         650       660       670       680       690       700       710       720
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3690 SGAQVAAAGAFTYLVEGSVADLLPAQGQRGTAVSLSGSNLCGGGTAIVAVTLGGVAASLKPTSTCNLVQFVAGSRNNTAA 3769
Cdd:COG3210   659 SNTTGVNTAGGTGGGTTGTVTSGATGGTTGTTLNAATGGTLNNAGNTLTISTGSITVTGQIGALANANGDTVTFGNLGTG 738
                         730       740       750       760       770       780       790       800
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3770 EAVDVVLESNTGALIEGTGRWTYVVEGAISsvlppgGVAGTLVTIRGSNLLGGGSTAAGVTLAGVSASVEQANATHVIVT 3849
Cdd:COG3210   739 ATLTLNAGVTITSGNAGTLSIGLTANTTAS------GTTLTLANANGNTSAGATLDNAGAEISIDITADGTITAAGTTAI 812
                         810       820       830       840       850       860       870       880
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3850 ANRGTTAGDVVVTSDTGSNVVLQDGFTYSRISSVSPAEGQEGTRVRLDGVGFFTGGASVDRVEICGVASSVTNQSDSRLD 3929
Cdd:COG3210   813 NVTGSGGTITINTATTGLTGTGDTTSGAGGSNTTDTTTGTTSDGASGGGTAGANSGSLAATAASITVGSGGVATSTGTAN 892
                         890       900       910       920       930       940       950       960
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3930 VVVPAATTLVPPLRCDVEVVSAFGVSIVAADAFDYLEPGEIAAVTPTSGHEGTVVTVSGARLLGGGSQVASVTFAGVEVH 4009
Cdd:COG3210   893 AGTLTNLGTTTNAASGNGAVLATVTATGTGGGGLTGGNAAAGGTGAGNGTTALSGTQGNAGLSAASASDGAGDTGASSAA 972
                         970       980       990      1000      1010      1020      1030      1040
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4010 DVLTQSDSEIVAVLRSGGAGGSGDVVVESDTGAVVRLAAGFRYVPQAQILHLTRASGQVGTETTIVGEGLQMGDVIVSVL 4089
Cdd:COG3210   973 GSSAVGTSANSAGSTGGVIAATGILVAGNSGTTASTTGGSGAIVAGGNGVTGTTGTASATGTGTAATAGGQNGVGVNASG 1052
                        1050      1060      1070      1080      1090      1100      1110      1120
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4090 LAGVPAQVLSQSDVNVTVRANTSTPATGDVMLVAGSGAFVELVNGWTYDDAGAIEDVQPAQGFAGNLVTISGRGLRGGSA 4169
Cdd:COG3210  1053 ISGGNAAALTASGTAGTTGGTAASNGGGGTAQASGAGTTHTLGGITNGGATGTSGGTTTSTGGVTASKVGGTTTVGATGT 1132
                        1130      1140      1150      1160      1170      1180      1190      1200
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4170 AVTRVTLVGVLATEIVHENDTVVVVRAGLPVDPFVMQTGRVVVMGSSGATITALDAFTYNVAGDITDVSPSFGRVGTRVR 4249
Cdd:COG3210  1133 STASTEAAGAGTLTGLVAVSAVAGGASSASAGDTTAVAAATTTTTGSAINGGADSAATEGTAGTDLKGGDSTGGSTTTIG 1212
                        1210      1220      1230      1240      1250      1260      1270      1280
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4250 LLGSNLLGGGTSAEVRFGGVTGAVTAVSETAIDVTVPAASGPSGLVNVSIVSDSGSHVLEVAGFRYTAPGSVAAVAPSSG 4329
Cdd:COG3210  1213 TTNVTTTTTLTASDTGNTTATGGSSAGQTGSFVAAGSASGTGDATTGATAGAVSNGATSTVAGNAGATATGSTVDIGSTS 1292
                        1290      1300      1310      1320      1330      1340      1350      1360
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4330 HEGTVVTISGASLLAEEADAARVTLGGVNATVVFANDTRLVVVAGASSTAGLGDVFIETVGGARLLAANAWMYVAQATIT 4409
Cdd:COG3210  1293 ATSAGGSLDTTGNTAGANGATVGTGIGGTTATGTAVAAVNSGGVNAGGGTINTTAANTGLNGGNGATDSAAGAGSGGAAG 1372
                        1370      1380      1390      1400      1410      1420      1430      1440
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4410 DVQPGSGQVGTRVTIRGTGLRCGGAAVTSVLLGSAVAPVVTEDDTTVIAEAPARAVGASPVDVTVVADTGAYVTADDAWT 4489
Cdd:COG3210  1373 SLAATAGAGTVLTGAGNNTGAEGTNAGRDGGVTTSGTGVGNNGGVSGTTVAGTTGSSATTGTGGTGNTTGTSVAGAGGGN 1452
                        1450      1460      1470      1480      1490      1500      1510      1520
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4490 FVTAGAVSSVVPSSGQEGTRVTLSGTNLLGSGSGVDQVLLAGVSATVVSAASSEVVVITSALPGGVVGPVTGNVTVVSTS 4569
Cdd:COG3210  1453 ADASAINTGNASSLGAGGSTAGNAVGGAVIGGTTTGGNGAGVAGATASNGGTSTGAGGTAGGTTAEVAKASLEGGEGTYG 1532
                        1530      1540      1550      1560      1570      1580      1590      1600
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4570 GALVHADTDSFTYVRAGAVTGVSPLAGVQGTRVTVTGERLLGGGSSIAAVQVAGVETRVIESSNNTHVVLRASNGTGSGD 4649
Cdd:COG3210  1533 GSSVAEAGTGGGILGAVSGAGSEGGAAGGVTGSVGVGGTDGAGGDTGGADDTGAQAPTAGNTATLTLSLAEGTNAEYGGT 1612
                        1610
                  ....*....|....*.
gi 514698100 4650 IELIADTGAKTVANVT 4665
Cdd:COG3210  1613 TNVTSGTAGNAGATGA 1628
TNFRSF16 cd13416
Tumor necrosis factor receptor superfamily member 16 (TNFRSF16), also known as p75 ...
6098-6261 3.47e-13

Tumor necrosis factor receptor superfamily member 16 (TNFRSF16), also known as p75 neurotrophin receptor (p75NTR) or CD271; TNFRSF16 (also known as nerve growth factor receptor (NGFR) or p75 neurotrophin receptor (p75NTR or p75(NTR)), CD271, Gp80-LNGFR) is a common receptor for both neurotrophins and proneurotrophins, and plays a diverse role in many tissues, including the nervous system. It has been shown to be expressed in various types of stem cells and has been used to prospectively isolate stem cells with different degrees of potency. p75NTR owes its signaling to the recruitment of intracellular binding proteins, leading to the activation of different signaling pathways. It binds nerve growth factor (NGF) and the complex can initiate a signaling cascade which has been associated with both neuronal apoptosis and neuronal survival of discrete populations of neurons, depending on the presence or absence of intracellular signaling molecules downstream of p75NTR (e.g. NF-kB, JNK, or p75NTR intracellular death domain). p75NTR can also bind NGF in concert with the neurotrophic tyrosine kinase receptor type 1 (TrkA) protein where it is thought to modulate the formation of the high-affinity neurotrophin binding complex. On melanoma cell, p75NTR is an immunosuppressive factor, induced by interferon (IFN)-gamma, and mediates down-regulation of melanoma antigens. It can interact with the aggregated form of amyloid beta (Abeta) peptides, and plays an important role in etiopathogenesis of Alzheimer's disease by influencing protein tau hyper-phosphorylation. p75(NTR) is involved in the formation and progression of retina diseases; its expression is induced in retinal pigment epithelium (RPE) cells and its knockdown rescues RPE cell proliferation activity and inhibits RPE apoptosis induced by hypoxia. It can therefore be a potential therapeutic target for RPE hypoxia or oxidative stress diseases.


Pssm-ID: 276921 [Multi-domain]  Cd Length: 159  Bit Score: 71.18  E-value: 3.47e-13
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6098 CGSGEYETRAPTATtDRKCAsvtQC-DSTQFvvSKPTATTDRdCAECDRCdSGTQYETATCTATTNRVCadltVCADTEY 6176
Cdd:cd13416    18 CPPGEGVARPCGDN-QTVCE---PClDGVTF--SDVVSHTEP-CQPCTRC-PGLMSMRAPCTATHDTVC----ECAYGYY 85
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6177 esvaaTDTSDRKCSSCRECTSSEYLVSGCSESANAVCKACtecPSGTFVSTActplADAE-CTECTRCGSGYFVQSPCTS 6255
Cdd:cd13416    86 -----LDEDSGTCEPCTVCPPGQGVVQSCGPNQDTVCEAC---PEGTYSDED----SSTDpCLPCTVCEDGEVELRECTP 153

                  ....*.
gi 514698100 6256 EADTTC 6261
Cdd:cd13416   154 VSDTVC 159
TNFRSF16 cd13416
Tumor necrosis factor receptor superfamily member 16 (TNFRSF16), also known as p75 ...
5716-5858 5.32e-11

Tumor necrosis factor receptor superfamily member 16 (TNFRSF16), also known as p75 neurotrophin receptor (p75NTR) or CD271; TNFRSF16 (also known as nerve growth factor receptor (NGFR) or p75 neurotrophin receptor (p75NTR or p75(NTR)), CD271, Gp80-LNGFR) is a common receptor for both neurotrophins and proneurotrophins, and plays a diverse role in many tissues, including the nervous system. It has been shown to be expressed in various types of stem cells and has been used to prospectively isolate stem cells with different degrees of potency. p75NTR owes its signaling to the recruitment of intracellular binding proteins, leading to the activation of different signaling pathways. It binds nerve growth factor (NGF) and the complex can initiate a signaling cascade which has been associated with both neuronal apoptosis and neuronal survival of discrete populations of neurons, depending on the presence or absence of intracellular signaling molecules downstream of p75NTR (e.g. NF-kB, JNK, or p75NTR intracellular death domain). p75NTR can also bind NGF in concert with the neurotrophic tyrosine kinase receptor type 1 (TrkA) protein where it is thought to modulate the formation of the high-affinity neurotrophin binding complex. On melanoma cell, p75NTR is an immunosuppressive factor, induced by interferon (IFN)-gamma, and mediates down-regulation of melanoma antigens. It can interact with the aggregated form of amyloid beta (Abeta) peptides, and plays an important role in etiopathogenesis of Alzheimer's disease by influencing protein tau hyper-phosphorylation. p75(NTR) is involved in the formation and progression of retina diseases; its expression is induced in retinal pigment epithelium (RPE) cells and its knockdown rescues RPE cell proliferation activity and inhibits RPE apoptosis induced by hypoxia. It can therefore be a potential therapeutic target for RPE hypoxia or oxidative stress diseases.


Pssm-ID: 276921 [Multi-domain]  Cd Length: 159  Bit Score: 64.63  E-value: 5.32e-11
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5716 SSDRVCVECAPGTFKA---TAGDGTCRAhrtCEDTEyeTVAPTSSSDRKCKALTVCQDDEWESKAPTITTD--------- 5783
Cdd:cd13416    10 SSGECCEQCPPGEGVArpcGDNQTVCEP---CLDGV--TFSDVVSHTEPCQPCTRCPGLMSMRAPCTATHDtvcecaygy 84
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5784 ------RECSPCGRCTDGLTLDKACTDTSPTKCVgcdECASDEYtlsSCTLSSQTQCRQCTTCGNDEYQTKACSVSQDTE 5857
Cdd:cd13416    85 yldedsGTCEPCTVCPPGQGVVQSCGPNQDTVCE---ACPEGTY---SDEDSSTDPCLPCTVCEDGEVELRECTPVSDTV 158

                  .
gi 514698100 5858 C 5858
Cdd:cd13416   159 C 159
TMEM132 pfam16070
Transmembrane protein family 132; This presumed domain is found in members of the TMEM132 ...
6687-6972 3.02e-10

Transmembrane protein family 132; This presumed domain is found in members of the TMEM132 family. TMEM132A may be involved in embryonic and postnatal brain development. TMEM132D may be a marker for oligodendrocyte differentiation.


Pssm-ID: 465003  Cd Length: 344  Bit Score: 66.16  E-value: 3.02e-10
                           10        20        30        40        50        60        70        80
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  6687 LVNTGLLTGIETSTQLVVTAYDEFGA-SSTATPTEC-SLDAGASGAALaavsaNCDAVtlssSASLPFSSPGGQAVVTVR 6764
Cdd:pfam16070    2 ILNTAILTGRTVAVPVKVVAVEADGTvTDVTESVSCsSTDEDVLKVSS-----SCDSV----YVNGKESRGSSNASVNFT 72
                           90       100       110       120       130       140       150       160
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  6765 QGQLEATTVVSVYVPASAPSVALDRTSLRALVPREVSLAFGVREPCAAAT--------------VFERTRVHVLANFTCT 6830
Cdd:pfam16070   73 YGTLSAQLEFTVWVPRLPLEIEVSDTELSQIKGWRVPIGSNKRRPARDSEdeeeddrkgrgcrlQYQHATVRVLARFVAE 152
                          170       180       190       200       210       220       230       240
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  6831 GVDGQACLPALPGQVQLDVAQLALE-LTVADDDVARVKDTYVV-GVADGTTEVRVEQPNSGVVLASTPVHVTrDEVVEID 6908
Cdd:pfam16070  153 DADTGQVSYLLGSDWQVDVTDLVADfLRVEDPRVARLQDGRVLqGREPGTTTVQVLSPLSDSVLGEKTITVL-DDKVTIT 231
                          250       260       270       280       290       300
                   ....*....|....*....|....*....|....*....|....*....|....*....|....
gi 514698100  6909 GLYAGSAESATLSLDHDAVHQLFDQVPVHVRlqsSPLRAEGDVTHVYAFVVLRDGTQFPIDVLD 6972
Cdd:pfam16070  232 DLGVQLVSGLSLSLQPSPGSNRAIVATTTAQ---ETLTAPKQEALLSAWLQFSDGSVTPLDLYD 292
TNFRSF16 cd13416
Tumor necrosis factor receptor superfamily member 16 (TNFRSF16), also known as p75 ...
5950-6116 1.80e-08

Tumor necrosis factor receptor superfamily member 16 (TNFRSF16), also known as p75 neurotrophin receptor (p75NTR) or CD271; TNFRSF16 (also known as nerve growth factor receptor (NGFR) or p75 neurotrophin receptor (p75NTR or p75(NTR)), CD271, Gp80-LNGFR) is a common receptor for both neurotrophins and proneurotrophins, and plays a diverse role in many tissues, including the nervous system. It has been shown to be expressed in various types of stem cells and has been used to prospectively isolate stem cells with different degrees of potency. p75NTR owes its signaling to the recruitment of intracellular binding proteins, leading to the activation of different signaling pathways. It binds nerve growth factor (NGF) and the complex can initiate a signaling cascade which has been associated with both neuronal apoptosis and neuronal survival of discrete populations of neurons, depending on the presence or absence of intracellular signaling molecules downstream of p75NTR (e.g. NF-kB, JNK, or p75NTR intracellular death domain). p75NTR can also bind NGF in concert with the neurotrophic tyrosine kinase receptor type 1 (TrkA) protein where it is thought to modulate the formation of the high-affinity neurotrophin binding complex. On melanoma cell, p75NTR is an immunosuppressive factor, induced by interferon (IFN)-gamma, and mediates down-regulation of melanoma antigens. It can interact with the aggregated form of amyloid beta (Abeta) peptides, and plays an important role in etiopathogenesis of Alzheimer's disease by influencing protein tau hyper-phosphorylation. p75(NTR) is involved in the formation and progression of retina diseases; its expression is induced in retinal pigment epithelium (RPE) cells and its knockdown rescues RPE cell proliferation activity and inhibits RPE apoptosis induced by hypoxia. It can therefore be a potential therapeutic target for RPE hypoxia or oxidative stress diseases.


Pssm-ID: 276921 [Multi-domain]  Cd Length: 159  Bit Score: 57.31  E-value: 1.80e-08
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5950 ACSAGHYVPRGRtggCAAFeCAAGH--VDQDEDAATACKLCEAGVNYAGSAGLT-RCTSVSECGAGEEETSAPTASTDRV 6026
Cdd:cd13416     2 ACPSGQYTSSGE---CCEQ-CPPGEgvARPCGDNQTVCEPCLDGVTFSDVVSHTePCQPCTRCPGLMSMRAPCTATHDTV 77
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6027 CStCASGKFKATTGQTpCEAVSTCEEDEYVYRAATVSTDTQCRaltACSDEQYETRAPTVNSDRECtglTTCGSGEYETR 6106
Cdd:cd13416    78 CE-CAYGYYLDEDSGT-CEPCTVCPPGQGVVQSCGPNQDTVCE---ACPEGTYSDEDSSTDPCLPC---TVCEDGEVELR 149
                         170
                  ....*....|
gi 514698100 6107 APTATTDRKC 6116
Cdd:cd13416   150 ECTPVSDTVC 159
TIG pfam01833
IPT/TIG domain; This family consists of a domain that has an immunoglobulin like fold. These ...
1327-1411 5.51e-08

IPT/TIG domain; This family consists of a domain that has an immunoglobulin like fold. These domains are found in cell surface receptors such as Met and Ron as well as in intracellular transcription factors where it is involved in DNA binding. CAUTION: This family does not currently recognize a significant number of members.


Pssm-ID: 460355 [Multi-domain]  Cd Length: 84  Bit Score: 53.60  E-value: 5.51e-08
                           10        20        30        40        50        60        70        80
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  1327 LSVTSVSPSSG--QGGTRVTVLGANLRLGSSAVTgVLLGSAACSLISENDTAVVCAAGVASAGSVPVTVEASSGAFASvg 1404
Cdd:pfam01833    1 PVITSISPSSGpaSGGTTITITGSNFGTDSSDLK-VTIGGTPCTVISVSSTTIVCTTPPGTSGLVNVSVTVGGGGISS-- 77

                   ....*..
gi 514698100  1405 GVLAFEY 1411
Cdd:pfam01833   78 SPLTFTY 84
VSP pfam03302
Giardia variant-specific surface protein;
5531-5819 6.41e-08

Giardia variant-specific surface protein;


Pssm-ID: 146106 [Multi-domain]  Cd Length: 397  Bit Score: 59.21  E-value: 6.41e-08
                           10        20        30        40        50        60        70        80
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  5531 PTASSDRVCEACPAGTTDANSDGSDACVTCGGGTYVPAGSTGTCSQyeCSAGTADTdsnaGTACEACDGtttyqpskgqe 5610
Cdd:pfam03302   50 PTSQCIDDCAKIGNYYYTTNANNKKICKECTVANCKTCEDQGQCQA--CNDGFYKS----GDACSPCHE----------- 112
                           90       100       110       120       130       140       150       160
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  5611 rclSVKTCGAGeeeTTSPsatrnrvCQPCQLGSTFK-AQSGQSTRCIS--VTTCGAGEEEIASPTLSTDRQCRTCASGTF 5687
Cdd:pfam03302  113 ---SCKTCSGG---TASD-------CTECLTGKALRyGNDGTKGTCGEgcTTGTGAGACKTCGLTIDGTSYCSECATETE 179
                          170       180       190       200       210       220       230       240
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  5688 KAAAG--QSTTCIAVSTCAAGftedvaptPSSDRVCVECAPGTFK------------------ATAGDGTCRAHRTCEDT 5747
Cdd:pfam03302  180 YPQNGvcTSTAARATATCKAS--------SVANGMCSSCANGYFRmnggcyettkfpgksvceEANSGGTCQKEAPGYKL 251
                          250       260       270       280       290       300       310
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*.
gi 514698100  5748 EYETVAPTSSSDRKCKALTVCQDDEwESKAPTITTDREC-SPCGRCTDGLTLDKACTD---TSPTKCVGCDECASD 5819
Cdd:pfam03302  252 NNGDLVTCSPGCKTCTSNTVCTTCM-DGYVKTSDSCTKCdSSCETCTGATTTCKTCATgyyKSGTGCVSCTSSESD 326
IPT cd00102
Immunoglobulin-like fold, Plexins, Transcription factors (IPT). IPTs are also known as ...
1935-2021 1.09e-07

Immunoglobulin-like fold, Plexins, Transcription factors (IPT). IPTs are also known as Transcription factor ImmunoGlobin (TIG) domains. They are present in intracellular transcription factors, cell surface receptors (such as plexins and scatter factor receptors), as well as, cyclodextrin glycosyltransferase and similar enzymes. Although they are involved in DNA binding in transcription factors, their function in other proteins is unknown. In these transcription factors, IPTs form homo- or heterodimers with the exception of the nuclear factor of activated Tcells (NFAT) transcription factors which are mainly monomers.


Pssm-ID: 238050 [Multi-domain]  Cd Length: 89  Bit Score: 53.23  E-value: 1.09e-07
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1935 VIQSVDPQSGQV--GTRITIVGSGLlgGSAFAREVVMGNSVPCSVLRGNDSVVVCVL-ADAGSPAAAVDVTVVGARGSRV 2011
Cdd:cd00102     2 VITSISPSSGPVsgGTEVTITGSNF--GSGSNLRVTFGGGVPCSVLSVSSTAIVCTTpPYANPGPGPVEVTVDRGNGGIT 79
                          90
                  ....*....|
gi 514698100 2012 VASLAFEVLP 2021
Cdd:cd00102    80 SSPLTFTYVP 89
IPT smart00429
ig-like, plexins, transcription factors;
1327-1394 4.65e-07

ig-like, plexins, transcription factors;


Pssm-ID: 214657 [Multi-domain]  Cd Length: 90  Bit Score: 51.27  E-value: 4.65e-07
                            10        20        30        40        50        60        70
                    ....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100   1327 LSVTSVSPSSG--QGGTRVTVLGANLRLGSSAVTGVLLGSAACSLISENDTAVVCAAGVASAGSVPVTVE 1394
Cdd:smart00429    2 PVITRISPTSGpvSGGTEITLCGKNLKSISVVFVEVGVGEAPCTFSPSSSTAIVCKTPPYHNIPGSVPVR 71
TNFR smart00208
Tumor necrosis factor receptor / nerve growth factor receptor repeats; Repeats in growth ...
6219-6261 6.67e-07

Tumor necrosis factor receptor / nerve growth factor receptor repeats; Repeats in growth factor receptors that are involved in growth factor binding. TNF/TNFR


Pssm-ID: 214558  Cd Length: 39  Bit Score: 49.39  E-value: 6.67e-07
                            10        20        30        40
                    ....*....|....*....|....*....|....*....|...
gi 514698100   6219 CPSGTFvstaCTPLADAECTECTRCGSGYFVQSPCTSEADTTC 6261
Cdd:smart00208    1 CKEGTY----CSDGNHSSCLRCRRCPPGLVVKQPCTATSDTVC 39
IPT smart00429
ig-like, plexins, transcription factors;
4496-4583 8.04e-07

ig-like, plexins, transcription factors;


Pssm-ID: 214657 [Multi-domain]  Cd Length: 90  Bit Score: 50.50  E-value: 8.04e-07
                            10        20        30        40        50        60        70        80
                    ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100   4496 VSSVVPSSG--QEGTRVTLSGTNLLGSGSGVDQVLLAGVSATVVSAASSEVVVITsalPGGVVGPVTGNVTVVSTSGALV 4573
Cdd:smart00429    4 ITRISPTSGpvSGGTEITLCGKNLKSISVVFVEVGVGEAPCTFSPSSSTAIVCKT---PPYHNIPGSVPVRTVGLRNGGV 80
                            90
                    ....*....|
gi 514698100   4574 HADTDSFTYV 4583
Cdd:smart00429   81 PSSPQPFTYV 90
TNFRSF5_teleost cd13422
Tumor necrosis factor receptor superfamily member 5 (TNFRSF5) in teleosts; also known as CD40; ...
5514-5576 2.79e-06

Tumor necrosis factor receptor superfamily member 5 (TNFRSF5) in teleosts; also known as CD40; TNFRSF5 (commonly known as CD40 and also as CDW40, p50, Bp50) is widely expressed in diverse cell types including B lymphocytes, dendritic cells, platelets, monocytes, endothelial cells, and fibroblasts. It is essential in mediating a wide variety of immune and inflammatory responses, including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation. Its natural immunomodulating ligand is CD40L, and a primary defect in the CD40/CD40L system is associated with X-linked hyper-IgM (XHIM) syndrome. It is also involved in tumorigenesis; CD40 expression is significantly higher in gastric carcinomas and it is associated with the lymphatic metastasis of cancer cells and their tumor node metastasis (TNM) classification. Upregulated levels of CD40/CD40L on B cells and T cells may play an important role in the immune pathogenesis of breast cancer. Consequently, the CD40/CD40L system serves as a link between tumorigenesis, atherosclerosis, and the immune system, and offers a potential target for drug therapy for related diseases, such as cancer, atherosclerosis, diabetes mellitus, and immunological rejection. Salmon CD40 and CD40L are widely expressed, particularly in immune tissues, and their importance for the immune response is indicated by their relatively high expression in salmon lymphoid organs and gills.


Pssm-ID: 276927 [Multi-domain]  Cd Length: 161  Bit Score: 51.27  E-value: 2.79e-06
                          10        20        30        40        50        60
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*.
gi 514698100 5514 VCRGLTTCGAGEQEKVAPTASSDRVCEACPAGTTDANSDGSDACVT---CGGGTYVPAGSTGTCSQ 5576
Cdd:cd13422    93 TCVPHTTCGPGQGVKSKGNHIRDTVCEECPDGTFSNNSSAEGVCKKwteCESGYKVEAAGTNTSDN 158
VSP pfam03302
Giardia variant-specific surface protein;
5985-6272 3.48e-06

Giardia variant-specific surface protein;


Pssm-ID: 146106 [Multi-domain]  Cd Length: 397  Bit Score: 53.82  E-value: 3.48e-06
                           10        20        30        40        50        60        70        80
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  5985 CKLCEAGvnYAGSAGLTRCTSVSECGAgeEETSAPTASTDRVCSTCASGKFKATTGQT--PCEAV-----STCEEDEYVY 6057
Cdd:pfam03302    1 CDECKPG--YELSADKTKCTSSAPCKT--ENCKACSNDKREVCEECNSNNYLTPTSQCidDCAKIgnyyyTTNANNKKIC 76
                           90       100       110       120       130       140       150       160
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  6058 RAATVSTDTQCR---ALTACSDEQY---ETRAPTVNSDRECTG-----LTTCGSGE---YETRAPTATTDRKCasVTQCD 6123
Cdd:pfam03302   77 KECTVANCKTCEdqgQCQACNDGFYksgDACSPCHESCKTCSGgtasdCTECLTGKalrYGNDGTKGTCGEGC--TTGTG 154
                          170       180       190       200       210       220       230       240
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  6124 STQfvvSKPTATTDRDCAECDRCDSGTQY-ETATCTATTNRVCADLTvcadteyesvaATDTSDRKCSSCrectSSEYLV 6202
Cdd:pfam03302  155 AGA---CKTCGLTIDGTSYCSECATETEYpQNGVCTSTAARATATCK-----------ASSVANGMCSSC----ANGYFR 216
                          250       260       270       280       290       300       310       320
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  6203 --SGCSESANAVCKA-CTECPSG-----------------TFVSTACTPLADAecTECTRCGSGYFVQSPCTSEADTTCK 6262
Cdd:pfam03302  217 mnGGCYETTKFPGKSvCEEANSGgtcqkeapgyklnngdlVTCSPGCKTCTSN--TVCTTCMDGYVKTSDSCTKCDSSCE 294
                          330
                   ....*....|....*..
gi 514698100  6263 -------RCRSCASGEY 6272
Cdd:pfam03302  295 tctgattTCKTCATGYY 311
TNFR_c6 pfam00020
TNFR/NGFR cysteine-rich region;
5816-5858 3.97e-06

TNFR/NGFR cysteine-rich region;


Pssm-ID: 459633 [Multi-domain]  Cd Length: 39  Bit Score: 46.92  E-value: 3.97e-06
                           10        20        30        40
                   ....*....|....*....|....*....|....*....|...
gi 514698100  5816 CASDEYTLSSctlsSQTQCRQCTTCGNDEYQTKACSVSQDTEC 5858
Cdd:pfam00020    1 CPPGTYTDNW----NGLKCLPCTVCPPGQVVVRPCTPTSDTVC 39
IPT_PCSR cd00603
IPT domain of Plexins and Cell Surface Receptors (PCSR) and related proteins . This subgroup ...
2732-2818 4.55e-06

IPT domain of Plexins and Cell Surface Receptors (PCSR) and related proteins . This subgroup contains IPT domains of plexins, receptors, like the plasminogen-related growth factor receptors, the hepatocyte growth factor-scatter factors, and the macrophage-stimulating receptors and of fibrocystin. Plexins are involved in the regulation of cell proliferation and of cellular adhesion and repulsion receptors. In general, there are three copies of the IPT_PCSR domain present preceeded by SEMA (semaphorin) and PSI (plexin, semaphorin, integrin) domains.


Pssm-ID: 238337 [Multi-domain]  Cd Length: 90  Bit Score: 48.60  E-value: 4.55e-06
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2732 PVVGEIEPSSGQL--GTVVTIRGSNLLAGGEALQlVTLAGVPAEAILSSNNSVVTVSSAQGSGATGPAVLVAAETGGRAV 2809
Cdd:cd00603     1 PVITSISPSSGPLsgGTRLTITGSNLGSGSPRVR-VTVGGVPCKVLNVSSTEIVCRTPAAATPGEGPVEVTVDGANVSAR 79

                  ....*....
gi 514698100 2810 GTPSVNYTY 2818
Cdd:cd00603    80 VLSNTTFTY 88
JmjC_2 pfam08007
JmjC domain; This entry includes proteins with a JmjC domain that belong to the cupin ...
4920-5049 1.21e-05

JmjC domain; This entry includes proteins with a JmjC domain that belong to the cupin superfamily, including Bifunctional lysine-specific demethylase and histidyl-hydroxylase NO66, Ribosomal oxygenase 1/2, and 50S ribosomal protein L16 3-hydroxylase from Escherichia coli. Proteins are bifunctional, acting as histone lysine demethylases and ribosomal histidine hydroxylases.


Pssm-ID: 462340  Cd Length: 116  Bit Score: 48.02  E-value: 1.21e-05
                           10        20        30        40        50        60        70        80
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  4920 PHTDPYDVLVIQLQGSKRWT---TCVPDayvsdsndddddsANERSNANSTAADRPPSEAEvlagfnaaqlgqlqeirsq 4996
Cdd:pfam08007   30 PHYDDYDVFLLQGEGRKRWRvgaPKVPD-------------LEFYSDPPLRILDDFEPVHD------------------- 77
                           90       100       110       120       130
                   ....*....|....*....|....*....|....*....|....*....|...
gi 514698100  4997 rqqgctgyqdsmlrgmrctnFTLREGDTMYMPKGIIHFALTEEqGSSHITISL 5049
Cdd:pfam08007   78 --------------------FVLEPGDMLYLPRGFIHQGVALD-ESLHYSVGF 109
RoxA COG2850
Ribosomal protein L16 Arg81 hydroxylase, contains JmjC domain [Translation, ribosomal ...
4920-5090 2.01e-05

Ribosomal protein L16 Arg81 hydroxylase, contains JmjC domain [Translation, ribosomal structure and biogenesis];


Pssm-ID: 442098  Cd Length: 274  Bit Score: 50.58  E-value: 2.01e-05
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4920 PHTDPYDVLVIQLQGSKRW---TTCVPDAYVsdsndddddsanersnanstaadRPPSEAEVLAGFNAAQlgqlqeirsq 4996
Cdd:COG2850   121 PHFDSYDVFLLQGEGRRRWrigDQPDDDPEL-----------------------VPDLPLRILADFEPEI---------- 167
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4997 rqqgctgyqdsmlrgmrctNFTLREGDTMYMPKGIIHFALTEEqGSSHITI-----------------SLERKGLA--WA 5057
Cdd:COG2850   168 -------------------DWVLEPGDMLYLPPGFAHDGVALE-ECMTYSIgfrapswaellseladyLADDLLGDqrYR 227
                         170       180       190
                  ....*....|....*....|....*....|...
gi 514698100 5058 DALMYGATAAGSVLHNRLfqTRFKQAMLKLLSD 5090
Cdd:COG2850   228 DPDLQARADPGEIPAAAL--DRLRAMLLDLLDD 258
TNFRSF1A_teleost cd15834
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) in teleosts; also known as ...
7951-8021 5.92e-05

Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) in teleosts; also known as TNFR1; This subfamily of TNFRSF1 ((also known as type I TNFR, TNFR1, DR1, TNFRSF1A, CD120a, p55) is found in teleosts. It binds TNF-alpha, through the death domain (DD), and activates NF-kappaB, mediates apoptosis and activates signaling pathways controlling inflammatory, immune, and stress responses. It mediates signal transduction by interacting with antiapoptotic protein BCL2-associated athanogene 4 (BAG4/SODD) and adaptor proteins TRAF2 and TRADD that play regulatory roles. The human genetic disorder called tumor necrosis factor associated periodic syndrome (TRAPS), or periodic fever syndrome, is associated with germline mutations of the extracellular domains of this receptor, possibly due to impaired receptor clearance. Serum levels of TNFRSF1A are elevated in schizophrenia and bipolar disorder, and high levels are also associated with cognitive impairment and dementia. Knockout studies in zebrafish embryos have shown that a signaling balance between TNFRSF1A and TNFRSF1B is required for endothelial cell integrity. TNFRSF1A signals apoptosis through caspase-8, whereas TNFRSF1B signals survival via NF-kappaB in endothelial cells. Thus, this apoptotic pathway seems to be evolutionarily conserved, as TNFalpha promotes apoptosis of human endothelial cells and triggers caspase-2 and P53 activation in these cells via TNFRSF1A.


Pssm-ID: 276930 [Multi-domain]  Cd Length: 150  Bit Score: 47.10  E-value: 5.92e-05
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 7951 RNACTlSCGEGEYGDIDAWV--CRAVRPCDLSSEYMVAPETPTSNRVCETLT------------------VCRPSSKyET 8010
Cdd:cd15834    33 RSQCT-PCPEGTYLEQINYSpnCRRCTLCKVKNEEEVSPCKKSSNTVCRCKKgyyksridsetreclkckTCGPGEI-EI 110
                          90
                  ....*....|.
gi 514698100 8011 TAATPTSDRVC 8021
Cdd:cd15834   111 QPCTPESNTVC 121
IPT_PCSR cd00603
IPT domain of Plexins and Cell Surface Receptors (PCSR) and related proteins . This subgroup ...
4496-4584 6.68e-05

IPT domain of Plexins and Cell Surface Receptors (PCSR) and related proteins . This subgroup contains IPT domains of plexins, receptors, like the plasminogen-related growth factor receptors, the hepatocyte growth factor-scatter factors, and the macrophage-stimulating receptors and of fibrocystin. Plexins are involved in the regulation of cell proliferation and of cellular adhesion and repulsion receptors. In general, there are three copies of the IPT_PCSR domain present preceeded by SEMA (semaphorin) and PSI (plexin, semaphorin, integrin) domains.


Pssm-ID: 238337 [Multi-domain]  Cd Length: 90  Bit Score: 45.14  E-value: 6.68e-05
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4496 VSSVVPSSG--QEGTRVTLSGTNLlGSGSGVDQVLLAGVSATVVSAASSEVVVITSALPGGVVGPVtgNVTVVSTSGALV 4573
Cdd:cd00603     3 ITSISPSSGplSGGTRLTITGSNL-GSGSPRVRVTVGGVPCKVLNVSSTEIVCRTPAAATPGEGPV--EVTVDGANVSAR 79
                          90
                  ....*....|.
gi 514698100 4574 HADTDSFTYVR 4584
Cdd:cd00603    80 VLSNTTFTYVE 90
IPT smart00429
ig-like, plexins, transcription factors;
3087-3172 9.53e-05

ig-like, plexins, transcription factors;


Pssm-ID: 214657 [Multi-domain]  Cd Length: 90  Bit Score: 44.72  E-value: 9.53e-05
                            10        20        30        40        50        60        70        80
                    ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100   3087 EIVSVSPSSGQL--GTVVTIEGRSLRGGSSAVVDVVLGGVSAlDVVSENDTRVVAVAGPSSGATGTESVQVVGQQGS-VV 3163
Cdd:smart00429    3 VITRISPTSGPVsgGTEITLCGKNLKSISVVFVEVGVGEAPC-TFSPSSSTAIVCKTPPYHNIPGSVPVRTVGLRNGgVP 81

                    ....*....
gi 514698100   3164 ARPSVWSYV 3172
Cdd:smart00429   82 SSPQPFTYV 90
TIG pfam01833
IPT/TIG domain; This family consists of a domain that has an immunoglobulin like fold. These ...
4496-4582 7.31e-04

IPT/TIG domain; This family consists of a domain that has an immunoglobulin like fold. These domains are found in cell surface receptors such as Met and Ron as well as in intracellular transcription factors where it is involved in DNA binding. CAUTION: This family does not currently recognize a significant number of members.


Pssm-ID: 460355 [Multi-domain]  Cd Length: 84  Bit Score: 42.05  E-value: 7.31e-04
                           10        20        30        40        50        60        70        80
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  4496 VSSVVPSSG--QEGTRVTLSGTNlLGSGSGVDQVLLAGVSATVVSAASSEVVVITsalPGGVVGPVTGNVTVVSTSGALv 4573
Cdd:pfam01833    3 ITSISPSSGpaSGGTTITITGSN-FGTDSSDLKVTIGGTPCTVISVSSTTIVCTT---PPGTSGLVNVSVTVGGGGISS- 77

                   ....*....
gi 514698100  4574 haDTDSFTY 4582
Cdd:pfam01833   78 --SPLTFTY 84
TNFR smart00208
Tumor necrosis factor receptor / nerve growth factor receptor repeats; Repeats in growth ...
5816-5858 7.73e-04

Tumor necrosis factor receptor / nerve growth factor receptor repeats; Repeats in growth factor receptors that are involved in growth factor binding. TNF/TNFR


Pssm-ID: 214558  Cd Length: 39  Bit Score: 40.53  E-value: 7.73e-04
                            10        20        30        40
                    ....*....|....*....|....*....|....*....|...
gi 514698100   5816 CASDEYtlssCTLSSQTQCRQCTTCGNDEYQTKACSVSQDTEC 5858
Cdd:smart00208    1 CKEGTY----CSDGNHSSCLRCRRCPPGLVVKQPCTATSDTVC 39
IPT_PCSR cd00603
IPT domain of Plexins and Cell Surface Receptors (PCSR) and related proteins . This subgroup ...
104-184 1.19e-03

IPT domain of Plexins and Cell Surface Receptors (PCSR) and related proteins . This subgroup contains IPT domains of plexins, receptors, like the plasminogen-related growth factor receptors, the hepatocyte growth factor-scatter factors, and the macrophage-stimulating receptors and of fibrocystin. Plexins are involved in the regulation of cell proliferation and of cellular adhesion and repulsion receptors. In general, there are three copies of the IPT_PCSR domain present preceeded by SEMA (semaphorin) and PSI (plexin, semaphorin, integrin) domains.


Pssm-ID: 238337 [Multi-domain]  Cd Length: 90  Bit Score: 41.67  E-value: 1.19e-03
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  104 VITAVRPAIG--RVGTLVTIEGERLQSGGSAVaRVDLGGVPATLLHGNDSTVVviCSAGSGA----GAVRVTSDVGGFVE 177
Cdd:cd00603     2 VITSISPSSGplSGGTRLTITGSNLGSGSPRV-RVTVGGVPCKVLNVSSTEIV--CRTPAAAtpgeGPVEVTVDGANVSA 78

                  ....*..
gi 514698100  178 GLLWTFV 184
Cdd:cd00603    79 RVLSNTT 85
PHA02714 PHA02714
CD-30-like protein; Provisional
6193-6280 4.70e-03

CD-30-like protein; Provisional


Pssm-ID: 165087 [Multi-domain]  Cd Length: 110  Bit Score: 40.77  E-value: 4.70e-03
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6193 RECTSSEYLvsgcsESANAVCKACTECPSGTFVSTACTPLADAECtectRCGSGYfvqsPCTSEADTTCKRCRSCASGEY 6272
Cdd:PHA02714   22 KTCPKDYYL-----EPEDGLCTACVTCLSNMVEKQSCGPDKPRKC----QCGPGL----KCTVPAVNSCARCTPDTTTKK 88
                          90
                  ....*....|
gi 514698100 6273 LHT--ACTTP 6280
Cdd:PHA02714   89 IEPeqCCTTP 98
TNFR_c6 pfam00020
TNFR/NGFR cysteine-rich region;
6030-6068 4.82e-03

TNFR/NGFR cysteine-rich region;


Pssm-ID: 459633 [Multi-domain]  Cd Length: 39  Bit Score: 38.45  E-value: 4.82e-03
                           10        20        30
                   ....*....|....*....|....*....|....*....
gi 514698100  6030 CASGKFKATTGQTPCEAVSTCEEDEYVYRAATVSTDTQC 6068
Cdd:pfam00020    1 CPPGTYTDNWNGLKCLPCTVCPPGQVVVRPCTPTSDTVC 39
IPT smart00429
ig-like, plexins, transcription factors;
1935-2014 5.55e-03

ig-like, plexins, transcription factors;


Pssm-ID: 214657 [Multi-domain]  Cd Length: 90  Bit Score: 39.71  E-value: 5.55e-03
                            10        20        30        40        50        60        70        80
                    ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100   1935 VIQSVDPQSGQV--GTRITIVGSGLLGGSAFaREVVMGNSVPCSVLRGNDSVVVCVLADAGSPAAAVDVTVVGARGSRVV 2012
Cdd:smart00429    3 VITRISPTSGPVsgGTEITLCGKNLKSISVV-FVEVGVGEAPCTFSPSSSTAIVCKTPPYHNIPGSVPVRTVGLRNGGVP 81

                    ..
gi 514698100   2013 AS 2014
Cdd:smart00429   82 SS 83
TIG pfam01833
IPT/TIG domain; This family consists of a domain that has an immunoglobulin like fold. These ...
2732-2818 8.21e-03

IPT/TIG domain; This family consists of a domain that has an immunoglobulin like fold. These domains are found in cell surface receptors such as Met and Ron as well as in intracellular transcription factors where it is involved in DNA binding. CAUTION: This family does not currently recognize a significant number of members.


Pssm-ID: 460355 [Multi-domain]  Cd Length: 84  Bit Score: 38.97  E-value: 8.21e-03
                           10        20        30        40        50        60        70        80
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  2732 PVVGEIEPSSGQL--GTVVTIRGSNLLAGGEALQlVTLAGVPAEAILSSNNSVVTVSsaqGSGATGPaVLVAAETGGRAV 2809
Cdd:pfam01833    1 PVITSISPSSGPAsgGTTITITGSNFGTDSSDLK-VTIGGTPCTVISVSSTTIVCTT---PPGTSGL-VNVSVTVGGGGI 75

                   ....*....
gi 514698100  2810 GTPSVNYTY 2818
Cdd:pfam01833   76 SSSPLTFTY 84
 
Name Accession Description Interval E-value
FhaB COG3210
Large exoprotein involved in heme utilization or adhesion [Intracellular trafficking, ...
211-1927 1.62e-17

Large exoprotein involved in heme utilization or adhesion [Intracellular trafficking, secretion, and vesicular transport];


Pssm-ID: 442443 [Multi-domain]  Cd Length: 1698  Bit Score: 92.14  E-value: 1.62e-17
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  211 GGATGVASVTVAGVAATLRSPILDYFAVVELGSAPAGTSGAVVVVAESGARVVSSQTFTYAEPATIAAVSPSSGQVGTRV 290
Cdd:COG3210     3 GGLAGTTGNKTIGVDIAVTTTAATLGSNTAGTSGLNILGSGGVGTAGGIASNAGTTASTSGGSGTAGGVGNTSASTGGIG 82
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  291 TITGTNLLGGGAAVERVTLAGVEASLVAQSATQIVVVASPSRERAAGPVVVYSDTGAFARLESAFAYQIPGRISTLSPSS 370
Cdd:COG3210    83 AAAANTAGTLETGLTSNIGGGSVNGSNSTGNGTLTTTAASATTGNNTGGTTTSSTNTVTTLGGTTTGNTVLSTSGAGNNT 162
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  371 GQAGTVVELTGFNLLGGGSALSSLSVHGVEVEQVTFASDALIAFVVPLTSVQGLGDVRIVSASGATVEAGDAFTLLEPGR 450
Cdd:COG3210   163 NTNNSSSGTNIGNSIPTTGGSLNVVAANPTGVTGVGGALINATAGVLANAGGGTAGGVASANSTLTGGVVAAGTGAGVIS 242
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  451 IVGVAPERGQEGTFVTIVGERLLGGGETIARAVLGATAAEAVVSSSDARVVVRAGAAVTFGPVGVTLWADTGAVVNTSAG 530
Cdd:COG3210   243 TGGTDISSLSVAAGAGTGGAGGTGNAGNTTIGTTVTGTNATGSNTAGASSGDTTTNGTSSVTGAGGTGVLGGGTAAGITT 322
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  531 LFEYLAPGMVASVLPVSGQAGTQVVIEGMELLGHETALEAVTLGGVQAAAILSFNRTHVVVTAGDGPASTGPVVLTASNG 610
Cdd:COG3210   323 TNTVGGNGDGNNTTANSGAGLVSGGTGGNNGTTGTGAGSGLTGTGNGGGLTTAGAGTVASTVGTATASTGNASSTTVLGS 402
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  611 SRVTGGAVWTQLERGAIGSVQPSSGHGGTRVTITGQRLLGGGAALASVELGGVLATEIAWANDTVAVVSAGASGSALAGG 690
Cdd:COG3210   403 GSLATGNTGTTIAGNGGSANAGGFTTTGGVLGITGNGTVTGGTIGGLTGSGTTNGAGLSGNTDVSGTGTVTNSAGNTTSA 482
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  691 NVTLVADTGAVTTGSGLWAYVAPAVISSVAPTSGQAGTVVTIRGNNLSMGGAVREVFLAGIPAVSVSLVNDSFVVAHASG 770
Cdd:COG3210   483 TTLAGGGIGTVTTNATISNNAGGDANGIATGLTGITAGGGGGGNATSGGTGGDGTTLSGSGLTTTVSGGASGTTAASGSN 562
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  771 ALSGRSSPAVVRNNFGAFVSSSVNWTYVPAGAVDITRPARAQFGTRVTVTGSNLLQGGAIIASASMAGVPCTVLSSNDTT 850
Cdd:COG3210   563 TANTLGVLAATGGTSNATTAGNSTSATGGTGTNSGGTVLSIGTGSAGATGTITLGAGTSGAGANATGGGAGLTGSAVGAA 642
                         650       660       670       680       690       700       710       720
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  851 VVVSVAGNFAATVASPSMTLVSDSGAVITFTSSTTAEPSGVVTAISPS-SGQYGTFVTLSGTQLLAHASNLRTVSLAGTq 929
Cdd:COG3210   643 LSGTGSGTTGTASANGSNTTGVNTAGGTGGGTTGTVTSGATGGTTGTTlNAATGGTLNNAGNTLTISTGSITVTGQIGA- 721
                         730       740       750       760       770       780       790       800
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  930 vlsIESATESEVIVRAGLGVNGTAGSPRLRASSGGVVAAATGVNFTYVRQGRIDTVSPLFG--QLGTLVTISGEHLLSGG 1007
Cdd:COG3210   722 ---LANANGDTVTFGNLGTGATLTLNAGVTITSGNAGTLSIGLTANTTASGTTLTLANANGntSAGATLDNAGAEISIDI 798
                         810       820       830       840       850       860       870       880
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1008 SSASRVLLAGlpaavvssnssvvvaraPLSNSTSIRTGSVVVLANTGALSAESSTTFTFRPAGFIASVSPSFGQRGTYVE 1087
Cdd:COG3210   799 TADGTITAAG-----------------TTAINVTGSGGTITINTATTGLTGTGDTTSGAGGSNTTDTTTGTTSDGASGGG 861
                         890       900       910       920       930       940       950       960
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1088 IAGNRLLDGSGLREVLLADVPAEVLSANDTFALVRAQASLPRVGDVVVRSDSGYEVVSSQAFVYIAPQHPDTVVPASGQF 1167
Cdd:COG3210   862 TAGANSGSLAATAASITVGSGGVATSTGTANAGTLTNLGTTTNAASGNGAVLATVTATGTGGGGLTGGNAAAGGTGAGNG 941
                         970       980       990      1000      1010      1020      1030      1040
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1168 GTRVTINGTGLLGGGATVQTVQFDAVAGSDPRVTAAGIEVSAPGGAAGVRNITVVANTGAYFTVARAFTVIAEPNVTAIT 1247
Cdd:COG3210   942 TTALSGTQGNAGLSAASASDGAGDTGASSAAGSSAVGTSANSAGSTGGVIAATGILVAGNSGTTASTTGGSGAIVAGGNG 1021
                        1050      1060      1070      1080      1090      1100      1110      1120
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1248 PSSGQAGAYVTVSGTELLGGGAFAERVFLAGVEADVVTSSPSSVVVRAPVSVAKVGPTVIVADTGATTTSLLNFTFTPQL 1327
Cdd:COG3210  1022 VTGTTGTASATGTGTAATAGGQNGVGVNASGISGGNAAALTASGTAGTTGGTAASNGGGGTAQASGAGTTHTLGGITNGG 1101
                        1130      1140      1150      1160      1170      1180      1190      1200
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1328 SVTSVSPSSGQGGTRVTVLGANLRLGSSAVTGVLLGSAACSLISENDTAVVCAAGVASAGSVPVTVEASSGAFASVGGVL 1407
Cdd:COG3210  1102 ATGTSGGTTTSTGGVTASKVGGTTTVGATGTSTASTEAAGAGTLTGLVAVSAVAGGASSASAGDTTAVAAATTTTTGSAI 1181
                        1210      1220      1230      1240      1250      1260      1270      1280
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1408 AfeyldAGVINSVEPGSGQQGTRVVVSGLRLLGGGIRVDQAFLGGVEATIRSSSAFAVTLAAGNGSEPSSGDIVLIADTG 1487
Cdd:COG3210  1182 N-----GGADSAATEGTAGTDLKGGDSTGGSTTTIGTTNVTTTTTLTASDTGNTTATGGSSAGQTGSFVAAGSASGTGDA 1256
                        1290      1300      1310      1320      1330      1340      1350      1360
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1488 AVVSRSGMWTYTEPCGVTDVSPPSGQAGTLVTITGTGFPCTGSSVSTVSLGGVGASIRTQSATQIVVEAPSGSGQGDVVV 1567
Cdd:COG3210  1257 TTGATAGAVSNGATSTVAGNAGATATGSTVDIGSTSATSAGGSLDTTGNTAGANGATVGTGIGGTTATGTAVAAVNSGGV 1336
                        1370      1380      1390      1400      1410      1420      1430      1440
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1568 TADDGSFAVSRGGWEFSRISSVTPASGQFGTAVTVAGQGLRLGFSSVTQVRLGDVAATILSENNTHVVVRAGTGSLVGVP 1647
Cdd:COG3210  1337 NAGGGTINTTAANTGLNGGNGATDSAAGAGSGGAAGSLAATAGAGTVLTGAGNNTGAEGTNAGRDGGVTTSGTGVGNNGG 1416
                        1450      1460      1470      1480      1490      1500      1510      1520
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1648 VDVQVISSGATTVQQSVAWTYLRDGVVSSVVPVQGQRGTRVTVRGERLLGGGSRLERVLLGDIAVDRILSYNDTVVVVEA 1727
Cdd:COG3210  1417 VSGTTVAGTTGSSATTGTGGTGNTTGTSVAGAGGGNADASAINTGNASSLGAGGSTAGNAVGGAVIGGTTTGGNGAGVAG 1496
                        1530      1540      1550      1560      1570      1580      1590      1600
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1728 GLSNSSAVVDVTLVSDTLAGVTGENVFTYVEPMTLYGLTRATGQAGTETTLLGRSLLGGSLAVTEVLLAGTGAQVIGFND 1807
Cdd:COG3210  1497 ATASNGGTSTGAGGTAGGTTAEVAKASLEGGEGTYGGSSVAEAGTGGGILGAVSGAGSEGGAAGGVTGSVGVGGTDGAGG 1576
                        1610      1620      1630      1640      1650      1660      1670      1680
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1808 THVTVrALAGTPGQGNVVIRTSNGAYLVAINGWSFSTPGAIAAVEPVSGQAGTRVTIVGSRLLGGGSRVASVALGSVVHT 1887
Cdd:COG3210  1577 DTGGA-DDTGAQAPTAGNTATLTLSLAEGTNAEYGGTTNVTSGTAGNAGATGANSNTVVTTNGGEGVLALVAGGNTTNGT 1655
                        1690      1700      1710      1720
                  ....*....|....*....|....*....|....*....|
gi 514698100 1888 SSVISGNDTQVVLDALAGPPGLSDVIITSDTRATVTAENV 1927
Cdd:COG3210  1656 TLSGAVNGAGNGWAVDLTDATLAGLGGATTAAAGNVATGD 1695
TNFRSF1B cd10577
Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B), also known as TNFR2; TNFRSF1B ...
5597-5762 5.72e-17

Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B), also known as TNFR2; TNFRSF1B (also known as TNFR2, type 2 TNFR, TNFBR, TNFR80, TNF-R75, TNF-R-II, p75, CD120b) binds TNF-alpha, but lacks the death domain (DD) that is associated with the cytoplasmic domain of TNFRSF1A (TNFR1). It is inducible and expressed exclusively by oligodendrocytes, astrocytes, T cells, thymocytes, myocytes, endothelial cells, and in human mesenchymal stem cells. TNFRSF1B protects oligodendrocyte progenitor cells (OLGs) against oxidative stress, and induces the up-regulation of cell survival genes. While pro-inflammatory and pathogen-clearing activities of TNF are mediated mainly through activation of TNFRSF1A, a strong activator of NF-kappaB, TNFRSF1B is more responsible for suppression of inflammation. Although the affinities of both receptors for soluble TNF are similar, TNFRSF1B is sometimes more abundantly expressed and thought to associate with TNF, thereby increasing its concentration near TNFRSF1A receptors, and making TNF available to activate TNFRSF1A (a ligand-passing mechanism).


Pssm-ID: 276903 [Multi-domain]  Cd Length: 163  Bit Score: 82.14  E-value: 5.72e-17
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5597 CDGTTTYQPSKGQeRCLSvkTCGAGEEETTSPSATRNRVCQPCQlGSTFKAQSGQSTRCISVTT-CGAGEEEIASPTLST 5675
Cdd:cd10577     1 CRNSKEYYDEKAQ-MCCS--KCPPGQHVKHSCTKTSDTVCAPCE-ESTYTQLWNWVPECLSCSSpCSSDQVETQACTRQQ 76
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5676 DRQCrTCASGTFKAAAGQSTT--CIAVSTCAAGFTEDVAPTPSSDRVCVECAPGTFKATAG-DGTCRAHRTCEDTeyeTV 5752
Cdd:cd10577    77 NRIC-SCKPGWYCVLKLQEGCrqCRPLKKCGPGFGVARPGTASSDVECKPCAPGTFSDTTSsTDTCRPHRICSSV---AI 152
                         170
                  ....*....|
gi 514698100 5753 APTSSSDRKC 5762
Cdd:cd10577   153 PGNASMDAVC 162
FhaB COG3210
Large exoprotein involved in heme utilization or adhesion [Intracellular trafficking, ...
2048-3743 1.07e-16

Large exoprotein involved in heme utilization or adhesion [Intracellular trafficking, secretion, and vesicular transport];


Pssm-ID: 442443 [Multi-domain]  Cd Length: 1698  Bit Score: 89.44  E-value: 1.07e-16
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2048 GGADRVVSATLAGAPGSARVVRENDTVVLVQVLVAMPVAFADLRLTASSGATVTFPSAFTALLPGTIASVLPLQGQAGTR 2127
Cdd:COG3210     2 SGGLAGTTGNKTIGVDIAVTTTAATLGSNTAGTSGLNILGSGGVGTAGGIASNAGTTASTSGGSGTAGGVGNTSASTGGI 81
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2128 VTVTGARLRGGSAAVTRATIAGVEATVVVESNDVVVLRATAAMAHPLQGPVVVVGEAGSLVSNAMINFTYLEQGVVTAAT 2207
Cdd:COG3210    82 GAAAANTAGTLETGLTSNIGGGSVNGSNSTGNGTLTTTAASATTGNNTGGTTTSSTNTVTTLGGTTTGNTVLSTSGAGNN 161
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2208 PAYGQRHTRVTVTGTNILGGGSRIVNASFGGVSALDVLASNNSMAVVIAPRLLPGQHSIQLVADSGAVVSSSNLFTARLE 2287
Cdd:COG3210   162 TNTNNSSSGTNIGNSIPTTGGSLNVVAANPTGVTGVGGALINATAGVLANAGGGTAGGVASANSTLTGGVVAAGTGAGVI 241
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2288 GNITSLMPGSGQRGTRITVNGNRLRGSGNEVVSAWVGNVPATVVSEGNSQVVIRPTSSGAAGTSVRIVLVADTGARVETA 2367
Cdd:COG3210   242 STGGTDISSLSVAAGAGTGGAGGTGNAGNTTIGTTVTGTNATGSNTAGASSGDTTTNGTSSVTGAGGTGVLGGGTAAGIT 321
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2368 TVQFDFVPPGDIQAVGPASGQEGTLVTIRGERLLGNGTALAYTYIGGVAAQIVSASNDEVVVVAGRSSNRFTLDqhpVIS 2447
Cdd:COG3210   322 TTNTVGGNGDGNNTTANSGAGLVSGGTGGNNGTTGTGAGSGLTGTGNGGGLTTAGAGTVASTVGTATASTGNAS---STT 398
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2448 DIVLVADNGAEVVAASSFTYLRPGVISSVFPLSGQAGTRVGISGVRLFGGGSRIVSVYLGATQAQVITQTVHAVVVTAKA 2527
Cdd:COG3210   399 VLGSGSLATGNTGTTIAGNGGSANAGGFTTTGGVLGITGNGTVTGGTIGGLTGSGTTNGAGLSGNTDVSGTGTVTNSAGN 478
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2528 GNVSASPEPIRIVADTGAVVTLNDTWSYVQAGRVASVNPASGHQGTLVTIQGTSLLGGGTTAVSVMLAGSSALVLSSNAT 2607
Cdd:COG3210   479 TTSATTLAGGGIGTVTTNATISNNAGGDANGIATGLTGITAGGGGGGNATSGGTGGDGTTLSGSGLTTTVSGGASGTTAA 558
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2608 DVVVTAGPGAQSSGDVVIVSETGATVARGAAWTYVEPGFIQRASPASGTAGTRVTITGASLLGGASTLARVTLAGVPVDS 2687
Cdd:COG3210   559 SGSNTANTLGVLAATGGTSNATTAGNSTSATGGTGTNSGGTVLSIGTGSAGATGTITLGAGTSGAGANATGGGAGLTGSA 638
                         650       660       670       680       690       700       710       720
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2688 IDHQSNEVVIVTAASGAQRMGAIVLTADTGAVVQRLNFWDYIATPVVGEIEPSSGQLGTVVTIRGSNLLAGGEALQLVTL 2767
Cdd:COG3210   639 VGAALSGTGSGTTGTASANGSNTTGVNTAGGTGGGTTGTVTSGATGGTTGTTLNAATGGTLNNAGNTLTISTGSITVTGQ 718
                         730       740       750       760       770       780       790       800
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2768 AGvpaeAILSSNNSVVTVSSAQGSGATGPAVLVAAETGGRAVGTPSVNYTYLAGSSIASVQPASG--QGGTFVDIVGERL 2845
Cdd:COG3210   719 IG----ALANANGDTVTFGNLGTGATLTLNAGVTITSGNAGTLSIGLTANTTASGTTLTLANANGntSAGATLDNAGAEI 794
                         810       820       830       840       850       860       870       880
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2846 LSGGSAVAAVSLAGVAAEVISGND---TFVRARAGPSAVTLTGDVVVTADTGGRAELVNAWAYNTAGVVDAVVPGSGQRG 2922
Cdd:COG3210   795 SIDITADGTITAAGTTAINVTGSGgtiTINTATTGLTGTGDTTSGAGGSNTTDTTTGTTSDGASGGGTAGANSGSLAATA 874
                         890       900       910       920       930       940       950       960
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2923 TRVTIQGTRLLGEGTRAVRVSLGDVRAHIVESTATAVVVVYPGRVT--LGVHDVEVESDTGSVVSAPAAWTALDNGVVHS 3000
Cdd:COG3210   875 ASITVGSGGVATSTGTANAGTLTNLGTTTNAASGNGAVLATVTATGtgGGGLTGGNAAAGGTGAGNGTTALSGTQGNAGL 954
                         970       980       990      1000      1010      1020      1030      1040
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3001 VNPDVGHGGTVVTIRGVRLLGGGDSVADVALAGVVTANVVSANNSVVVVVAELQAQAVTLGDVVVRADTNATVVSSTGLF 3080
Cdd:COG3210   955 SAASASDGAGDTGASSAAGSSAVGTSANSAGSTGGVIAATGILVAGNSGTTASTTGGSGAIVAGGNGVTGTTGTASATGT 1034
                        1050      1060      1070      1080      1090      1100      1110      1120
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3081 DYVAPGEIVSVSPSSGQLGTVVTIEGRSLRGGSSAVVDVVLGGVSALDVVSENDTRVVAVAGPSSGATGTESVQVVGQQG 3160
Cdd:COG3210  1035 GTAATAGGQNGVGVNASGISGGNAAALTASGTAGTTGGTAASNGGGGTAQASGAGTTHTLGGITNGGATGTSGGTTTSTG 1114
                        1130      1140      1150      1160      1170      1180      1190      1200
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3161 SVVARPSVWSYVAPAEVLDVAPQQGRAGTRVTVRGQGLLQGGGRIAQATVAGVTTARIVDSNDTTVVLEAEVAPAGVTPV 3240
Cdd:COG3210  1115 GVTASKVGGTTTVGATGTSTASTEAAGAGTLTGLVAVSAVAGGASSASAGDTTAVAAATTTTTGSAINGGADSAATEGTA 1194
                        1210      1220      1230      1240      1250      1260      1270      1280
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3241 GDVQLVSDTGARVNASVTWQYLAAAVIDSVQPTSGQEGVFVELRGQHLLGGGSAIVDASLAGVAVERVVQSNDTFVRVVA 3320
Cdd:COG3210  1195 GTDLKGGDSTGGSTTTIGTTNVTTTTTLTASDTGNTTATGGSSAGQTGSFVAAGSASGTGDATTGATAGAVSNGATSTVA 1274
                        1290      1300      1310      1320      1330      1340      1350      1360
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3321 GAKNASVVGDVVARGDTGALLRVVNGWQYAVPSVINSVVPASGQEGTLVTVSGVRLLGSLPGRITFVEVCGTEAEVVSES 3400
Cdd:COG3210  1275 GNAGATATGSTVDIGSTSATSAGGSLDTTGNTAGANGATVGTGIGGTTATGTAVAAVNSGGVNAGGGTINTTAANTGLNG 1354
                        1370      1380      1390      1400      1410      1420      1430      1440
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3401 DTLVVARLRSNGGASQLGDVVVRADNGARTRAVNGFTYLSTSMIAAVTPAEGQYGTRVTITGQRLLGGGAAVQAVELAGV 3480
Cdd:COG3210  1355 GNGATDSAAGAGSGGAAGSLAATAGAGTVLTGAGNNTGAEGTNAGRDGGVTTSGTGVGNNGGVSGTTVAGTTGSSATTGT 1434
                        1450      1460      1470      1480      1490      1500      1510      1520
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3481 AATVVSGSDTEVVVAAGNGTAGDVGDVVITSDSGAVSVDALAWRYLDASHITSVTPRHGQKGTVVTINGTLLRGHGSGVA 3560
Cdd:COG3210  1435 GGTGNTTGTSVAGAGGGNADASAINTGNASSLGAGGSTAGNAVGGAVIGGTTTGGNGAGVAGATASNGGTSTGAGGTAGG 1514
                        1530      1540      1550      1560      1570      1580      1590      1600
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3561 VVLLAGEAANVLSESDTSVVVAASAFGGSKSGPVTIIASNGATAVSTPTAFEYRAPGAVSAIVPNSGHRGTYVTIKGSNL 3640
Cdd:COG3210  1515 TTAEVAKASLEGGEGTYGGSSVAEAGTGGGILGAVSGAGSEGGAAGGVTGSVGVGGTDGAGGDTGGADDTGAQAPTAGNT 1594
                        1610      1620      1630      1640      1650      1660      1670      1680
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3641 RGHGPTVMSVTLGGVAGHIVSENSSSVVVRVERLSVAVATPVDVVLTSRSGAQVAAAGAFTYLVEGSVADLLPAQGQRGT 3720
Cdd:COG3210  1595 ATLTLSLAEGTNAEYGGTTNVTSGTAGNAGATGANSNTVVTTNGGEGVLALVAGGNTTNGTTLSGAVNGAGNGWAVDLTD 1674
                        1690      1700
                  ....*....|....*....|...
gi 514698100 3721 AVSLSGSNLCGGGTAIVAVTLGG 3743
Cdd:COG3210  1675 ATLAGLGGATTAAAGNVATGDTA 1697
FhaB COG3210
Large exoprotein involved in heme utilization or adhesion [Intracellular trafficking, ...
1862-3550 4.54e-15

Large exoprotein involved in heme utilization or adhesion [Intracellular trafficking, secretion, and vesicular transport];


Pssm-ID: 442443 [Multi-domain]  Cd Length: 1698  Bit Score: 84.05  E-value: 4.54e-15
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1862 VTIVGSRLLGGGSRVASVALGSVVHTSSVISGNDTQVVLDALAGPPGLSDVIITSDTRATVTAENVWTYLQPGVIQSVDP 1941
Cdd:COG3210     1 GSGGLAGTTGNKTIGVDIAVTTTAATLGSNTAGTSGLNILGSGGVGTAGGIASNAGTTASTSGGSGTAGGVGNTSASTGG 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1942 QSGQVGTRITIVGSGLLGGSAFAREVVMGNSVPCSVLRGNDSVVVCVLADAGSPAAAVDVTVVGARGSRVVASLAFEVLP 2021
Cdd:COG3210    81 IGAAAANTAGTLETGLTSNIGGGSVNGSNSTGNGTLTTTAASATTGNNTGGTTTSSTNTVTTLGGTTTGNTVLSTSGAGN 160
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2022 ASNITSVSPPMGQYGTIITVHGSRLRGGADRVVSATLAGAPGSARVVRENDTVVLVQVLVAMPVAFADLRLTASSGATVT 2101
Cdd:COG3210   161 NTNTNNSSSGTNIGNSIPTTGGSLNVVAANPTGVTGVGGALINATAGVLANAGGGTAGGVASANSTLTGGVVAAGTGAGV 240
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2102 FPSAFTALLPGTIASVLPLQGQAGTRVTVTGARLRGGSAAVTRATIAGVEATVVVESNDVVVLRATAAMAHPLQGPVVVV 2181
Cdd:COG3210   241 ISTGGTDISSLSVAAGAGTGGAGGTGNAGNTTIGTTVTGTNATGSNTAGASSGDTTTNGTSSVTGAGGTGVLGGGTAAGI 320
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2182 GEAGSLVSNAMINFTYLEQGVVTAATPAYGQRHTRVTVTGTNILGGGSRIVNASFGGVSALDVLASNNSMAVVIAPRLLP 2261
Cdd:COG3210   321 TTTNTVGGNGDGNNTTANSGAGLVSGGTGGNNGTTGTGAGSGLTGTGNGGGLTTAGAGTVASTVGTATASTGNASSTTVL 400
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2262 GQHSIQLVADSGAVVSSSNLFTARLEGNITSLMPGSGQRGTRITVNGNRLRGSGNEVVSAWVGNVPATVVSEGNSQVVIR 2341
Cdd:COG3210   401 GSGSLATGNTGTTIAGNGGSANAGGFTTTGGVLGITGNGTVTGGTIGGLTGSGTTNGAGLSGNTDVSGTGTVTNSAGNTT 480
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2342 PTSSGAAGTSVRIVLVADTGARVETATVQFDFVPPGDIQAVGPASGQEGTLVTIRGERLLGNGTALAYTYIGGVAAQIVS 2421
Cdd:COG3210   481 SATTLAGGGIGTVTTNATISNNAGGDANGIATGLTGITAGGGGGGNATSGGTGGDGTTLSGSGLTTTVSGGASGTTAASG 560
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2422 ASNDEVVVVAGRSSNRFTLDQHPVISDIVLVADNGAEVVAASSFTYLRPGVISSVFPLSGQAGTRVGISGVRLFGGGSRI 2501
Cdd:COG3210   561 SNTANTLGVLAATGGTSNATTAGNSTSATGGTGTNSGGTVLSIGTGSAGATGTITLGAGTSGAGANATGGGAGLTGSAVG 640
                         650       660       670       680       690       700       710       720
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2502 VSVYLGATQAQVITQTVHAVVVTAKAGNVSASPEPIRIVADTGAVVTLNDTWSYVQAGRVASVNPASGHQGTLVTIQGTS 2581
Cdd:COG3210   641 AALSGTGSGTTGTASANGSNTTGVNTAGGTGGGTTGTVTSGATGGTTGTTLNAATGGTLNNAGNTLTISTGSITVTGQIG 720
                         730       740       750       760       770       780       790       800
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2582 LLGGGTTAVSVMLAGSSALVLSSNATDVVVTAGPGAQSSGDVVIVSETGATVARGAAWTYVEPGFIQRAS----PASGTA 2657
Cdd:COG3210   721 ALANANGDTVTFGNLGTGATLTLNAGVTITSGNAGTLSIGLTANTTASGTTLTLANANGNTSAGATLDNAgaeiSIDITA 800
                         810       820       830       840       850       860       870       880
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2658 GTRVTITGASLLGGASTLARVTLAGVPVDSIDHQSNEVVIVTAASGAQRMGAIVLTADTGAVVQRLNFWDYIATPVVGEI 2737
Cdd:COG3210   801 DGTITAAGTTAINVTGSGGTITINTATTGLTGTGDTTSGAGGSNTTDTTTGTTSDGASGGGTAGANSGSLAATAASITVG 880
                         890       900       910       920       930       940       950       960
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2738 EPSSGQLGTVVTIRGSNLLAGGEALQLVTLAGVPAEAILSSNNSVVTVSSAQGSGATGPAVLVAAETGGRAVGTPSVNYT 2817
Cdd:COG3210   881 SGGVATSTGTANAGTLTNLGTTTNAASGNGAVLATVTATGTGGGGLTGGNAAAGGTGAGNGTTALSGTQGNAGLSAASAS 960
                         970       980       990      1000      1010      1020      1030      1040
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2818 YLAGSSIASVQPASGQGGTFVDIVGERLLSGGSAVAAVSLAGVAAEVISGNDTFVRARAGPSAVTLTGDVVVTADTGGRA 2897
Cdd:COG3210   961 DGAGDTGASSAAGSSAVGTSANSAGSTGGVIAATGILVAGNSGTTASTTGGSGAIVAGGNGVTGTTGTASATGTGTAATA 1040
                        1050      1060      1070      1080      1090      1100      1110      1120
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2898 ELVNAWAYNTAGVVDAVVPGSGQRGTRVTIQGTRLLGEGTRAVRVSLGDVRAHIVESTATAVVVVYPGRVTLGVHDVEVE 2977
Cdd:COG3210  1041 GGQNGVGVNASGISGGNAAALTASGTAGTTGGTAASNGGGGTAQASGAGTTHTLGGITNGGATGTSGGTTTSTGGVTASK 1120
                        1130      1140      1150      1160      1170      1180      1190      1200
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2978 SDTGSVVSAPAAWTALDNGVVHSVNPDVGHGGTVVTIRGVRLLGGGDSVADVALAGVVTANVVSANNSVVVVVAELQAQA 3057
Cdd:COG3210  1121 VGGTTTVGATGTSTASTEAAGAGTLTGLVAVSAVAGGASSASAGDTTAVAAATTTTTGSAINGGADSAATEGTAGTDLKG 1200
                        1210      1220      1230      1240      1250      1260      1270      1280
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3058 VTLGDVVVRADTNATVVSSTGLFDYVAPGEIVSVSPSSGQLGTVVTIEGRSLRGGSSAVVDVVLGGVSALDVVSENDTRV 3137
Cdd:COG3210  1201 GDSTGGSTTTIGTTNVTTTTTLTASDTGNTTATGGSSAGQTGSFVAAGSASGTGDATTGATAGAVSNGATSTVAGNAGAT 1280
                        1290      1300      1310      1320      1330      1340      1350      1360
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3138 VAVAGPSSGATGTESVQVVGQQGSVVARPSVWSYVAPAEVLDVAPQQGRAGTRVTVRGQGLLQGGGRIAQATVAGVTTAR 3217
Cdd:COG3210  1281 ATGSTVDIGSTSATSAGGSLDTTGNTAGANGATVGTGIGGTTATGTAVAAVNSGGVNAGGGTINTTAANTGLNGGNGATD 1360
                        1370      1380      1390      1400      1410      1420      1430      1440
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3218 IVDSNDTTVVLeaeVAPAGVTPVGDVQLVSDTGARVNASVTWQYLAAAVIDSVQPTSGQEGVFVELRGQHLLGGGSAIVD 3297
Cdd:COG3210  1361 SAAGAGSGGAA---GSLAATAGAGTVLTGAGNNTGAEGTNAGRDGGVTTSGTGVGNNGGVSGTTVAGTTGSSATTGTGGT 1437
                        1450      1460      1470      1480      1490      1500      1510      1520
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3298 ASLAGVAVERVVQSNDTFVRVVAGAKNASVVGDVVARGDTGALLRVVNGWQYAVPSVINSVVPASGQEGTLVTVSGVRLL 3377
Cdd:COG3210  1438 GNTTGTSVAGAGGGNADASAINTGNASSLGAGGSTAGNAVGGAVIGGTTTGGNGAGVAGATASNGGTSTGAGGTAGGTTA 1517
                        1530      1540      1550      1560      1570      1580      1590      1600
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3378 GSLPGRITFVEVCGTEAEVVSESDTLVVARLRSNGGASQLGDVVVRADNGARTRAVNGFTYLSTSMIAAVTPAEGQYGTR 3457
Cdd:COG3210  1518 EVAKASLEGGEGTYGGSSVAEAGTGGGILGAVSGAGSEGGAAGGVTGSVGVGGTDGAGGDTGGADDTGAQAPTAGNTATL 1597
                        1610      1620      1630      1640      1650      1660      1670      1680
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3458 VTITGQRLLGGGAAVQAVELAGVAATVVSGSDTEVVVAAGNGTAGDVGDVVITSDSGAVSVDALAWRYLDASHITSVTPR 3537
Cdd:COG3210  1598 TLSLAEGTNAEYGGTTNVTSGTAGNAGATGANSNTVVTTNGGEGVLALVAGGNTTNGTTLSGAVNGAGNGWAVDLTDATL 1677
                        1690
                  ....*....|...
gi 514698100 3538 HGQKGTVVTINGT 3550
Cdd:COG3210  1678 AGLGGATTAAAGN 1690
FhaB COG3210
Large exoprotein involved in heme utilization or adhesion [Intracellular trafficking, ...
1797-3515 6.90e-15

Large exoprotein involved in heme utilization or adhesion [Intracellular trafficking, secretion, and vesicular transport];


Pssm-ID: 442443 [Multi-domain]  Cd Length: 1698  Bit Score: 83.28  E-value: 6.90e-15
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1797 GTGAQVIGFNDTHVTVRALAGTPGQGNVVIRTSNGAYLVAINGWSFSTPGAIAAVEPVSGQAGTRVTIVGSRLLGGGSRV 1876
Cdd:COG3210     1 GSGGLAGTTGNKTIGVDIAVTTTAATLGSNTAGTSGLNILGSGGVGTAGGIASNAGTTASTSGGSGTAGGVGNTSASTGG 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1877 ASVALGSVVHTSSVISGNDTQVVLDALAGPPGLSDVIITSDTRATVTAENVWTYLQPGVIQSVDPQSGQVGTRITIVGSG 1956
Cdd:COG3210    81 IGAAAANTAGTLETGLTSNIGGGSVNGSNSTGNGTLTTTAASATTGNNTGGTTTSSTNTVTTLGGTTTGNTVLSTSGAGN 160
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1957 LLGGSAFAREVVMGNSVPCSVLRGNDSVVVCVLADAGSPAAAVDVTVVGARGSRVVASLAFEVLPASNITSVSPPMGQYG 2036
Cdd:COG3210   161 NTNTNNSSSGTNIGNSIPTTGGSLNVVAANPTGVTGVGGALINATAGVLANAGGGTAGGVASANSTLTGGVVAAGTGAGV 240
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2037 TIITVHGSRLRGGADRVVSATLAGAPGSARVVRENDTVVLVQVLVAMPVAFADLRLTASSGATVTFPSAFTALLPGTIAS 2116
Cdd:COG3210   241 ISTGGTDISSLSVAAGAGTGGAGGTGNAGNTTIGTTVTGTNATGSNTAGASSGDTTTNGTSSVTGAGGTGVLGGGTAAGI 320
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2117 VLPLQGQAGTRVTVTGARLRGGSAAVTRATIAGVEATVVVESNDVVVLRATAAMAHPLQGPVVVVGEAGSLVSNAMINFT 2196
Cdd:COG3210   321 TTTNTVGGNGDGNNTTANSGAGLVSGGTGGNNGTTGTGAGSGLTGTGNGGGLTTAGAGTVASTVGTATASTGNASSTTVL 400
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2197 YLEQGVVTAATPAYGQRHTRVTVTGTNILGGGSRIVNASFGGVSALDVLASNNSMAVVIAPRLLPGQHSIQLVADSGAVV 2276
Cdd:COG3210   401 GSGSLATGNTGTTIAGNGGSANAGGFTTTGGVLGITGNGTVTGGTIGGLTGSGTTNGAGLSGNTDVSGTGTVTNSAGNTT 480
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2277 SSSNLFTARLEGNITSLMPGSGQRGTRITVNGNRLRGSGNEVVSAWVGNVPATVVSEGNSQVVIRPTSSGAAGTSVRIVL 2356
Cdd:COG3210   481 SATTLAGGGIGTVTTNATISNNAGGDANGIATGLTGITAGGGGGGNATSGGTGGDGTTLSGSGLTTTVSGGASGTTAASG 560
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2357 VADTGARVETATVQFDFVPPGDIQAVGPASGQEGTLVTIRGERLLGNGTALAYTYIGGVAAQIVSASNDEVVVVAGRSSN 2436
Cdd:COG3210   561 SNTANTLGVLAATGGTSNATTAGNSTSATGGTGTNSGGTVLSIGTGSAGATGTITLGAGTSGAGANATGGGAGLTGSAVG 640
                         650       660       670       680       690       700       710       720
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2437 RFTLDQHPVISDIVLVADNGAEVVAASSFTYLRPGVISSVFPLSGQAGTRVGISGVRLFGGGSRIVSVYLGATQAQVITQ 2516
Cdd:COG3210   641 AALSGTGSGTTGTASANGSNTTGVNTAGGTGGGTTGTVTSGATGGTTGTTLNAATGGTLNNAGNTLTISTGSITVTGQIG 720
                         730       740       750       760       770       780       790       800
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2517 TV------HAVVVTAKAGNVSASPEPIRIVADTGAVVTLNDTWSYVQAGRVASVNPASG--HQGTLVTIQGTSLLGGGTT 2588
Cdd:COG3210   721 ALanangdTVTFGNLGTGATLTLNAGVTITSGNAGTLSIGLTANTTASGTTLTLANANGntSAGATLDNAGAEISIDITA 800
                         810       820       830       840       850       860       870       880
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2589 AVSVMLAGSSALVLSSNATDVVVTAGPGAQSSGDVVIVSETGATVARGAawtyvepGFIQRASPASGTAGTRVTITGASL 2668
Cdd:COG3210   801 DGTITAAGTTAINVTGSGGTITINTATTGLTGTGDTTSGAGGSNTTDTT-------TGTTSDGASGGGTAGANSGSLAAT 873
                         890       900       910       920       930       940       950       960
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2669 LGGASTLARVTLAGVPVDSIDHQSNEVVIVTAASGAQRMGAIVLTADTGAVVQRLNFWDYIATPVVGEIEPSSGQLGTVV 2748
Cdd:COG3210   874 AASITVGSGGVATSTGTANAGTLTNLGTTTNAASGNGAVLATVTATGTGGGGLTGGNAAAGGTGAGNGTTALSGTQGNAG 953
                         970       980       990      1000      1010      1020      1030      1040
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2749 TIRGSNLLAGGEALQLVTLAGVPAEAILSSNNSVVTVSSAQGSGATGPAVLVAAETGGRAVGTPSVNYTYLAGSSIASVQ 2828
Cdd:COG3210   954 LSAASASDGAGDTGASSAAGSSAVGTSANSAGSTGGVIAATGILVAGNSGTTASTTGGSGAIVAGGNGVTGTTGTASATG 1033
                        1050      1060      1070      1080      1090      1100      1110      1120
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2829 PASGQGGTFVDIVGERLLSGGSAVAAVSLAGVAAEVISGNDTFVRARAGPSAVTLTGDVVVTADTGGRAELVNAWAYNTA 2908
Cdd:COG3210  1034 TGTAATAGGQNGVGVNASGISGGNAAALTASGTAGTTGGTAASNGGGGTAQASGAGTTHTLGGITNGGATGTSGGTTTST 1113
                        1130      1140      1150      1160      1170      1180      1190      1200
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2909 GVVDAVVPGSGQRGTRVTIQGTRLLGEGTRAVRVSLGDVRAHIVESTATAVVVVYPGRVTLGVHDVEVESDTGSVVSAPA 2988
Cdd:COG3210  1114 GGVTASKVGGTTTVGATGTSTASTEAAGAGTLTGLVAVSAVAGGASSASAGDTTAVAAATTTTTGSAINGGADSAATEGT 1193
                        1210      1220      1230      1240      1250      1260      1270      1280
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2989 AWTALDNGVVHSVNPDVGHGGTVVTIRGVRLLGGGDSVADVALAGVVTANVVSANNSVVVVVAELQAQAVTLGDVVVRAD 3068
Cdd:COG3210  1194 AGTDLKGGDSTGGSTTTIGTTNVTTTTTLTASDTGNTTATGGSSAGQTGSFVAAGSASGTGDATTGATAGAVSNGATSTV 1273
                        1290      1300      1310      1320      1330      1340      1350      1360
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3069 TNATVVSSTGLFDYVAPGEIVSVSPSSGQLGTVVTIEGRSLRGGSSAVVDVVLGGVSALDVVSENDTRVVAVAGPSSGAT 3148
Cdd:COG3210  1274 AGNAGATATGSTVDIGSTSATSAGGSLDTTGNTAGANGATVGTGIGGTTATGTAVAAVNSGGVNAGGGTINTTAANTGLN 1353
                        1370      1380      1390      1400      1410      1420      1430      1440
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3149 GTESVQVVGQQGSVvarpsvwsyvapaevldvapqqGRAGTRVTVRGQGLLQGGGRIAQATVAGVTTARIVDSNDTTVVL 3228
Cdd:COG3210  1354 GGNGATDSAAGAGS----------------------GGAAGSLAATAGAGTVLTGAGNNTGAEGTNAGRDGGVTTSGTGV 1411
                        1450      1460      1470      1480      1490      1500      1510      1520
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3229 EAEVAPAGVTPVGDVQLVSDTGARVNASVTWQYLAAAVIDSVQPTSGQEGVFVELRGQHLLGGGSAIVDASLAGVAVERV 3308
Cdd:COG3210  1412 GNNGGVSGTTVAGTTGSSATTGTGGTGNTTGTSVAGAGGGNADASAINTGNASSLGAGGSTAGNAVGGAVIGGTTTGGNG 1491
                        1530      1540      1550      1560      1570      1580      1590      1600
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3309 VQSNDTFVRVVAGAKNASVVGDVVARGDTGALLRVVNGWQYAVPSVINSVVPASGQEGTLVTVSGVRLLGSLPGRITFVE 3388
Cdd:COG3210  1492 AGVAGATASNGGTSTGAGGTAGGTTAEVAKASLEGGEGTYGGSSVAEAGTGGGILGAVSGAGSEGGAAGGVTGSVGVGGT 1571
                        1610      1620      1630      1640      1650      1660      1670      1680
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3389 VCGTEAEVVSESDTLVVARLRSNGGASQLGDVVVRADNGARTRAVNGFTYLSTSMIAAVTPAEGQYGTRVTITGQRLLGG 3468
Cdd:COG3210  1572 DGAGGDTGGADDTGAQAPTAGNTATLTLSLAEGTNAEYGGTTNVTSGTAGNAGATGANSNTVVTTNGGEGVLALVAGGNT 1651
                        1690      1700      1710      1720
                  ....*....|....*....|....*....|....*....|....*..
gi 514698100 3469 GAAVQAVELAGVAATVVSGSDTEVVVAAGNGTAGDVGDVVITSDSGA 3515
Cdd:COG3210  1652 TNGTTLSGAVNGAGNGWAVDLTDATLAGLGGATTAAAGNVATGDTAP 1698
FhaB COG3210
Large exoprotein involved in heme utilization or adhesion [Intracellular trafficking, ...
811-2432 9.58e-15

Large exoprotein involved in heme utilization or adhesion [Intracellular trafficking, secretion, and vesicular transport];


Pssm-ID: 442443 [Multi-domain]  Cd Length: 1698  Bit Score: 82.89  E-value: 9.58e-15
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  811 AQFGTRVTVTGSNLLQGGAIIASASMAGVPCTVLSSNDTTVVVSVAGNFAATVASPSMTLVSDSGAVITFTSSTTAEPSG 890
Cdd:COG3210    47 TAGGIASNAGTTASTSGGSGTAGGVGNTSASTGGIGAAAANTAGTLETGLTSNIGGGSVNGSNSTGNGTLTTTAASATTG 126
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  891 VVTAISPSSGQYGTFVTLSGTQLLAHASNLRTVSLAGTQVLSIESATESEVIVRAGLGVNGTAGSPRLRASSGGVVAAAT 970
Cdd:COG3210   127 NNTGGTTTSSTNTVTTLGGTTTGNTVLSTSGAGNNTNTNNSSSGTNIGNSIPTTGGSLNVVAANPTGVTGVGGALINATA 206
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  971 GVNFTYVRQGRIDTVSPLFGQLGTLVTISGEHLLSGGSSASRVLLAGLPAAVVSSNSSVVVARAPLSNSTSIRTGSVVVL 1050
Cdd:COG3210   207 GVLANAGGGTAGGVASANSTLTGGVVAAGTGAGVISTGGTDISSLSVAAGAGTGGAGGTGNAGNTTIGTTVTGTNATGSN 286
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1051 ANTGALSAESSTTFTFRPAGFIASVSPSFGQRGTYVEIAGNRLLDGSGLREVLLADVPAEVLSANDTFALVRAQASLPRV 1130
Cdd:COG3210   287 TAGASSGDTTTNGTSSVTGAGGTGVLGGGTAAGITTTNTVGGNGDGNNTTANSGAGLVSGGTGGNNGTTGTGAGSGLTGT 366
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1131 GDVVVRSDSGYEVVSSQAFVYIAPQHPDTVVPASGQFGTRVTINGTGLLGGGATVQTVQFDAVAGSDPRVTAAGIEVSAP 1210
Cdd:COG3210   367 GNGGGLTTAGAGTVASTVGTATASTGNASSTTVLGSGSLATGNTGTTIAGNGGSANAGGFTTTGGVLGITGNGTVTGGTI 446
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1211 GGAAGVRNITVVANTGAYFTVARAFTVIAEPNVTAITPSSGQAGAYVTVSGTELLGGGAFAERVFLAGVEADVVTSSPSS 1290
Cdd:COG3210   447 GGLTGSGTTNGAGLSGNTDVSGTGTVTNSAGNTTSATTLAGGGIGTVTTNATISNNAGGDANGIATGLTGITAGGGGGGN 526
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1291 VVVRAPVSVAKVGPTVIVADTGATTTSLLNFTFTPQLSVTSVSPSSGQGGTRVTVLGANLRLGSSAVTGVLLGSAACSLI 1370
Cdd:COG3210   527 ATSGGTGGDGTTLSGSGLTTTVSGGASGTTAASGSNTANTLGVLAATGGTSNATTAGNSTSATGGTGTNSGGTVLSIGTG 606
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1371 SENDTAVVCAAGVASAGSVPVTVEASSGAFASVGGVLAFEYLDAGVINSVEPGSGQQGTrvvVSGLRLLGGGIRVDQAFL 1450
Cdd:COG3210   607 SAGATGTITLGAGTSGAGANATGGGAGLTGSAVGAALSGTGSGTTGTASANGSNTTGVN---TAGGTGGGTTGTVTSGAT 683
                         650       660       670       680       690       700       710       720
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1451 GGVEATIRSSSAFAVTLAAGNGSEPSSGDIVLIADTGAVVSRSGMWTYTEPCGVTD-------VSPPSGQAGTLVTITGT 1523
Cdd:COG3210   684 GGTTGTTLNAATGGTLNNAGNTLTISTGSITVTGQIGALANANGDTVTFGNLGTGAtltlnagVTITSGNAGTLSIGLTA 763
                         730       740       750       760       770       780       790       800
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1524 GFPCTGSSVSTVSLGGVGASIRTQSATQIVVEAP-------SGSGQGDVVVTADDGSFAVSRGGWEFSRISSVTPASGQF 1596
Cdd:COG3210   764 NTTASGTTLTLANANGNTSAGATLDNAGAEISIDitadgtiTAAGTTAINVTGSGGTITINTATTGLTGTGDTTSGAGGS 843
                         810       820       830       840       850       860       870       880
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1597 GTAVTVAGQGLRLGFSSVTQVRLGDVAATILSENNTHVVVRAGTGSLVGVPVDVQVISSGATTVQQSVAWTYLRDGVVSS 1676
Cdd:COG3210   844 NTTDTTTGTTSDGASGGGTAGANSGSLAATAASITVGSGGVATSTGTANAGTLTNLGTTTNAASGNGAVLATVTATGTGG 923
                         890       900       910       920       930       940       950       960
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1677 VVPVQGQRGTRVTVRGERLLGGGSRLERVLLGDIAVDRILSYNDTVVVVEAGLSNSSAVVDVTLVSDTLAGVTGENVFTY 1756
Cdd:COG3210   924 GGLTGGNAAAGGTGAGNGTTALSGTQGNAGLSAASASDGAGDTGASSAAGSSAVGTSANSAGSTGGVIAATGILVAGNSG 1003
                         970       980       990      1000      1010      1020      1030      1040
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1757 VEPMTLYGLTRATGQAGTETTLLGRSLLGGSLAVTEVLLAGTGAQVIGFNDTHVTVRALAGTPGQGNVVIRTSNGAYLVA 1836
Cdd:COG3210  1004 TTASTTGGSGAIVAGGNGVTGTTGTASATGTGTAATAGGQNGVGVNASGISGGNAAALTASGTAGTTGGTAASNGGGGTA 1083
                        1050      1060      1070      1080      1090      1100      1110      1120
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1837 INGWSFSTPGAIAAVEPVSGQAGTRVTIVGSRLLGGGSRVASVALGSVVHTSSVISGNDTQVVLDALAGPPGLSDVIITS 1916
Cdd:COG3210  1084 QASGAGTTHTLGGITNGGATGTSGGTTTSTGGVTASKVGGTTTVGATGTSTASTEAAGAGTLTGLVAVSAVAGGASSASA 1163
                        1130      1140      1150      1160      1170      1180      1190      1200
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1917 DTRATVTAENVWTYLQPGVIQSVDPQSGQVGTRITIVGSGLLGGSAFAREVVMGNSVPCSVLRGNDSVVVCVLADAGSPA 1996
Cdd:COG3210  1164 GDTTAVAAATTTTTGSAINGGADSAATEGTAGTDLKGGDSTGGSTTTIGTTNVTTTTTLTASDTGNTTATGGSSAGQTGS 1243
                        1210      1220      1230      1240      1250      1260      1270      1280
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1997 AAVDVTVVGARGSRVVASLAFEVLPASNITSVSPPMGQYGTIITVHGSRLRGGADRVVSATLAGAPGSARVVRENDTVVL 2076
Cdd:COG3210  1244 FVAAGSASGTGDATTGATAGAVSNGATSTVAGNAGATATGSTVDIGSTSATSAGGSLDTTGNTAGANGATVGTGIGGTTA 1323
                        1290      1300      1310      1320      1330      1340      1350      1360
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2077 VQVLVAMPVAFADLRLTASSGATVTFPSAFTALLPGTIASVLPLQGQAGTRVTVTGARLRGGSAAVTRATIAGVEATVVV 2156
Cdd:COG3210  1324 TGTAVAAVNSGGVNAGGGTINTTAANTGLNGGNGATDSAAGAGSGGAAGSLAATAGAGTVLTGAGNNTGAEGTNAGRDGG 1403
                        1370      1380      1390      1400      1410      1420      1430      1440
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2157 ESNDVVVLRATAAMAHPLQGPVVVVGEAGSLVSNAMINFTYLEQGVVTAATPAYGQRHTRVTVTGTNILGGGSRIVNASF 2236
Cdd:COG3210  1404 VTTSGTGVGNNGGVSGTTVAGTTGSSATTGTGGTGNTTGTSVAGAGGGNADASAINTGNASSLGAGGSTAGNAVGGAVIG 1483
                        1450      1460      1470      1480      1490      1500      1510      1520
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2237 GGVSALDVLASNNSMAVVIAPRLLPGQHSIQLVADSGAVVSSSNLFTARLEGNITSLMPGSGQRGTRITVNGNRLRGSGN 2316
Cdd:COG3210  1484 GTTTGGNGAGVAGATASNGGTSTGAGGTAGGTTAEVAKASLEGGEGTYGGSSVAEAGTGGGILGAVSGAGSEGGAAGGVT 1563
                        1530      1540      1550      1560      1570      1580      1590      1600
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2317 EVVSAWVGNVPATVVSEGNSQVVIRPTSSGAAGTSVRIVLVADTGARVETATVQFDFVPPGDIQAVGPASGQEGTLVTIR 2396
Cdd:COG3210  1564 GSVGVGGTDGAGGDTGGADDTGAQAPTAGNTATLTLSLAEGTNAEYGGTTNVTSGTAGNAGATGANSNTVVTTNGGEGVL 1643
                        1610      1620      1630
                  ....*....|....*....|....*....|....*.
gi 514698100 2397 GERLLGNGTALAYTYIGGVAAQIVSASNDEVVVVAG 2432
Cdd:COG3210  1644 ALVAGGNTTNGTTLSGAVNGAGNGWAVDLTDATLAG 1679
FhaB COG3210
Large exoprotein involved in heme utilization or adhesion [Intracellular trafficking, ...
2854-4583 1.56e-14

Large exoprotein involved in heme utilization or adhesion [Intracellular trafficking, secretion, and vesicular transport];


Pssm-ID: 442443 [Multi-domain]  Cd Length: 1698  Bit Score: 82.12  E-value: 1.56e-14
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2854 AVSLAGVAAEVISGNDTFVRARAGPSAVTLTGDVVVTADTGGRAELVNAWAYNTAGVVDAVVPGSGQRGTRVTIQGTRLL 2933
Cdd:COG3210     1 GSGGLAGTTGNKTIGVDIAVTTTAATLGSNTAGTSGLNILGSGGVGTAGGIASNAGTTASTSGGSGTAGGVGNTSASTGG 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2934 GEGTRAVRVSLGDVRAHIVESTATAVVVVYPGRVTLGVHDVEVESDTGSVVSAPAAWTALDNGVVHSVNPDVGHGGTVVT 3013
Cdd:COG3210    81 IGAAAANTAGTLETGLTSNIGGGSVNGSNSTGNGTLTTTAASATTGNNTGGTTTSSTNTVTTLGGTTTGNTVLSTSGAGN 160
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3014 IRGVRLLGGGDSVADVALAGVVTANVVSANNSVVVVVAELQAQAVTLGDVVVRADTNATVVSSTGLFDYVAPGEIVSVSP 3093
Cdd:COG3210   161 NTNTNNSSSGTNIGNSIPTTGGSLNVVAANPTGVTGVGGALINATAGVLANAGGGTAGGVASANSTLTGGVVAAGTGAGV 240
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3094 SSGQLGTVVTIEGRSLRGGSSAVVDVVLGGVSALDVVSENDTRVVAVAGPSSGATGTESVQVVGQQGSVVARPSVWSYVA 3173
Cdd:COG3210   241 ISTGGTDISSLSVAAGAGTGGAGGTGNAGNTTIGTTVTGTNATGSNTAGASSGDTTTNGTSSVTGAGGTGVLGGGTAAGI 320
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3174 paevldvapqqgrAGTRVTVRGQGLLQGGGRIAQATVAGVTTARIVDSNDTTVVLEAEVAPAGVTPVGDVQLVSDTGARV 3253
Cdd:COG3210   321 -------------TTTNTVGGNGDGNNTTANSGAGLVSGGTGGNNGTTGTGAGSGLTGTGNGGGLTTAGAGTVASTVGTA 387
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3254 NASVTWQYLAAAVIDSVQPTSGQEGVFVELRGQHLLGGGSAIVDASLAGVAVERVVQSNDTFVRVVAGAKNASVVGDVVA 3333
Cdd:COG3210   388 TASTGNASSTTVLGSGSLATGNTGTTIAGNGGSANAGGFTTTGGVLGITGNGTVTGGTIGGLTGSGTTNGAGLSGNTDVS 467
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3334 RGDTGALLRVVNGWQYAVPSVINSVVPASGQEGTLVTVSGVRLLGSLPGRITFVEVCGTEAEVVSESDTLVVARLRSNGG 3413
Cdd:COG3210   468 GTGTVTNSAGNTTSATTLAGGGIGTVTTNATISNNAGGDANGIATGLTGITAGGGGGGNATSGGTGGDGTTLSGSGLTTT 547
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3414 ASQLGDVVVRADNGARTRAVNGFTYLSTSMIAAVTPAEGQYGTRVTITGQRLLGGGAAVQAVELAGVAATVVSGSDTEVV 3493
Cdd:COG3210   548 VSGGASGTTAASGSNTANTLGVLAATGGTSNATTAGNSTSATGGTGTNSGGTVLSIGTGSAGATGTITLGAGTSGAGANA 627
                         650       660       670       680       690       700       710       720
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3494 VAAGNGTAGDVGDVVITSDSGAVSVDALAwryldashiTSVTPRHGQKGTVVTINGTLLRGHGSGVAVVLLAGEAANVLS 3573
Cdd:COG3210   628 TGGGAGLTGSAVGAALSGTGSGTTGTASA---------NGSNTTGVNTAGGTGGGTTGTVTSGATGGTTGTTLNAATGGT 698
                         730       740       750       760       770       780       790       800
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3574 ESDTSVVVAASAFGGSKSGPVTIIASNGATAVSTPTAFEYRAPGAVSAIVPNSGHRGTYVTIKGSNLRGHGptvMSVTLG 3653
Cdd:COG3210   699 LNNAGNTLTISTGSITVTGQIGALANANGDTVTFGNLGTGATLTLNAGVTITSGNAGTLSIGLTANTTASG---TTLTLA 775
                         810       820       830       840       850       860       870       880
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3654 GVAGHIVSENSSSVVVRVERLSVAvatpvdvvltsrSGAQVAAAGAFTYLVEGSVADLLPAQGQRGTAVSLSGSNLCGGG 3733
Cdd:COG3210   776 NANGNTSAGATLDNAGAEISIDIT------------ADGTITAAGTTAINVTGSGGTITINTATTGLTGTGDTTSGAGGS 843
                         890       900       910       920       930       940       950       960
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3734 TAIVAVTLGGVAASLKPTSTCNLVQFVAGSRNNTAAEAVDVVLESNTGALIEGTGRWTY----VVEGAISSVLPPGGVAG 3809
Cdd:COG3210   844 NTTDTTTGTTSDGASGGGTAGANSGSLAATAASITVGSGGVATSTGTANAGTLTNLGTTtnaaSGNGAVLATVTATGTGG 923
                         970       980       990      1000      1010      1020      1030      1040
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3810 TLVTIRGSNLLGGGSTAAGVTLAGVSASVEQANATHVIVTANRGTTAGDVVVTSDTGSNVVLQDGFTYSRISSVSPAEGQ 3889
Cdd:COG3210   924 GGLTGGNAAAGGTGAGNGTTALSGTQGNAGLSAASASDGAGDTGASSAAGSSAVGTSANSAGSTGGVIAATGILVAGNSG 1003
                        1050      1060      1070      1080      1090      1100      1110      1120
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3890 EGTRVRLDGVGFFTGGASVDRVEICGVASSVTNQSDSRLDVVVPAATTLVPPLRCDVEVVSAFGVSIVAADAFDYLEPGE 3969
Cdd:COG3210  1004 TTASTTGGSGAIVAGGNGVTGTTGTASATGTGTAATAGGQNGVGVNASGISGGNAAALTASGTAGTTGGTAASNGGGGTA 1083
                        1130      1140      1150      1160      1170      1180      1190      1200
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3970 IAAVTPTSGHEGTVVTVSGARLLGGGSQVASVTFAGVEVHDVLTQSDSEIVAVLRSGGAGGSGDVVVESDTGAVVRLAAG 4049
Cdd:COG3210  1084 QASGAGTTHTLGGITNGGATGTSGGTTTSTGGVTASKVGGTTTVGATGTSTASTEAAGAGTLTGLVAVSAVAGGASSASA 1163
                        1210      1220      1230      1240      1250      1260      1270      1280
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4050 FRYVPQAQILHLTRASGQVGTETTIVGEGLQMGDVIVSVLLAGVPAQVLSQSDVNVTVRANTSTPATGDVMLVAGSGAFV 4129
Cdd:COG3210  1164 GDTTAVAAATTTTTGSAINGGADSAATEGTAGTDLKGGDSTGGSTTTIGTTNVTTTTTLTASDTGNTTATGGSSAGQTGS 1243
                        1290      1300      1310      1320      1330      1340      1350      1360
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4130 ELVNGWTYDDAGAIEDVQPAQGFAGNLVTISGRGLRGGSAAVTRVTLVGVLATEIVHENDTVVVVRAGLPVDPFVMQTGR 4209
Cdd:COG3210  1244 FVAAGSASGTGDATTGATAGAVSNGATSTVAGNAGATATGSTVDIGSTSATSAGGSLDTTGNTAGANGATVGTGIGGTTA 1323
                        1370      1380      1390      1400      1410      1420      1430      1440
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4210 VVVMGSSGATITALDAFTYNVAGDITDVSPSFGRVGTRVRLLGSNLLGGGTSAEVRFGGVTGAVTAVSETAIDVTVPAAS 4289
Cdd:COG3210  1324 TGTAVAAVNSGGVNAGGGTINTTAANTGLNGGNGATDSAAGAGSGGAAGSLAATAGAGTVLTGAGNNTGAEGTNAGRDGG 1403
                        1450      1460      1470      1480      1490      1500      1510      1520
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4290 GPSGLVNVSIVSDSGSHVLEVAGFRYTAPGSVAAVAPSSGHEGTVVTISGASLLAEEADAARVTLGGVNATVVFANDTRL 4369
Cdd:COG3210  1404 VTTSGTGVGNNGGVSGTTVAGTTGSSATTGTGGTGNTTGTSVAGAGGGNADASAINTGNASSLGAGGSTAGNAVGGAVIG 1483
                        1530      1540      1550      1560      1570      1580      1590      1600
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4370 VVVAGASSTAGLGDVFIETVGGARLLAANAWMYVAQATITDVQPGSGQVGTRVTIRGTGLRCGGAAVTSVLLGSAVAPVV 4449
Cdd:COG3210  1484 GTTTGGNGAGVAGATASNGGTSTGAGGTAGGTTAEVAKASLEGGEGTYGGSSVAEAGTGGGILGAVSGAGSEGGAAGGVT 1563
                        1610      1620      1630      1640      1650      1660      1670      1680
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4450 TEDDTTVIAEAPARAVGASPVDVTVVADTGAYVTADDAWTFVTAGAVSSVVPSSGQEGTRVTLSGTNLLGSGSGVDQVLL 4529
Cdd:COG3210  1564 GSVGVGGTDGAGGDTGGADDTGAQAPTAGNTATLTLSLAEGTNAEYGGTTNVTSGTAGNAGATGANSNTVVTTNGGEGVL 1643
                        1690      1700      1710      1720      1730
                  ....*....|....*....|....*....|....*....|....*....|....
gi 514698100 4530 AGVSATVVSAASSEVVVITSALPGGVVGPVTGNVTVVSTSGALVHADTDSFTYV 4583
Cdd:COG3210  1644 ALVAGGNTTNGTTLSGAVNGAGNGWAVDLTDATLAGLGGATTAAAGNVATGDTA 1697
TNFRSF1B cd10577
Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B), also known as TNFR2; TNFRSF1B ...
5804-5948 3.12e-14

Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B), also known as TNFR2; TNFRSF1B (also known as TNFR2, type 2 TNFR, TNFBR, TNFR80, TNF-R75, TNF-R-II, p75, CD120b) binds TNF-alpha, but lacks the death domain (DD) that is associated with the cytoplasmic domain of TNFRSF1A (TNFR1). It is inducible and expressed exclusively by oligodendrocytes, astrocytes, T cells, thymocytes, myocytes, endothelial cells, and in human mesenchymal stem cells. TNFRSF1B protects oligodendrocyte progenitor cells (OLGs) against oxidative stress, and induces the up-regulation of cell survival genes. While pro-inflammatory and pathogen-clearing activities of TNF are mediated mainly through activation of TNFRSF1A, a strong activator of NF-kappaB, TNFRSF1B is more responsible for suppression of inflammation. Although the affinities of both receptors for soluble TNF are similar, TNFRSF1B is sometimes more abundantly expressed and thought to associate with TNF, thereby increasing its concentration near TNFRSF1A receptors, and making TNF available to activate TNFRSF1A (a ligand-passing mechanism).


Pssm-ID: 276903 [Multi-domain]  Cd Length: 163  Bit Score: 74.05  E-value: 3.12e-14
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5804 DTSPTKCvgCDECASDEYTLSSCTLSSQTQCRQC-----TTCGNDEYQTKACSvsqdtecatlTTCSSTQFEVEAPTATR 5878
Cdd:cd10577     9 DEKAQMC--CSKCPPGQHVKHSCTKTSDTVCAPCeestyTQLWNWVPECLSCS----------SPCSSDQVETQACTRQQ 76
                          90       100       110       120       130       140       150
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5879 DRRCkdltACQPGEYeCTAATLTTDRECCGVTQCVPGSEETSAPTATSDRECRQCVAGTTDADGSGTTPC 5948
Cdd:cd10577    77 NRIC----SCKPGWY-CVLKLQEGCRQCRPLKKCGPGFGVARPGTASSDVECKPCAPGTFSDTTSSTDTC 141
FhaB COG3210
Large exoprotein involved in heme utilization or adhesion [Intracellular trafficking, ...
3055-4665 4.30e-14

Large exoprotein involved in heme utilization or adhesion [Intracellular trafficking, secretion, and vesicular transport];


Pssm-ID: 442443 [Multi-domain]  Cd Length: 1698  Bit Score: 80.97  E-value: 4.30e-14
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3055 AQAVTLGDVVVRADTNATVVSSTGLFDYVAPGEIVSVSPSSGQLGTVVTIEGRSLRGGSSAVVDVVLGGVSALDVVSEND 3134
Cdd:COG3210    19 AVTTTAATLGSNTAGTSGLNILGSGGVGTAGGIASNAGTTASTSGGSGTAGGVGNTSASTGGIGAAAANTAGTLETGLTS 98
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3135 TRVVAVAGPSSGATGTESVQVVGQQGSVVARPSVWSYVAPAEVLDVAPQQGRAGTRVTVRGQGLLQGGGRIAQATVAGVT 3214
Cdd:COG3210    99 NIGGGSVNGSNSTGNGTLTTTAASATTGNNTGGTTTSSTNTVTTLGGTTTGNTVLSTSGAGNNTNTNNSSSGTNIGNSIP 178
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3215 TARIVDSNDTTVVLEAEVAPAGVTPVGDVQLVSDTGARVNASVTWQYLAAAVIDSVQPTSGQEGVFVELRGQHLLGGGSA 3294
Cdd:COG3210   179 TTGGSLNVVAANPTGVTGVGGALINATAGVLANAGGGTAGGVASANSTLTGGVVAAGTGAGVISTGGTDISSLSVAAGAG 258
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3295 IVDASLAGVAVERVVQSNDTFVRVVAGAKNASVVGDVVARGDTGALLRVVNGWQYAVPSVINSVVPASGQEGTLVTVSGV 3374
Cdd:COG3210   259 TGGAGGTGNAGNTTIGTTVTGTNATGSNTAGASSGDTTTNGTSSVTGAGGTGVLGGGTAAGITTTNTVGGNGDGNNTTAN 338
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3375 RLLGSLPGRITFVEVCGTEAEVVSESDTLVVARL--RSNGGASQLGDVVVRADNGARTRAVNGFTYLSTSMIAAVTPAEG 3452
Cdd:COG3210   339 SGAGLVSGGTGGNNGTTGTGAGSGLTGTGNGGGLttAGAGTVASTVGTATASTGNASSTTVLGSGSLATGNTGTTIAGNG 418
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3453 QYGTRVTITGQRLLGGGAAVQAVELAGVAATVVSGSDTEVVVAAGNGTAGDVGDVVITSDSGAVSVDALAWRYLDASHIT 3532
Cdd:COG3210   419 GSANAGGFTTTGGVLGITGNGTVTGGTIGGLTGSGTTNGAGLSGNTDVSGTGTVTNSAGNTTSATTLAGGGIGTVTTNAT 498
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3533 SVTPRHGQKGTVVTINGTL---LRGHGSGVAVVLLAGEAANVLSESDTSVVVAASAFGGSKSGPVTIIASNGATAVSTPT 3609
Cdd:COG3210   499 ISNNAGGDANGIATGLTGItagGGGGGNATSGGTGGDGTTLSGSGLTTTVSGGASGTTAASGSNTANTLGVLAATGGTSN 578
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3610 AFEYRAPGAVSAIVPNSGHRGTYVTIKGSNLRGHGPTVMSVTLGGVAGHIVSENSSSVVVRVERLSVAVATPVDVVLTSR 3689
Cdd:COG3210   579 ATTAGNSTSATGGTGTNSGGTVLSIGTGSAGATGTITLGAGTSGAGANATGGGAGLTGSAVGAALSGTGSGTTGTASANG 658
                         650       660       670       680       690       700       710       720
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3690 SGAQVAAAGAFTYLVEGSVADLLPAQGQRGTAVSLSGSNLCGGGTAIVAVTLGGVAASLKPTSTCNLVQFVAGSRNNTAA 3769
Cdd:COG3210   659 SNTTGVNTAGGTGGGTTGTVTSGATGGTTGTTLNAATGGTLNNAGNTLTISTGSITVTGQIGALANANGDTVTFGNLGTG 738
                         730       740       750       760       770       780       790       800
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3770 EAVDVVLESNTGALIEGTGRWTYVVEGAISsvlppgGVAGTLVTIRGSNLLGGGSTAAGVTLAGVSASVEQANATHVIVT 3849
Cdd:COG3210   739 ATLTLNAGVTITSGNAGTLSIGLTANTTAS------GTTLTLANANGNTSAGATLDNAGAEISIDITADGTITAAGTTAI 812
                         810       820       830       840       850       860       870       880
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3850 ANRGTTAGDVVVTSDTGSNVVLQDGFTYSRISSVSPAEGQEGTRVRLDGVGFFTGGASVDRVEICGVASSVTNQSDSRLD 3929
Cdd:COG3210   813 NVTGSGGTITINTATTGLTGTGDTTSGAGGSNTTDTTTGTTSDGASGGGTAGANSGSLAATAASITVGSGGVATSTGTAN 892
                         890       900       910       920       930       940       950       960
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3930 VVVPAATTLVPPLRCDVEVVSAFGVSIVAADAFDYLEPGEIAAVTPTSGHEGTVVTVSGARLLGGGSQVASVTFAGVEVH 4009
Cdd:COG3210   893 AGTLTNLGTTTNAASGNGAVLATVTATGTGGGGLTGGNAAAGGTGAGNGTTALSGTQGNAGLSAASASDGAGDTGASSAA 972
                         970       980       990      1000      1010      1020      1030      1040
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4010 DVLTQSDSEIVAVLRSGGAGGSGDVVVESDTGAVVRLAAGFRYVPQAQILHLTRASGQVGTETTIVGEGLQMGDVIVSVL 4089
Cdd:COG3210   973 GSSAVGTSANSAGSTGGVIAATGILVAGNSGTTASTTGGSGAIVAGGNGVTGTTGTASATGTGTAATAGGQNGVGVNASG 1052
                        1050      1060      1070      1080      1090      1100      1110      1120
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4090 LAGVPAQVLSQSDVNVTVRANTSTPATGDVMLVAGSGAFVELVNGWTYDDAGAIEDVQPAQGFAGNLVTISGRGLRGGSA 4169
Cdd:COG3210  1053 ISGGNAAALTASGTAGTTGGTAASNGGGGTAQASGAGTTHTLGGITNGGATGTSGGTTTSTGGVTASKVGGTTTVGATGT 1132
                        1130      1140      1150      1160      1170      1180      1190      1200
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4170 AVTRVTLVGVLATEIVHENDTVVVVRAGLPVDPFVMQTGRVVVMGSSGATITALDAFTYNVAGDITDVSPSFGRVGTRVR 4249
Cdd:COG3210  1133 STASTEAAGAGTLTGLVAVSAVAGGASSASAGDTTAVAAATTTTTGSAINGGADSAATEGTAGTDLKGGDSTGGSTTTIG 1212
                        1210      1220      1230      1240      1250      1260      1270      1280
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4250 LLGSNLLGGGTSAEVRFGGVTGAVTAVSETAIDVTVPAASGPSGLVNVSIVSDSGSHVLEVAGFRYTAPGSVAAVAPSSG 4329
Cdd:COG3210  1213 TTNVTTTTTLTASDTGNTTATGGSSAGQTGSFVAAGSASGTGDATTGATAGAVSNGATSTVAGNAGATATGSTVDIGSTS 1292
                        1290      1300      1310      1320      1330      1340      1350      1360
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4330 HEGTVVTISGASLLAEEADAARVTLGGVNATVVFANDTRLVVVAGASSTAGLGDVFIETVGGARLLAANAWMYVAQATIT 4409
Cdd:COG3210  1293 ATSAGGSLDTTGNTAGANGATVGTGIGGTTATGTAVAAVNSGGVNAGGGTINTTAANTGLNGGNGATDSAAGAGSGGAAG 1372
                        1370      1380      1390      1400      1410      1420      1430      1440
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4410 DVQPGSGQVGTRVTIRGTGLRCGGAAVTSVLLGSAVAPVVTEDDTTVIAEAPARAVGASPVDVTVVADTGAYVTADDAWT 4489
Cdd:COG3210  1373 SLAATAGAGTVLTGAGNNTGAEGTNAGRDGGVTTSGTGVGNNGGVSGTTVAGTTGSSATTGTGGTGNTTGTSVAGAGGGN 1452
                        1450      1460      1470      1480      1490      1500      1510      1520
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4490 FVTAGAVSSVVPSSGQEGTRVTLSGTNLLGSGSGVDQVLLAGVSATVVSAASSEVVVITSALPGGVVGPVTGNVTVVSTS 4569
Cdd:COG3210  1453 ADASAINTGNASSLGAGGSTAGNAVGGAVIGGTTTGGNGAGVAGATASNGGTSTGAGGTAGGTTAEVAKASLEGGEGTYG 1532
                        1530      1540      1550      1560      1570      1580      1590      1600
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4570 GALVHADTDSFTYVRAGAVTGVSPLAGVQGTRVTVTGERLLGGGSSIAAVQVAGVETRVIESSNNTHVVLRASNGTGSGD 4649
Cdd:COG3210  1533 GSSVAEAGTGGGILGAVSGAGSEGGAAGGVTGSVGVGGTDGAGGDTGGADDTGAQAPTAGNTATLTLSLAEGTNAEYGGT 1612
                        1610
                  ....*....|....*.
gi 514698100 4650 IELIADTGAKTVANVT 4665
Cdd:COG3210  1613 TNVTSGTAGNAGATGA 1628
TNFRSF16 cd13416
Tumor necrosis factor receptor superfamily member 16 (TNFRSF16), also known as p75 ...
5618-5762 4.46e-14

Tumor necrosis factor receptor superfamily member 16 (TNFRSF16), also known as p75 neurotrophin receptor (p75NTR) or CD271; TNFRSF16 (also known as nerve growth factor receptor (NGFR) or p75 neurotrophin receptor (p75NTR or p75(NTR)), CD271, Gp80-LNGFR) is a common receptor for both neurotrophins and proneurotrophins, and plays a diverse role in many tissues, including the nervous system. It has been shown to be expressed in various types of stem cells and has been used to prospectively isolate stem cells with different degrees of potency. p75NTR owes its signaling to the recruitment of intracellular binding proteins, leading to the activation of different signaling pathways. It binds nerve growth factor (NGF) and the complex can initiate a signaling cascade which has been associated with both neuronal apoptosis and neuronal survival of discrete populations of neurons, depending on the presence or absence of intracellular signaling molecules downstream of p75NTR (e.g. NF-kB, JNK, or p75NTR intracellular death domain). p75NTR can also bind NGF in concert with the neurotrophic tyrosine kinase receptor type 1 (TrkA) protein where it is thought to modulate the formation of the high-affinity neurotrophin binding complex. On melanoma cell, p75NTR is an immunosuppressive factor, induced by interferon (IFN)-gamma, and mediates down-regulation of melanoma antigens. It can interact with the aggregated form of amyloid beta (Abeta) peptides, and plays an important role in etiopathogenesis of Alzheimer's disease by influencing protein tau hyper-phosphorylation. p75(NTR) is involved in the formation and progression of retina diseases; its expression is induced in retinal pigment epithelium (RPE) cells and its knockdown rescues RPE cell proliferation activity and inhibits RPE apoptosis induced by hypoxia. It can therefore be a potential therapeutic target for RPE hypoxia or oxidative stress diseases.


Pssm-ID: 276921 [Multi-domain]  Cd Length: 159  Bit Score: 73.49  E-value: 4.46e-14
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5618 CGAGEEETTSPSATrNRVCQPCQLGSTFKAQSGQSTRCISVTTCGAGEEEIASPTLSTDRQCRtCASGTFKaaAGQSTTC 5697
Cdd:cd13416    18 CPPGEGVARPCGDN-QTVCEPCLDGVTFSDVVSHTEPCQPCTRCPGLMSMRAPCTATHDTVCE-CAYGYYL--DEDSGTC 93
                          90       100       110       120       130       140
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*.
gi 514698100 5698 IAVSTCAAGFTEDVAPTPSSDRVCVECAPGTFKATAGDG-TCRAHRTCEDTEYETVAPTSSSDRKC 5762
Cdd:cd13416    94 EPCTVCPPGQGVVQSCGPNQDTVCEACPEGTYSDEDSSTdPCLPCTVCEDGEVELRECTPVSDTVC 159
TNFRSF16 cd13416
Tumor necrosis factor receptor superfamily member 16 (TNFRSF16), also known as p75 ...
6098-6261 3.47e-13

Tumor necrosis factor receptor superfamily member 16 (TNFRSF16), also known as p75 neurotrophin receptor (p75NTR) or CD271; TNFRSF16 (also known as nerve growth factor receptor (NGFR) or p75 neurotrophin receptor (p75NTR or p75(NTR)), CD271, Gp80-LNGFR) is a common receptor for both neurotrophins and proneurotrophins, and plays a diverse role in many tissues, including the nervous system. It has been shown to be expressed in various types of stem cells and has been used to prospectively isolate stem cells with different degrees of potency. p75NTR owes its signaling to the recruitment of intracellular binding proteins, leading to the activation of different signaling pathways. It binds nerve growth factor (NGF) and the complex can initiate a signaling cascade which has been associated with both neuronal apoptosis and neuronal survival of discrete populations of neurons, depending on the presence or absence of intracellular signaling molecules downstream of p75NTR (e.g. NF-kB, JNK, or p75NTR intracellular death domain). p75NTR can also bind NGF in concert with the neurotrophic tyrosine kinase receptor type 1 (TrkA) protein where it is thought to modulate the formation of the high-affinity neurotrophin binding complex. On melanoma cell, p75NTR is an immunosuppressive factor, induced by interferon (IFN)-gamma, and mediates down-regulation of melanoma antigens. It can interact with the aggregated form of amyloid beta (Abeta) peptides, and plays an important role in etiopathogenesis of Alzheimer's disease by influencing protein tau hyper-phosphorylation. p75(NTR) is involved in the formation and progression of retina diseases; its expression is induced in retinal pigment epithelium (RPE) cells and its knockdown rescues RPE cell proliferation activity and inhibits RPE apoptosis induced by hypoxia. It can therefore be a potential therapeutic target for RPE hypoxia or oxidative stress diseases.


Pssm-ID: 276921 [Multi-domain]  Cd Length: 159  Bit Score: 71.18  E-value: 3.47e-13
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6098 CGSGEYETRAPTATtDRKCAsvtQC-DSTQFvvSKPTATTDRdCAECDRCdSGTQYETATCTATTNRVCadltVCADTEY 6176
Cdd:cd13416    18 CPPGEGVARPCGDN-QTVCE---PClDGVTF--SDVVSHTEP-CQPCTRC-PGLMSMRAPCTATHDTVC----ECAYGYY 85
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6177 esvaaTDTSDRKCSSCRECTSSEYLVSGCSESANAVCKACtecPSGTFVSTActplADAE-CTECTRCGSGYFVQSPCTS 6255
Cdd:cd13416    86 -----LDEDSGTCEPCTVCPPGQGVVQSCGPNQDTVCEAC---PEGTYSDED----SSTDpCLPCTVCEDGEVELRECTP 153

                  ....*.
gi 514698100 6256 EADTTC 6261
Cdd:cd13416   154 VSDTVC 159
TNFRSF16 cd13416
Tumor necrosis factor receptor superfamily member 16 (TNFRSF16), also known as p75 ...
6143-6279 2.75e-12

Tumor necrosis factor receptor superfamily member 16 (TNFRSF16), also known as p75 neurotrophin receptor (p75NTR) or CD271; TNFRSF16 (also known as nerve growth factor receptor (NGFR) or p75 neurotrophin receptor (p75NTR or p75(NTR)), CD271, Gp80-LNGFR) is a common receptor for both neurotrophins and proneurotrophins, and plays a diverse role in many tissues, including the nervous system. It has been shown to be expressed in various types of stem cells and has been used to prospectively isolate stem cells with different degrees of potency. p75NTR owes its signaling to the recruitment of intracellular binding proteins, leading to the activation of different signaling pathways. It binds nerve growth factor (NGF) and the complex can initiate a signaling cascade which has been associated with both neuronal apoptosis and neuronal survival of discrete populations of neurons, depending on the presence or absence of intracellular signaling molecules downstream of p75NTR (e.g. NF-kB, JNK, or p75NTR intracellular death domain). p75NTR can also bind NGF in concert with the neurotrophic tyrosine kinase receptor type 1 (TrkA) protein where it is thought to modulate the formation of the high-affinity neurotrophin binding complex. On melanoma cell, p75NTR is an immunosuppressive factor, induced by interferon (IFN)-gamma, and mediates down-regulation of melanoma antigens. It can interact with the aggregated form of amyloid beta (Abeta) peptides, and plays an important role in etiopathogenesis of Alzheimer's disease by influencing protein tau hyper-phosphorylation. p75(NTR) is involved in the formation and progression of retina diseases; its expression is induced in retinal pigment epithelium (RPE) cells and its knockdown rescues RPE cell proliferation activity and inhibits RPE apoptosis induced by hypoxia. It can therefore be a potential therapeutic target for RPE hypoxia or oxidative stress diseases.


Pssm-ID: 276921 [Multi-domain]  Cd Length: 159  Bit Score: 68.48  E-value: 2.75e-12
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6143 CDRCDSGTQYETAtCTATtNRVCAdltVCAD--TEYESVAATDtsdrKCSSCRECTSSEYLVSGCSESANAVCkactECP 6220
Cdd:cd13416    15 CEQCPPGEGVARP-CGDN-QTVCE---PCLDgvTFSDVVSHTE----PCQPCTRCPGLMSMRAPCTATHDTVC----ECA 81
                          90       100       110       120       130       140       150
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*..
gi 514698100 6221 SGTFVSTActplaDAECTECTRCGSGYFVQSPCTSEADTTCKR------------------CRSCASGEYLHTACTT 6279
Cdd:cd13416    82 YGYYLDED-----SGTCEPCTVCPPGQGVVQSCGPNQDTVCEAcpegtysdedsstdpclpCTVCEDGEVELRECTP 153
FhaB COG3210
Large exoprotein involved in heme utilization or adhesion [Intracellular trafficking, ...
1163-2674 5.65e-12

Large exoprotein involved in heme utilization or adhesion [Intracellular trafficking, secretion, and vesicular transport];


Pssm-ID: 442443 [Multi-domain]  Cd Length: 1698  Bit Score: 73.65  E-value: 5.65e-12
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1163 ASGQFGTRVTINGTGLLGGGATVQTVQFDAVAGSDPRVTAAGIEVSAPGGAAGVRNITVVANTGAYFTVARAFTVIAEPN 1242
Cdd:COG3210   174 GNSIPTTGGSLNVVAANPTGVTGVGGALINATAGVLANAGGGTAGGVASANSTLTGGVVAAGTGAGVISTGGTDISSLSV 253
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1243 VTAITPSSGQAGAYVTVSGTELLGGGAFAERVFLAGVEADVVTSSPSSVVVRAPVSVAKVGPTVIVADTGATTTSLLNFT 1322
Cdd:COG3210   254 AAGAGTGGAGGTGNAGNTTIGTTVTGTNATGSNTAGASSGDTTTNGTSSVTGAGGTGVLGGGTAAGITTTNTVGGNGDGN 333
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1323 FTPQLSVTSVSPSSGQGGTRVTVLGANLRLGSSAVTGVLLGSAACSLISENDTAVVCAAGVASAGSVPVTVEASSGAFAS 1402
Cdd:COG3210   334 NTTANSGAGLVSGGTGGNNGTTGTGAGSGLTGTGNGGGLTTAGAGTVASTVGTATASTGNASSTTVLGSGSLATGNTGTT 413
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1403 VGGVLAFEYLDAGVINSVEPGSGQQGTRVVVSGLRLLGGGIRVDQAFLGGVEATIRSSSAFAVTLAAGNGSEPSSGDIVL 1482
Cdd:COG3210   414 IAGNGGSANAGGFTTTGGVLGITGNGTVTGGTIGGLTGSGTTNGAGLSGNTDVSGTGTVTNSAGNTTSATTLAGGGIGTV 493
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1483 IADTGAVVSRSGMWTYTEPCGVTDVSPPSGQAGTLVTITGTGFPCTGSSVSTVSLGGVGASIRTQSATQIVVEAPSGSGQ 1562
Cdd:COG3210   494 TTNATISNNAGGDANGIATGLTGITAGGGGGGNATSGGTGGDGTTLSGSGLTTTVSGGASGTTAASGSNTANTLGVLAAT 573
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1563 GDVVVTADDGSFAVSRGGWEFSRISSVTPASGQFGTAVTVAGQGLRLGFSSVTQVRLGDVAATILSENNTHVVVRAGTGS 1642
Cdd:COG3210   574 GGTSNATTAGNSTSATGGTGTNSGGTVLSIGTGSAGATGTITLGAGTSGAGANATGGGAGLTGSAVGAALSGTGSGTTGT 653
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1643 LVGVPVDVQVISSGATTVQQSVAWTYLRDGVVSSVVPVQGQRGTRVTVRGERLLGGGSRLErvllGDIAVDRILSYNDTV 1722
Cdd:COG3210   654 ASANGSNTTGVNTAGGTGGGTTGTVTSGATGGTTGTTLNAATGGTLNNAGNTLTISTGSIT----VTGQIGALANANGDT 729
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1723 VVVEAGLSNSSAVVD--VTLVSDTLAGVTGENVFTYVEPMTLYGLTRATGQAGTETTLL--GRSLLGGSLAVTEVLLAGT 1798
Cdd:COG3210   730 VTFGNLGTGATLTLNagVTITSGNAGTLSIGLTANTTASGTTLTLANANGNTSAGATLDnaGAEISIDITADGTITAAGT 809
                         650       660       670       680       690       700       710       720
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1799 GAQVIGFNDTHVTVRALAGTPGQGNVVIRTSNGAYLVAINGWSFSTPGAIAAVEPVSGQAGTRVTIVGSRLLGGGSRVAS 1878
Cdd:COG3210   810 TAINVTGSGGTITINTATTGLTGTGDTTSGAGGSNTTDTTTGTTSDGASGGGTAGANSGSLAATAASITVGSGGVATSTG 889
                         730       740       750       760       770       780       790       800
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1879 VALGSVVHTSSVISGNDTQVVLDALAGPPGLSDVIITSDTRATVTAENVWTYLQPGVIQSVDPQSGQVGTRITIVGSGLL 1958
Cdd:COG3210   890 TANAGTLTNLGTTTNAASGNGAVLATVTATGTGGGGLTGGNAAAGGTGAGNGTTALSGTQGNAGLSAASASDGAGDTGAS 969
                         810       820       830       840       850       860       870       880
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1959 GGSAFAREVVMGNSVPCSVLRGNDSVVVCVLADAGSPAAAVDVTVVGARGSRVVASLAFEVLPASNITSVSPPMGQYGTI 2038
Cdd:COG3210   970 SAAGSSAVGTSANSAGSTGGVIAATGILVAGNSGTTASTTGGSGAIVAGGNGVTGTTGTASATGTGTAATAGGQNGVGVN 1049
                         890       900       910       920       930       940       950       960
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2039 ITVHGSRLRGGADRVVSATLAGAPGSARVVRENDTVVLVQVLVAMPVAFADLRLTASSGATVTFPSAFTALLPGTIASVL 2118
Cdd:COG3210  1050 ASGISGGNAAALTASGTAGTTGGTAASNGGGGTAQASGAGTTHTLGGITNGGATGTSGGTTTSTGGVTASKVGGTTTVGA 1129
                         970       980       990      1000      1010      1020      1030      1040
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2119 PLQ---------GQAGTRVTVTGARLRGGSAAVTRATIAGVEATVVVESNDVVVLRATAAMAHPLQGPVVVVGEAGSLVS 2189
Cdd:COG3210  1130 TGTstasteaagAGTLTGLVAVSAVAGGASSASAGDTTAVAAATTTTTGSAINGGADSAATEGTAGTDLKGGDSTGGSTT 1209
                        1050      1060      1070      1080      1090      1100      1110      1120
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2190 NAMINFTYLEQGVVTAATPAYGQRHTRVTVTGTNILGGGSRIVNASFGGVSALDVLASNNSMAVVIAPRLLPGQHSIQLV 2269
Cdd:COG3210  1210 TIGTTNVTTTTTLTASDTGNTTATGGSSAGQTGSFVAAGSASGTGDATTGATAGAVSNGATSTVAGNAGATATGSTVDIG 1289
                        1130      1140      1150      1160      1170      1180      1190      1200
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2270 ADSGAVVSSSNLFTARLEGNITSLMPGSGQRGTRITVNGNRLRGSGNEVVSAWVGNVPATVVSEGNSQVVIRPTSSGAAG 2349
Cdd:COG3210  1290 STSATSAGGSLDTTGNTAGANGATVGTGIGGTTATGTAVAAVNSGGVNAGGGTINTTAANTGLNGGNGATDSAAGAGSGG 1369
                        1210      1220      1230      1240      1250      1260      1270      1280
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2350 TSVRIVLVADTGARVETATVQFDFVPPGDIQAVGPASGQEGTLVTIRGERLLGNGTALAYTYIGGVAAQIVSASNDEVVV 2429
Cdd:COG3210  1370 AAGSLAATAGAGTVLTGAGNNTGAEGTNAGRDGGVTTSGTGVGNNGGVSGTTVAGTTGSSATTGTGGTGNTTGTSVAGAG 1449
                        1290      1300      1310      1320      1330      1340      1350      1360
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2430 VAGRSSNRFTLDQHPVISDIVLVADNGAEVVAASSFTYLRPGVISSVFPLSGQAGTRVGISGVRLFGGGSRIVSVYLGAT 2509
Cdd:COG3210  1450 GGNADASAINTGNASSLGAGGSTAGNAVGGAVIGGTTTGGNGAGVAGATASNGGTSTGAGGTAGGTTAEVAKASLEGGEG 1529
                        1370      1380      1390      1400      1410      1420      1430      1440
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2510 QAQVITQTVHAVVVTAKAGNVSASPEPIRIVADTGAVVTLNDTWSYVQAGRVASVNPASGHQGTLVTIQGTSLLGGGTTA 2589
Cdd:COG3210  1530 TYGGSSVAEAGTGGGILGAVSGAGSEGGAAGGVTGSVGVGGTDGAGGDTGGADDTGAQAPTAGNTATLTLSLAEGTNAEY 1609
                        1450      1460      1470      1480      1490      1500      1510      1520
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2590 VSVMLAGSSALVLSSNATDVVVTAGPGAQSSGDVVIVSETGATVARGAAWTYVEPGFIQRASPASGTAGTRVTITGASLL 2669
Cdd:COG3210  1610 GGTTNVTSGTAGNAGATGANSNTVVTTNGGEGVLALVAGGNTTNGTTLSGAVNGAGNGWAVDLTDATLAGLGGATTAAAG 1689

                  ....*
gi 514698100 2670 GGAST 2674
Cdd:COG3210  1690 NVATG 1694
TNFRSF cd00185
Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) ...
5616-5701 1.04e-11

Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) interactions with TNF superfamily (TNFSF) ligands (TNFL) control key cellular processes such as differentiation, proliferation, apoptosis, and cell growth. Dysregulation of these pathways has been shown to result in a wide range of pathological conditions, including autoimmune diseases, inflammation, cancer, and viral infection. There are 29 very diverse family members of TNFRSF reported in humans: 22 are type I transmembrane receptors (single pass with the N terminus on extracellular side of the cell membrane) and have a clear signal peptide; the remaining 7 members are either type III transmembrane receptors (single pass with the N terminus on extracellular side of the membrane but no signal sequence; TNFR13B, TNFR13C, TNFR17, and XEDAR), or attached to the membrane via a glycosylphosphatidylinositol (GPI) linker (TNFR10C), or secreted as soluble receptors (TNFR11B and TNFR6B). All TNFRs contain relatively short cysteine-rich domains (CRDs) in the ectodomain, and are involved in interaction with the TNF homology domain (THD) of their ligands. TNFRs often have multiple CRDs (between one and six), with the most frequent configurations of three or four copies; most CRDs possess three disulfide bridges, but could have between one and four. Localized or genome-wide duplication and evolution of the TNFRSF members appear to have paralleled the emergence of the adaptive immune system; teleosts (i.e. ray-finned, bony fish), which possess an immune system with B and T cells, possess primary and secondary lymphoid organs, and are capable of adaptive responses to pathogens also display several characteristics that are different from the mammalian immune system, making teleost TNFSF orthologs and paralogs of interest to better understand immune system evolution and the immunological pathways elicited to pathogens.


Pssm-ID: 276900 [Multi-domain]  Cd Length: 87  Bit Score: 64.54  E-value: 1.04e-11
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5616 KTCGAGEEETTSPSATRNRVCQPCQLGsTFKAQSGQSTRCISVTTCGAGEEEIASPTLSTDRQCRTCASGTFKAAAGQST 5695
Cdd:cd00185     3 QRCPPGEYLSSDCTATTDTVCSPCPPG-TYSESWNSLSKCLPCTTCGGGNQVEKTPCTATDNRCCTCKPGFYCDEGTNVE 81

                  ....*.
gi 514698100 5696 TCIAVS 5701
Cdd:cd00185    82 ECKPCT 87
TNFRSF1A_teleost cd15834
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) in teleosts; also known as ...
5678-5797 1.52e-11

Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) in teleosts; also known as TNFR1; This subfamily of TNFRSF1 ((also known as type I TNFR, TNFR1, DR1, TNFRSF1A, CD120a, p55) is found in teleosts. It binds TNF-alpha, through the death domain (DD), and activates NF-kappaB, mediates apoptosis and activates signaling pathways controlling inflammatory, immune, and stress responses. It mediates signal transduction by interacting with antiapoptotic protein BCL2-associated athanogene 4 (BAG4/SODD) and adaptor proteins TRAF2 and TRADD that play regulatory roles. The human genetic disorder called tumor necrosis factor associated periodic syndrome (TRAPS), or periodic fever syndrome, is associated with germline mutations of the extracellular domains of this receptor, possibly due to impaired receptor clearance. Serum levels of TNFRSF1A are elevated in schizophrenia and bipolar disorder, and high levels are also associated with cognitive impairment and dementia. Knockout studies in zebrafish embryos have shown that a signaling balance between TNFRSF1A and TNFRSF1B is required for endothelial cell integrity. TNFRSF1A signals apoptosis through caspase-8, whereas TNFRSF1B signals survival via NF-kappaB in endothelial cells. Thus, this apoptotic pathway seems to be evolutionarily conserved, as TNFalpha promotes apoptosis of human endothelial cells and triggers caspase-2 and P53 activation in these cells via TNFRSF1A.


Pssm-ID: 276930 [Multi-domain]  Cd Length: 150  Bit Score: 65.97  E-value: 1.52e-11
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5678 QCRTCASGTFKAAAGQSTTCIAVSTCAAGFTEDVAP-TPSSDRVCvECAPGTFKATAGDGT--CRAHRTCEDTEYETVAP 5754
Cdd:cd15834    35 QCTPCPEGTYLEQINYSPNCRRCTLCKVKNEEEVSPcKKSSNTVC-RCKKGYYKSRIDSETreCLKCKTCGPGEIEIQPC 113
                          90       100       110       120
                  ....*....|....*....|....*....|....*....|...
gi 514698100 5755 TSSSDRKCKaltvCQDDEWESKaptittdRECSPCGRCTDGLT 5797
Cdd:cd15834   114 TPESNTVCE----CKDNYYRNN-------NKCKPCQKCSLDCQ 145
TNFRSF6B cd10575
Tumor necrosis factor receptor superfamily member 6B (TNFRSF6B), also known as decoy receptor ...
5547-5724 3.17e-11

Tumor necrosis factor receptor superfamily member 6B (TNFRSF6B), also known as decoy receptor 3 (DcR3); The subfamily TNFRSF6B is also known as decoy receptor 3 (DcR3), M68, or TR6. This protein is a soluble receptor without death domain and cytoplasmic domain, and secreted by cells. It acts as a decoy receptor that competes with death receptors for ligand binding. It is a pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases, and cancer. Over-expression of this gene has been noted in several cancers, including pancreatic carcinoma, and gastrointestinal tract tumors. It can neutralize the biological effects of three tumor necrosis factor superfamily (TNFSF) members: TNFSF6 (Fas ligand/FasL/CD95L) and TNFSF14 (LIGHT) which are both involved in apoptosis and inflammation, and TNFSF15 (TNF-like molecule 1A/TL1A), which is a T cell co-stimulator and involved in gut inflammation. DcR3 is a novel inflammatory marker; higher DcR3 levels strongly correlate with inflammation and independently predict cardiovascular and all-cause mortality in chronic kidney disease (CKD) patients on hemodialysis. Increased synovial inflammatory cells infiltration in rheumatoid arthritis and ankylosing spondylitis is also associated with the elevated DcR3 expression. In cartilaginous fish, mRNA expression of DcR3 in the thymus and leydig, which are the representative lymphoid tissues of elasmobranchs, suggests that DcR3 may act as a modulator in the immune system. Interestingly, in banded dogfish (Triakis scyllia), DcR3 mRNA is strongly expressed in the gill, compared with human expression in the normal lung; both are respiratory organs, suggesting potential relevance of DcR3 to respiratory function.


Pssm-ID: 276901 [Multi-domain]  Cd Length: 163  Bit Score: 65.51  E-value: 3.17e-11
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5547 TDANSDGSDACVTCGGGTYVpagstgtcsQYECsagTADTDsnagTACEACDGTTTYQPSKGQERCLSVKT-CGAGEEET 5625
Cdd:cd10575     6 KDDVTGESLTCDQCPPGTFV---------AKHC---TRDRP----TVCGPCPDLHYTQFWNYLEKCRYCNVfCTERQVEK 69
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5626 TSPSATRNRVCQpCQLGSTFKAQSgqstrCISVTTCGAGEEEIASPTLSTDRQCRTCASGTFKAAAGQSTTCIAVSTCAA 5705
Cdd:cd10575    70 RQCNATHNRVCE-CKPGYYMEHGF-----CLRHSSCPPGEGVIKLGTPYSDTQCEPCPPGFFSASSSSTEPCQPHTNCTQ 143
                         170       180
                  ....*....|....*....|
gi 514698100 5706 GFTEDVAP-TPSSDRVCVEC 5724
Cdd:cd10575   144 GGLETNVPgNDYHDTLCTSC 163
TNFRSF16 cd13416
Tumor necrosis factor receptor superfamily member 16 (TNFRSF16), also known as p75 ...
5716-5858 5.32e-11

Tumor necrosis factor receptor superfamily member 16 (TNFRSF16), also known as p75 neurotrophin receptor (p75NTR) or CD271; TNFRSF16 (also known as nerve growth factor receptor (NGFR) or p75 neurotrophin receptor (p75NTR or p75(NTR)), CD271, Gp80-LNGFR) is a common receptor for both neurotrophins and proneurotrophins, and plays a diverse role in many tissues, including the nervous system. It has been shown to be expressed in various types of stem cells and has been used to prospectively isolate stem cells with different degrees of potency. p75NTR owes its signaling to the recruitment of intracellular binding proteins, leading to the activation of different signaling pathways. It binds nerve growth factor (NGF) and the complex can initiate a signaling cascade which has been associated with both neuronal apoptosis and neuronal survival of discrete populations of neurons, depending on the presence or absence of intracellular signaling molecules downstream of p75NTR (e.g. NF-kB, JNK, or p75NTR intracellular death domain). p75NTR can also bind NGF in concert with the neurotrophic tyrosine kinase receptor type 1 (TrkA) protein where it is thought to modulate the formation of the high-affinity neurotrophin binding complex. On melanoma cell, p75NTR is an immunosuppressive factor, induced by interferon (IFN)-gamma, and mediates down-regulation of melanoma antigens. It can interact with the aggregated form of amyloid beta (Abeta) peptides, and plays an important role in etiopathogenesis of Alzheimer's disease by influencing protein tau hyper-phosphorylation. p75(NTR) is involved in the formation and progression of retina diseases; its expression is induced in retinal pigment epithelium (RPE) cells and its knockdown rescues RPE cell proliferation activity and inhibits RPE apoptosis induced by hypoxia. It can therefore be a potential therapeutic target for RPE hypoxia or oxidative stress diseases.


Pssm-ID: 276921 [Multi-domain]  Cd Length: 159  Bit Score: 64.63  E-value: 5.32e-11
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5716 SSDRVCVECAPGTFKA---TAGDGTCRAhrtCEDTEyeTVAPTSSSDRKCKALTVCQDDEWESKAPTITTD--------- 5783
Cdd:cd13416    10 SSGECCEQCPPGEGVArpcGDNQTVCEP---CLDGV--TFSDVVSHTEPCQPCTRCPGLMSMRAPCTATHDtvcecaygy 84
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5784 ------RECSPCGRCTDGLTLDKACTDTSPTKCVgcdECASDEYtlsSCTLSSQTQCRQCTTCGNDEYQTKACSVSQDTE 5857
Cdd:cd13416    85 yldedsGTCEPCTVCPPGQGVVQSCGPNQDTVCE---ACPEGTY---SDEDSSTDPCLPCTVCEDGEVELRECTPVSDTV 158

                  .
gi 514698100 5858 C 5858
Cdd:cd13416   159 C 159
TNFRSF5_teleost cd13422
Tumor necrosis factor receptor superfamily member 5 (TNFRSF5) in teleosts; also known as CD40; ...
5597-5762 5.85e-11

Tumor necrosis factor receptor superfamily member 5 (TNFRSF5) in teleosts; also known as CD40; TNFRSF5 (commonly known as CD40 and also as CDW40, p50, Bp50) is widely expressed in diverse cell types including B lymphocytes, dendritic cells, platelets, monocytes, endothelial cells, and fibroblasts. It is essential in mediating a wide variety of immune and inflammatory responses, including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation. Its natural immunomodulating ligand is CD40L, and a primary defect in the CD40/CD40L system is associated with X-linked hyper-IgM (XHIM) syndrome. It is also involved in tumorigenesis; CD40 expression is significantly higher in gastric carcinomas and it is associated with the lymphatic metastasis of cancer cells and their tumor node metastasis (TNM) classification. Upregulated levels of CD40/CD40L on B cells and T cells may play an important role in the immune pathogenesis of breast cancer. Consequently, the CD40/CD40L system serves as a link between tumorigenesis, atherosclerosis, and the immune system, and offers a potential target for drug therapy for related diseases, such as cancer, atherosclerosis, diabetes mellitus, and immunological rejection. Salmon CD40 and CD40L are widely expressed, particularly in immune tissues, and their importance for the immune response is indicated by their relatively high expression in salmon lymphoid organs and gills.


Pssm-ID: 276927 [Multi-domain]  Cd Length: 161  Bit Score: 64.76  E-value: 5.85e-11
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5597 CDGTTTYQpsKGQERClsvKTCGAGEEETTSPSATRNRvCQPCQLG---STFKAQsgqsTRCISVTTCGAGEE-EIASPT 5672
Cdd:cd13422     1 CDPETQYE--KDGECC---KMCGPGTRMSSDSGCLDPQ-CQPCGEDeyqDKYTKE----NKCKRQPYCDPNKNfEISVNK 70
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5673 LSTDRQCRTCASGtFKAAAGQSTTCIAVSTCAAGFTEDVAPTPSSDRVCVECAPGTFKA-TAGDGTCRAHRTCEDTEYET 5751
Cdd:cd13422    71 SKTSRSVCKCKPG-FHCSSEECLTCVPHTTCGPGQGVKSKGNHIRDTVCEECPDGTFSNnSSAEGVCKKWTECESGYKVE 149
                         170
                  ....*....|.
gi 514698100 5752 VAPTSSSDRKC 5762
Cdd:cd13422   150 AAGTNTSDNIC 160
TNFRSF cd00185
Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) ...
6192-6275 6.82e-11

Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) interactions with TNF superfamily (TNFSF) ligands (TNFL) control key cellular processes such as differentiation, proliferation, apoptosis, and cell growth. Dysregulation of these pathways has been shown to result in a wide range of pathological conditions, including autoimmune diseases, inflammation, cancer, and viral infection. There are 29 very diverse family members of TNFRSF reported in humans: 22 are type I transmembrane receptors (single pass with the N terminus on extracellular side of the cell membrane) and have a clear signal peptide; the remaining 7 members are either type III transmembrane receptors (single pass with the N terminus on extracellular side of the membrane but no signal sequence; TNFR13B, TNFR13C, TNFR17, and XEDAR), or attached to the membrane via a glycosylphosphatidylinositol (GPI) linker (TNFR10C), or secreted as soluble receptors (TNFR11B and TNFR6B). All TNFRs contain relatively short cysteine-rich domains (CRDs) in the ectodomain, and are involved in interaction with the TNF homology domain (THD) of their ligands. TNFRs often have multiple CRDs (between one and six), with the most frequent configurations of three or four copies; most CRDs possess three disulfide bridges, but could have between one and four. Localized or genome-wide duplication and evolution of the TNFRSF members appear to have paralleled the emergence of the adaptive immune system; teleosts (i.e. ray-finned, bony fish), which possess an immune system with B and T cells, possess primary and secondary lymphoid organs, and are capable of adaptive responses to pathogens also display several characteristics that are different from the mammalian immune system, making teleost TNFSF orthologs and paralogs of interest to better understand immune system evolution and the immunological pathways elicited to pathogens.


Pssm-ID: 276900 [Multi-domain]  Cd Length: 87  Bit Score: 62.23  E-value: 6.82e-11
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6192 CRECTSSEYLVSGCSESANAVCKActeCPSGTFVSTACTplaDAECTECTRCGSG-YFVQSPCTSEADttckRCRSCASG 6270
Cdd:cd00185     2 CQRCPPGEYLSSDCTATTDTVCSP---CPPGTYSESWNS---LSKCLPCTTCGGGnQVEKTPCTATDN----RCCTCKPG 71

                  ....*
gi 514698100 6271 EYLHT 6275
Cdd:cd00185    72 FYCDE 76
TNFRSF16 cd13416
Tumor necrosis factor receptor superfamily member 16 (TNFRSF16), also known as p75 ...
5780-5952 2.41e-10

Tumor necrosis factor receptor superfamily member 16 (TNFRSF16), also known as p75 neurotrophin receptor (p75NTR) or CD271; TNFRSF16 (also known as nerve growth factor receptor (NGFR) or p75 neurotrophin receptor (p75NTR or p75(NTR)), CD271, Gp80-LNGFR) is a common receptor for both neurotrophins and proneurotrophins, and plays a diverse role in many tissues, including the nervous system. It has been shown to be expressed in various types of stem cells and has been used to prospectively isolate stem cells with different degrees of potency. p75NTR owes its signaling to the recruitment of intracellular binding proteins, leading to the activation of different signaling pathways. It binds nerve growth factor (NGF) and the complex can initiate a signaling cascade which has been associated with both neuronal apoptosis and neuronal survival of discrete populations of neurons, depending on the presence or absence of intracellular signaling molecules downstream of p75NTR (e.g. NF-kB, JNK, or p75NTR intracellular death domain). p75NTR can also bind NGF in concert with the neurotrophic tyrosine kinase receptor type 1 (TrkA) protein where it is thought to modulate the formation of the high-affinity neurotrophin binding complex. On melanoma cell, p75NTR is an immunosuppressive factor, induced by interferon (IFN)-gamma, and mediates down-regulation of melanoma antigens. It can interact with the aggregated form of amyloid beta (Abeta) peptides, and plays an important role in etiopathogenesis of Alzheimer's disease by influencing protein tau hyper-phosphorylation. p75(NTR) is involved in the formation and progression of retina diseases; its expression is induced in retinal pigment epithelium (RPE) cells and its knockdown rescues RPE cell proliferation activity and inhibits RPE apoptosis induced by hypoxia. It can therefore be a potential therapeutic target for RPE hypoxia or oxidative stress diseases.


Pssm-ID: 276921 [Multi-domain]  Cd Length: 159  Bit Score: 62.70  E-value: 2.41e-10
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5780 ITTDRECspCGRCTDGLTLDKACTDTSpTKCVGCdecaSDEYTLSScTLSSQTQCRQCTTCGNDEYQTKACSVSQDTECA 5859
Cdd:cd13416     8 YTSSGEC--CEQCPPGEGVARPCGDNQ-TVCEPC----LDGVTFSD-VVSHTEPCQPCTRCPGLMSMRAPCTATHDTVCE 79
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5860 tlttCSSTQFEVEAptatrDRRCKDLTACQPGEyectaatlttdreccGVT-QCvpgseetsapTATSDRECRQCVAGTT 5938
Cdd:cd13416    80 ----CAYGYYLDED-----SGTCEPCTVCPPGQ---------------GVVqSC----------GPNQDTVCEACPEGTY 125
                         170
                  ....*....|....
gi 514698100 5939 DADGSGTTPCVACS 5952
Cdd:cd13416   126 SDEDSSTDPCLPCT 139
TMEM132 pfam16070
Transmembrane protein family 132; This presumed domain is found in members of the TMEM132 ...
6687-6972 3.02e-10

Transmembrane protein family 132; This presumed domain is found in members of the TMEM132 family. TMEM132A may be involved in embryonic and postnatal brain development. TMEM132D may be a marker for oligodendrocyte differentiation.


Pssm-ID: 465003  Cd Length: 344  Bit Score: 66.16  E-value: 3.02e-10
                           10        20        30        40        50        60        70        80
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  6687 LVNTGLLTGIETSTQLVVTAYDEFGA-SSTATPTEC-SLDAGASGAALaavsaNCDAVtlssSASLPFSSPGGQAVVTVR 6764
Cdd:pfam16070    2 ILNTAILTGRTVAVPVKVVAVEADGTvTDVTESVSCsSTDEDVLKVSS-----SCDSV----YVNGKESRGSSNASVNFT 72
                           90       100       110       120       130       140       150       160
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  6765 QGQLEATTVVSVYVPASAPSVALDRTSLRALVPREVSLAFGVREPCAAAT--------------VFERTRVHVLANFTCT 6830
Cdd:pfam16070   73 YGTLSAQLEFTVWVPRLPLEIEVSDTELSQIKGWRVPIGSNKRRPARDSEdeeeddrkgrgcrlQYQHATVRVLARFVAE 152
                          170       180       190       200       210       220       230       240
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  6831 GVDGQACLPALPGQVQLDVAQLALE-LTVADDDVARVKDTYVV-GVADGTTEVRVEQPNSGVVLASTPVHVTrDEVVEID 6908
Cdd:pfam16070  153 DADTGQVSYLLGSDWQVDVTDLVADfLRVEDPRVARLQDGRVLqGREPGTTTVQVLSPLSDSVLGEKTITVL-DDKVTIT 231
                          250       260       270       280       290       300
                   ....*....|....*....|....*....|....*....|....*....|....*....|....
gi 514698100  6909 GLYAGSAESATLSLDHDAVHQLFDQVPVHVRlqsSPLRAEGDVTHVYAFVVLRDGTQFPIDVLD 6972
Cdd:pfam16070  232 DLGVQLVSGLSLSLQPSPGSNRAIVATTTAQ---ETLTAPKQEALLSAWLQFSDGSVTPLDLYD 292
TNFRSF6B cd10575
Tumor necrosis factor receptor superfamily member 6B (TNFRSF6B), also known as decoy receptor ...
5803-5955 3.24e-10

Tumor necrosis factor receptor superfamily member 6B (TNFRSF6B), also known as decoy receptor 3 (DcR3); The subfamily TNFRSF6B is also known as decoy receptor 3 (DcR3), M68, or TR6. This protein is a soluble receptor without death domain and cytoplasmic domain, and secreted by cells. It acts as a decoy receptor that competes with death receptors for ligand binding. It is a pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases, and cancer. Over-expression of this gene has been noted in several cancers, including pancreatic carcinoma, and gastrointestinal tract tumors. It can neutralize the biological effects of three tumor necrosis factor superfamily (TNFSF) members: TNFSF6 (Fas ligand/FasL/CD95L) and TNFSF14 (LIGHT) which are both involved in apoptosis and inflammation, and TNFSF15 (TNF-like molecule 1A/TL1A), which is a T cell co-stimulator and involved in gut inflammation. DcR3 is a novel inflammatory marker; higher DcR3 levels strongly correlate with inflammation and independently predict cardiovascular and all-cause mortality in chronic kidney disease (CKD) patients on hemodialysis. Increased synovial inflammatory cells infiltration in rheumatoid arthritis and ankylosing spondylitis is also associated with the elevated DcR3 expression. In cartilaginous fish, mRNA expression of DcR3 in the thymus and leydig, which are the representative lymphoid tissues of elasmobranchs, suggests that DcR3 may act as a modulator in the immune system. Interestingly, in banded dogfish (Triakis scyllia), DcR3 mRNA is strongly expressed in the gill, compared with human expression in the normal lung; both are respiratory organs, suggesting potential relevance of DcR3 to respiratory function.


Pssm-ID: 276901 [Multi-domain]  Cd Length: 163  Bit Score: 62.81  E-value: 3.24e-10
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5803 TDTSPTKCVGCDECASDEYTLSSCTLSSQTQCRQCTTCGNDEY-----QTKACSVsqdtecatltTCSSTQFEVEAPTAT 5877
Cdd:cd10575     6 KDDVTGESLTCDQCPPGTFVAKHCTRDRPTVCGPCPDLHYTQFwnyleKCRYCNV----------FCTERQVEKRQCNAT 75
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5878 RDRRCKdltaCQPGEYectaatlttdRE---CCGVTQCVPGSEETSAPTATSDRECRQCVAGTTDADGSGTTPCVA---C 5951
Cdd:cd10575    76 HNRVCE----CKPGYY----------MEhgfCLRHSSCPPGEGVIKLGTPYSDTQCEPCPPGFFSASSSSTEPCQPhtnC 141

                  ....
gi 514698100 5952 SAGH 5955
Cdd:cd10575   142 TQGG 145
TNFRSF cd00185
Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) ...
6098-6192 3.34e-10

Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) interactions with TNF superfamily (TNFSF) ligands (TNFL) control key cellular processes such as differentiation, proliferation, apoptosis, and cell growth. Dysregulation of these pathways has been shown to result in a wide range of pathological conditions, including autoimmune diseases, inflammation, cancer, and viral infection. There are 29 very diverse family members of TNFRSF reported in humans: 22 are type I transmembrane receptors (single pass with the N terminus on extracellular side of the cell membrane) and have a clear signal peptide; the remaining 7 members are either type III transmembrane receptors (single pass with the N terminus on extracellular side of the membrane but no signal sequence; TNFR13B, TNFR13C, TNFR17, and XEDAR), or attached to the membrane via a glycosylphosphatidylinositol (GPI) linker (TNFR10C), or secreted as soluble receptors (TNFR11B and TNFR6B). All TNFRs contain relatively short cysteine-rich domains (CRDs) in the ectodomain, and are involved in interaction with the TNF homology domain (THD) of their ligands. TNFRs often have multiple CRDs (between one and six), with the most frequent configurations of three or four copies; most CRDs possess three disulfide bridges, but could have between one and four. Localized or genome-wide duplication and evolution of the TNFRSF members appear to have paralleled the emergence of the adaptive immune system; teleosts (i.e. ray-finned, bony fish), which possess an immune system with B and T cells, possess primary and secondary lymphoid organs, and are capable of adaptive responses to pathogens also display several characteristics that are different from the mammalian immune system, making teleost TNFSF orthologs and paralogs of interest to better understand immune system evolution and the immunological pathways elicited to pathogens.


Pssm-ID: 276900 [Multi-domain]  Cd Length: 87  Bit Score: 60.30  E-value: 3.34e-10
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6098 CGSGEYETRAPTATTDRKCASvtqCDSTQFvvsKPTATTDRDCAECDRCDSGTQYETATCTATTNRVCadltVCADTEYE 6177
Cdd:cd00185     5 CPPGEYLSSDCTATTDTVCSP---CPPGTY---SESWNSLSKCLPCTTCGGGNQVEKTPCTATDNRCC----TCKPGFYC 74
                          90
                  ....*....|....*
gi 514698100 6178 SvaaTDTSDRKCSSC 6192
Cdd:cd00185    75 D---EGTNVEECKPC 86
FhaB COG3210
Large exoprotein involved in heme utilization or adhesion [Intracellular trafficking, ...
9-1488 3.60e-10

Large exoprotein involved in heme utilization or adhesion [Intracellular trafficking, secretion, and vesicular transport];


Pssm-ID: 442443 [Multi-domain]  Cd Length: 1698  Bit Score: 67.87  E-value: 3.60e-10
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100    9 TATIGTSAFSWQGAARGREAGCTRVTVTGERLLGGGSSIAAVQVAGVETRVIESSNNTHVVLRASNGTGSGDIELIADTG 88
Cdd:COG3210   188 AANPTGVTGVGGALINATAGVLANAGGGTAGGVASANSTLTGGVVAAGTGAGVISTGGTDISSLSVAAGAGTGGAGGTGN 267
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100   89 AKTVANVTFSYLELGVITAVRPAIGRVGTLVTIEGERLQSGGSAVARVDLGGVPATLLHGNDSTVVVICSAGSGAGAVRV 168
Cdd:COG3210   268 AGNTTIGTTVTGTNATGSNTAGASSGDTTTNGTSSVTGAGGTGVLGGGTAAGITTTNTVGGNGDGNNTTANSGAGLVSGG 347
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  169 TSDVGGFVEGLLWTFVDSRIDSVEPSQGQEGTVVRIHGSGLFGGATGVASVTVAGVAATLRSPILDYFAVVELGSAPAGT 248
Cdd:COG3210   348 TGGNNGTTGTGAGSGLTGTGNGGGLTTAGAGTVASTVGTATASTGNASSTTVLGSGSLATGNTGTTIAGNGGSANAGGFT 427
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  249 SGAVVVVAESGARVVSSQTFTYAEPATIAAVSPSSGQVGTRVTITGTNLLGGGAAVERVTLAGVEASLVAQSATQIVVVA 328
Cdd:COG3210   428 TTGGVLGITGNGTVTGGTIGGLTGSGTTNGAGLSGNTDVSGTGTVTNSAGNTTSATTLAGGGIGTVTTNATISNNAGGDA 507
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  329 SPSRERAAGPVVVYSDTGAFARLESAFAYQIPGRISTLSPSSGQAGTVVELTGFNLLGGGSALSSLSVHGVEVEQVTFAS 408
Cdd:COG3210   508 NGIATGLTGITAGGGGGGNATSGGTGGDGTTLSGSGLTTTVSGGASGTTAASGSNTANTLGVLAATGGTSNATTAGNSTS 587
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  409 ----------DALIAFVVPLTSVQGLGDVRIVSASGATVEAGDAFTLLEPGRIVGVAPERGQEGTFVTIVGERLLGGGET 478
Cdd:COG3210   588 atggtgtnsgGTVLSIGTGSAGATGTITLGAGTSGAGANATGGGAGLTGSAVGAALSGTGSGTTGTASANGSNTTGVNTA 667
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  479 IARAVLGATAAEAVVSSSDARVVVRAGAAVTFGPVGVTLWADTGAVvnTSAGLFEYLAPGMVASVLPVSGQAGTQVVIEG 558
Cdd:COG3210   668 GGTGGGTTGTVTSGATGGTTGTTLNAATGGTLNNAGNTLTISTGSI--TVTGQIGALANANGDTVTFGNLGTGATLTLNA 745
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  559 MELL---GHETALEAVTLGGVQAAAILSFNRTHVVVTAGDGPASTGPVVLTASNGSRVTGGAVWTQL----ERGAIGSVQ 631
Cdd:COG3210   746 GVTItsgNAGTLSIGLTANTTASGTTLTLANANGNTSAGATLDNAGAEISIDITADGTITAAGTTAInvtgSGGTITINT 825
                         650       660       670       680       690       700       710       720
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  632 PSSGHGGTRVTITGQRLLGGGAALASVELGGVLATEIAWANDTVAVVSAGASGSALAGGNVTLVADTGAVTTGSGLWAYV 711
Cdd:COG3210   826 ATTGLTGTGDTTSGAGGSNTTDTTTGTTSDGASGGGTAGANSGSLAATAASITVGSGGVATSTGTANAGTLTNLGTTTNA 905
                         730       740       750       760       770       780       790       800
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  712 APAVISSVAPTSGQAGTVVTIRGNNLSMGGAVREVFLAGIPAVSVSLVNDSFVVAHASGALSGRSSPAVVRNNFGAFVSS 791
Cdd:COG3210   906 ASGNGAVLATVTATGTGGGGLTGGNAAAGGTGAGNGTTALSGTQGNAGLSAASASDGAGDTGASSAAGSSAVGTSANSAG 985
                         810       820       830       840       850       860       870       880
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  792 SVNWTYVPAGAVDITRPARAQFGTRVTVTGSNLLQGGAIIASASMAGVPCTVLSSNDTTVVVSVAGNFAATVASPSMTLV 871
Cdd:COG3210   986 STGGVIAATGILVAGNSGTTASTTGGSGAIVAGGNGVTGTTGTASATGTGTAATAGGQNGVGVNASGISGGNAAALTASG 1065
                         890       900       910       920       930       940       950       960
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  872 SDSGAVITFTSSTTAEPSGVVTAISPSSGQYGTFVTLSGTQLLAHASNLRTVSLAGTQVLSIESATESEVIVRAGLGVNG 951
Cdd:COG3210  1066 TAGTTGGTAASNGGGGTAQASGAGTTHTLGGITNGGATGTSGGTTTSTGGVTASKVGGTTTVGATGTSTASTEAAGAGTL 1145
                         970       980       990      1000      1010      1020      1030      1040
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  952 TAGSPRLRASSGGVV-AAATGVNFTYVRQGRIDTVSPLFGQLGTLVTISGEHLLSGGSSASRVLLAGLPAAVVSSNSSVV 1030
Cdd:COG3210  1146 TGLVAVSAVAGGASSaSAGDTTAVAAATTTTTGSAINGGADSAATEGTAGTDLKGGDSTGGSTTTIGTTNVTTTTTLTAS 1225
                        1050      1060      1070      1080      1090      1100      1110      1120
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1031 VARAPLSNSTSIRTGSVVVLANTGALSAESSTTFTFRPAGFIASVSPSFGQRGTYVEIAGNRLLDGSGLREVLLADVPAE 1110
Cdd:COG3210  1226 DTGNTTATGGSSAGQTGSFVAAGSASGTGDATTGATAGAVSNGATSTVAGNAGATATGSTVDIGSTSATSAGGSLDTTGN 1305
                        1130      1140      1150      1160      1170      1180      1190      1200
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1111 VLSANDTFALVRAQASLPRVGDVVVRSDSGYEVVSSQAFVYIAPQHPDTVVPASGQFGTRVTINGTGLLGGGATVQTVQF 1190
Cdd:COG3210  1306 TAGANGATVGTGIGGTTATGTAVAAVNSGGVNAGGGTINTTAANTGLNGGNGATDSAAGAGSGGAAGSLAATAGAGTVLT 1385
                        1210      1220      1230      1240      1250      1260      1270      1280
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1191 DAVAGSDPRVTAAGIEVSAPGGAAGVRNITVVANTGAYFTVARAFTVIAEPNVTAITPSSGQAGAYVTVSGTELLGGGAF 1270
Cdd:COG3210  1386 GAGNNTGAEGTNAGRDGGVTTSGTGVGNNGGVSGTTVAGTTGSSATTGTGGTGNTTGTSVAGAGGGNADASAINTGNASS 1465
                        1290      1300      1310      1320      1330      1340      1350      1360
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1271 AERVFLAGVEADVVTSSPSSVVVRAPVSVAKVGPTVIVADTGATTTSLLNFTFTPQLSVTSVSPSSGQGGTRVTVLGANL 1350
Cdd:COG3210  1466 LGAGGSTAGNAVGGAVIGGTTTGGNGAGVAGATASNGGTSTGAGGTAGGTTAEVAKASLEGGEGTYGGSSVAEAGTGGGI 1545
                        1370      1380      1390      1400      1410      1420      1430      1440
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1351 RLGSSAVTGVLLGSAACSLISENDTAVVCAAGVASAGSVPVTVEASSGAFASVGGVLAFEYLDAGVINSVEPGSGQQGTR 1430
Cdd:COG3210  1546 LGAVSGAGSEGGAAGGVTGSVGVGGTDGAGGDTGGADDTGAQAPTAGNTATLTLSLAEGTNAEYGGTTNVTSGTAGNAGA 1625
                        1450      1460      1470      1480      1490
                  ....*....|....*....|....*....|....*....|....*....|....*...
gi 514698100 1431 VVVSGLRLLGGGIRVDQAFLGGVEATIRSSSAFAVTLAAGNGSEPSSGDIVLIADTGA 1488
Cdd:COG3210  1626 TGANSNTVVTTNGGEGVLALVAGGNTTNGTTLSGAVNGAGNGWAVDLTDATLAGLGGA 1683
TNFRSF cd00185
Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) ...
5661-5741 5.29e-10

Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) interactions with TNF superfamily (TNFSF) ligands (TNFL) control key cellular processes such as differentiation, proliferation, apoptosis, and cell growth. Dysregulation of these pathways has been shown to result in a wide range of pathological conditions, including autoimmune diseases, inflammation, cancer, and viral infection. There are 29 very diverse family members of TNFRSF reported in humans: 22 are type I transmembrane receptors (single pass with the N terminus on extracellular side of the cell membrane) and have a clear signal peptide; the remaining 7 members are either type III transmembrane receptors (single pass with the N terminus on extracellular side of the membrane but no signal sequence; TNFR13B, TNFR13C, TNFR17, and XEDAR), or attached to the membrane via a glycosylphosphatidylinositol (GPI) linker (TNFR10C), or secreted as soluble receptors (TNFR11B and TNFR6B). All TNFRs contain relatively short cysteine-rich domains (CRDs) in the ectodomain, and are involved in interaction with the TNF homology domain (THD) of their ligands. TNFRs often have multiple CRDs (between one and six), with the most frequent configurations of three or four copies; most CRDs possess three disulfide bridges, but could have between one and four. Localized or genome-wide duplication and evolution of the TNFRSF members appear to have paralleled the emergence of the adaptive immune system; teleosts (i.e. ray-finned, bony fish), which possess an immune system with B and T cells, possess primary and secondary lymphoid organs, and are capable of adaptive responses to pathogens also display several characteristics that are different from the mammalian immune system, making teleost TNFSF orthologs and paralogs of interest to better understand immune system evolution and the immunological pathways elicited to pathogens.


Pssm-ID: 276900 [Multi-domain]  Cd Length: 87  Bit Score: 59.53  E-value: 5.29e-10
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5661 CGAGEEEIASPTLSTDRQCRTCASGTFKAAAGQSTTCIAVSTCAAGFTEDVAP-TPSSDRVCvECAPGTF-KATAGDGTC 5738
Cdd:cd00185     5 CPPGEYLSSDCTATTDTVCSPCPPGTYSESWNSLSKCLPCTTCGGGNQVEKTPcTATDNRCC-TCKPGFYcDEGTNVEEC 83

                  ...
gi 514698100 5739 RAH 5741
Cdd:cd00185    84 KPC 86
TNFRSF11B_teleost cd13412
Tumor necrosis factor receptor superfamily 11B (TNFRSF11B) in teleost; also known as ...
6143-6264 6.20e-10

Tumor necrosis factor receptor superfamily 11B (TNFRSF11B) in teleost; also known as Osteoprotegerin (OPG); This subfamily of TNFRSF11B (also known as Osteoprotegerin, OPG, TR1, OCIF) is found in teleosts. It is a secreted glycoprotein that regulates bone resorption. It binds to two ligands, RANKL (receptor activator of nuclear factor kappaB ligand, also known as osteoprotegerin ligand, OPGL, TRANCE, TNF-related activation induced cytokine), a critical cytokine for osteoclast differentiation, and TRAIL (TNF-related apoptosis-inducing ligand), involved in immune surveillance. Therefore, acting as a decoy receptor for RANKL and TRAIL, OPG inhibits the regulatory effects of nuclear factor-kappaB on inflammation, skeletal, and vascular systems, and prevents TRAIL-induced apoptosis. Studies in mice counterparts suggest that this protein and its ligand also play a role in lymph-node organogenesis and vascular calcification. Circulating OPG levels have emerged as independent biomarkers of cardiovascular disease (CVD) in patients with acute or chronic heart disease. OPG has also been implicated in various inflammations and linked to diabetes and poor glycemic control. Alternatively spliced transcript variants of this gene have been reported, although their full length nature has not been determined. Genetic analysis of the Japanese rice fish medaka (Oryzias latipes) has shown that entire networks for bone formation are conserved between teleosts and mammals; enabling medaka to be used as a genetic model to monitor bone homeostasis in vivo.


Pssm-ID: 276917 [Multi-domain]  Cd Length: 129  Bit Score: 60.97  E-value: 6.20e-10
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6143 CDRCDSGTqYETATCTATTNRVCadlTVCADTEYesvaaTDTSD--RKCSSCRE-CTSSEYLVSGCSESANAVCkactEC 6219
Cdd:cd13412    22 CKKCPPGT-HMAAHCTATTQTKC---LPCPAAHY-----TELWNylPRCLYCNNfCSENQEVEIECSATNNRVC----RC 88
                          90       100       110       120
                  ....*....|....*....|....*....|....*....|....*
gi 514698100 6220 PSGTFvstactpLADAECTECTRCGSGYFVQSPCTSEADTTCKRC 6264
Cdd:cd13412    89 KEGYY-------MDSDFCIRHTECGPGYGVKTKGTTKQDTVCEKC 126
TNFRSF1B cd10577
Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B), also known as TNFR2; TNFRSF1B ...
6098-6261 9.04e-10

Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B), also known as TNFR2; TNFRSF1B (also known as TNFR2, type 2 TNFR, TNFBR, TNFR80, TNF-R75, TNF-R-II, p75, CD120b) binds TNF-alpha, but lacks the death domain (DD) that is associated with the cytoplasmic domain of TNFRSF1A (TNFR1). It is inducible and expressed exclusively by oligodendrocytes, astrocytes, T cells, thymocytes, myocytes, endothelial cells, and in human mesenchymal stem cells. TNFRSF1B protects oligodendrocyte progenitor cells (OLGs) against oxidative stress, and induces the up-regulation of cell survival genes. While pro-inflammatory and pathogen-clearing activities of TNF are mediated mainly through activation of TNFRSF1A, a strong activator of NF-kappaB, TNFRSF1B is more responsible for suppression of inflammation. Although the affinities of both receptors for soluble TNF are similar, TNFRSF1B is sometimes more abundantly expressed and thought to associate with TNF, thereby increasing its concentration near TNFRSF1A receptors, and making TNF available to activate TNFRSF1A (a ligand-passing mechanism).


Pssm-ID: 276903 [Multi-domain]  Cd Length: 163  Bit Score: 61.34  E-value: 9.04e-10
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6098 CGSGEYETRAPTATTDRKCASVTQCDSTQFVVSKPTattdrdCAECD-RCDSGtQYETATCTATTNRVCAdltvCADTEY 6176
Cdd:cd10577    19 CPPGQHVKHSCTKTSDTVCAPCEESTYTQLWNWVPE------CLSCSsPCSSD-QVETQACTRQQNRICS----CKPGWY 87
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6177 eSVAATDTSDRKCSSCRECTSSEYLVSGCSESANAVCKActeCPSGTFVSTACTplaDAECTECTRCGSgyfVQSPCTSE 6256
Cdd:cd10577    88 -CVLKLQEGCRQCRPLKKCGPGFGVARPGTASSDVECKP---CAPGTFSDTTSS---TDTCRPHRICSS---VAIPGNAS 157

                  ....*
gi 514698100 6257 ADTTC 6261
Cdd:cd10577   158 MDAVC 162
TNFRSF1B cd10577
Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B), also known as TNFR2; TNFRSF1B ...
6143-6291 2.18e-09

Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B), also known as TNFR2; TNFRSF1B (also known as TNFR2, type 2 TNFR, TNFBR, TNFR80, TNF-R75, TNF-R-II, p75, CD120b) binds TNF-alpha, but lacks the death domain (DD) that is associated with the cytoplasmic domain of TNFRSF1A (TNFR1). It is inducible and expressed exclusively by oligodendrocytes, astrocytes, T cells, thymocytes, myocytes, endothelial cells, and in human mesenchymal stem cells. TNFRSF1B protects oligodendrocyte progenitor cells (OLGs) against oxidative stress, and induces the up-regulation of cell survival genes. While pro-inflammatory and pathogen-clearing activities of TNF are mediated mainly through activation of TNFRSF1A, a strong activator of NF-kappaB, TNFRSF1B is more responsible for suppression of inflammation. Although the affinities of both receptors for soluble TNF are similar, TNFRSF1B is sometimes more abundantly expressed and thought to associate with TNF, thereby increasing its concentration near TNFRSF1A receptors, and making TNF available to activate TNFRSF1A (a ligand-passing mechanism).


Pssm-ID: 276903 [Multi-domain]  Cd Length: 163  Bit Score: 60.18  E-value: 2.18e-09
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6143 CDRCDSGtQYETATCTATTNRVCADltvCADTEYESVAatdTSDRKCSSCRE-CTSSEYLVSGCSESANAVCKacteCPS 6221
Cdd:cd10577    16 CSKCPPG-QHVKHSCTKTSDTVCAP---CEESTYTQLW---NWVPECLSCSSpCSSDQVETQACTRQQNRICS----CKP 84
                          90       100       110       120       130       140       150
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|...
gi 514698100 6222 GTFvstaCTPLADAECTECTR---CGSGYFVQSPCTSEADTTCKrcrSCASGEYLHTACTTplpiaNVQRSHR 6291
Cdd:cd10577    85 GWY----CVLKLQEGCRQCRPlkkCGPGFGVARPGTASSDVECK---PCAPGTFSDTTSST-----DTCRPHR 145
TNFRSF21 cd10583
Tumor necrosis factor receptor superfamily member 21 (TNFRSF21), also known as death receptor ...
5605-5769 3.70e-09

Tumor necrosis factor receptor superfamily member 21 (TNFRSF21), also known as death receptor (DR6); TNFRSF21 (also known as death receptor 6 (DR6), CD358, BM-018) is highly expressed in differentiating neurons as well as in the adult brain, and is upregulated in injured neurons. DR6 negatively regulates neurondendrocyte, axondendrocyte, and oligodendrocyte survival, hinders axondendrocyte and oligodendrocyte regeneration and its inhibition has a neuro-protective effect in nerve injury. It activates nuclear factor kappa-B (NFkB) and mitogen-activated protein kinase 8 (MAPK8, also called c-Jun N-terminal kinase 1), and induces cell apoptosis by associating with TNFRSF1A-associated via death domain (TRADD), which is known to mediate signal transduction of tumor necrosis factor receptors. TNFRSF21 plays a role in T-helper cell activation, and may be involved in inflammation and immune regulation. Its possible ligand is alpha-amyloid precursor protein (APP), hence probably involved in the development of Alzheimer's disease; when released, APP binds in an autocrine/paracrine manner to activate a caspase-dependent self-destruction program that removes unnecessary or connectionless axons. Increasing beta-catenin levels in brain endothelium upregulates TNFRSF21 and TNFRSF19, indicating that these death receptors are downstream target genes of Wnt/beta-catenin signaling, which has been shown to be required for blood-brain barrier development. DR6 is up-regulated in numerous solid tumors as well as in tumor vascular cells, including ovarian cancer and may be a clinically useful diagnostic and predictive serum biomarker for some adult sarcoma subtypes.


Pssm-ID: 276909 [Multi-domain]  Cd Length: 159  Bit Score: 59.38  E-value: 3.70e-09
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5605 PSKGQErcLSVKTCGAGEEETTSPSATRNRVCQPCQLGSTFKAQSG--QSTRCISvtTCGAGEEEIASPTLSTDRQCrTC 5682
Cdd:cd10583     7 PATGTQ--LTCDKCPAGTYVSKHCTETSLRECSPCPNGTFTRHENGieQCHRCRK--PCPAPMIEKTPCTALTDREC-TC 81
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5683 ASGTFKaaagQSTTCIAVSTCAAGFTEDVAPTPSSDRVCVECAPGTFKATagdgtcrahrtcedteyetvaptSSSDRKC 5762
Cdd:cd10583    82 PPGTFL----SNDTCVPHSVCPVGWGVRKKGTETEDVRCKPCPRGTFSDV-----------------------PSSVLKC 134

                  ....*..
gi 514698100 5763 KALTVCQ 5769
Cdd:cd10583   135 KTYTDCL 141
TNFRSF11B cd10581
Tumor necrosis factor receptor superfamily member 11B (TNFRSF11B), also known as ...
6143-6264 4.47e-09

Tumor necrosis factor receptor superfamily member 11B (TNFRSF11B), also known as Osteoprotegerin (OPG); TNFRSF11B (also known as Osteoprotegerin, OPG, TR1, OCIF) is a secreted glycoprotein that regulates bone resorption. It binds to two ligands, RANKL (receptor activator of nuclear factor kappaB ligand, also known as osteoprotegerin ligand, OPGL, TRANCE, TNF-related activation induced cytokine), a critical cytokine for osteoclast differentiation, and TRAIL (TNF-related apoptosis-inducing ligand), involved in immune surveillance. Therefore, acting as a decoy receptor for RANKL and TRAIL, OPG inhibits the regulatory effects of nuclear factor-kappaB on inflammation, skeletal, and vascular systems, and prevents TRAIL-induced apoptosis. Studies in mice counterparts suggest that this protein and its ligand also play a role in lymph-node organogenesis and vascular calcification. Circulating OPG levels have emerged as independent biomarkers of cardiovascular disease (CVD) in patients with acute or chronic heart disease. OPG has also been implicated in various inflammations and linked to diabetes and poor glycemic control. Alternatively spliced transcript variants of this gene have been reported, although their full length nature has not been determined.


Pssm-ID: 276907 [Multi-domain]  Cd Length: 147  Bit Score: 59.02  E-value: 4.47e-09
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6143 CDRCDSGTqYETATCTATTNRVCADltvCADTEYesvAATDTSDRKCSSCRE-CTSSEYLVSGCSESANAVCkactECPS 6221
Cdd:cd10581    36 CDQCPPGT-YVKQHCSASRKTVCAP---CPDHHY---ADDWNSNDECQYCNTvCKELQYVKQECNSTHNRVC----ECVE 104
                          90       100       110       120
                  ....*....|....*....|....*....|....*....|....
gi 514698100 6222 GTFVstactplaDAE-CTECTRCGSGYFVQSPCTSEADTTCKRC 6264
Cdd:cd10581   105 GRYL--------ELEfCLKHTECPPGFGVVQPGTPESDTVCERC 140
TNFRSF16 cd13416
Tumor necrosis factor receptor superfamily member 16 (TNFRSF16), also known as p75 ...
6029-6213 6.99e-09

Tumor necrosis factor receptor superfamily member 16 (TNFRSF16), also known as p75 neurotrophin receptor (p75NTR) or CD271; TNFRSF16 (also known as nerve growth factor receptor (NGFR) or p75 neurotrophin receptor (p75NTR or p75(NTR)), CD271, Gp80-LNGFR) is a common receptor for both neurotrophins and proneurotrophins, and plays a diverse role in many tissues, including the nervous system. It has been shown to be expressed in various types of stem cells and has been used to prospectively isolate stem cells with different degrees of potency. p75NTR owes its signaling to the recruitment of intracellular binding proteins, leading to the activation of different signaling pathways. It binds nerve growth factor (NGF) and the complex can initiate a signaling cascade which has been associated with both neuronal apoptosis and neuronal survival of discrete populations of neurons, depending on the presence or absence of intracellular signaling molecules downstream of p75NTR (e.g. NF-kB, JNK, or p75NTR intracellular death domain). p75NTR can also bind NGF in concert with the neurotrophic tyrosine kinase receptor type 1 (TrkA) protein where it is thought to modulate the formation of the high-affinity neurotrophin binding complex. On melanoma cell, p75NTR is an immunosuppressive factor, induced by interferon (IFN)-gamma, and mediates down-regulation of melanoma antigens. It can interact with the aggregated form of amyloid beta (Abeta) peptides, and plays an important role in etiopathogenesis of Alzheimer's disease by influencing protein tau hyper-phosphorylation. p75(NTR) is involved in the formation and progression of retina diseases; its expression is induced in retinal pigment epithelium (RPE) cells and its knockdown rescues RPE cell proliferation activity and inhibits RPE apoptosis induced by hypoxia. It can therefore be a potential therapeutic target for RPE hypoxia or oxidative stress diseases.


Pssm-ID: 276921 [Multi-domain]  Cd Length: 159  Bit Score: 58.47  E-value: 6.99e-09
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6029 TCASGKFkATTGQTpCEAvstCEEDEYVYRAATVsTDTQCRAltaCSDEqyETRAPTVNSDRECTGLTTCGSGEYeTRAP 6108
Cdd:cd13416     2 ACPSGQY-TSSGEC-CEQ---CPPGEGVARPCGD-NQTVCEP---CLDG--VTFSDVVSHTEPCQPCTRCPGLMS-MRAP 69
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6109 -TATTDRKCAsvtqCDSTQFVVSKptattDRDCAECDRCDSGtQYETATCTATTNRVCAdltVCADTEYesvAATDTSDR 6187
Cdd:cd13416    70 cTATHDTVCE----CAYGYYLDED-----SGTCEPCTVCPPG-QGVVQSCGPNQDTVCE---ACPEGTY---SDEDSSTD 133
                         170       180
                  ....*....|....*....|....*.
gi 514698100 6188 KCSSCRECTSSEYLVSGCSESANAVC 6213
Cdd:cd13416   134 PCLPCTVCEDGEVELRECTPVSDTVC 159
TNFRSF cd00185
Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) ...
5789-5858 1.64e-08

Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) interactions with TNF superfamily (TNFSF) ligands (TNFL) control key cellular processes such as differentiation, proliferation, apoptosis, and cell growth. Dysregulation of these pathways has been shown to result in a wide range of pathological conditions, including autoimmune diseases, inflammation, cancer, and viral infection. There are 29 very diverse family members of TNFRSF reported in humans: 22 are type I transmembrane receptors (single pass with the N terminus on extracellular side of the cell membrane) and have a clear signal peptide; the remaining 7 members are either type III transmembrane receptors (single pass with the N terminus on extracellular side of the membrane but no signal sequence; TNFR13B, TNFR13C, TNFR17, and XEDAR), or attached to the membrane via a glycosylphosphatidylinositol (GPI) linker (TNFR10C), or secreted as soluble receptors (TNFR11B and TNFR6B). All TNFRs contain relatively short cysteine-rich domains (CRDs) in the ectodomain, and are involved in interaction with the TNF homology domain (THD) of their ligands. TNFRs often have multiple CRDs (between one and six), with the most frequent configurations of three or four copies; most CRDs possess three disulfide bridges, but could have between one and four. Localized or genome-wide duplication and evolution of the TNFRSF members appear to have paralleled the emergence of the adaptive immune system; teleosts (i.e. ray-finned, bony fish), which possess an immune system with B and T cells, possess primary and secondary lymphoid organs, and are capable of adaptive responses to pathogens also display several characteristics that are different from the mammalian immune system, making teleost TNFSF orthologs and paralogs of interest to better understand immune system evolution and the immunological pathways elicited to pathogens.


Pssm-ID: 276900 [Multi-domain]  Cd Length: 87  Bit Score: 55.29  E-value: 1.64e-08
                          10        20        30        40        50        60        70
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|.
gi 514698100 5789 CGRCTDGLTLDKACTDTSPTKCVgcdECASDEYTLSSctlSSQTQCRQCTTCG-NDEYQTKACSVSQDTEC 5858
Cdd:cd00185     2 CQRCPPGEYLSSDCTATTDTVCS---PCPPGTYSESW---NSLSKCLPCTTCGgGNQVEKTPCTATDNRCC 66
TNFRSF10 cd10580
Tumor necrosis factor receptor superfamily member 10 (TNFRSF10), includes TNFRSF10A (DR4), ...
5634-5722 1.79e-08

Tumor necrosis factor receptor superfamily member 10 (TNFRSF10), includes TNFRSF10A (DR4), TNFRSF10B (DR5), TNFRSF10C (DcR1) and TNFRSF10D (DcR2); TNFRSF10 family contains TNFRSF10A (also known as DR4, Apo2, TRAIL-R1, CD261), TNFRSF10B (also known as DR5, KILLER, TRICK2A, TRAIL-R2, TRICKB, CD262), TNFRSF10C (also known as DcR1, TRAIL-R3, LIT, TRID, CD263), and TNFRSF10D (also known as DcR2, TRUNDD, TRAIL-R4, CD264). Tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL) binds to all 4 receptors. DR4 (TRAIL-R1) and DR5 (TRAIL-R2) are membrane-bound and contain a death domain in their intracellular portion, which is able to transmit an apoptotic signal, thus often called death receptors. In contrast, DcR1 (TRAIL-R3), which lacks the complete intracellular portion and DcR2 (TRAIL-R4), which has a truncated cytoplasmic death domain, do not transmit an apoptotic signal, thus known as decoy receptors. Apoptosis mediated by DR4 and DR5 requires Fas (TNFRSF6)-associated via death domain (FADD), a death domain containing adaptor protein. Two transcript variants encoding different isoforms and one non-coding transcript have been found for TNFRSF10B/DR5. DcR1 appears to function as an antagonistic receptor that protects cells from TRAIL-induced apoptosis; it has been found to be a p53-regulated DNA damage-inducible gene. The expression of this gene is detected in many normal tissues but not in most cancer cell lines, which may explain the specific sensitivity of cancer cells to the apoptosis-inducing activity of TRAIL. DcR2 has been shown to play an inhibitory role in TRAIL-induced cell apoptosis. The membrane expression of all of these receptors (DR4, DR5, DcR1, and DcR2) is greater in normal endometrium (NE) than in endometrioid adenocarcinoma (EAC). In EAC patients, membrane expression of these receptors are not independent predictors of survival. DcR1 and DcR2 expression is critical in cell growth and apoptosis in cutaneous or uveal melanoma; DcR1 and DcR2 are frequently methylated in both, leading to loss of gene expression and melanomagenesis. On the other hand, DR4 and DR5 methylation is rare in cutaneous melanoma and frequent in uveal melanoma; their expression is wholly independent of the promoter methylation status. DcR1 and DcR2 genes are also reported to be hyper-methylated in prostate cancer. The TRAIL ligand, a potent and specific inducer of apoptosis in cancer cells, has been explored as a therapeutic drug; experimental data has shown that DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.


Pssm-ID: 276906 [Multi-domain]  Cd Length: 103  Bit Score: 55.73  E-value: 1.79e-08
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5634 RVCQPCQLGSTFKAQSGQSTRCISVTTCGAGEEEIASPTLSTDRQCRtCASGTFKAAagQSttCIAVSTCAAGFTED--- 5710
Cdd:cd10580    16 GDCIPCKEGVDYTEHPNGLPSCLPCTVCKSDEEELSPCTTTRNTECQ-CKPGTFCDP--DS--PEVCQKCSTRCPEGmve 90
                          90
                  ....*....|...
gi 514698100 5711 VAP-TPSSDRVCV 5722
Cdd:cd10580    91 VSPcTPWSDLKCV 103
TNFRSF16 cd13416
Tumor necrosis factor receptor superfamily member 16 (TNFRSF16), also known as p75 ...
5950-6116 1.80e-08

Tumor necrosis factor receptor superfamily member 16 (TNFRSF16), also known as p75 neurotrophin receptor (p75NTR) or CD271; TNFRSF16 (also known as nerve growth factor receptor (NGFR) or p75 neurotrophin receptor (p75NTR or p75(NTR)), CD271, Gp80-LNGFR) is a common receptor for both neurotrophins and proneurotrophins, and plays a diverse role in many tissues, including the nervous system. It has been shown to be expressed in various types of stem cells and has been used to prospectively isolate stem cells with different degrees of potency. p75NTR owes its signaling to the recruitment of intracellular binding proteins, leading to the activation of different signaling pathways. It binds nerve growth factor (NGF) and the complex can initiate a signaling cascade which has been associated with both neuronal apoptosis and neuronal survival of discrete populations of neurons, depending on the presence or absence of intracellular signaling molecules downstream of p75NTR (e.g. NF-kB, JNK, or p75NTR intracellular death domain). p75NTR can also bind NGF in concert with the neurotrophic tyrosine kinase receptor type 1 (TrkA) protein where it is thought to modulate the formation of the high-affinity neurotrophin binding complex. On melanoma cell, p75NTR is an immunosuppressive factor, induced by interferon (IFN)-gamma, and mediates down-regulation of melanoma antigens. It can interact with the aggregated form of amyloid beta (Abeta) peptides, and plays an important role in etiopathogenesis of Alzheimer's disease by influencing protein tau hyper-phosphorylation. p75(NTR) is involved in the formation and progression of retina diseases; its expression is induced in retinal pigment epithelium (RPE) cells and its knockdown rescues RPE cell proliferation activity and inhibits RPE apoptosis induced by hypoxia. It can therefore be a potential therapeutic target for RPE hypoxia or oxidative stress diseases.


Pssm-ID: 276921 [Multi-domain]  Cd Length: 159  Bit Score: 57.31  E-value: 1.80e-08
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5950 ACSAGHYVPRGRtggCAAFeCAAGH--VDQDEDAATACKLCEAGVNYAGSAGLT-RCTSVSECGAGEEETSAPTASTDRV 6026
Cdd:cd13416     2 ACPSGQYTSSGE---CCEQ-CPPGEgvARPCGDNQTVCEPCLDGVTFSDVVSHTePCQPCTRCPGLMSMRAPCTATHDTV 77
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6027 CStCASGKFKATTGQTpCEAVSTCEEDEYVYRAATVSTDTQCRaltACSDEQYETRAPTVNSDRECtglTTCGSGEYETR 6106
Cdd:cd13416    78 CE-CAYGYYLDEDSGT-CEPCTVCPPGQGVVQSCGPNQDTVCE---ACPEGTYSDEDSSTDPCLPC---TVCEDGEVELR 149
                         170
                  ....*....|
gi 514698100 6107 APTATTDRKC 6116
Cdd:cd13416   150 ECTPVSDTVC 159
TNFRSF16 cd13416
Tumor necrosis factor receptor superfamily member 16 (TNFRSF16), also known as p75 ...
5894-6068 1.95e-08

Tumor necrosis factor receptor superfamily member 16 (TNFRSF16), also known as p75 neurotrophin receptor (p75NTR) or CD271; TNFRSF16 (also known as nerve growth factor receptor (NGFR) or p75 neurotrophin receptor (p75NTR or p75(NTR)), CD271, Gp80-LNGFR) is a common receptor for both neurotrophins and proneurotrophins, and plays a diverse role in many tissues, including the nervous system. It has been shown to be expressed in various types of stem cells and has been used to prospectively isolate stem cells with different degrees of potency. p75NTR owes its signaling to the recruitment of intracellular binding proteins, leading to the activation of different signaling pathways. It binds nerve growth factor (NGF) and the complex can initiate a signaling cascade which has been associated with both neuronal apoptosis and neuronal survival of discrete populations of neurons, depending on the presence or absence of intracellular signaling molecules downstream of p75NTR (e.g. NF-kB, JNK, or p75NTR intracellular death domain). p75NTR can also bind NGF in concert with the neurotrophic tyrosine kinase receptor type 1 (TrkA) protein where it is thought to modulate the formation of the high-affinity neurotrophin binding complex. On melanoma cell, p75NTR is an immunosuppressive factor, induced by interferon (IFN)-gamma, and mediates down-regulation of melanoma antigens. It can interact with the aggregated form of amyloid beta (Abeta) peptides, and plays an important role in etiopathogenesis of Alzheimer's disease by influencing protein tau hyper-phosphorylation. p75(NTR) is involved in the formation and progression of retina diseases; its expression is induced in retinal pigment epithelium (RPE) cells and its knockdown rescues RPE cell proliferation activity and inhibits RPE apoptosis induced by hypoxia. It can therefore be a potential therapeutic target for RPE hypoxia or oxidative stress diseases.


Pssm-ID: 276921 [Multi-domain]  Cd Length: 159  Bit Score: 57.31  E-value: 1.95e-08
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5894 ECTAATLTTDRECCgvTQCVPGsEETSAPTATSDRECRQCVAGTTDADGSGTT----PCVACSAGHYVPRgrtggcaafE 5969
Cdd:cd13416     2 ACPSGQYTSSGECC--EQCPPG-EGVARPCGDNQTVCEPCLDGVTFSDVVSHTepcqPCTRCPGLMSMRA---------P 69
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5970 CAAGHvdqdeDAatackLCEAGVNYAGSAGLTRCTSVSECGAGEEETSAPTASTDRVCSTCASGKFKATTGQT-PCEAVS 6048
Cdd:cd13416    70 CTATH-----DT-----VCECAYGYYLDEDSGTCEPCTVCPPGQGVVQSCGPNQDTVCEACPEGTYSDEDSSTdPCLPCT 139
                         170       180
                  ....*....|....*....|
gi 514698100 6049 TCEEDEYVYRAATVSTDTQC 6068
Cdd:cd13416   140 VCEDGEVELRECTPVSDTVC 159
TNFRSF5_teleost cd13422
Tumor necrosis factor receptor superfamily member 5 (TNFRSF5) in teleosts; also known as CD40; ...
5623-5722 2.66e-08

Tumor necrosis factor receptor superfamily member 5 (TNFRSF5) in teleosts; also known as CD40; TNFRSF5 (commonly known as CD40 and also as CDW40, p50, Bp50) is widely expressed in diverse cell types including B lymphocytes, dendritic cells, platelets, monocytes, endothelial cells, and fibroblasts. It is essential in mediating a wide variety of immune and inflammatory responses, including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation. Its natural immunomodulating ligand is CD40L, and a primary defect in the CD40/CD40L system is associated with X-linked hyper-IgM (XHIM) syndrome. It is also involved in tumorigenesis; CD40 expression is significantly higher in gastric carcinomas and it is associated with the lymphatic metastasis of cancer cells and their tumor node metastasis (TNM) classification. Upregulated levels of CD40/CD40L on B cells and T cells may play an important role in the immune pathogenesis of breast cancer. Consequently, the CD40/CD40L system serves as a link between tumorigenesis, atherosclerosis, and the immune system, and offers a potential target for drug therapy for related diseases, such as cancer, atherosclerosis, diabetes mellitus, and immunological rejection. Salmon CD40 and CD40L are widely expressed, particularly in immune tissues, and their importance for the immune response is indicated by their relatively high expression in salmon lymphoid organs and gills.


Pssm-ID: 276927 [Multi-domain]  Cd Length: 161  Bit Score: 57.05  E-value: 2.66e-08
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5623 EETTSPSATRNRVCQpCQLGstFKAQSGQSTRCISVTTCGAGEEEIASPTLSTDRQCRTCASGTFKAAAGQSTTCIAVST 5702
Cdd:cd13422    65 EISVNKSKTSRSVCK-CKPG--FHCSSEECLTCVPHTTCGPGQGVKSKGNHIRDTVCEECPDGTFSNNSSAEGVCKKWTE 141
                          90       100
                  ....*....|....*....|
gi 514698100 5703 CAAGFTEDVAPTPSSDRVCV 5722
Cdd:cd13422   142 CESGYKVEAAGTNTSDNICV 161
TNFRSF5_teleost cd13422
Tumor necrosis factor receptor superfamily member 5 (TNFRSF5) in teleosts; also known as CD40; ...
5828-5963 3.97e-08

Tumor necrosis factor receptor superfamily member 5 (TNFRSF5) in teleosts; also known as CD40; TNFRSF5 (commonly known as CD40 and also as CDW40, p50, Bp50) is widely expressed in diverse cell types including B lymphocytes, dendritic cells, platelets, monocytes, endothelial cells, and fibroblasts. It is essential in mediating a wide variety of immune and inflammatory responses, including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation. Its natural immunomodulating ligand is CD40L, and a primary defect in the CD40/CD40L system is associated with X-linked hyper-IgM (XHIM) syndrome. It is also involved in tumorigenesis; CD40 expression is significantly higher in gastric carcinomas and it is associated with the lymphatic metastasis of cancer cells and their tumor node metastasis (TNM) classification. Upregulated levels of CD40/CD40L on B cells and T cells may play an important role in the immune pathogenesis of breast cancer. Consequently, the CD40/CD40L system serves as a link between tumorigenesis, atherosclerosis, and the immune system, and offers a potential target for drug therapy for related diseases, such as cancer, atherosclerosis, diabetes mellitus, and immunological rejection. Salmon CD40 and CD40L are widely expressed, particularly in immune tissues, and their importance for the immune response is indicated by their relatively high expression in salmon lymphoid organs and gills.


Pssm-ID: 276927 [Multi-domain]  Cd Length: 161  Bit Score: 56.67  E-value: 3.97e-08
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5828 LSSQTQCR--QCTTCGNDEYQTKacsVSQDTECATLTTCSSTQ-FEVEAPTATRDRR-CKdltaCQPGeYECTAATLTTd 5903
Cdd:cd13422    23 MSSDSGCLdpQCQPCGEDEYQDK---YTKENKCKRQPYCDPNKnFEISVNKSKTSRSvCK----CKPG-FHCSSEECLT- 93
                          90       100       110       120       130       140
                  ....*....|....*....|....*....|....*....|....*....|....*....|...
gi 514698100 5904 reCCGVTQCVPGSEETSAPTATSDRECRQCVAGTTDADGSGTTPC---VACSAGHYVPRGRTG 5963
Cdd:cd13422    94 --CVPHTTCGPGQGVKSKGNHIRDTVCEECPDGTFSNNSSAEGVCkkwTECESGYKVEAAGTN 154
TNFRSF cd00185
Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) ...
6171-6264 4.15e-08

Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) interactions with TNF superfamily (TNFSF) ligands (TNFL) control key cellular processes such as differentiation, proliferation, apoptosis, and cell growth. Dysregulation of these pathways has been shown to result in a wide range of pathological conditions, including autoimmune diseases, inflammation, cancer, and viral infection. There are 29 very diverse family members of TNFRSF reported in humans: 22 are type I transmembrane receptors (single pass with the N terminus on extracellular side of the cell membrane) and have a clear signal peptide; the remaining 7 members are either type III transmembrane receptors (single pass with the N terminus on extracellular side of the membrane but no signal sequence; TNFR13B, TNFR13C, TNFR17, and XEDAR), or attached to the membrane via a glycosylphosphatidylinositol (GPI) linker (TNFR10C), or secreted as soluble receptors (TNFR11B and TNFR6B). All TNFRs contain relatively short cysteine-rich domains (CRDs) in the ectodomain, and are involved in interaction with the TNF homology domain (THD) of their ligands. TNFRs often have multiple CRDs (between one and six), with the most frequent configurations of three or four copies; most CRDs possess three disulfide bridges, but could have between one and four. Localized or genome-wide duplication and evolution of the TNFRSF members appear to have paralleled the emergence of the adaptive immune system; teleosts (i.e. ray-finned, bony fish), which possess an immune system with B and T cells, possess primary and secondary lymphoid organs, and are capable of adaptive responses to pathogens also display several characteristics that are different from the mammalian immune system, making teleost TNFSF orthologs and paralogs of interest to better understand immune system evolution and the immunological pathways elicited to pathogens.


Pssm-ID: 276900 [Multi-domain]  Cd Length: 87  Bit Score: 54.14  E-value: 4.15e-08
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6171 CADTEYESVAATDTSDRKCSSCRECTSSEYlvsgcsESANAVCKACTECPSG-TFVSTACTPLADAECTectrCGSGYFv 6249
Cdd:cd00185     5 CPPGEYLSSDCTATTDTVCSPCPPGTYSES------WNSLSKCLPCTTCGGGnQVEKTPCTATDNRCCT----CKPGFY- 73
                          90
                  ....*....|....*
gi 514698100 6250 qsPCTSEADTTCKRC 6264
Cdd:cd00185    74 --CDEGTNVEECKPC 86
TNFRSF26 cd15837
Tumor necrosis factor receptor superfamily member 26 (TNFRSF26), also known as tumor necrosis ...
6098-6261 4.50e-08

Tumor necrosis factor receptor superfamily member 26 (TNFRSF26), also known as tumor necrosis factor receptor homolog 3 (TNFRH3); TNFRSF26 (also known as tumor necrosis factor receptor homolog 3 (TNFRH3) or TNFRSF24) is predominantly expressed in embryos and lymphoid cell types, along with its closely related TNFRSF22 and TNFRSF23 orthologs, and is developmentally regulated. Unlike TNFRSF22/23, TNFRSF26 does not serve as a TRAIL decoy receptor; it remains an orphan receptor.


Pssm-ID: 276933 [Multi-domain]  Cd Length: 118  Bit Score: 55.06  E-value: 4.50e-08
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6098 CGSGEYETraptattDRKCASvtQCDSTQFVvSKPtATTDRDCAECDRCDSGTQYETATctattnrvcaDLTVCadteye 6177
Cdd:cd15837     1 CGPGEYKS-------ANLCCQ--LCPAGHYV-SEP-CQENHGVGECAPCEPGTFTAHPN----------GETSC------ 53
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6178 svaatdtsdRKCSSCREctsSEYLVSGCSESANAVCkactECPSGTFVSTACTPladAECTECTRCGSGYFVQSPCTSEA 6257
Cdd:cd15837    54 ---------FPCSQCRD---DQEVVAECSATSDRQC----QCKQGHFYCDENCL---ESCFRCSRCPGGRVVLQPCNATR 114

                  ....
gi 514698100 6258 DTTC 6261
Cdd:cd15837   115 DTVC 118
TNFRSF cd00185
Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) ...
6216-6278 5.29e-08

Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) interactions with TNF superfamily (TNFSF) ligands (TNFL) control key cellular processes such as differentiation, proliferation, apoptosis, and cell growth. Dysregulation of these pathways has been shown to result in a wide range of pathological conditions, including autoimmune diseases, inflammation, cancer, and viral infection. There are 29 very diverse family members of TNFRSF reported in humans: 22 are type I transmembrane receptors (single pass with the N terminus on extracellular side of the cell membrane) and have a clear signal peptide; the remaining 7 members are either type III transmembrane receptors (single pass with the N terminus on extracellular side of the membrane but no signal sequence; TNFR13B, TNFR13C, TNFR17, and XEDAR), or attached to the membrane via a glycosylphosphatidylinositol (GPI) linker (TNFR10C), or secreted as soluble receptors (TNFR11B and TNFR6B). All TNFRs contain relatively short cysteine-rich domains (CRDs) in the ectodomain, and are involved in interaction with the TNF homology domain (THD) of their ligands. TNFRs often have multiple CRDs (between one and six), with the most frequent configurations of three or four copies; most CRDs possess three disulfide bridges, but could have between one and four. Localized or genome-wide duplication and evolution of the TNFRSF members appear to have paralleled the emergence of the adaptive immune system; teleosts (i.e. ray-finned, bony fish), which possess an immune system with B and T cells, possess primary and secondary lymphoid organs, and are capable of adaptive responses to pathogens also display several characteristics that are different from the mammalian immune system, making teleost TNFSF orthologs and paralogs of interest to better understand immune system evolution and the immunological pathways elicited to pathogens.


Pssm-ID: 276900 [Multi-domain]  Cd Length: 87  Bit Score: 53.75  E-value: 5.29e-08
                          10        20        30        40        50        60
                  ....*....|....*....|....*....|....*....|....*....|....*....|....
gi 514698100 6216 CTECPSGTFVSTACTPLADaecTECTRCGSGYFVQSPCTseaDTTCKRCRSCASG-EYLHTACT 6278
Cdd:cd00185     2 CQRCPPGEYLSSDCTATTD---TVCSPCPPGTYSESWNS---LSKCLPCTTCGGGnQVEKTPCT 59
TIG pfam01833
IPT/TIG domain; This family consists of a domain that has an immunoglobulin like fold. These ...
1327-1411 5.51e-08

IPT/TIG domain; This family consists of a domain that has an immunoglobulin like fold. These domains are found in cell surface receptors such as Met and Ron as well as in intracellular transcription factors where it is involved in DNA binding. CAUTION: This family does not currently recognize a significant number of members.


Pssm-ID: 460355 [Multi-domain]  Cd Length: 84  Bit Score: 53.60  E-value: 5.51e-08
                           10        20        30        40        50        60        70        80
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  1327 LSVTSVSPSSG--QGGTRVTVLGANLRLGSSAVTgVLLGSAACSLISENDTAVVCAAGVASAGSVPVTVEASSGAFASvg 1404
Cdd:pfam01833    1 PVITSISPSSGpaSGGTTITITGSNFGTDSSDLK-VTIGGTPCTVISVSSTTIVCTTPPGTSGLVNVSVTVGGGGISS-- 77

                   ....*..
gi 514698100  1405 GVLAFEY 1411
Cdd:pfam01833   78 SPLTFTY 84
TNFRSF6B cd10575
Tumor necrosis factor receptor superfamily member 6B (TNFRSF6B), also known as decoy receptor ...
6121-6279 5.55e-08

Tumor necrosis factor receptor superfamily member 6B (TNFRSF6B), also known as decoy receptor 3 (DcR3); The subfamily TNFRSF6B is also known as decoy receptor 3 (DcR3), M68, or TR6. This protein is a soluble receptor without death domain and cytoplasmic domain, and secreted by cells. It acts as a decoy receptor that competes with death receptors for ligand binding. It is a pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases, and cancer. Over-expression of this gene has been noted in several cancers, including pancreatic carcinoma, and gastrointestinal tract tumors. It can neutralize the biological effects of three tumor necrosis factor superfamily (TNFSF) members: TNFSF6 (Fas ligand/FasL/CD95L) and TNFSF14 (LIGHT) which are both involved in apoptosis and inflammation, and TNFSF15 (TNF-like molecule 1A/TL1A), which is a T cell co-stimulator and involved in gut inflammation. DcR3 is a novel inflammatory marker; higher DcR3 levels strongly correlate with inflammation and independently predict cardiovascular and all-cause mortality in chronic kidney disease (CKD) patients on hemodialysis. Increased synovial inflammatory cells infiltration in rheumatoid arthritis and ankylosing spondylitis is also associated with the elevated DcR3 expression. In cartilaginous fish, mRNA expression of DcR3 in the thymus and leydig, which are the representative lymphoid tissues of elasmobranchs, suggests that DcR3 may act as a modulator in the immune system. Interestingly, in banded dogfish (Triakis scyllia), DcR3 mRNA is strongly expressed in the gill, compared with human expression in the normal lung; both are respiratory organs, suggesting potential relevance of DcR3 to respiratory function.


Pssm-ID: 276901 [Multi-domain]  Cd Length: 163  Bit Score: 56.26  E-value: 5.55e-08
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6121 QCDSTQFVVSKPTATTDRDCAEC------------DRCD------SGTQYETATCTATTNRVCadltvcadteyesvaat 6182
Cdd:cd10575    18 QCPPGTFVAKHCTRDRPTVCGPCpdlhytqfwnylEKCRycnvfcTERQVEKRQCNATHNRVC----------------- 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6183 dtsdrkcsscrECTSSEYLVSG-CSESAnavckactECPSGTFVSTACTPLADaecTECTRCGSGYFVQSPCTSEAdttC 6261
Cdd:cd10575    81 -----------ECKPGYYMEHGfCLRHS--------SCPPGEGVIKLGTPYSD---TQCEPCPPGFFSASSSSTEP---C 135
                         170       180
                  ....*....|....*....|....*..
gi 514698100 6262 KRCRSCASGE---------YLHTACTT 6279
Cdd:cd10575   136 QPHTNCTQGGletnvpgndYHDTLCTS 162
VSP pfam03302
Giardia variant-specific surface protein;
5531-5819 6.41e-08

Giardia variant-specific surface protein;


Pssm-ID: 146106 [Multi-domain]  Cd Length: 397  Bit Score: 59.21  E-value: 6.41e-08
                           10        20        30        40        50        60        70        80
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  5531 PTASSDRVCEACPAGTTDANSDGSDACVTCGGGTYVPAGSTGTCSQyeCSAGTADTdsnaGTACEACDGtttyqpskgqe 5610
Cdd:pfam03302   50 PTSQCIDDCAKIGNYYYTTNANNKKICKECTVANCKTCEDQGQCQA--CNDGFYKS----GDACSPCHE----------- 112
                           90       100       110       120       130       140       150       160
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  5611 rclSVKTCGAGeeeTTSPsatrnrvCQPCQLGSTFK-AQSGQSTRCIS--VTTCGAGEEEIASPTLSTDRQCRTCASGTF 5687
Cdd:pfam03302  113 ---SCKTCSGG---TASD-------CTECLTGKALRyGNDGTKGTCGEgcTTGTGAGACKTCGLTIDGTSYCSECATETE 179
                          170       180       190       200       210       220       230       240
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  5688 KAAAG--QSTTCIAVSTCAAGftedvaptPSSDRVCVECAPGTFK------------------ATAGDGTCRAHRTCEDT 5747
Cdd:pfam03302  180 YPQNGvcTSTAARATATCKAS--------SVANGMCSSCANGYFRmnggcyettkfpgksvceEANSGGTCQKEAPGYKL 251
                          250       260       270       280       290       300       310
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*.
gi 514698100  5748 EYETVAPTSSSDRKCKALTVCQDDEwESKAPTITTDREC-SPCGRCTDGLTLDKACTD---TSPTKCVGCDECASD 5819
Cdd:pfam03302  252 NNGDLVTCSPGCKTCTSNTVCTTCM-DGYVKTSDSCTKCdSSCETCTGATTTCKTCATgyyKSGTGCVSCTSSESD 326
TNFRSF5_teleost cd13422
Tumor necrosis factor receptor superfamily member 5 (TNFRSF5) in teleosts; also known as CD40; ...
6098-6261 6.53e-08

Tumor necrosis factor receptor superfamily member 5 (TNFRSF5) in teleosts; also known as CD40; TNFRSF5 (commonly known as CD40 and also as CDW40, p50, Bp50) is widely expressed in diverse cell types including B lymphocytes, dendritic cells, platelets, monocytes, endothelial cells, and fibroblasts. It is essential in mediating a wide variety of immune and inflammatory responses, including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation. Its natural immunomodulating ligand is CD40L, and a primary defect in the CD40/CD40L system is associated with X-linked hyper-IgM (XHIM) syndrome. It is also involved in tumorigenesis; CD40 expression is significantly higher in gastric carcinomas and it is associated with the lymphatic metastasis of cancer cells and their tumor node metastasis (TNM) classification. Upregulated levels of CD40/CD40L on B cells and T cells may play an important role in the immune pathogenesis of breast cancer. Consequently, the CD40/CD40L system serves as a link between tumorigenesis, atherosclerosis, and the immune system, and offers a potential target for drug therapy for related diseases, such as cancer, atherosclerosis, diabetes mellitus, and immunological rejection. Salmon CD40 and CD40L are widely expressed, particularly in immune tissues, and their importance for the immune response is indicated by their relatively high expression in salmon lymphoid organs and gills.


Pssm-ID: 276927 [Multi-domain]  Cd Length: 161  Bit Score: 55.90  E-value: 6.53e-08
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6098 CGSGEYETRAptaTTDRKCASVTQCDSTQ-FVVSKPTATTDRdcAECdRCDSGTQYETATCTattnrVCADLTVCADTEy 6176
Cdd:cd13422    37 CGEDEYQDKY---TKENKCKRQPYCDPNKnFEISVNKSKTSR--SVC-KCKPGFHCSSEECL-----TCVPHTTCGPGQ- 104
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6177 esvaatdtsdrkcsscrectssEYLVSGcSESANAVCKactECPSGTFVSTACtplADAECTECTRCGSGYFVQSPCTSE 6256
Cdd:cd13422   105 ----------------------GVKSKG-NHIRDTVCE---ECPDGTFSNNSS---AEGVCKKWTECESGYKVEAAGTNT 155

                  ....*
gi 514698100 6257 ADTTC 6261
Cdd:cd13422   156 SDNIC 160
IPT cd00102
Immunoglobulin-like fold, Plexins, Transcription factors (IPT). IPTs are also known as ...
1935-2021 1.09e-07

Immunoglobulin-like fold, Plexins, Transcription factors (IPT). IPTs are also known as Transcription factor ImmunoGlobin (TIG) domains. They are present in intracellular transcription factors, cell surface receptors (such as plexins and scatter factor receptors), as well as, cyclodextrin glycosyltransferase and similar enzymes. Although they are involved in DNA binding in transcription factors, their function in other proteins is unknown. In these transcription factors, IPTs form homo- or heterodimers with the exception of the nuclear factor of activated Tcells (NFAT) transcription factors which are mainly monomers.


Pssm-ID: 238050 [Multi-domain]  Cd Length: 89  Bit Score: 53.23  E-value: 1.09e-07
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1935 VIQSVDPQSGQV--GTRITIVGSGLlgGSAFAREVVMGNSVPCSVLRGNDSVVVCVL-ADAGSPAAAVDVTVVGARGSRV 2011
Cdd:cd00102     2 VITSISPSSGPVsgGTEVTITGSNF--GSGSNLRVTFGGGVPCSVLSVSSTAIVCTTpPYANPGPGPVEVTVDRGNGGIT 79
                          90
                  ....*....|
gi 514698100 2012 VASLAFEVLP 2021
Cdd:cd00102    80 SSPLTFTYVP 89
TNFRSF1A_teleost cd15834
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) in teleosts; also known as ...
6143-6270 1.31e-07

Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) in teleosts; also known as TNFR1; This subfamily of TNFRSF1 ((also known as type I TNFR, TNFR1, DR1, TNFRSF1A, CD120a, p55) is found in teleosts. It binds TNF-alpha, through the death domain (DD), and activates NF-kappaB, mediates apoptosis and activates signaling pathways controlling inflammatory, immune, and stress responses. It mediates signal transduction by interacting with antiapoptotic protein BCL2-associated athanogene 4 (BAG4/SODD) and adaptor proteins TRAF2 and TRADD that play regulatory roles. The human genetic disorder called tumor necrosis factor associated periodic syndrome (TRAPS), or periodic fever syndrome, is associated with germline mutations of the extracellular domains of this receptor, possibly due to impaired receptor clearance. Serum levels of TNFRSF1A are elevated in schizophrenia and bipolar disorder, and high levels are also associated with cognitive impairment and dementia. Knockout studies in zebrafish embryos have shown that a signaling balance between TNFRSF1A and TNFRSF1B is required for endothelial cell integrity. TNFRSF1A signals apoptosis through caspase-8, whereas TNFRSF1B signals survival via NF-kappaB in endothelial cells. Thus, this apoptotic pathway seems to be evolutionarily conserved, as TNFalpha promotes apoptosis of human endothelial cells and triggers caspase-2 and P53 activation in these cells via TNFRSF1A.


Pssm-ID: 276930 [Multi-domain]  Cd Length: 150  Bit Score: 54.80  E-value: 1.31e-07
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6143 CDRCDSGTQYETaTCTATTNR-VCadlTVCADTEYesvaaTDTSD--RKCSSCRECTSS-EYLVSGCSESANAVCkactE 6218
Cdd:cd15834    14 CNKCHPGYKLKE-ECTAPGERsQC---TPCPEGTY-----LEQINysPNCRRCTLCKVKnEEEVSPCKKSSNTVC----R 80
                          90       100       110       120       130       140
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*...
gi 514698100 6219 CPSGTFVSTActplaDA---ECTECTRCGSGYFVQSPCTSEADT-------------TCKRCRSCASG 6270
Cdd:cd15834    81 CKKGYYKSRI-----DSetrECLKCKTCGPGEIEIQPCTPESNTvceckdnyyrnnnKCKPCQKCSLD 143
TNFRSF cd00185
Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) ...
5701-5789 1.34e-07

Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) interactions with TNF superfamily (TNFSF) ligands (TNFL) control key cellular processes such as differentiation, proliferation, apoptosis, and cell growth. Dysregulation of these pathways has been shown to result in a wide range of pathological conditions, including autoimmune diseases, inflammation, cancer, and viral infection. There are 29 very diverse family members of TNFRSF reported in humans: 22 are type I transmembrane receptors (single pass with the N terminus on extracellular side of the cell membrane) and have a clear signal peptide; the remaining 7 members are either type III transmembrane receptors (single pass with the N terminus on extracellular side of the membrane but no signal sequence; TNFR13B, TNFR13C, TNFR17, and XEDAR), or attached to the membrane via a glycosylphosphatidylinositol (GPI) linker (TNFR10C), or secreted as soluble receptors (TNFR11B and TNFR6B). All TNFRs contain relatively short cysteine-rich domains (CRDs) in the ectodomain, and are involved in interaction with the TNF homology domain (THD) of their ligands. TNFRs often have multiple CRDs (between one and six), with the most frequent configurations of three or four copies; most CRDs possess three disulfide bridges, but could have between one and four. Localized or genome-wide duplication and evolution of the TNFRSF members appear to have paralleled the emergence of the adaptive immune system; teleosts (i.e. ray-finned, bony fish), which possess an immune system with B and T cells, possess primary and secondary lymphoid organs, and are capable of adaptive responses to pathogens also display several characteristics that are different from the mammalian immune system, making teleost TNFSF orthologs and paralogs of interest to better understand immune system evolution and the immunological pathways elicited to pathogens.


Pssm-ID: 276900 [Multi-domain]  Cd Length: 87  Bit Score: 52.98  E-value: 1.34e-07
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5701 STCAAGFTEDVAPTPSSDRVCVECAPGTFKATAGDGT-CRAHRTCEDTEYETVAP-TSSSDRKCkaltVCQDDEWESkap 5778
Cdd:cd00185     3 QRCPPGEYLSSDCTATTDTVCSPCPPGTYSESWNSLSkCLPCTTCGGGNQVEKTPcTATDNRCC----TCKPGFYCD--- 75
                          90
                  ....*....|.
gi 514698100 5779 TITTDRECSPC 5789
Cdd:cd00185    76 EGTNVEECKPC 86
TNFRSF_viral cd15839
Tumor necrosis factor receptor superfamily members, virus-encoded; This family contains viral ...
6074-6216 1.37e-07

Tumor necrosis factor receptor superfamily members, virus-encoded; This family contains viral TNFR homologs that include vaccinia virus (VACV) cytokine response modifier E (CrmE), an encoded TNFR that shares significant sequence similarity with mammalian type 2 TNF receptors (TNFSFR1B, p75, TNFR type 2), a cowpox virus encoded cytokine-response modifier B (crmB), which is a secreted form of TNF receptor that can contribute to the modification of TNF-mediated antiviral processes, and a myxoma virus (MYXV) T2 (M-T2) protein that binds and inhibits rabbit TNF-alpha. The CrmE structure confirms that the canonical TNFR fold is adopted, but only one of the two "ligand-binding" loops of TNFRSF1A is conserved, suggesting a mechanism for the higher affinity of poxvirus TNFRs for TNFalpha over lymphotoxin-alpha. CrmB protein specifically binds TNF-alpha and TNF-beta indicating that cowpox virus seeks to invade antiviral processes mediated by TNF. Intracellular M-T2 blocks virus-induced lymphocyte apoptosis via a highly conserved viral preligand assembly domain (vPLAD), which controls receptor signaling competency prior to ligand binding.


Pssm-ID: 276935 [Multi-domain]  Cd Length: 125  Bit Score: 54.10  E-value: 1.37e-07
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6074 CSDEQYETraptvNSDRECTglTTCGSGEYETRAPTATTDRKCasvTQCDSTQFvvskpTATTDR--DCAECD-RCDSgT 6150
Cdd:cd15839     1 CNGNDYNS-----NSNNLCC--KSCPPGTYASHLCDTTSNTKC---DPCPSDTF-----TSIPNHipACLSCRgRCSS-N 64
                          90       100       110       120       130       140
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*.
gi 514698100 6151 QYETATCTATTNRVCadltVCADTEYESVAATDTSdRKCSSCRECtSSEYLVSGCSESANAVCKAC 6216
Cdd:cd15839    65 QVETKSCSNTQNRIC----SCAPGYYCLLKGSDGC-VACAPKTKC-GVGYGVSGHTSTGDVICKKC 124
TNFRSF10 cd10580
Tumor necrosis factor receptor superfamily member 10 (TNFRSF10), includes TNFRSF10A (DR4), ...
5948-6069 1.54e-07

Tumor necrosis factor receptor superfamily member 10 (TNFRSF10), includes TNFRSF10A (DR4), TNFRSF10B (DR5), TNFRSF10C (DcR1) and TNFRSF10D (DcR2); TNFRSF10 family contains TNFRSF10A (also known as DR4, Apo2, TRAIL-R1, CD261), TNFRSF10B (also known as DR5, KILLER, TRICK2A, TRAIL-R2, TRICKB, CD262), TNFRSF10C (also known as DcR1, TRAIL-R3, LIT, TRID, CD263), and TNFRSF10D (also known as DcR2, TRUNDD, TRAIL-R4, CD264). Tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL) binds to all 4 receptors. DR4 (TRAIL-R1) and DR5 (TRAIL-R2) are membrane-bound and contain a death domain in their intracellular portion, which is able to transmit an apoptotic signal, thus often called death receptors. In contrast, DcR1 (TRAIL-R3), which lacks the complete intracellular portion and DcR2 (TRAIL-R4), which has a truncated cytoplasmic death domain, do not transmit an apoptotic signal, thus known as decoy receptors. Apoptosis mediated by DR4 and DR5 requires Fas (TNFRSF6)-associated via death domain (FADD), a death domain containing adaptor protein. Two transcript variants encoding different isoforms and one non-coding transcript have been found for TNFRSF10B/DR5. DcR1 appears to function as an antagonistic receptor that protects cells from TRAIL-induced apoptosis; it has been found to be a p53-regulated DNA damage-inducible gene. The expression of this gene is detected in many normal tissues but not in most cancer cell lines, which may explain the specific sensitivity of cancer cells to the apoptosis-inducing activity of TRAIL. DcR2 has been shown to play an inhibitory role in TRAIL-induced cell apoptosis. The membrane expression of all of these receptors (DR4, DR5, DcR1, and DcR2) is greater in normal endometrium (NE) than in endometrioid adenocarcinoma (EAC). In EAC patients, membrane expression of these receptors are not independent predictors of survival. DcR1 and DcR2 expression is critical in cell growth and apoptosis in cutaneous or uveal melanoma; DcR1 and DcR2 are frequently methylated in both, leading to loss of gene expression and melanomagenesis. On the other hand, DR4 and DR5 methylation is rare in cutaneous melanoma and frequent in uveal melanoma; their expression is wholly independent of the promoter methylation status. DcR1 and DcR2 genes are also reported to be hyper-methylated in prostate cancer. The TRAIL ligand, a potent and specific inducer of apoptosis in cancer cells, has been explored as a therapeutic drug; experimental data has shown that DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.


Pssm-ID: 276906 [Multi-domain]  Cd Length: 103  Bit Score: 53.03  E-value: 1.54e-07
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5948 CVACSAGHYVprgrtggcaafecaaghvdqdEDAATACKLCEAGVNY-AGSAGLTRCTSVSECGAGEEETSAPTASTDRV 6026
Cdd:cd10580     2 CGLCPAGTYV---------------------SEDSGDCIPCKEGVDYtEHPNGLPSCLPCTVCKSDEEELSPCTTTRNTE 60
                          90       100       110       120
                  ....*....|....*....|....*....|....*....|....*..
gi 514698100 6027 CsTCASGKFKattGQTPCEAV----STCEEDEYVYRAATVSTDTQCR 6069
Cdd:cd10580    61 C-QCKPGTFC---DPDSPEVCqkcsTRCPEGMVEVSPCTPWSDLKCV 103
TNFRSF5 cd13407
Tumor necrosis factor receptor superfamily member 5 (TNFRSF5), also known as CD40; TNFRSF5 ...
6002-6140 2.13e-07

Tumor necrosis factor receptor superfamily member 5 (TNFRSF5), also known as CD40; TNFRSF5 (commonly known as CD40 and also as CDW40, p50, Bp50) is widely expressed in diverse cell types including B lymphocytes, dendritic cells, platelets, monocytes, endothelial cells, and fibroblasts. It is essential in mediating a wide variety of immune and inflammatory responses, including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation. Its natural immunomodulating ligand is CD40L, and a primary defect in the CD40/CD40L system is associated with X-linked hyper-IgM (XHIM) syndrome. It is also involved in tumorigenesis; CD40 expression is significantly higher in gastric carcinomas and it is associated with the lymphatic metastasis of cancer cells and their tumor node metastasis (TNM) classification. Upregulated levels of CD40/CD40L on B cells and T cells may play an important role in the immune pathogenesis of breast cancer. Consequently, the CD40/CD40L system serves as a link between tumorigenesis, atherosclerosis, and the immune system, and offers a potential target for drug therapy for related diseases, such as cancer, atherosclerosis, diabetes mellitus, and immunological rejection.


Pssm-ID: 276912 [Multi-domain]  Cd Length: 161  Bit Score: 54.33  E-value: 2.13e-07
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6002 RCTSVseCGAGEEETSAPTASTDRVCSTCASGKFKAT-TGQTPCEAVSTCEEDE--YVYRAATVSTDT--QCRALTACSD 6076
Cdd:cd13407    11 RCCSL--CPPGQKLVSDCTEATDTECLPCEEGEFQDTwNRERHCHQHRYCDPNLglRVQTEGTAETDTtcTCQEGQHCTS 88
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6077 EQYETraptvnsdreCTGLTTCGSGEYETRAPTATTD------------------RKCASVTQCDSTQFVVSKP-TATTD 6137
Cdd:cd13407    89 EACET----------CALHTSCKPGFGVKQIATGVSDticepcpvgffsnvssafEKCHPWTSCETKGLVELQAgTNKTD 158

                  ...
gi 514698100 6138 RDC 6140
Cdd:cd13407   159 VVC 161
TNFRSF4 cd13406
Tumor necrosis factor receptor superfamily member 4 (TNFRSF4), also known as CD134 or OXO40; ...
5875-5965 2.15e-07

Tumor necrosis factor receptor superfamily member 4 (TNFRSF4), also known as CD134 or OXO40; TNFRSF4 (also known as OX40, ACT35, CD134, IMD16, TXGP1L) activates NF-kappaB through its interaction with adaptor proteins TRAF2 and TRAF5. It also promotes the expression of apoptosis inhibitors BCL2 and BCL2lL1/BCL2-XL, and thus suppresses apoptosis. It is primarily expressed on activated CD4+ and CD8+ T cells, where it is transiently expressed and upregulated on the most recently antigen-activated T cells within inflammatory lesions. This makes it an attractive target to modulate immune responses, i.e. TNFRSF4 (OX40) blocking agents to inhibit adverse inflammation or agonists to enhance immune responses. An artificially created biologic fusion protein, OX40-immunoglobulin (OX40-Ig), prevents OX40 from reaching the T-cell receptors, thus reducing the T-cell response. Some single nucleotide polymorphisms (SNPs) of its natural ligand OX40 ligand (OX40L, CD252), which is also found on activated T cells, have been associated with systemic lupus erythematosus.


Pssm-ID: 276911 [Multi-domain]  Cd Length: 142  Bit Score: 53.94  E-value: 2.15e-07
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5875 TATRDRRCkdlTACQPGEYEctaaTLTTDRECCGVTQC--VPGSEETSAPTATSDRECRqCVAGTTDADGSG-TTPCVAC 5951
Cdd:cd13406    29 TGTQDTVC---SPCEPGFYN----EAVNYEPCKPCTQCnqRSGSEEKQKCTKTSDTVCR-CRPGTQPLDSYKpGVDCVPC 100
                          90
                  ....*....|....
gi 514698100 5952 SAGHYvPRGRTGGC 5965
Cdd:cd13406   101 PPGHF-SRGDNQAC 113
TNFRSF1B cd10577
Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B), also known as TNFR2; TNFRSF1B ...
5639-5840 2.18e-07

Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B), also known as TNFR2; TNFRSF1B (also known as TNFR2, type 2 TNFR, TNFBR, TNFR80, TNF-R75, TNF-R-II, p75, CD120b) binds TNF-alpha, but lacks the death domain (DD) that is associated with the cytoplasmic domain of TNFRSF1A (TNFR1). It is inducible and expressed exclusively by oligodendrocytes, astrocytes, T cells, thymocytes, myocytes, endothelial cells, and in human mesenchymal stem cells. TNFRSF1B protects oligodendrocyte progenitor cells (OLGs) against oxidative stress, and induces the up-regulation of cell survival genes. While pro-inflammatory and pathogen-clearing activities of TNF are mediated mainly through activation of TNFRSF1A, a strong activator of NF-kappaB, TNFRSF1B is more responsible for suppression of inflammation. Although the affinities of both receptors for soluble TNF are similar, TNFRSF1B is sometimes more abundantly expressed and thought to associate with TNF, thereby increasing its concentration near TNFRSF1A receptors, and making TNF available to activate TNFRSF1A (a ligand-passing mechanism).


Pssm-ID: 276903 [Multi-domain]  Cd Length: 163  Bit Score: 54.40  E-value: 2.18e-07
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5639 CQLGSTFKAQSGQstRCISvtTCGAGEEEIASPTLSTDRQCRTCASGTFKAAAGQSTTCIAVST-CAAGFTEDVAPTPSS 5717
Cdd:cd10577     1 CRNSKEYYDEKAQ--MCCS--KCPPGQHVKHSCTKTSDTVCAPCEESTYTQLWNWVPECLSCSSpCSSDQVETQACTRQQ 76
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5718 DRVCvecapgtfkatagdgTCRAHRTCedteyetVAPTSSSDRKCKALtvcqddeweskaptittdRECSPcgrctdGLT 5797
Cdd:cd10577    77 NRIC---------------SCKPGWYC-------VLKLQEGCRQCRPL------------------KKCGP------GFG 110
                         170       180       190       200
                  ....*....|....*....|....*....|....*....|...
gi 514698100 5798 LDKACTDTSPTKCVGCDECasdeyTLSScTLSSQTQCRQCTTC 5840
Cdd:cd10577   111 VARPGTASSDVECKPCAPG-----TFSD-TTSSTDTCRPHRIC 147
IPT_PCSR cd00603
IPT domain of Plexins and Cell Surface Receptors (PCSR) and related proteins . This subgroup ...
1328-1413 2.48e-07

IPT domain of Plexins and Cell Surface Receptors (PCSR) and related proteins . This subgroup contains IPT domains of plexins, receptors, like the plasminogen-related growth factor receptors, the hepatocyte growth factor-scatter factors, and the macrophage-stimulating receptors and of fibrocystin. Plexins are involved in the regulation of cell proliferation and of cellular adhesion and repulsion receptors. In general, there are three copies of the IPT_PCSR domain present preceeded by SEMA (semaphorin) and PSI (plexin, semaphorin, integrin) domains.


Pssm-ID: 238337 [Multi-domain]  Cd Length: 90  Bit Score: 52.07  E-value: 2.48e-07
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1328 SVTSVSPSSG--QGGTRVTVLGANLRLGSSAVTgVLLGSAACSLISENDTAVVC---AAGVASAGSVPVTVEASSGAFAS 1402
Cdd:cd00603     2 VITSISPSSGplSGGTRLTITGSNLGSGSPRVR-VTVGGVPCKVLNVSSTEIVCrtpAAATPGEGPVEVTVDGANVSARV 80
                          90
                  ....*....|.
gi 514698100 1403 VGGVLaFEYLD 1413
Cdd:cd00603    81 LSNTT-FTYVE 90
TNFRSF10 cd10580
Tumor necrosis factor receptor superfamily member 10 (TNFRSF10), includes TNFRSF10A (DR4), ...
5813-5931 2.53e-07

Tumor necrosis factor receptor superfamily member 10 (TNFRSF10), includes TNFRSF10A (DR4), TNFRSF10B (DR5), TNFRSF10C (DcR1) and TNFRSF10D (DcR2); TNFRSF10 family contains TNFRSF10A (also known as DR4, Apo2, TRAIL-R1, CD261), TNFRSF10B (also known as DR5, KILLER, TRICK2A, TRAIL-R2, TRICKB, CD262), TNFRSF10C (also known as DcR1, TRAIL-R3, LIT, TRID, CD263), and TNFRSF10D (also known as DcR2, TRUNDD, TRAIL-R4, CD264). Tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL) binds to all 4 receptors. DR4 (TRAIL-R1) and DR5 (TRAIL-R2) are membrane-bound and contain a death domain in their intracellular portion, which is able to transmit an apoptotic signal, thus often called death receptors. In contrast, DcR1 (TRAIL-R3), which lacks the complete intracellular portion and DcR2 (TRAIL-R4), which has a truncated cytoplasmic death domain, do not transmit an apoptotic signal, thus known as decoy receptors. Apoptosis mediated by DR4 and DR5 requires Fas (TNFRSF6)-associated via death domain (FADD), a death domain containing adaptor protein. Two transcript variants encoding different isoforms and one non-coding transcript have been found for TNFRSF10B/DR5. DcR1 appears to function as an antagonistic receptor that protects cells from TRAIL-induced apoptosis; it has been found to be a p53-regulated DNA damage-inducible gene. The expression of this gene is detected in many normal tissues but not in most cancer cell lines, which may explain the specific sensitivity of cancer cells to the apoptosis-inducing activity of TRAIL. DcR2 has been shown to play an inhibitory role in TRAIL-induced cell apoptosis. The membrane expression of all of these receptors (DR4, DR5, DcR1, and DcR2) is greater in normal endometrium (NE) than in endometrioid adenocarcinoma (EAC). In EAC patients, membrane expression of these receptors are not independent predictors of survival. DcR1 and DcR2 expression is critical in cell growth and apoptosis in cutaneous or uveal melanoma; DcR1 and DcR2 are frequently methylated in both, leading to loss of gene expression and melanomagenesis. On the other hand, DR4 and DR5 methylation is rare in cutaneous melanoma and frequent in uveal melanoma; their expression is wholly independent of the promoter methylation status. DcR1 and DcR2 genes are also reported to be hyper-methylated in prostate cancer. The TRAIL ligand, a potent and specific inducer of apoptosis in cancer cells, has been explored as a therapeutic drug; experimental data has shown that DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.


Pssm-ID: 276906 [Multi-domain]  Cd Length: 103  Bit Score: 52.65  E-value: 2.53e-07
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5813 CDECASD-EYTLSSCTLSSqtqCRQCTTCGNDEYQTKACSVSQDTECatlttcsstqfeveaptatrdrRCKDLTACQPG 5891
Cdd:cd10580    18 CIPCKEGvDYTEHPNGLPS---CLPCTVCKSDEEELSPCTTTRNTEC----------------------QCKPGTFCDPD 72
                          90       100       110       120
                  ....*....|....*....|....*....|....*....|.
gi 514698100 5892 EYE-CtaatlttdRECcgVTQCVPGSEETSAPTATSDRECR 5931
Cdd:cd10580    73 SPEvC--------QKC--STRCPEGMVEVSPCTPWSDLKCV 103
TNFRSF1A_teleost cd15834
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) in teleosts; also known as ...
6120-6238 3.43e-07

Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) in teleosts; also known as TNFR1; This subfamily of TNFRSF1 ((also known as type I TNFR, TNFR1, DR1, TNFRSF1A, CD120a, p55) is found in teleosts. It binds TNF-alpha, through the death domain (DD), and activates NF-kappaB, mediates apoptosis and activates signaling pathways controlling inflammatory, immune, and stress responses. It mediates signal transduction by interacting with antiapoptotic protein BCL2-associated athanogene 4 (BAG4/SODD) and adaptor proteins TRAF2 and TRADD that play regulatory roles. The human genetic disorder called tumor necrosis factor associated periodic syndrome (TRAPS), or periodic fever syndrome, is associated with germline mutations of the extracellular domains of this receptor, possibly due to impaired receptor clearance. Serum levels of TNFRSF1A are elevated in schizophrenia and bipolar disorder, and high levels are also associated with cognitive impairment and dementia. Knockout studies in zebrafish embryos have shown that a signaling balance between TNFRSF1A and TNFRSF1B is required for endothelial cell integrity. TNFRSF1A signals apoptosis through caspase-8, whereas TNFRSF1B signals survival via NF-kappaB in endothelial cells. Thus, this apoptotic pathway seems to be evolutionarily conserved, as TNFalpha promotes apoptosis of human endothelial cells and triggers caspase-2 and P53 activation in these cells via TNFRSF1A.


Pssm-ID: 276930 [Multi-domain]  Cd Length: 150  Bit Score: 53.65  E-value: 3.43e-07
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6120 TQCDSTQFVVSKPTATTdrdCAECDRCDSGTQYETATCTATTNRVCadltVCADTEYESVaaTDTSDRKCSSCRECTSSE 6199
Cdd:cd15834    37 TPCPEGTYLEQINYSPN---CRRCTLCKVKNEEEVSPCKKSSNTVC----RCKKGYYKSR--IDSETRECLKCKTCGPGE 107
                          90       100       110       120
                  ....*....|....*....|....*....|....*....|....*....
gi 514698100 6200 YLVSGCSESANAVC----------KACTECpsgtfvsTACTPLADAECT 6238
Cdd:cd15834   108 IEIQPCTPESNTVCeckdnyyrnnNKCKPC-------QKCSLDCQHLCT 149
IPT_CGTD cd00604
IPT domain (domain D) of cyclodextrin glycosyltransferase (CGTase) and similar enzymes. These ...
1506-1572 4.46e-07

IPT domain (domain D) of cyclodextrin glycosyltransferase (CGTase) and similar enzymes. These enzymes are involved in the enzymatic hydrolysis of alpha-1,4 linkages of starch polymers and belong to the glycosyl hydrolase family 13. Most consist of three domains (A,B,C) but CGTase is more complex and has two additional domains (D,E). The function of the IPT/D domain is unknown.


Pssm-ID: 238338 [Multi-domain]  Cd Length: 81  Bit Score: 51.19  E-value: 4.46e-07
                          10        20        30        40        50        60
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*...
gi 514698100 1506 DVSPPSGQAGTLVTITGTGFpctGSSVSTVSLGGVGASIRTQSATQIVVEAPSGS-GQGDVVVTADDG 1572
Cdd:cd00604     5 SVGPVMGKPGNTVTISGEGF---GSTGGTVYFGGTAAEVLSWSDTSIVVEVPRVApGNYNISVTTVDG 69
IPT smart00429
ig-like, plexins, transcription factors;
1327-1394 4.65e-07

ig-like, plexins, transcription factors;


Pssm-ID: 214657 [Multi-domain]  Cd Length: 90  Bit Score: 51.27  E-value: 4.65e-07
                            10        20        30        40        50        60        70
                    ....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100   1327 LSVTSVSPSSG--QGGTRVTVLGANLRLGSSAVTGVLLGSAACSLISENDTAVVCAAGVASAGSVPVTVE 1394
Cdd:smart00429    2 PVITRISPTSGpvSGGTEITLCGKNLKSISVVFVEVGVGEAPCTFSPSSSTAIVCKTPPYHNIPGSVPVR 71
TNFR smart00208
Tumor necrosis factor receptor / nerve growth factor receptor repeats; Repeats in growth ...
6219-6261 6.67e-07

Tumor necrosis factor receptor / nerve growth factor receptor repeats; Repeats in growth factor receptors that are involved in growth factor binding. TNF/TNFR


Pssm-ID: 214558  Cd Length: 39  Bit Score: 49.39  E-value: 6.67e-07
                            10        20        30        40
                    ....*....|....*....|....*....|....*....|...
gi 514698100   6219 CPSGTFvstaCTPLADAECTECTRCGSGYFVQSPCTSEADTTC 6261
Cdd:smart00208    1 CKEGTY----CSDGNHSSCLRCRRCPPGLVVKQPCTATSDTVC 39
IPT cd00102
Immunoglobulin-like fold, Plexins, Transcription factors (IPT). IPTs are also known as ...
1327-1413 6.77e-07

Immunoglobulin-like fold, Plexins, Transcription factors (IPT). IPTs are also known as Transcription factor ImmunoGlobin (TIG) domains. They are present in intracellular transcription factors, cell surface receptors (such as plexins and scatter factor receptors), as well as, cyclodextrin glycosyltransferase and similar enzymes. Although they are involved in DNA binding in transcription factors, their function in other proteins is unknown. In these transcription factors, IPTs form homo- or heterodimers with the exception of the nuclear factor of activated Tcells (NFAT) transcription factors which are mainly monomers.


Pssm-ID: 238050 [Multi-domain]  Cd Length: 89  Bit Score: 50.92  E-value: 6.77e-07
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1327 LSVTSVSPSSG--QGGTRVTVLGANlrLGSSAVTGVLL-GSAACSLISENDTAVVC---AAGVASAGSVPVTVEASSGAF 1400
Cdd:cd00102     1 PVITSISPSSGpvSGGTEVTITGSN--FGSGSNLRVTFgGGVPCSVLSVSSTAIVCttpPYANPGPGPVEVTVDRGNGGI 78
                          90
                  ....*....|...
gi 514698100 1401 ASVGGVlaFEYLD 1413
Cdd:cd00102    79 TSSPLT--FTYVP 89
TIG pfam01833
IPT/TIG domain; This family consists of a domain that has an immunoglobulin like fold. These ...
1504-1577 7.06e-07

IPT/TIG domain; This family consists of a domain that has an immunoglobulin like fold. These domains are found in cell surface receptors such as Met and Ron as well as in intracellular transcription factors where it is involved in DNA binding. CAUTION: This family does not currently recognize a significant number of members.


Pssm-ID: 460355 [Multi-domain]  Cd Length: 84  Bit Score: 50.52  E-value: 7.06e-07
                           10        20        30        40        50        60        70
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*..
gi 514698100  1504 VTDVSPPSGQA--GTLVTITGTGFPcTGSSVSTVSLGGVGASIRTQSATQIVVEAPSG-SGQGDVVVTADDGSFAVS 1577
Cdd:pfam01833    3 ITSISPSSGPAsgGTTITITGSNFG-TDSSDLKVTIGGTPCTVISVSSTTIVCTTPPGtSGLVNVSVTVGGGGISSS 78
TNFRSF10 cd10580
Tumor necrosis factor receptor superfamily member 10 (TNFRSF10), includes TNFRSF10A (DR4), ...
5557-5680 7.61e-07

Tumor necrosis factor receptor superfamily member 10 (TNFRSF10), includes TNFRSF10A (DR4), TNFRSF10B (DR5), TNFRSF10C (DcR1) and TNFRSF10D (DcR2); TNFRSF10 family contains TNFRSF10A (also known as DR4, Apo2, TRAIL-R1, CD261), TNFRSF10B (also known as DR5, KILLER, TRICK2A, TRAIL-R2, TRICKB, CD262), TNFRSF10C (also known as DcR1, TRAIL-R3, LIT, TRID, CD263), and TNFRSF10D (also known as DcR2, TRUNDD, TRAIL-R4, CD264). Tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL) binds to all 4 receptors. DR4 (TRAIL-R1) and DR5 (TRAIL-R2) are membrane-bound and contain a death domain in their intracellular portion, which is able to transmit an apoptotic signal, thus often called death receptors. In contrast, DcR1 (TRAIL-R3), which lacks the complete intracellular portion and DcR2 (TRAIL-R4), which has a truncated cytoplasmic death domain, do not transmit an apoptotic signal, thus known as decoy receptors. Apoptosis mediated by DR4 and DR5 requires Fas (TNFRSF6)-associated via death domain (FADD), a death domain containing adaptor protein. Two transcript variants encoding different isoforms and one non-coding transcript have been found for TNFRSF10B/DR5. DcR1 appears to function as an antagonistic receptor that protects cells from TRAIL-induced apoptosis; it has been found to be a p53-regulated DNA damage-inducible gene. The expression of this gene is detected in many normal tissues but not in most cancer cell lines, which may explain the specific sensitivity of cancer cells to the apoptosis-inducing activity of TRAIL. DcR2 has been shown to play an inhibitory role in TRAIL-induced cell apoptosis. The membrane expression of all of these receptors (DR4, DR5, DcR1, and DcR2) is greater in normal endometrium (NE) than in endometrioid adenocarcinoma (EAC). In EAC patients, membrane expression of these receptors are not independent predictors of survival. DcR1 and DcR2 expression is critical in cell growth and apoptosis in cutaneous or uveal melanoma; DcR1 and DcR2 are frequently methylated in both, leading to loss of gene expression and melanomagenesis. On the other hand, DR4 and DR5 methylation is rare in cutaneous melanoma and frequent in uveal melanoma; their expression is wholly independent of the promoter methylation status. DcR1 and DcR2 genes are also reported to be hyper-methylated in prostate cancer. The TRAIL ligand, a potent and specific inducer of apoptosis in cancer cells, has been explored as a therapeutic drug; experimental data has shown that DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.


Pssm-ID: 276906 [Multi-domain]  Cd Length: 103  Bit Score: 51.11  E-value: 7.61e-07
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5557 CVTCGGGTYVPAGStGTCSQyeCSAGTADTDSnagtaceacdgtttyqpSKGQERCLSVKTCGAGEEETTSPSATRNRVC 5636
Cdd:cd10580     2 CGLCPAGTYVSEDS-GDCIP--CKEGVDYTEH-----------------PNGLPSCLPCTVCKSDEEELSPCTTTRNTEC 61
                          90       100       110       120
                  ....*....|....*....|....*....|....*....|....*...
gi 514698100 5637 QpCQLGsTFKAQsgQS----TRCisVTTCGAGEEEIASPTLSTDRQCR 5680
Cdd:cd10580    62 Q-CKPG-TFCDP--DSpevcQKC--STRCPEGMVEVSPCTPWSDLKCV 103
IPT smart00429
ig-like, plexins, transcription factors;
4496-4583 8.04e-07

ig-like, plexins, transcription factors;


Pssm-ID: 214657 [Multi-domain]  Cd Length: 90  Bit Score: 50.50  E-value: 8.04e-07
                            10        20        30        40        50        60        70        80
                    ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100   4496 VSSVVPSSG--QEGTRVTLSGTNLLGSGSGVDQVLLAGVSATVVSAASSEVVVITsalPGGVVGPVTGNVTVVSTSGALV 4573
Cdd:smart00429    4 ITRISPTSGpvSGGTEITLCGKNLKSISVVFVEVGVGEAPCTFSPSSSTAIVCKT---PPYHNIPGSVPVRTVGLRNGGV 80
                            90
                    ....*....|
gi 514698100   4574 HADTDSFTYV 4583
Cdd:smart00429   81 PSSPQPFTYV 90
FhaB COG3210
Large exoprotein involved in heme utilization or adhesion [Intracellular trafficking, ...
3760-4711 8.32e-07

Large exoprotein involved in heme utilization or adhesion [Intracellular trafficking, secretion, and vesicular transport];


Pssm-ID: 442443 [Multi-domain]  Cd Length: 1698  Bit Score: 56.70  E-value: 8.32e-07
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3760 VAGSRNNTAAEAVDVVLESNTGALIEGTGRWTYVVEGAISSVLPPGGVAGTLVTIRGSNLLGGGSTAAGVTLAGVSASVE 3839
Cdd:COG3210    25 ATLGSNTAGTSGLNILGSGGVGTAGGIASNAGTTASTSGGSGTAGGVGNTSASTGGIGAAAANTAGTLETGLTSNIGGGS 104
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3840 QANATHVIVTANRGTTAGDVVVTSDTGSNVVLQDGFTYSRISSVSPAEGQEGTRVRLDGVGFFTGGASVDRVEICGVASS 3919
Cdd:COG3210   105 VNGSNSTGNGTLTTTAASATTGNNTGGTTTSSTNTVTTLGGTTTGNTVLSTSGAGNNTNTNNSSSGTNIGNSIPTTGGSL 184
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3920 VTNQSDSRLDVVVPAATTLVPPLRCDVEVVSAFGVSIVAADAFDYLEPGEIAAVTPTSGHEGTVVTVSGARLLGGGSQVA 3999
Cdd:COG3210   185 NVVAANPTGVTGVGGALINATAGVLANAGGGTAGGVASANSTLTGGVVAAGTGAGVISTGGTDISSLSVAAGAGTGGAGG 264
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4000 SVTFAGVEVHDVLTQSDSEIVAVLRSGGAGGSGDVVVESDTGAVVRLAAGFRYVPQAQILHLTRASGQVGTETTIVGEGL 4079
Cdd:COG3210   265 TGNAGNTTIGTTVTGTNATGSNTAGASSGDTTTNGTSSVTGAGGTGVLGGGTAAGITTTNTVGGNGDGNNTTANSGAGLV 344
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4080 QMGDVIVSVLLAGVPAQVLSQSDVNVTVRANTSTPATGDVMLVAGSGAFVELVNGWTYDDAGAIEDVQPAQGFAGNLVTI 4159
Cdd:COG3210   345 SGGTGGNNGTTGTGAGSGLTGTGNGGGLTTAGAGTVASTVGTATASTGNASSTTVLGSGSLATGNTGTTIAGNGGSANAG 424
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4160 SGRGLRGGSAAVTRVTLVGVLATEIVHENDTVVVVRAGLPVDPFVMQTGRVVVMGSSGATITALDAFTYNVAGDITDVSP 4239
Cdd:COG3210   425 GFTTTGGVLGITGNGTVTGGTIGGLTGSGTTNGAGLSGNTDVSGTGTVTNSAGNTTSATTLAGGGIGTVTTNATISNNAG 504
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4240 SFGRVGTRVRLLGSNLLGGGTSAEVRFGGVTGAVTAVSETAIDVTVPAASGPSGLVNVSIVSDSGSHVLEVAGFRYTAPG 4319
Cdd:COG3210   505 GDANGIATGLTGITAGGGGGGNATSGGTGGDGTTLSGSGLTTTVSGGASGTTAASGSNTANTLGVLAATGGTSNATTAGN 584
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4320 SVAAVAPSSGHEGTVVTISGASLLAEEADAARVTLGGVNATVVFANDTRLVVVAGASSTAGLGDVFIETVGGARLLAANA 4399
Cdd:COG3210   585 STSATGGTGTNSGGTVLSIGTGSAGATGTITLGAGTSGAGANATGGGAGLTGSAVGAALSGTGSGTTGTASANGSNTTGV 664
                         650       660       670       680       690       700       710       720
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4400 WMYVAQATITDVQPGSGQVGTRVTIRGTGLRCGGAAVTSVLLGSAVAPVVTEDDTTVIAEAPARAVGASPVD-------- 4471
Cdd:COG3210   665 NTAGGTGGGTTGTVTSGATGGTTGTTLNAATGGTLNNAGNTLTISTGSITVTGQIGALANANGDTVTFGNLGtgatltln 744
                         730       740       750       760       770       780       790       800
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4472 --VTVVADTGAYVTADDAWTFVTAGAVSSVVPSSG--QEGTRVTLSGTNLLGSGSGVDQVLLAGvSATVVSAASSEVVVI 4547
Cdd:COG3210   745 agVTITSGNAGTLSIGLTANTTASGTTLTLANANGntSAGATLDNAGAEISIDITADGTITAAG-TTAINVTGSGGTITI 823
                         810       820       830       840       850       860       870       880
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4548 TSALPGGVVGPVTGNVTVVSTSGALVHADTDSFTYVRAGAVTGVSPLAGVQGTRVTVTGERLLGGGSSIAAVQVAGVETR 4627
Cdd:COG3210   824 NTATTGLTGTGDTTSGAGGSNTTDTTTGTTSDGASGGGTAGANSGSLAATAASITVGSGGVATSTGTANAGTLTNLGTTT 903
                         890       900       910       920       930       940       950       960
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4628 VIESSNNTHVVLRASNGTGSGDIELIADTGAKTVANVTFSYLELGVITAVRPAIGRVGTLVTIEGERLQSGGSAVARVDL 4707
Cdd:COG3210   904 NAASGNGAVLATVTATGTGGGGLTGGNAAAGGTGAGNGTTALSGTQGNAGLSAASASDGAGDTGASSAAGSSAVGTSANS 983

                  ....
gi 514698100 4708 GPAA 4711
Cdd:COG3210   984 AGST 987
TNFRSF4 cd13406
Tumor necrosis factor receptor superfamily member 4 (TNFRSF4), also known as CD134 or OXO40; ...
5610-5762 9.19e-07

Tumor necrosis factor receptor superfamily member 4 (TNFRSF4), also known as CD134 or OXO40; TNFRSF4 (also known as OX40, ACT35, CD134, IMD16, TXGP1L) activates NF-kappaB through its interaction with adaptor proteins TRAF2 and TRAF5. It also promotes the expression of apoptosis inhibitors BCL2 and BCL2lL1/BCL2-XL, and thus suppresses apoptosis. It is primarily expressed on activated CD4+ and CD8+ T cells, where it is transiently expressed and upregulated on the most recently antigen-activated T cells within inflammatory lesions. This makes it an attractive target to modulate immune responses, i.e. TNFRSF4 (OX40) blocking agents to inhibit adverse inflammation or agonists to enhance immune responses. An artificially created biologic fusion protein, OX40-immunoglobulin (OX40-Ig), prevents OX40 from reaching the T-cell receptors, thus reducing the T-cell response. Some single nucleotide polymorphisms (SNPs) of its natural ligand OX40 ligand (OX40L, CD252), which is also found on activated T cells, have been associated with systemic lupus erythematosus.


Pssm-ID: 276911 [Multi-domain]  Cd Length: 142  Bit Score: 52.02  E-value: 9.19e-07
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5610 ERClsVKTCGAGEEETTSPSATRNRVCQPCQLGstFKAQSGQSTRCISVTTC--GAGEEEIASPTLSTDRQCRtcasgtf 5687
Cdd:cd13406    12 EKC--CHECPPGEGMESRCTGTQDTVCSPCEPG--FYNEAVNYEPCKPCTQCnqRSGSEEKQKCTKTSDTVCR------- 80
                          90       100       110       120       130       140       150
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*.
gi 514698100 5688 kaaagqsttCIAVSTCAAGFTEDVaptpssdrVCVECAPGTFkATAGDGTCRAHRTCEDTEYETVAP-TSSSDRKC 5762
Cdd:cd13406    81 ---------CRPGTQPLDSYKPGV--------DCVPCPPGHF-SRGDNQACKPWTNCSLAGKRTLRPgSSTSDAVC 138
TNFRSF26 cd15837
Tumor necrosis factor receptor superfamily member 26 (TNFRSF26), also known as tumor necrosis ...
6171-6265 1.01e-06

Tumor necrosis factor receptor superfamily member 26 (TNFRSF26), also known as tumor necrosis factor receptor homolog 3 (TNFRH3); TNFRSF26 (also known as tumor necrosis factor receptor homolog 3 (TNFRH3) or TNFRSF24) is predominantly expressed in embryos and lymphoid cell types, along with its closely related TNFRSF22 and TNFRSF23 orthologs, and is developmentally regulated. Unlike TNFRSF22/23, TNFRSF26 does not serve as a TRAIL decoy receptor; it remains an orphan receptor.


Pssm-ID: 276933 [Multi-domain]  Cd Length: 118  Bit Score: 51.21  E-value: 1.01e-06
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6171 CADTEYESvaatdtsdrKCSSCRECTSSEYLVSGCSESANAVckACTECPSGTFVS-----TACTPLA----DAE-CTEC 6240
Cdd:cd15837     1 CGPGEYKS---------ANLCCQLCPAGHYVSEPCQENHGVG--ECAPCEPGTFTAhpngeTSCFPCSqcrdDQEvVAEC 69
                          90       100       110
                  ....*....|....*....|....*....|..
gi 514698100 6241 TR-------CGSGYFVQSPCTSEADTTCKRCR 6265
Cdd:cd15837    70 SAtsdrqcqCKQGHFYCDENCLESCFRCSRCP 101
TNFRSF5 cd13407
Tumor necrosis factor receptor superfamily member 5 (TNFRSF5), also known as CD40; TNFRSF5 ...
5611-5762 1.05e-06

Tumor necrosis factor receptor superfamily member 5 (TNFRSF5), also known as CD40; TNFRSF5 (commonly known as CD40 and also as CDW40, p50, Bp50) is widely expressed in diverse cell types including B lymphocytes, dendritic cells, platelets, monocytes, endothelial cells, and fibroblasts. It is essential in mediating a wide variety of immune and inflammatory responses, including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation. Its natural immunomodulating ligand is CD40L, and a primary defect in the CD40/CD40L system is associated with X-linked hyper-IgM (XHIM) syndrome. It is also involved in tumorigenesis; CD40 expression is significantly higher in gastric carcinomas and it is associated with the lymphatic metastasis of cancer cells and their tumor node metastasis (TNM) classification. Upregulated levels of CD40/CD40L on B cells and T cells may play an important role in the immune pathogenesis of breast cancer. Consequently, the CD40/CD40L system serves as a link between tumorigenesis, atherosclerosis, and the immune system, and offers a potential target for drug therapy for related diseases, such as cancer, atherosclerosis, diabetes mellitus, and immunological rejection.


Pssm-ID: 276912 [Multi-domain]  Cd Length: 161  Bit Score: 52.41  E-value: 1.05e-06
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5611 RCLSVktCGAGEEETTSPSATRNRVCQPCQLGStFKAQSGQSTRCISVTTC--GAGEEEIASPTLSTDRQCrTCASGTFk 5688
Cdd:cd13407    11 RCCSL--CPPGQKLVSDCTEATDTECLPCEEGE-FQDTWNRERHCHQHRYCdpNLGLRVQTEGTAETDTTC-TCQEGQH- 85
                          90       100       110       120       130       140       150
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*.
gi 514698100 5689 AAAGQSTTCIAVSTCAAGFTEDVAPTPSSDRVCVECAPGTFKATAGD-GTCRAHRTCEDTE-YETVAPTSSSDRKC 5762
Cdd:cd13407    86 CTSEACETCALHTSCKPGFGVKQIATGVSDTICEPCPVGFFSNVSSAfEKCHPWTSCETKGlVELQAGTNKTDVVC 161
TNFRSF10 cd10580
Tumor necrosis factor receptor superfamily member 10 (TNFRSF10), includes TNFRSF10A (DR4), ...
5721-5835 1.17e-06

Tumor necrosis factor receptor superfamily member 10 (TNFRSF10), includes TNFRSF10A (DR4), TNFRSF10B (DR5), TNFRSF10C (DcR1) and TNFRSF10D (DcR2); TNFRSF10 family contains TNFRSF10A (also known as DR4, Apo2, TRAIL-R1, CD261), TNFRSF10B (also known as DR5, KILLER, TRICK2A, TRAIL-R2, TRICKB, CD262), TNFRSF10C (also known as DcR1, TRAIL-R3, LIT, TRID, CD263), and TNFRSF10D (also known as DcR2, TRUNDD, TRAIL-R4, CD264). Tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL) binds to all 4 receptors. DR4 (TRAIL-R1) and DR5 (TRAIL-R2) are membrane-bound and contain a death domain in their intracellular portion, which is able to transmit an apoptotic signal, thus often called death receptors. In contrast, DcR1 (TRAIL-R3), which lacks the complete intracellular portion and DcR2 (TRAIL-R4), which has a truncated cytoplasmic death domain, do not transmit an apoptotic signal, thus known as decoy receptors. Apoptosis mediated by DR4 and DR5 requires Fas (TNFRSF6)-associated via death domain (FADD), a death domain containing adaptor protein. Two transcript variants encoding different isoforms and one non-coding transcript have been found for TNFRSF10B/DR5. DcR1 appears to function as an antagonistic receptor that protects cells from TRAIL-induced apoptosis; it has been found to be a p53-regulated DNA damage-inducible gene. The expression of this gene is detected in many normal tissues but not in most cancer cell lines, which may explain the specific sensitivity of cancer cells to the apoptosis-inducing activity of TRAIL. DcR2 has been shown to play an inhibitory role in TRAIL-induced cell apoptosis. The membrane expression of all of these receptors (DR4, DR5, DcR1, and DcR2) is greater in normal endometrium (NE) than in endometrioid adenocarcinoma (EAC). In EAC patients, membrane expression of these receptors are not independent predictors of survival. DcR1 and DcR2 expression is critical in cell growth and apoptosis in cutaneous or uveal melanoma; DcR1 and DcR2 are frequently methylated in both, leading to loss of gene expression and melanomagenesis. On the other hand, DR4 and DR5 methylation is rare in cutaneous melanoma and frequent in uveal melanoma; their expression is wholly independent of the promoter methylation status. DcR1 and DcR2 genes are also reported to be hyper-methylated in prostate cancer. The TRAIL ligand, a potent and specific inducer of apoptosis in cancer cells, has been explored as a therapeutic drug; experimental data has shown that DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.


Pssm-ID: 276906 [Multi-domain]  Cd Length: 103  Bit Score: 50.72  E-value: 1.17e-06
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5721 CVECAPGTFKATAGdGTCRAhrtCED----TEYETVAPtsssdrKCKALTVCQDDEWESKAPTITTDRECspcgRCTDGl 5796
Cdd:cd10580     2 CGLCPAGTYVSEDS-GDCIP---CKEgvdyTEHPNGLP------SCLPCTVCKSDEEELSPCTTTRNTEC----QCKPG- 66
                          90       100       110       120
                  ....*....|....*....|....*....|....*....|
gi 514698100 5797 TLdkaCTDTSPTKCVGC-DECASDEYTLSSCTLSSQTQCR 5835
Cdd:cd10580    67 TF---CDPDSPEVCQKCsTRCPEGMVEVSPCTPWSDLKCV 103
TNFRSF cd00185
Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) ...
6009-6093 1.22e-06

Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) interactions with TNF superfamily (TNFSF) ligands (TNFL) control key cellular processes such as differentiation, proliferation, apoptosis, and cell growth. Dysregulation of these pathways has been shown to result in a wide range of pathological conditions, including autoimmune diseases, inflammation, cancer, and viral infection. There are 29 very diverse family members of TNFRSF reported in humans: 22 are type I transmembrane receptors (single pass with the N terminus on extracellular side of the cell membrane) and have a clear signal peptide; the remaining 7 members are either type III transmembrane receptors (single pass with the N terminus on extracellular side of the membrane but no signal sequence; TNFR13B, TNFR13C, TNFR17, and XEDAR), or attached to the membrane via a glycosylphosphatidylinositol (GPI) linker (TNFR10C), or secreted as soluble receptors (TNFR11B and TNFR6B). All TNFRs contain relatively short cysteine-rich domains (CRDs) in the ectodomain, and are involved in interaction with the TNF homology domain (THD) of their ligands. TNFRs often have multiple CRDs (between one and six), with the most frequent configurations of three or four copies; most CRDs possess three disulfide bridges, but could have between one and four. Localized or genome-wide duplication and evolution of the TNFRSF members appear to have paralleled the emergence of the adaptive immune system; teleosts (i.e. ray-finned, bony fish), which possess an immune system with B and T cells, possess primary and secondary lymphoid organs, and are capable of adaptive responses to pathogens also display several characteristics that are different from the mammalian immune system, making teleost TNFSF orthologs and paralogs of interest to better understand immune system evolution and the immunological pathways elicited to pathogens.


Pssm-ID: 276900 [Multi-domain]  Cd Length: 87  Bit Score: 49.90  E-value: 1.22e-06
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6009 CGAGEEETSAPTASTDRVCSTCASGKFKATTGQ-TPCEAVSTCEEDEYVYRAATVSTDTQCRaltACSDEQYETRAPTVN 6087
Cdd:cd00185     5 CPPGEYLSSDCTATTDTVCSPCPPGTYSESWNSlSKCLPCTTCGGGNQVEKTPCTATDNRCC---TCKPGFYCDEGTNVE 81

                  ....*.
gi 514698100 6088 SDRECT 6093
Cdd:cd00185    82 ECKPCT 87
TNFRSF26 cd15837
Tumor necrosis factor receptor superfamily member 26 (TNFRSF26), also known as tumor necrosis ...
5560-5661 1.28e-06

Tumor necrosis factor receptor superfamily member 26 (TNFRSF26), also known as tumor necrosis factor receptor homolog 3 (TNFRH3); TNFRSF26 (also known as tumor necrosis factor receptor homolog 3 (TNFRH3) or TNFRSF24) is predominantly expressed in embryos and lymphoid cell types, along with its closely related TNFRSF22 and TNFRSF23 orthologs, and is developmentally regulated. Unlike TNFRSF22/23, TNFRSF26 does not serve as a TRAIL decoy receptor; it remains an orphan receptor.


Pssm-ID: 276933 [Multi-domain]  Cd Length: 118  Bit Score: 50.83  E-value: 1.28e-06
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5560 CGGGTYVPAGstgTCSQYeCSAGT---ADTDSNAG-TACEACD-GTTTYQPSkGQERCLSVKTCGAGEEETTSPSATRNR 5634
Cdd:cd15837     1 CGPGEYKSAN---LCCQL-CPAGHyvsEPCQENHGvGECAPCEpGTFTAHPN-GETSCFPCSQCRDDQEVVAECSATSDR 75
                          90       100
                  ....*....|....*....|....*..
gi 514698100 5635 VCQpCQLGsTFKAQSGQSTRCISVTTC 5661
Cdd:cd15837    76 QCQ-CKQG-HFYCDENCLESCFRCSRC 100
VSP pfam03302
Giardia variant-specific surface protein;
5636-6056 1.28e-06

Giardia variant-specific surface protein;


Pssm-ID: 146106 [Multi-domain]  Cd Length: 397  Bit Score: 54.98  E-value: 1.28e-06
                           10        20        30        40        50        60        70        80
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  5636 CQPCQLGSTFKAQSgqsTRCISVTTCGAGEEEIASPtlSTDRQCRTCASGTFKAAAGQsttCIavSTCAAGFTEDVAPTP 5715
Cdd:pfam03302    1 CDECKPGYELSADK---TKCTSSAPCKTENCKACSN--DKREVCEECNSNNYLTPTSQ---CI--DDCAKIGNYYYTTNA 70
                           90       100       110       120       130       140       150       160
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  5716 SSDRVCVECAPGTFKATAGDGTCRahrTCEDTEY---ETVAPTSSSDRKCKALTVcqddeweskaptittdrecSPCGRC 5792
Cdd:pfam03302   71 NNKKICKECTVANCKTCEDQGQCQ---ACNDGFYksgDACSPCHESCKTCSGGTA-------------------SDCTEC 128
                          170       180       190       200       210       220       230       240
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  5793 TDGLTLDKACTDTSPTKCVGCdecasdeytlssctlSSQTQCRQCTTCGNDEYQTKACSvsqdtECATLTtcSSTQFEVE 5872
Cdd:pfam03302  129 LTGKALRYGNDGTKGTCGEGC---------------TTGTGAGACKTCGLTIDGTSYCS-----ECATET--EYPQNGVC 186
                          250       260       270       280       290       300       310       320
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  5873 APTATRDRR-CKDLTACQPGEYECTAATLTTDRECCGVTQcVPGseETSAPTATSDRECRQCVAGTTDADGSGTTPCVAC 5951
Cdd:pfam03302  187 TSTAARATAtCKASSVANGMCSSCANGYFRMNGGCYETTK-FPG--KSVCEEANSGGTCQKEAPGYKLNNGDLVTCSPGC 263
                          330       340       350       360       370       380       390       400
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  5952 SaghyvprgrtggcaafECAAghvdqdedaATACKLCEAGvnYAGSAGL-TRCTSVSECGAGEEETsaptastdrvCSTC 6030
Cdd:pfam03302  264 K----------------TCTS---------NTVCTTCMDG--YVKTSDScTKCDSSCETCTGATTT----------CKTC 306
                          410       420
                   ....*....|....*....|....*.
gi 514698100  6031 ASGKFKATTGQTPCEAvstCEEDEYV 6056
Cdd:pfam03302  307 ATGYYKSGTGCVSCTS---SESDNGI 329
TNFRSF1A_teleost cd15834
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) in teleosts; also known as ...
5578-5710 1.34e-06

Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) in teleosts; also known as TNFR1; This subfamily of TNFRSF1 ((also known as type I TNFR, TNFR1, DR1, TNFRSF1A, CD120a, p55) is found in teleosts. It binds TNF-alpha, through the death domain (DD), and activates NF-kappaB, mediates apoptosis and activates signaling pathways controlling inflammatory, immune, and stress responses. It mediates signal transduction by interacting with antiapoptotic protein BCL2-associated athanogene 4 (BAG4/SODD) and adaptor proteins TRAF2 and TRADD that play regulatory roles. The human genetic disorder called tumor necrosis factor associated periodic syndrome (TRAPS), or periodic fever syndrome, is associated with germline mutations of the extracellular domains of this receptor, possibly due to impaired receptor clearance. Serum levels of TNFRSF1A are elevated in schizophrenia and bipolar disorder, and high levels are also associated with cognitive impairment and dementia. Knockout studies in zebrafish embryos have shown that a signaling balance between TNFRSF1A and TNFRSF1B is required for endothelial cell integrity. TNFRSF1A signals apoptosis through caspase-8, whereas TNFRSF1B signals survival via NF-kappaB in endothelial cells. Thus, this apoptotic pathway seems to be evolutionarily conserved, as TNFalpha promotes apoptosis of human endothelial cells and triggers caspase-2 and P53 activation in these cells via TNFRSF1A.


Pssm-ID: 276930 [Multi-domain]  Cd Length: 150  Bit Score: 51.72  E-value: 1.34e-06
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5578 ECSAgtadtdSNAGTACEACDGTTTYQPSKGQERCLSVKTCGAGEEETTSP-SATRNRVCQpCQLGsTFKAQSGQSTR-C 5655
Cdd:cd15834    26 ECTA------PGERSQCTPCPEGTYLEQINYSPNCRRCTLCKVKNEEEVSPcKKSSNTVCR-CKKG-YYKSRIDSETReC 97
                          90       100       110       120       130
                  ....*....|....*....|....*....|....*....|....*....|....*
gi 514698100 5656 ISVTTCGAGEEEIASPTLSTDRQCRtCASGTFKaaagQSTTCIAVSTCAAGFTED 5710
Cdd:cd15834    98 LKCKTCGPGEIEIQPCTPESNTVCE-CKDNYYR----NNNKCKPCQKCSLDCQHL 147
TNFRSF26 cd15837
Tumor necrosis factor receptor superfamily member 26 (TNFRSF26), also known as tumor necrosis ...
5943-6068 1.35e-06

Tumor necrosis factor receptor superfamily member 26 (TNFRSF26), also known as tumor necrosis factor receptor homolog 3 (TNFRH3); TNFRSF26 (also known as tumor necrosis factor receptor homolog 3 (TNFRH3) or TNFRSF24) is predominantly expressed in embryos and lymphoid cell types, along with its closely related TNFRSF22 and TNFRSF23 orthologs, and is developmentally regulated. Unlike TNFRSF22/23, TNFRSF26 does not serve as a TRAIL decoy receptor; it remains an orphan receptor.


Pssm-ID: 276933 [Multi-domain]  Cd Length: 118  Bit Score: 50.83  E-value: 1.35e-06
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5943 SGTTPCVACSAGHYVPRgrtggcaafECAAGHvdqdedAATACKLCEAGVNYAGSAGLTRCTSVSECGAGEEETSAPTAS 6022
Cdd:cd15837     8 SANLCCQLCPAGHYVSE---------PCQENH------GVGECAPCEPGTFTAHPNGETSCFPCSQCRDDQEVVAECSAT 72
                          90       100       110       120
                  ....*....|....*....|....*....|....*....|....*..
gi 514698100 6023 TDRVCStCASGKFKATTG-QTPCEAVSTCEEDEYVYRAATVSTDTQC 6068
Cdd:cd15837    73 SDRQCQ-CKQGHFYCDENcLESCFRCSRCPGGRVVLQPCNATRDTVC 118
TNFRSF5 cd13407
Tumor necrosis factor receptor superfamily member 5 (TNFRSF5), also known as CD40; TNFRSF5 ...
5579-5721 1.36e-06

Tumor necrosis factor receptor superfamily member 5 (TNFRSF5), also known as CD40; TNFRSF5 (commonly known as CD40 and also as CDW40, p50, Bp50) is widely expressed in diverse cell types including B lymphocytes, dendritic cells, platelets, monocytes, endothelial cells, and fibroblasts. It is essential in mediating a wide variety of immune and inflammatory responses, including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation. Its natural immunomodulating ligand is CD40L, and a primary defect in the CD40/CD40L system is associated with X-linked hyper-IgM (XHIM) syndrome. It is also involved in tumorigenesis; CD40 expression is significantly higher in gastric carcinomas and it is associated with the lymphatic metastasis of cancer cells and their tumor node metastasis (TNM) classification. Upregulated levels of CD40/CD40L on B cells and T cells may play an important role in the immune pathogenesis of breast cancer. Consequently, the CD40/CD40L system serves as a link between tumorigenesis, atherosclerosis, and the immune system, and offers a potential target for drug therapy for related diseases, such as cancer, atherosclerosis, diabetes mellitus, and immunological rejection.


Pssm-ID: 276912 [Multi-domain]  Cd Length: 161  Bit Score: 52.02  E-value: 1.36e-06
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5579 CSAG---TADTDSNAGTACEACDgTTTYQPSKGQER-CLSVKTC--GAGEEETTSPSATRNRVCQpCQLGStfKAQSGQS 5652
Cdd:cd13407    16 CPPGqklVSDCTEATDTECLPCE-EGEFQDTWNRERhCHQHRYCdpNLGLRVQTEGTAETDTTCT-CQEGQ--HCTSEAC 91
                          90       100       110       120       130       140       150
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5653 TRCISVTTCGAGEEEIASPTLSTDRQCRTCASGTFKAAAGQSTTCIAVSTCAA-GFTEDVAPTPSSDRVC 5721
Cdd:cd13407    92 ETCALHTSCKPGFGVKQIATGVSDTICEPCPVGFFSNVSSAFEKCHPWTSCETkGLVELQAGTNKTDVVC 161
IPT_plexin_repeat2 cd01179
Second repeat of the IPT domain of Plexins and Cell Surface Receptors (PCSR) . Plexins are ...
1328-1393 1.38e-06

Second repeat of the IPT domain of Plexins and Cell Surface Receptors (PCSR) . Plexins are involved in the regulation of cell proliferation and of cellular adhesion and repulsion receptors. In general, there are three copies of the IPT domain present preceeded by SEMA (semaphorin) and PSI (plexin, semaphorin, integrin) domains.


Pssm-ID: 238584  Cd Length: 85  Bit Score: 49.92  E-value: 1.38e-06
                          10        20        30        40        50        60
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....
gi 514698100 1328 SVTSVSPSSG--QGGTRVTVLGANLRLGSSAVtgVLLGSAACSLISENDTAVVC-AAGVASAGSVPVTV 1393
Cdd:cd01179     2 SITSLSPSYGpqSGGTRLTITGKHLNAGSSVR--VTVGGQPCKILSVSSSQIVClTPPSASPGEAPVKV 68
TNFRSF5 cd13407
Tumor necrosis factor receptor superfamily member 5 (TNFRSF5), also known as CD40; TNFRSF5 ...
5789-5948 1.68e-06

Tumor necrosis factor receptor superfamily member 5 (TNFRSF5), also known as CD40; TNFRSF5 (commonly known as CD40 and also as CDW40, p50, Bp50) is widely expressed in diverse cell types including B lymphocytes, dendritic cells, platelets, monocytes, endothelial cells, and fibroblasts. It is essential in mediating a wide variety of immune and inflammatory responses, including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation. Its natural immunomodulating ligand is CD40L, and a primary defect in the CD40/CD40L system is associated with X-linked hyper-IgM (XHIM) syndrome. It is also involved in tumorigenesis; CD40 expression is significantly higher in gastric carcinomas and it is associated with the lymphatic metastasis of cancer cells and their tumor node metastasis (TNM) classification. Upregulated levels of CD40/CD40L on B cells and T cells may play an important role in the immune pathogenesis of breast cancer. Consequently, the CD40/CD40L system serves as a link between tumorigenesis, atherosclerosis, and the immune system, and offers a potential target for drug therapy for related diseases, such as cancer, atherosclerosis, diabetes mellitus, and immunological rejection.


Pssm-ID: 276912 [Multi-domain]  Cd Length: 161  Bit Score: 51.64  E-value: 1.68e-06
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5789 CGRCTDGLTLDKACTDTSPTKCVGCDEcasDEYtlssctLSSQTQCRQCTtcgndeyQTKACSvsqdtecatlttcSSTQ 5868
Cdd:cd13407    13 CSLCPPGQKLVSDCTEATDTECLPCEE---GEF------QDTWNRERHCH-------QHRYCD-------------PNLG 63
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5869 FEVEAP-TATRDRRCkdltACQPGEYeCTAATLTTdreCCGVTQCVPGSEETSAPTATSDRECRQCVAGTTDADGSGTTP 5947
Cdd:cd13407    64 LRVQTEgTAETDTTC----TCQEGQH-CTSEACET---CALHTSCKPGFGVKQIATGVSDTICEPCPVGFFSNVSSAFEK 135

                  .
gi 514698100 5948 C 5948
Cdd:cd13407   136 C 136
TNFRSF1B_teleost cd15835
Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B) in teleost; also known as ...
5789-5906 2.02e-06

Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B) in teleost; also known as TNFR2; This subfamily of TNFRSF1B (also known as TNFR2, type 2 TNFR, TNFBR, TNFR80, TNF-R75, TNF-R-II, p75, CD120b) is found in teleosts. It binds TNF-alpha, but lacks the death domain (DD) that is associated with the cytoplasmic domain of TNFRSF1A (TNFR1). It is inducible and expressed exclusively by oligodendrocytes, astrocytes, T cells, thymocytes, myocytes, endothelial cells, and in human mesenchymal stem cells. TNFRSF1B protects oligodendrocyte progenitor cells (OLGs) against oxidative stress, and induces the up-regulation of cell survival genes. While pro-inflammatory and pathogen-clearing activities of TNF are mediated mainly through activation of TNFRSF1A, a strong activator of NF-kappaB, TNFRSF1B is more responsible for suppression of inflammation. Although the affinities of both receptors for soluble TNF are similar, TNFRSF1B is sometimes more abundantly expressed and thought to associate with TNF, thereby increasing its concentration near TNFRSF1A receptors, and making TNF available to activate TNFRSF1A (a ligand-passing mechanism). Knockout studies in zebrafish embryos have shown that a signaling balance between TNFRSF1A and TNFRSF1B is required for endothelial cell integrity. TNFRSF1A signals apoptosis through caspase-8, whereas TNFRSF1B signals survival via NF-kB in endothelial cells. In goldfish (Carassius aurutus L.), TNFRSF1B expression is substantially higher than that of TNFRSF1 in tissues and various immune cell types. Both receptors are most robustly expressed in monocytes; mRNA levels of TNFRSF1B are lowest in peripheral blood leukocytes.


Pssm-ID: 276931 [Multi-domain]  Cd Length: 130  Bit Score: 50.90  E-value: 2.02e-06
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5789 CGRCTDGLTLDKACTDTSPTKcvgCDECASDEYtlsSCTLSSQTQCRQCTTCGND---EYqTKACSVSQDTECA--TLTT 5863
Cdd:cd15835    21 CSKCRPGTRLKTKCSETSDTV---CEPCPSGQY---SENWNYYPNCFSCPKCKERkglQY-AQNCSSTTNAVCVckPGMY 93
                          90       100       110       120
                  ....*....|....*....|....*....|....*....|...
gi 514698100 5864 CSSTQFEveaPTATrdrRCKDLTACQPGEYECTAATLTTDREC 5906
Cdd:cd15835    94 CIMGFDH---PSCS---ECKKYRTCKPGYGVSVPGTPTSDVKC 130
TNFRSF1B cd10577
Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B), also known as TNFR2; TNFRSF1B ...
5574-5721 2.36e-06

Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B), also known as TNFR2; TNFRSF1B (also known as TNFR2, type 2 TNFR, TNFBR, TNFR80, TNF-R75, TNF-R-II, p75, CD120b) binds TNF-alpha, but lacks the death domain (DD) that is associated with the cytoplasmic domain of TNFRSF1A (TNFR1). It is inducible and expressed exclusively by oligodendrocytes, astrocytes, T cells, thymocytes, myocytes, endothelial cells, and in human mesenchymal stem cells. TNFRSF1B protects oligodendrocyte progenitor cells (OLGs) against oxidative stress, and induces the up-regulation of cell survival genes. While pro-inflammatory and pathogen-clearing activities of TNF are mediated mainly through activation of TNFRSF1A, a strong activator of NF-kappaB, TNFRSF1B is more responsible for suppression of inflammation. Although the affinities of both receptors for soluble TNF are similar, TNFRSF1B is sometimes more abundantly expressed and thought to associate with TNF, thereby increasing its concentration near TNFRSF1A receptors, and making TNF available to activate TNFRSF1A (a ligand-passing mechanism).


Pssm-ID: 276903 [Multi-domain]  Cd Length: 163  Bit Score: 51.32  E-value: 2.36e-06
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5574 CSQyeCSAG---TADTDSNAGTACEACDGTTTYQPSKGQERCLSVKT-CGAGEEETTSPSATRNRVCQpCQLGSTFKAQS 5649
Cdd:cd10577    16 CSK--CPPGqhvKHSCTKTSDTVCAPCEESTYTQLWNWVPECLSCSSpCSSDQVETQACTRQQNRICS-CKPGWYCVLKL 92
                          90       100       110       120       130       140       150
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|...
gi 514698100 5650 GQSTR-CISVTTCGAGEEEIASPTLSTDRQCRTCASGTFKAAAGQSTTCIAVSTCAagfTEDVAPTPSSDRVC 5721
Cdd:cd10577    93 QEGCRqCRPLKKCGPGFGVARPGTASSDVECKPCAPGTFSDTTSSTDTCRPHRICS---SVAIPGNASMDAVC 162
TNFRSF1A_teleost cd15834
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) in teleosts; also known as ...
5768-5897 2.77e-06

Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) in teleosts; also known as TNFR1; This subfamily of TNFRSF1 ((also known as type I TNFR, TNFR1, DR1, TNFRSF1A, CD120a, p55) is found in teleosts. It binds TNF-alpha, through the death domain (DD), and activates NF-kappaB, mediates apoptosis and activates signaling pathways controlling inflammatory, immune, and stress responses. It mediates signal transduction by interacting with antiapoptotic protein BCL2-associated athanogene 4 (BAG4/SODD) and adaptor proteins TRAF2 and TRADD that play regulatory roles. The human genetic disorder called tumor necrosis factor associated periodic syndrome (TRAPS), or periodic fever syndrome, is associated with germline mutations of the extracellular domains of this receptor, possibly due to impaired receptor clearance. Serum levels of TNFRSF1A are elevated in schizophrenia and bipolar disorder, and high levels are also associated with cognitive impairment and dementia. Knockout studies in zebrafish embryos have shown that a signaling balance between TNFRSF1A and TNFRSF1B is required for endothelial cell integrity. TNFRSF1A signals apoptosis through caspase-8, whereas TNFRSF1B signals survival via NF-kappaB in endothelial cells. Thus, this apoptotic pathway seems to be evolutionarily conserved, as TNFalpha promotes apoptosis of human endothelial cells and triggers caspase-2 and P53 activation in these cells via TNFRSF1A.


Pssm-ID: 276930 [Multi-domain]  Cd Length: 150  Bit Score: 50.95  E-value: 2.77e-06
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5768 CQDDEWESKAPTI--------------TTDRECSPCGRCTDGLTLDKActDTSPTkCVGCDECASD-EYTLSSCTLSSQT 5832
Cdd:cd15834     1 CLDSEYLSENGICcnkchpgyklkeecTAPGERSQCTPCPEGTYLEQI--NYSPN-CRRCTLCKVKnEEEVSPCKKSSNT 77
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5833 QCR------------------QCTTCGNDEYQTKACSVSQDTECAtlttCSSTQFEveaptatRDRRCKDLTACQPG-EY 5893
Cdd:cd15834    78 VCRckkgyyksridsetreclKCKTCGPGEIEIQPCTPESNTVCE----CKDNYYR-------NNNKCKPCQKCSLDcQH 146

                  ....
gi 514698100 5894 ECTA 5897
Cdd:cd15834   147 LCTT 150
TNFRSF5_teleost cd13422
Tumor necrosis factor receptor superfamily member 5 (TNFRSF5) in teleosts; also known as CD40; ...
5514-5576 2.79e-06

Tumor necrosis factor receptor superfamily member 5 (TNFRSF5) in teleosts; also known as CD40; TNFRSF5 (commonly known as CD40 and also as CDW40, p50, Bp50) is widely expressed in diverse cell types including B lymphocytes, dendritic cells, platelets, monocytes, endothelial cells, and fibroblasts. It is essential in mediating a wide variety of immune and inflammatory responses, including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation. Its natural immunomodulating ligand is CD40L, and a primary defect in the CD40/CD40L system is associated with X-linked hyper-IgM (XHIM) syndrome. It is also involved in tumorigenesis; CD40 expression is significantly higher in gastric carcinomas and it is associated with the lymphatic metastasis of cancer cells and their tumor node metastasis (TNM) classification. Upregulated levels of CD40/CD40L on B cells and T cells may play an important role in the immune pathogenesis of breast cancer. Consequently, the CD40/CD40L system serves as a link between tumorigenesis, atherosclerosis, and the immune system, and offers a potential target for drug therapy for related diseases, such as cancer, atherosclerosis, diabetes mellitus, and immunological rejection. Salmon CD40 and CD40L are widely expressed, particularly in immune tissues, and their importance for the immune response is indicated by their relatively high expression in salmon lymphoid organs and gills.


Pssm-ID: 276927 [Multi-domain]  Cd Length: 161  Bit Score: 51.27  E-value: 2.79e-06
                          10        20        30        40        50        60
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*.
gi 514698100 5514 VCRGLTTCGAGEQEKVAPTASSDRVCEACPAGTTDANSDGSDACVT---CGGGTYVPAGSTGTCSQ 5576
Cdd:cd13422    93 TCVPHTTCGPGQGVKSKGNHIRDTVCEECPDGTFSNNSSAEGVCKKwteCESGYKVEAAGTNTSDN 158
TNFRSF21 cd10583
Tumor necrosis factor receptor superfamily member 21 (TNFRSF21), also known as death receptor ...
5557-5721 3.27e-06

Tumor necrosis factor receptor superfamily member 21 (TNFRSF21), also known as death receptor (DR6); TNFRSF21 (also known as death receptor 6 (DR6), CD358, BM-018) is highly expressed in differentiating neurons as well as in the adult brain, and is upregulated in injured neurons. DR6 negatively regulates neurondendrocyte, axondendrocyte, and oligodendrocyte survival, hinders axondendrocyte and oligodendrocyte regeneration and its inhibition has a neuro-protective effect in nerve injury. It activates nuclear factor kappa-B (NFkB) and mitogen-activated protein kinase 8 (MAPK8, also called c-Jun N-terminal kinase 1), and induces cell apoptosis by associating with TNFRSF1A-associated via death domain (TRADD), which is known to mediate signal transduction of tumor necrosis factor receptors. TNFRSF21 plays a role in T-helper cell activation, and may be involved in inflammation and immune regulation. Its possible ligand is alpha-amyloid precursor protein (APP), hence probably involved in the development of Alzheimer's disease; when released, APP binds in an autocrine/paracrine manner to activate a caspase-dependent self-destruction program that removes unnecessary or connectionless axons. Increasing beta-catenin levels in brain endothelium upregulates TNFRSF21 and TNFRSF19, indicating that these death receptors are downstream target genes of Wnt/beta-catenin signaling, which has been shown to be required for blood-brain barrier development. DR6 is up-regulated in numerous solid tumors as well as in tumor vascular cells, including ovarian cancer and may be a clinically useful diagnostic and predictive serum biomarker for some adult sarcoma subtypes.


Pssm-ID: 276909 [Multi-domain]  Cd Length: 159  Bit Score: 50.90  E-value: 3.27e-06
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5557 CVTCGGGTYVPAGSTGTcSQYECSAgtadtdsnagtaceaCDGTTTYQPSKGQERCLSV-KTCGAGEEETTSPSATRNRV 5635
Cdd:cd10583    15 CDKCPAGTYVSKHCTET-SLRECSP---------------CPNGTFTRHENGIEQCHRCrKPCPAPMIEKTPCTALTDRE 78
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5636 CQpCQLGsTFKaqsgQSTRCISVTTC--GAGEEEIASPTlsTDRQCRTCASGTFKAAAGQSTTCIAVSTCAA-GFTEDVA 5712
Cdd:cd10583    79 CT-CPPG-TFL----SNDTCVPHSVCpvGWGVRKKGTET--EDVRCKPCPRGTFSDVPSSVLKCKTYTDCLGlGLVVIKP 150

                  ....*....
gi 514698100 5713 PTPSSDRVC 5721
Cdd:cd10583   151 GTKETDNVC 159
TNFRSF5 cd13407
Tumor necrosis factor receptor superfamily member 5 (TNFRSF5), also known as CD40; TNFRSF5 ...
6122-6264 3.37e-06

Tumor necrosis factor receptor superfamily member 5 (TNFRSF5), also known as CD40; TNFRSF5 (commonly known as CD40 and also as CDW40, p50, Bp50) is widely expressed in diverse cell types including B lymphocytes, dendritic cells, platelets, monocytes, endothelial cells, and fibroblasts. It is essential in mediating a wide variety of immune and inflammatory responses, including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation. Its natural immunomodulating ligand is CD40L, and a primary defect in the CD40/CD40L system is associated with X-linked hyper-IgM (XHIM) syndrome. It is also involved in tumorigenesis; CD40 expression is significantly higher in gastric carcinomas and it is associated with the lymphatic metastasis of cancer cells and their tumor node metastasis (TNM) classification. Upregulated levels of CD40/CD40L on B cells and T cells may play an important role in the immune pathogenesis of breast cancer. Consequently, the CD40/CD40L system serves as a link between tumorigenesis, atherosclerosis, and the immune system, and offers a potential target for drug therapy for related diseases, such as cancer, atherosclerosis, diabetes mellitus, and immunological rejection.


Pssm-ID: 276912 [Multi-domain]  Cd Length: 161  Bit Score: 50.86  E-value: 3.37e-06
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6122 CDSTQFVVskptattDRDCaeCDRCDSGtQYETATCTATTNRVCADltvCADTEYEsvaATDTSDRKCSSCRECTSSEYL 6201
Cdd:cd13407     1 CREKQYLH-------NGRC--CSLCPPG-QKLVSDCTEATDTECLP---CEEGEFQ---DTWNRERHCHQHRYCDPNLGL 64
                          90       100       110       120       130       140
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....
gi 514698100 6202 V---SGCSESaNAVCkactECPSGTFvstaCTplaDAECTEC---TRCGSGYFVQSPCTSEADTTCKRC 6264
Cdd:cd13407    65 RvqtEGTAET-DTTC----TCQEGQH----CT---SEACETCalhTSCKPGFGVKQIATGVSDTICEPC 121
TNFRSF14_teleost cd13405
Tumor necrosis factor receptor superfamily member 14 (TNFRSF14) in teleost; also known as ...
6171-6277 3.44e-06

Tumor necrosis factor receptor superfamily member 14 (TNFRSF14) in teleost; also known as herpes virus entry mediator (HVEM); This subfamily of TNFRSF14 (also known as herpes virus entry mediator or HVEM, ATAR, CD270, HVEA, LIGHTR, TR2) is found in teleosts, many of which are as yet uncharacterized. It regulates T-cell immune responses by activating inflammatory as well as inhibitory signaling pathways. HVEM acts as a receptor for the canonical TNF-related ligand LIGHT (lymphotoxin-like), which exhibits inducible expression, and competes with herpes simplex virus glycoprotein D for HVEM. It also acts as a ligand for the immunoglobulin superfamily proteins BTLA (B and T lymphocyte attenuator) and CD160, a feature distinguishing HVEM from other immune regulatory molecules, thus, creating a functionally diverse set of intrinsic and bidirectional signaling pathways. HVEM is highly expressed in the gut epithelium. Genome-wide association studies have shown that HVEM is an inflammatory bowel disease (IBD) risk gene, suggesting that HVEM could have a regulatory role influencing the regulation of epithelial barrier, host defense, and the microbiota. Mouse models have revealed that HVEM is involved in colitis pathogenesis, mucosal host defense, and epithelial immunity, thus acting as a mucosal gatekeeper with multiple regulatory functions in the mucosa. HVEM plays a critical role in both tumor progression and resistance to antitumor immune responses, possibly through direct and indirect mechanisms. It is known to be expressed in several human malignancies, including esophageal squamous cell carcinoma, follicular lymphoma, and melanoma. HVEM network may therefore be an attractive target for drug intervention. In Asian seabass, the up-regulation of differentially expressed TNFRSF14 gene has been observed.


Pssm-ID: 276910 [Multi-domain]  Cd Length: 111  Bit Score: 49.63  E-value: 3.44e-06
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6171 CADTEYESvaatdtsDRKCssCRECTSSEYLVSGCSESANAVCKACTEcpsGTFVStacTPLADAECTECTRC--GSGYF 6248
Cdd:cd13405     1 CGPAEYEI-------NGEC--CPMCPPGSRVSRHCTEDTSTSCVPCPD---GTYMD---EPNGLEKCFPCTNCdpGFGLR 65
                          90       100       110
                  ....*....|....*....|....*....|....*....
gi 514698100 6249 VQSPCTSEADTTC----------KRCRSCASGEYlHTAC 6277
Cdd:cd13405    66 VKQGCTYTSDTVCeplegfycidSTKDGCSAAQR-HSSC 103
VSP pfam03302
Giardia variant-specific surface protein;
5985-6272 3.48e-06

Giardia variant-specific surface protein;


Pssm-ID: 146106 [Multi-domain]  Cd Length: 397  Bit Score: 53.82  E-value: 3.48e-06
                           10        20        30        40        50        60        70        80
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  5985 CKLCEAGvnYAGSAGLTRCTSVSECGAgeEETSAPTASTDRVCSTCASGKFKATTGQT--PCEAV-----STCEEDEYVY 6057
Cdd:pfam03302    1 CDECKPG--YELSADKTKCTSSAPCKT--ENCKACSNDKREVCEECNSNNYLTPTSQCidDCAKIgnyyyTTNANNKKIC 76
                           90       100       110       120       130       140       150       160
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  6058 RAATVSTDTQCR---ALTACSDEQY---ETRAPTVNSDRECTG-----LTTCGSGE---YETRAPTATTDRKCasVTQCD 6123
Cdd:pfam03302   77 KECTVANCKTCEdqgQCQACNDGFYksgDACSPCHESCKTCSGgtasdCTECLTGKalrYGNDGTKGTCGEGC--TTGTG 154
                          170       180       190       200       210       220       230       240
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  6124 STQfvvSKPTATTDRDCAECDRCDSGTQY-ETATCTATTNRVCADLTvcadteyesvaATDTSDRKCSSCrectSSEYLV 6202
Cdd:pfam03302  155 AGA---CKTCGLTIDGTSYCSECATETEYpQNGVCTSTAARATATCK-----------ASSVANGMCSSC----ANGYFR 216
                          250       260       270       280       290       300       310       320
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  6203 --SGCSESANAVCKA-CTECPSG-----------------TFVSTACTPLADAecTECTRCGSGYFVQSPCTSEADTTCK 6262
Cdd:pfam03302  217 mnGGCYETTKFPGKSvCEEANSGgtcqkeapgyklnngdlVTCSPGCKTCTSN--TVCTTCMDGYVKTSDSCTKCDSSCE 294
                          330
                   ....*....|....*..
gi 514698100  6263 -------RCRSCASGEY 6272
Cdd:pfam03302  295 tctgattTCKTCATGYY 311
COG4625 COG4625
Uncharacterized conserved protein, contains a C-terminal beta-barrel porin domain [Function ...
3441-3909 3.52e-06

Uncharacterized conserved protein, contains a C-terminal beta-barrel porin domain [Function unknown];


Pssm-ID: 443664 [Multi-domain]  Cd Length: 900  Bit Score: 54.40  E-value: 3.52e-06
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3441 TSMIAAVTPAEGQYGTRVTITGQRLLGGGAAVQAVELAGVAATVVSGSDTEVVVAAGNGTAGDVGDVVITSDSGAVSVDA 3520
Cdd:COG4625    16 GTGGGGAGGGGGAGGGAGGGGAGGGGGGGGGGGGAGGGGGGGGTGGGGGGGGGGGGGGAGGGGGGGGGGGGGGGTGGVGG 95
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3521 LAWRYLDASHITSVTPRHGQKGTVVTINGTLLRGHGSGVAVVLLAGEAANVLSESDTSVVVAASAFGGSKSGPVTIIASN 3600
Cdd:COG4625    96 GGGGGGGGGGGGGGGGGGGGGGSAGGGGGGAGGAGGGGGGGAGGGGGGGGGGGAGGGGGGGAGGAGGGGGGGGGGGGGGG 175
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3601 GATAVSTPTAFEYRAPGAVSAIVPNSGHRGTYVTIKGSNLRGHGPTVMSVTLGGVAGHIVSENSSSVVVRVERLSVAVAT 3680
Cdd:COG4625   176 GGGGGGGGGGGGGGGGGNGGGGGGGGGGGGGGGGGGGGAGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGAGGGGGGG 255
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3681 PVDVVLTSRSGAQVAAAGAFTYLVEGSVADLLPAQGQRGTAVSLSGSNLCGGGTAIVAVTLGGVAASLKPTSTCNLVQFV 3760
Cdd:COG4625   256 GGNGGGGGAGGGGGGGGGGSGGGGGGGGGGGSGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGAG 335
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3761 AGSRNNTAAEAVDVVLESNTGALIEGTGRWTYVVEGAI-------SSVLPPGGVAGTLVTIRGSNLLGGGSTAAGVTLAG 3833
Cdd:COG4625   336 GGGGSGGAGAGGGGAGGGGAGGGGGGGTGGGGGGGGGGgggsgggGAGGGGGSGGGGGGGAGGGGGGGGAGGTGGGGAGG 415
                         410       420       430       440       450       460       470
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*.
gi 514698100 3834 VSASVEQANATHVIVTANRGTTAGDVVVTSDTGSNVVLQDGFTYSRISSVSPAEGQEGTRVRLDGVGFFTGGASVD 3909
Cdd:COG4625   416 GGGAAGGGGGGTGAGGGGGGGGTGAGGGGATGGGGGGGGGAGGSGGGAGAGGGSGSGAGTLTLTGNNTYTGTTTVN 491
TNFRSF1B_teleost cd15835
Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B) in teleost; also known as ...
6143-6272 3.92e-06

Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B) in teleost; also known as TNFR2; This subfamily of TNFRSF1B (also known as TNFR2, type 2 TNFR, TNFBR, TNFR80, TNF-R75, TNF-R-II, p75, CD120b) is found in teleosts. It binds TNF-alpha, but lacks the death domain (DD) that is associated with the cytoplasmic domain of TNFRSF1A (TNFR1). It is inducible and expressed exclusively by oligodendrocytes, astrocytes, T cells, thymocytes, myocytes, endothelial cells, and in human mesenchymal stem cells. TNFRSF1B protects oligodendrocyte progenitor cells (OLGs) against oxidative stress, and induces the up-regulation of cell survival genes. While pro-inflammatory and pathogen-clearing activities of TNF are mediated mainly through activation of TNFRSF1A, a strong activator of NF-kappaB, TNFRSF1B is more responsible for suppression of inflammation. Although the affinities of both receptors for soluble TNF are similar, TNFRSF1B is sometimes more abundantly expressed and thought to associate with TNF, thereby increasing its concentration near TNFRSF1A receptors, and making TNF available to activate TNFRSF1A (a ligand-passing mechanism). Knockout studies in zebrafish embryos have shown that a signaling balance between TNFRSF1A and TNFRSF1B is required for endothelial cell integrity. TNFRSF1A signals apoptosis through caspase-8, whereas TNFRSF1B signals survival via NF-kB in endothelial cells. In goldfish (Carassius aurutus L.), TNFRSF1B expression is substantially higher than that of TNFRSF1 in tissues and various immune cell types. Both receptors are most robustly expressed in monocytes; mRNA levels of TNFRSF1B are lowest in peripheral blood leukocytes.


Pssm-ID: 276931 [Multi-domain]  Cd Length: 130  Bit Score: 49.74  E-value: 3.92e-06
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6143 CDRCDSGTQYETaTCTATTNRVCADltvCADTEY-ESVAATdtsdRKCSSCRECTSSEYLVSG--CSESANAVCkactEC 6219
Cdd:cd15835    21 CSKCRPGTRLKT-KCSETSDTVCEP---CPSGQYsENWNYY----PNCFSCPKCKERKGLQYAqnCSSTTNAVC----VC 88
                          90       100       110       120       130
                  ....*....|....*....|....*....|....*....|....*....|...
gi 514698100 6220 PSGTFvstactpladaectectrCGSGYFVQSpCTSeadttCKRCRSCASGEY 6272
Cdd:cd15835    89 KPGMY------------------CIMGFDHPS-CSE-----CKKYRTCKPGYG 117
TNFR_c6 pfam00020
TNFR/NGFR cysteine-rich region;
5816-5858 3.97e-06

TNFR/NGFR cysteine-rich region;


Pssm-ID: 459633 [Multi-domain]  Cd Length: 39  Bit Score: 46.92  E-value: 3.97e-06
                           10        20        30        40
                   ....*....|....*....|....*....|....*....|...
gi 514698100  5816 CASDEYTLSSctlsSQTQCRQCTTCGNDEYQTKACSVSQDTEC 5858
Cdd:pfam00020    1 CPPGTYTDNW----NGLKCLPCTVCPPGQVVVRPCTPTSDTVC 39
TNFRSF1B_teleost cd15835
Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B) in teleost; also known as ...
5595-5721 4.36e-06

Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B) in teleost; also known as TNFR2; This subfamily of TNFRSF1B (also known as TNFR2, type 2 TNFR, TNFBR, TNFR80, TNF-R75, TNF-R-II, p75, CD120b) is found in teleosts. It binds TNF-alpha, but lacks the death domain (DD) that is associated with the cytoplasmic domain of TNFRSF1A (TNFR1). It is inducible and expressed exclusively by oligodendrocytes, astrocytes, T cells, thymocytes, myocytes, endothelial cells, and in human mesenchymal stem cells. TNFRSF1B protects oligodendrocyte progenitor cells (OLGs) against oxidative stress, and induces the up-regulation of cell survival genes. While pro-inflammatory and pathogen-clearing activities of TNF are mediated mainly through activation of TNFRSF1A, a strong activator of NF-kappaB, TNFRSF1B is more responsible for suppression of inflammation. Although the affinities of both receptors for soluble TNF are similar, TNFRSF1B is sometimes more abundantly expressed and thought to associate with TNF, thereby increasing its concentration near TNFRSF1A receptors, and making TNF available to activate TNFRSF1A (a ligand-passing mechanism). Knockout studies in zebrafish embryos have shown that a signaling balance between TNFRSF1A and TNFRSF1B is required for endothelial cell integrity. TNFRSF1A signals apoptosis through caspase-8, whereas TNFRSF1B signals survival via NF-kB in endothelial cells. In goldfish (Carassius aurutus L.), TNFRSF1B expression is substantially higher than that of TNFRSF1 in tissues and various immune cell types. Both receptors are most robustly expressed in monocytes; mRNA levels of TNFRSF1B are lowest in peripheral blood leukocytes.


Pssm-ID: 276931 [Multi-domain]  Cd Length: 130  Bit Score: 49.74  E-value: 4.36e-06
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5595 EACDGTTTYQPSKGQERCLSvkTCGAGEEETTSPSATRNRVCQPCQLGsTFKAQSGQSTRCISVTTC--GAGEEEIASPT 5672
Cdd:cd15835     3 GNCRNTTTEYYNDGSNLCCS--KCRPGTRLKTKCSETSDTVCEPCPSG-QYSENWNYYPNCFSCPKCkeRKGLQYAQNCS 79
                          90       100       110       120       130
                  ....*....|....*....|....*....|....*....|....*....|..
gi 514698100 5673 LSTDRQCrTCASGTFKAAAGQS---TTCIAVSTCAAGFTEDVAPTPSSDRVC 5721
Cdd:cd15835    80 STTNAVC-VCKPGMYCIMGFDHpscSECKKYRTCKPGYGVSVPGTPTSDVKC 130
IPT_PCSR cd00603
IPT domain of Plexins and Cell Surface Receptors (PCSR) and related proteins . This subgroup ...
2732-2818 4.55e-06

IPT domain of Plexins and Cell Surface Receptors (PCSR) and related proteins . This subgroup contains IPT domains of plexins, receptors, like the plasminogen-related growth factor receptors, the hepatocyte growth factor-scatter factors, and the macrophage-stimulating receptors and of fibrocystin. Plexins are involved in the regulation of cell proliferation and of cellular adhesion and repulsion receptors. In general, there are three copies of the IPT_PCSR domain present preceeded by SEMA (semaphorin) and PSI (plexin, semaphorin, integrin) domains.


Pssm-ID: 238337 [Multi-domain]  Cd Length: 90  Bit Score: 48.60  E-value: 4.55e-06
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2732 PVVGEIEPSSGQL--GTVVTIRGSNLLAGGEALQlVTLAGVPAEAILSSNNSVVTVSSAQGSGATGPAVLVAAETGGRAV 2809
Cdd:cd00603     1 PVITSISPSSGPLsgGTRLTITGSNLGSGSPRVR-VTVGGVPCKVLNVSSTEIVCRTPAAATPGEGPVEVTVDGANVSAR 79

                  ....*....
gi 514698100 2810 GTPSVNYTY 2818
Cdd:cd00603    80 VLSNTTFTY 88
TNFRSF1A_teleost cd15834
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) in teleosts; also known as ...
6006-6156 4.84e-06

Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) in teleosts; also known as TNFR1; This subfamily of TNFRSF1 ((also known as type I TNFR, TNFR1, DR1, TNFRSF1A, CD120a, p55) is found in teleosts. It binds TNF-alpha, through the death domain (DD), and activates NF-kappaB, mediates apoptosis and activates signaling pathways controlling inflammatory, immune, and stress responses. It mediates signal transduction by interacting with antiapoptotic protein BCL2-associated athanogene 4 (BAG4/SODD) and adaptor proteins TRAF2 and TRADD that play regulatory roles. The human genetic disorder called tumor necrosis factor associated periodic syndrome (TRAPS), or periodic fever syndrome, is associated with germline mutations of the extracellular domains of this receptor, possibly due to impaired receptor clearance. Serum levels of TNFRSF1A are elevated in schizophrenia and bipolar disorder, and high levels are also associated with cognitive impairment and dementia. Knockout studies in zebrafish embryos have shown that a signaling balance between TNFRSF1A and TNFRSF1B is required for endothelial cell integrity. TNFRSF1A signals apoptosis through caspase-8, whereas TNFRSF1B signals survival via NF-kappaB in endothelial cells. Thus, this apoptotic pathway seems to be evolutionarily conserved, as TNFalpha promotes apoptosis of human endothelial cells and triggers caspase-2 and P53 activation in these cells via TNFRSF1A.


Pssm-ID: 276930 [Multi-domain]  Cd Length: 150  Bit Score: 50.18  E-value: 4.84e-06
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6006 VSECGAGEEETsaptastdrVCSTCASGKFKATTGQTP-CEAVSTCEED-EYVYRAATVSTDTQCRaltaCSDEQYETRA 6083
Cdd:cd15834    24 KEECTAPGERS---------QCTPCPEGTYLEQINYSPnCRRCTLCKVKnEEEVSPCKKSSNTVCR----CKKGYYKSRI 90
                          90       100       110       120       130       140       150
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|...
gi 514698100 6084 PTVNsdRECTGLTTCGSGEYETRAPTATTDRKCasvtQCDSTQFvvskptaTTDRDCAECDRCDSGTQYETAT 6156
Cdd:cd15834    91 DSET--RECLKCKTCGPGEIEIQPCTPESNTVC----ECKDNYY-------RNNNKCKPCQKCSLDCQHLCTT 150
TNFRSF26 cd15837
Tumor necrosis factor receptor superfamily member 26 (TNFRSF26), also known as tumor necrosis ...
5768-5930 5.00e-06

Tumor necrosis factor receptor superfamily member 26 (TNFRSF26), also known as tumor necrosis factor receptor homolog 3 (TNFRH3); TNFRSF26 (also known as tumor necrosis factor receptor homolog 3 (TNFRH3) or TNFRSF24) is predominantly expressed in embryos and lymphoid cell types, along with its closely related TNFRSF22 and TNFRSF23 orthologs, and is developmentally regulated. Unlike TNFRSF22/23, TNFRSF26 does not serve as a TRAIL decoy receptor; it remains an orphan receptor.


Pssm-ID: 276933 [Multi-domain]  Cd Length: 118  Bit Score: 49.29  E-value: 5.00e-06
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5768 CQDDEWESkaptittDRECspCGRCTDGLTLDKACTdtSPTKCVGCDECASDEYTLSSctlSSQTQCRQCTTCGNDEYQT 5847
Cdd:cd15837     1 CGPGEYKS-------ANLC--CQLCPAGHYVSEPCQ--ENHGVGECAPCEPGTFTAHP---NGETSCFPCSQCRDDQEVV 66
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5848 KACSvsqdtecatlttcsstqfeveaptATRDRRCKdltaCQPGEYECTAATLTTDRECcgvtQCVPGSEETSAP-TATS 5926
Cdd:cd15837    67 AECS------------------------ATSDRQCQ----CKQGHFYCDENCLESCFRC----SRCPGGRVVLQPcNATR 114

                  ....
gi 514698100 5927 DREC 5930
Cdd:cd15837   115 DTVC 118
TNFRSF cd00185
Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) ...
5948-6048 5.12e-06

Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) interactions with TNF superfamily (TNFSF) ligands (TNFL) control key cellular processes such as differentiation, proliferation, apoptosis, and cell growth. Dysregulation of these pathways has been shown to result in a wide range of pathological conditions, including autoimmune diseases, inflammation, cancer, and viral infection. There are 29 very diverse family members of TNFRSF reported in humans: 22 are type I transmembrane receptors (single pass with the N terminus on extracellular side of the cell membrane) and have a clear signal peptide; the remaining 7 members are either type III transmembrane receptors (single pass with the N terminus on extracellular side of the membrane but no signal sequence; TNFR13B, TNFR13C, TNFR17, and XEDAR), or attached to the membrane via a glycosylphosphatidylinositol (GPI) linker (TNFR10C), or secreted as soluble receptors (TNFR11B and TNFR6B). All TNFRs contain relatively short cysteine-rich domains (CRDs) in the ectodomain, and are involved in interaction with the TNF homology domain (THD) of their ligands. TNFRs often have multiple CRDs (between one and six), with the most frequent configurations of three or four copies; most CRDs possess three disulfide bridges, but could have between one and four. Localized or genome-wide duplication and evolution of the TNFRSF members appear to have paralleled the emergence of the adaptive immune system; teleosts (i.e. ray-finned, bony fish), which possess an immune system with B and T cells, possess primary and secondary lymphoid organs, and are capable of adaptive responses to pathogens also display several characteristics that are different from the mammalian immune system, making teleost TNFSF orthologs and paralogs of interest to better understand immune system evolution and the immunological pathways elicited to pathogens.


Pssm-ID: 276900 [Multi-domain]  Cd Length: 87  Bit Score: 48.36  E-value: 5.12e-06
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5948 CVACSAGHYVprgrtggcaAFECAAGHvdqdedaATACKLCEAGVNYAGSAGLTRCTSVSECGAGEEETSAPTASTDRVC 6027
Cdd:cd00185     2 CQRCPPGEYL---------SSDCTATT-------DTVCSPCPPGTYSESWNSLSKCLPCTTCGGGNQVEKTPCTATDNRC 65
                          90       100
                  ....*....|....*....|..
gi 514698100 6028 STCASGKF-KATTGQTPCEAVS 6048
Cdd:cd00185    66 CTCKPGFYcDEGTNVEECKPCT 87
TNFRSF1A cd10576
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A), also known as TNFR1; TNFRSF1A ...
6143-6274 5.49e-06

Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A), also known as TNFR1; TNFRSF1A (also known as type I TNFR, TNFR1, DR1, TNFRSF1A, CD120a, p55) binds TNF-alpha, through the death domain (DD), and activates NF-kappaB, mediates apoptosis and activates signaling pathways controlling inflammatory, immune, and stress responses. It mediates signal transduction by interacting with antiapoptotic protein BCL2-associated athanogene 4 (BAG4/SODD) and adaptor proteins TRAF2 and TRADD that play regulatory roles. The human genetic disorder called tumor necrosis factor associated periodic syndrome (TRAPS), or periodic fever syndrome, is associated with germline mutations of the extracellular domains of this receptor, possibly due to impaired receptor clearance. TNFRSF1A polymorphisms rs1800693 and rs4149584 are associated with elevated risk of multiple sclerosis. Serum levels of TNFRSF1A are elevated in schizophrenia and bipolar disorder, and high levels are also associated with cognitive impairment and dementia. Patients with idiopathic recurrent acute pericarditis (IRAP), presumed to be an autoimmune process, have also been shown to carry rare mutations (R104Q and D12E) in the TNFRSF1A gene.


Pssm-ID: 276902 [Multi-domain]  Cd Length: 130  Bit Score: 49.66  E-value: 5.49e-06
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6143 CDRCDSGTqYETATCTATtNRVcadlTVCADTEYESVAATDTSDRKCSSCRECTS--SEYLVSGCSESANAVCKacteCP 6220
Cdd:cd10576    15 CTKCHKGT-YLYNDCPGP-GQD----TVCRECENGTFTASENYLRKCLSCSRCRKemGQVEISPCTVDQDTVCG----CR 84
                          90       100       110       120       130
                  ....*....|....*....|....*....|....*....|....*....|....*.
gi 514698100 6221 SGTFVSTactplaDAECTECTRCGSGY--FVQSPCTSEADTTCkrcrSCASGEYLH 6274
Cdd:cd10576    85 KNQYQHY------WSSLFQCKNCSLCLngTIRQPCQEKQDTIC----TCHTGFFLR 130
IPT smart00429
ig-like, plexins, transcription factors;
275-357 5.67e-06

ig-like, plexins, transcription factors;


Pssm-ID: 214657 [Multi-domain]  Cd Length: 90  Bit Score: 48.19  E-value: 5.67e-06
                            10        20        30        40        50        60        70        80
                    ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100    275 TIAAVSPSSGQV--GTRVTITGTNLLGGGAAVERVTLAGVEASLVAQSATQIVVVASPSRE-RAAGPVV-VYSDTGAFAR 350
Cdd:smart00429    3 VITRISPTSGPVsgGTEITLCGKNLKSISVVFVEVGVGEAPCTFSPSSSTAIVCKTPPYHNiPGSVPVRtVGLRNGGVPS 82

                    ....*..
gi 514698100    351 LESAFAY 357
Cdd:smart00429   83 SPQPFTY 89
TNFRSF_viral cd15839
Tumor necrosis factor receptor superfamily members, virus-encoded; This family contains viral ...
5547-5664 5.84e-06

Tumor necrosis factor receptor superfamily members, virus-encoded; This family contains viral TNFR homologs that include vaccinia virus (VACV) cytokine response modifier E (CrmE), an encoded TNFR that shares significant sequence similarity with mammalian type 2 TNF receptors (TNFSFR1B, p75, TNFR type 2), a cowpox virus encoded cytokine-response modifier B (crmB), which is a secreted form of TNF receptor that can contribute to the modification of TNF-mediated antiviral processes, and a myxoma virus (MYXV) T2 (M-T2) protein that binds and inhibits rabbit TNF-alpha. The CrmE structure confirms that the canonical TNFR fold is adopted, but only one of the two "ligand-binding" loops of TNFRSF1A is conserved, suggesting a mechanism for the higher affinity of poxvirus TNFRs for TNFalpha over lymphotoxin-alpha. CrmB protein specifically binds TNF-alpha and TNF-beta indicating that cowpox virus seeks to invade antiviral processes mediated by TNF. Intracellular M-T2 blocks virus-induced lymphocyte apoptosis via a highly conserved viral preligand assembly domain (vPLAD), which controls receptor signaling competency prior to ligand binding.


Pssm-ID: 276935 [Multi-domain]  Cd Length: 125  Bit Score: 49.48  E-value: 5.84e-06
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5547 TDANSDGSDACVT-CGGGTYvpagSTGTCsqyecsagtadtDSNAGTACEAC-DGTTTYQPSKGQErCLSVK-TCGAGEE 5623
Cdd:cd15839     4 NDYNSNSNNLCCKsCPPGTY----ASHLC------------DTTSNTKCDPCpSDTFTSIPNHIPA-CLSCRgRCSSNQV 66
                          90       100       110       120
                  ....*....|....*....|....*....|....*....|...
gi 514698100 5624 ETTSPSATRNRVCQpCQLGST--FKAQSGQSTrCISVTTCGAG 5664
Cdd:cd15839    67 ETKSCSNTQNRICS-CAPGYYclLKGSDGCVA-CAPKTKCGVG 107
TNFRSF6B cd10575
Tumor necrosis factor receptor superfamily member 6B (TNFRSF6B), also known as decoy receptor ...
6143-6265 5.89e-06

Tumor necrosis factor receptor superfamily member 6B (TNFRSF6B), also known as decoy receptor 3 (DcR3); The subfamily TNFRSF6B is also known as decoy receptor 3 (DcR3), M68, or TR6. This protein is a soluble receptor without death domain and cytoplasmic domain, and secreted by cells. It acts as a decoy receptor that competes with death receptors for ligand binding. It is a pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases, and cancer. Over-expression of this gene has been noted in several cancers, including pancreatic carcinoma, and gastrointestinal tract tumors. It can neutralize the biological effects of three tumor necrosis factor superfamily (TNFSF) members: TNFSF6 (Fas ligand/FasL/CD95L) and TNFSF14 (LIGHT) which are both involved in apoptosis and inflammation, and TNFSF15 (TNF-like molecule 1A/TL1A), which is a T cell co-stimulator and involved in gut inflammation. DcR3 is a novel inflammatory marker; higher DcR3 levels strongly correlate with inflammation and independently predict cardiovascular and all-cause mortality in chronic kidney disease (CKD) patients on hemodialysis. Increased synovial inflammatory cells infiltration in rheumatoid arthritis and ankylosing spondylitis is also associated with the elevated DcR3 expression. In cartilaginous fish, mRNA expression of DcR3 in the thymus and leydig, which are the representative lymphoid tissues of elasmobranchs, suggests that DcR3 may act as a modulator in the immune system. Interestingly, in banded dogfish (Triakis scyllia), DcR3 mRNA is strongly expressed in the gill, compared with human expression in the normal lung; both are respiratory organs, suggesting potential relevance of DcR3 to respiratory function.


Pssm-ID: 276901 [Multi-domain]  Cd Length: 163  Bit Score: 50.10  E-value: 5.89e-06
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6143 CDRCDSGTqYETATCTATTNRVCADltvCAD---TEYESVAatdtsdRKCSSC-RECTSSEYLVSGCSESANAVCkactE 6218
Cdd:cd10575    16 CDQCPPGT-FVAKHCTRDRPTVCGP---CPDlhyTQFWNYL------EKCRYCnVFCTERQVEKRQCNATHNRVC----E 81
                          90       100       110       120
                  ....*....|....*....|....*....|....*....|....*...
gi 514698100 6219 CPSGTFvstactplADAE-CTECTRCGSGYFVQSPCTSEADTTCKRCR 6265
Cdd:cd10575    82 CKPGYY--------MEHGfCLRHSSCPPGEGVIKLGTPYSDTQCEPCP 121
IPT_PCSR cd00603
IPT domain of Plexins and Cell Surface Receptors (PCSR) and related proteins . This subgroup ...
1935-2014 6.10e-06

IPT domain of Plexins and Cell Surface Receptors (PCSR) and related proteins . This subgroup contains IPT domains of plexins, receptors, like the plasminogen-related growth factor receptors, the hepatocyte growth factor-scatter factors, and the macrophage-stimulating receptors and of fibrocystin. Plexins are involved in the regulation of cell proliferation and of cellular adhesion and repulsion receptors. In general, there are three copies of the IPT_PCSR domain present preceeded by SEMA (semaphorin) and PSI (plexin, semaphorin, integrin) domains.


Pssm-ID: 238337 [Multi-domain]  Cd Length: 90  Bit Score: 48.22  E-value: 6.10e-06
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1935 VIQSVDPQSG--QVGTRITIVGSGLlgGSAFAREVVMGNSVPCSVLRGNDSVVVCVL-ADAGSPAAAVDVTVVGARGSRV 2011
Cdd:cd00603     2 VITSISPSSGplSGGTRLTITGSNL--GSGSPRVRVTVGGVPCKVLNVSSTEIVCRTpAAATPGEGPVEVTVDGANVSAR 79

                  ...
gi 514698100 2012 VAS 2014
Cdd:cd00603    80 VLS 82
TNFRSF21 cd10583
Tumor necrosis factor receptor superfamily member 21 (TNFRSF21), also known as death receptor ...
6216-6277 7.65e-06

Tumor necrosis factor receptor superfamily member 21 (TNFRSF21), also known as death receptor (DR6); TNFRSF21 (also known as death receptor 6 (DR6), CD358, BM-018) is highly expressed in differentiating neurons as well as in the adult brain, and is upregulated in injured neurons. DR6 negatively regulates neurondendrocyte, axondendrocyte, and oligodendrocyte survival, hinders axondendrocyte and oligodendrocyte regeneration and its inhibition has a neuro-protective effect in nerve injury. It activates nuclear factor kappa-B (NFkB) and mitogen-activated protein kinase 8 (MAPK8, also called c-Jun N-terminal kinase 1), and induces cell apoptosis by associating with TNFRSF1A-associated via death domain (TRADD), which is known to mediate signal transduction of tumor necrosis factor receptors. TNFRSF21 plays a role in T-helper cell activation, and may be involved in inflammation and immune regulation. Its possible ligand is alpha-amyloid precursor protein (APP), hence probably involved in the development of Alzheimer's disease; when released, APP binds in an autocrine/paracrine manner to activate a caspase-dependent self-destruction program that removes unnecessary or connectionless axons. Increasing beta-catenin levels in brain endothelium upregulates TNFRSF21 and TNFRSF19, indicating that these death receptors are downstream target genes of Wnt/beta-catenin signaling, which has been shown to be required for blood-brain barrier development. DR6 is up-regulated in numerous solid tumors as well as in tumor vascular cells, including ovarian cancer and may be a clinically useful diagnostic and predictive serum biomarker for some adult sarcoma subtypes.


Pssm-ID: 276909 [Multi-domain]  Cd Length: 159  Bit Score: 49.75  E-value: 7.65e-06
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6216 CTECPSGTFVSTACTPLADAECTEC-----TR--------------CGSGYFVQSPCTSEADTTCkrcrSCASGEYL--- 6273
Cdd:cd10583    15 CDKCPAGTYVSKHCTETSLRECSPCpngtfTRhengieqchrcrkpCPAPMIEKTPCTALTDREC----TCPPGTFLsnd 90

                  ....*...
gi 514698100 6274 ----HTAC 6277
Cdd:cd10583    91 tcvpHSVC 98
TNFRSF26 cd15837
Tumor necrosis factor receptor superfamily member 26 (TNFRSF26), also known as tumor necrosis ...
5612-5721 7.74e-06

Tumor necrosis factor receptor superfamily member 26 (TNFRSF26), also known as tumor necrosis factor receptor homolog 3 (TNFRH3); TNFRSF26 (also known as tumor necrosis factor receptor homolog 3 (TNFRH3) or TNFRSF24) is predominantly expressed in embryos and lymphoid cell types, along with its closely related TNFRSF22 and TNFRSF23 orthologs, and is developmentally regulated. Unlike TNFRSF22/23, TNFRSF26 does not serve as a TRAIL decoy receptor; it remains an orphan receptor.


Pssm-ID: 276933 [Multi-domain]  Cd Length: 118  Bit Score: 48.90  E-value: 7.74e-06
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5612 CLSVKTCGAGEeeTTSPSATRNR---VCQPCQLGsTFKAQSGQSTRCISVTTCGAGEEEIASPTLSTDRQCRtCASGTFK 5688
Cdd:cd15837    10 NLCCQLCPAGH--YVSEPCQENHgvgECAPCEPG-TFTAHPNGETSCFPCSQCRDDQEVVAECSATSDRQCQ-CKQGHFY 85
                          90       100       110
                  ....*....|....*....|....*....|...
gi 514698100 5689 AAAGQSTTCIAVSTCAAGFTEDVAPTPSSDRVC 5721
Cdd:cd15837    86 CDENCLESCFRCSRCPGGRVVLQPCNATRDTVC 118
TNFRSF26 cd15837
Tumor necrosis factor receptor superfamily member 26 (TNFRSF26), also known as tumor necrosis ...
5661-5810 9.39e-06

Tumor necrosis factor receptor superfamily member 26 (TNFRSF26), also known as tumor necrosis factor receptor homolog 3 (TNFRH3); TNFRSF26 (also known as tumor necrosis factor receptor homolog 3 (TNFRH3) or TNFRSF24) is predominantly expressed in embryos and lymphoid cell types, along with its closely related TNFRSF22 and TNFRSF23 orthologs, and is developmentally regulated. Unlike TNFRSF22/23, TNFRSF26 does not serve as a TRAIL decoy receptor; it remains an orphan receptor.


Pssm-ID: 276933 [Multi-domain]  Cd Length: 118  Bit Score: 48.52  E-value: 9.39e-06
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5661 CGAGE---EEIASPtlSTDRQCRTCASGTFKAAAGQSTTCIAVSTCAAGfTEDVAP-TPSSDRVCvECAPGTFkatagdg 5736
Cdd:cd15837    16 CPAGHyvsEPCQEN--HGVGECAPCEPGTFTAHPNGETSCFPCSQCRDD-QEVVAEcSATSDRQC-QCKQGHF------- 84
                          90       100       110       120       130       140       150
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....
gi 514698100 5737 tcrahrtcedteyetvaptsssdrkckaltVCQDDEWESkaptittdreCSPCGRCTDGLTLDKACTDTSPTKC 5810
Cdd:cd15837    85 ------------------------------YCDENCLES----------CFRCSRCPGGRVVLQPCNATRDTVC 118
TNFRSF1B cd10577
Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B), also known as TNFR2; TNFRSF1B ...
5906-6068 9.76e-06

Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B), also known as TNFR2; TNFRSF1B (also known as TNFR2, type 2 TNFR, TNFBR, TNFR80, TNF-R75, TNF-R-II, p75, CD120b) binds TNF-alpha, but lacks the death domain (DD) that is associated with the cytoplasmic domain of TNFRSF1A (TNFR1). It is inducible and expressed exclusively by oligodendrocytes, astrocytes, T cells, thymocytes, myocytes, endothelial cells, and in human mesenchymal stem cells. TNFRSF1B protects oligodendrocyte progenitor cells (OLGs) against oxidative stress, and induces the up-regulation of cell survival genes. While pro-inflammatory and pathogen-clearing activities of TNF are mediated mainly through activation of TNFRSF1A, a strong activator of NF-kappaB, TNFRSF1B is more responsible for suppression of inflammation. Although the affinities of both receptors for soluble TNF are similar, TNFRSF1B is sometimes more abundantly expressed and thought to associate with TNF, thereby increasing its concentration near TNFRSF1A receptors, and making TNF available to activate TNFRSF1A (a ligand-passing mechanism).


Pssm-ID: 276903 [Multi-domain]  Cd Length: 163  Bit Score: 49.78  E-value: 9.76e-06
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5906 CCgvTQCVPGSEETSAPTATSDRECRQCVAGTTDADGSGTTPCVACSaghyvPRGRTGGCAAFECAaghvdQDEDAATAC 5985
Cdd:cd10577    15 CC--SKCPPGQHVKHSCTKTSDTVCAPCEESTYTQLWNWVPECLSCS-----SPCSSDQVETQACT-----RQQNRICSC 82
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5986 K---LCEAGVNyagsAGLTRCTSVSECGAGEEETSAPTASTDRVCSTCASGKFKATTGQT-PCEAVSTCEEdeyVYRAAT 6061
Cdd:cd10577    83 KpgwYCVLKLQ----EGCRQCRPLKKCGPGFGVARPGTASSDVECKPCAPGTFSDTTSSTdTCRPHRICSS---VAIPGN 155

                  ....*..
gi 514698100 6062 VSTDTQC 6068
Cdd:cd10577   156 ASMDAVC 162
TNFRSF4 cd13406
Tumor necrosis factor receptor superfamily member 4 (TNFRSF4), also known as CD134 or OXO40; ...
6185-6305 9.87e-06

Tumor necrosis factor receptor superfamily member 4 (TNFRSF4), also known as CD134 or OXO40; TNFRSF4 (also known as OX40, ACT35, CD134, IMD16, TXGP1L) activates NF-kappaB through its interaction with adaptor proteins TRAF2 and TRAF5. It also promotes the expression of apoptosis inhibitors BCL2 and BCL2lL1/BCL2-XL, and thus suppresses apoptosis. It is primarily expressed on activated CD4+ and CD8+ T cells, where it is transiently expressed and upregulated on the most recently antigen-activated T cells within inflammatory lesions. This makes it an attractive target to modulate immune responses, i.e. TNFRSF4 (OX40) blocking agents to inhibit adverse inflammation or agonists to enhance immune responses. An artificially created biologic fusion protein, OX40-immunoglobulin (OX40-Ig), prevents OX40 from reaching the T-cell receptors, thus reducing the T-cell response. Some single nucleotide polymorphisms (SNPs) of its natural ligand OX40 ligand (OX40L, CD252), which is also found on activated T cells, have been associated with systemic lupus erythematosus.


Pssm-ID: 276911 [Multi-domain]  Cd Length: 142  Bit Score: 48.93  E-value: 9.87e-06
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6185 SDRKCssCRECTSSEYLVSGCSESANAVckaCTECPSGtFVSTA-----CTPladaeCTECTRcGSGYFVQSPCTSEADT 6259
Cdd:cd13406    10 SGEKC--CHECPPGEGMESRCTGTQDTV---CSPCEPG-FYNEAvnyepCKP-----CTQCNQ-RSGSEEKQKCTKTSDT 77
                          90       100       110       120
                  ....*....|....*....|....*....|....*....|....*.
gi 514698100 6260 TCkRCRscasgeylhtACTTPLpianvqrsHRAHMGRFNSPLPPPH 6305
Cdd:cd13406    78 VC-RCR----------PGTQPL--------DSYKPGVDCVPCPPGH 104
COG4625 COG4625
Uncharacterized conserved protein, contains a C-terminal beta-barrel porin domain [Function ...
4207-4667 1.03e-05

Uncharacterized conserved protein, contains a C-terminal beta-barrel porin domain [Function unknown];


Pssm-ID: 443664 [Multi-domain]  Cd Length: 900  Bit Score: 52.86  E-value: 1.03e-05
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4207 TGRVVVMGSSGATITALDAFTYNVAGDITDVSPSFGRVGTRVRLLGSNLLGGGTSAEVRFGGVTGAVTAVSETAIDVTVP 4286
Cdd:COG4625    39 GGGGGGGGGGGAGGGGGGGGTGGGGGGGGGGGGGGAGGGGGGGGGGGGGGGTGGVGGGGGGGGGGGGGGGGGGGGGGGGS 118
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4287 AASGPSGLVNVSIVSDSGSHVLEVAGFRYTAPGSVAAVAPSSGHEGTVVTISGASLLAEEADAARVTLGGVNATVVFAND 4366
Cdd:COG4625   119 AGGGGGGAGGAGGGGGGGAGGGGGGGGGGGAGGGGGGGAGGAGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGNGGGGG 198
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4367 TRLVVVAGASSTAGLGDVFIETVGGARLLAANAWMYVAQATITDVQPGSGQVGTRVTIRGTGLRCGGAAVTSVLLGSAVA 4446
Cdd:COG4625   199 GGGGGGGGGGGGGGGAGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGAGGGGGGGGGNGGGGGAGGGGGGGGGGSGGG 278
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4447 PVVTEDDTTVIAEAPARAVGASPVDVTVVADTGAYVTADDAWTFVTAGAVSSVVPSSGQEGTRVTLSGTNLLGSGSGVDQ 4526
Cdd:COG4625   279 GGGGGGGGSGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGAGGGGGSGGAGAGGGGAGGGGAGGG 358
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4527 VLLAGVSATVVSAASSEVVVITSALPGGVVGPVTGNVTVVSTSGALVHADTDSFTYVRAGAVTGVSPLAGVQGTRVTVTG 4606
Cdd:COG4625   359 GGGGTGGGGGGGGGGGGGSGGGGAGGGGGSGGGGGGGAGGGGGGGGAGGTGGGGAGGGGGAAGGGGGGTGAGGGGGGGGT 438
                         410       420       430       440       450       460
                  ....*....|....*....|....*....|....*....|....*....|....*....|.
gi 514698100 4607 ERLLGGGSSIAAVQVAGVETRVIESSNNTHVVLRASNGTGSGDIELIADTGAKTVANVTFS 4667
Cdd:COG4625   439 GAGGGGATGGGGGGGGGAGGSGGGAGAGGGSGSGAGTLTLTGNNTYTGTTTVNGGGNYTQS 499
IPT_PCSR cd00603
IPT domain of Plexins and Cell Surface Receptors (PCSR) and related proteins . This subgroup ...
275-341 1.20e-05

IPT domain of Plexins and Cell Surface Receptors (PCSR) and related proteins . This subgroup contains IPT domains of plexins, receptors, like the plasminogen-related growth factor receptors, the hepatocyte growth factor-scatter factors, and the macrophage-stimulating receptors and of fibrocystin. Plexins are involved in the regulation of cell proliferation and of cellular adhesion and repulsion receptors. In general, there are three copies of the IPT_PCSR domain present preceeded by SEMA (semaphorin) and PSI (plexin, semaphorin, integrin) domains.


Pssm-ID: 238337 [Multi-domain]  Cd Length: 90  Bit Score: 47.45  E-value: 1.20e-05
                          10        20        30        40        50        60
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....
gi 514698100  275 TIAAVSPSSG--QVGTRVTITGTNLlGGGAAVERVTLAGVEASLVAQSATQIVVVASPSRERAAGPVVV 341
Cdd:cd00603     2 VITSISPSSGplSGGTRLTITGSNL-GSGSPRVRVTVGGVPCKVLNVSSTEIVCRTPAAATPGEGPVEV 69
JmjC_2 pfam08007
JmjC domain; This entry includes proteins with a JmjC domain that belong to the cupin ...
4920-5049 1.21e-05

JmjC domain; This entry includes proteins with a JmjC domain that belong to the cupin superfamily, including Bifunctional lysine-specific demethylase and histidyl-hydroxylase NO66, Ribosomal oxygenase 1/2, and 50S ribosomal protein L16 3-hydroxylase from Escherichia coli. Proteins are bifunctional, acting as histone lysine demethylases and ribosomal histidine hydroxylases.


Pssm-ID: 462340  Cd Length: 116  Bit Score: 48.02  E-value: 1.21e-05
                           10        20        30        40        50        60        70        80
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  4920 PHTDPYDVLVIQLQGSKRWT---TCVPDayvsdsndddddsANERSNANSTAADRPPSEAEvlagfnaaqlgqlqeirsq 4996
Cdd:pfam08007   30 PHYDDYDVFLLQGEGRKRWRvgaPKVPD-------------LEFYSDPPLRILDDFEPVHD------------------- 77
                           90       100       110       120       130
                   ....*....|....*....|....*....|....*....|....*....|...
gi 514698100  4997 rqqgctgyqdsmlrgmrctnFTLREGDTMYMPKGIIHFALTEEqGSSHITISL 5049
Cdd:pfam08007   78 --------------------FVLEPGDMLYLPRGFIHQGVALD-ESLHYSVGF 109
TNFRSF21 cd10583
Tumor necrosis factor receptor superfamily member 21 (TNFRSF21), also known as death receptor ...
5813-5950 1.37e-05

Tumor necrosis factor receptor superfamily member 21 (TNFRSF21), also known as death receptor (DR6); TNFRSF21 (also known as death receptor 6 (DR6), CD358, BM-018) is highly expressed in differentiating neurons as well as in the adult brain, and is upregulated in injured neurons. DR6 negatively regulates neurondendrocyte, axondendrocyte, and oligodendrocyte survival, hinders axondendrocyte and oligodendrocyte regeneration and its inhibition has a neuro-protective effect in nerve injury. It activates nuclear factor kappa-B (NFkB) and mitogen-activated protein kinase 8 (MAPK8, also called c-Jun N-terminal kinase 1), and induces cell apoptosis by associating with TNFRSF1A-associated via death domain (TRADD), which is known to mediate signal transduction of tumor necrosis factor receptors. TNFRSF21 plays a role in T-helper cell activation, and may be involved in inflammation and immune regulation. Its possible ligand is alpha-amyloid precursor protein (APP), hence probably involved in the development of Alzheimer's disease; when released, APP binds in an autocrine/paracrine manner to activate a caspase-dependent self-destruction program that removes unnecessary or connectionless axons. Increasing beta-catenin levels in brain endothelium upregulates TNFRSF21 and TNFRSF19, indicating that these death receptors are downstream target genes of Wnt/beta-catenin signaling, which has been shown to be required for blood-brain barrier development. DR6 is up-regulated in numerous solid tumors as well as in tumor vascular cells, including ovarian cancer and may be a clinically useful diagnostic and predictive serum biomarker for some adult sarcoma subtypes.


Pssm-ID: 276909 [Multi-domain]  Cd Length: 159  Bit Score: 48.98  E-value: 1.37e-05
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5813 CDECASDEYTLSSCTlssQTQCRQCTTCGNDEYQTKACSVSQDTECATltTCSSTQFEVEAPTATRDRRCkdltACQPGe 5892
Cdd:cd10583    15 CDKCPAGTYVSKHCT---ETSLRECSPCPNGTFTRHENGIEQCHRCRK--PCPAPMIEKTPCTALTDREC----TCPPG- 84
                          90       100       110       120       130
                  ....*....|....*....|....*....|....*....|....*....|....*...
gi 514698100 5893 yectaaTLTTDRECCGVTQCVPGSEETSAPTATSDRECRQCVAGTTDADGSGTTPCVA 5950
Cdd:cd10583    85 ------TFLSNDTCVPHSVCPVGWGVRKKGTETEDVRCKPCPRGTFSDVPSSVLKCKT 136
TNFRSF cd00185
Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) ...
5573-5659 1.47e-05

Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) interactions with TNF superfamily (TNFSF) ligands (TNFL) control key cellular processes such as differentiation, proliferation, apoptosis, and cell growth. Dysregulation of these pathways has been shown to result in a wide range of pathological conditions, including autoimmune diseases, inflammation, cancer, and viral infection. There are 29 very diverse family members of TNFRSF reported in humans: 22 are type I transmembrane receptors (single pass with the N terminus on extracellular side of the cell membrane) and have a clear signal peptide; the remaining 7 members are either type III transmembrane receptors (single pass with the N terminus on extracellular side of the membrane but no signal sequence; TNFR13B, TNFR13C, TNFR17, and XEDAR), or attached to the membrane via a glycosylphosphatidylinositol (GPI) linker (TNFR10C), or secreted as soluble receptors (TNFR11B and TNFR6B). All TNFRs contain relatively short cysteine-rich domains (CRDs) in the ectodomain, and are involved in interaction with the TNF homology domain (THD) of their ligands. TNFRs often have multiple CRDs (between one and six), with the most frequent configurations of three or four copies; most CRDs possess three disulfide bridges, but could have between one and four. Localized or genome-wide duplication and evolution of the TNFRSF members appear to have paralleled the emergence of the adaptive immune system; teleosts (i.e. ray-finned, bony fish), which possess an immune system with B and T cells, possess primary and secondary lymphoid organs, and are capable of adaptive responses to pathogens also display several characteristics that are different from the mammalian immune system, making teleost TNFSF orthologs and paralogs of interest to better understand immune system evolution and the immunological pathways elicited to pathogens.


Pssm-ID: 276900 [Multi-domain]  Cd Length: 87  Bit Score: 46.82  E-value: 1.47e-05
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5573 TCSQyeCSAGT---ADTDSNAGTACEACdGTTTYQPSKGQE-RCLSVKTCGAGEEETTSP-SATRNRVCQpCQLGsTFKA 5647
Cdd:cd00185     1 CCQR--CPPGEylsSDCTATTDTVCSPC-PPGTYSESWNSLsKCLPCTTCGGGNQVEKTPcTATDNRCCT-CKPG-FYCD 75
                          90
                  ....*....|..
gi 514698100 5648 QSGQSTRCISVT 5659
Cdd:cd00185    76 EGTNVEECKPCT 87
PksD COG3321
Acyl transferase domain in polyketide synthase (PKS) enzymes [Secondary metabolites ...
4195-4727 1.78e-05

Acyl transferase domain in polyketide synthase (PKS) enzymes [Secondary metabolites biosynthesis, transport and catabolism];


Pssm-ID: 442550 [Multi-domain]  Cd Length: 1386  Bit Score: 52.18  E-value: 1.78e-05
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4195 RAGLPVDPFVMQTGRVVVMGSSGATITALDAFTynvagditdvsPSFGRVGTRVRLLGSNLLGGGTSAEVRFGGVTGAVT 4274
Cdd:COG3321   860 RVPLPTYPFQREDAAAALLAAALAAALAAAAAL-----------GALLLAALAAALAAALLALAAAAAAALALAAAALAA 928
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4275 AVSETAIDVTVPAASGPSGLVNVSIVSDSGSHVLEVAGFRYTAPGSVAAVAPSSGHEGTVVTISGASLLAEEADAARVTL 4354
Cdd:COG3321   929 LLALVALAAAAAALLALAAAAAAAAAALAAAEAGALLLLAAAAAAAAAAAAAAAAAAAAAAAAAAAALAAAAALALLAAA 1008
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4355 GGVNATVVFANDTRLVVVAGASSTAGLGDVFIETVGGARLLAANAWMYVAQATITDVQPGSGQVGTRVTIRGTGLRCGGA 4434
Cdd:COG3321  1009 ALLLAAAAAAAALLALAALLAAAAAALAAAAAAAAAAAALAALAAAAAAAAALALALAALLLLAALAELALAAAALALAA 1088
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4435 AVTSVLLGSAVAPVVTEDDTTVIAEAPARAVGASPVDVTVVADTGAYVTADDAWTFVTAGAVSSVVPSSGQEGTRVTLSG 4514
Cdd:COG3321  1089 ALAAAALALALAALAAALLLLALLAALALAAAAAALLALAALLAAAAAAAALAAAAAAAAALALAAAAAALAAALAAALL 1168
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4515 TNLLGSGSGVDQVLLAGVSATVVSAASSEVVVITSALPGGVVGPVTGNVTVVSTSGALVHADTDSFTYVRAGAVTGVSPL 4594
Cdd:COG3321  1169 AAAALLLALALALAAALAAALAGLAALLLAALLAALLAALLALALAALAAAAAALLAAAAAAAALALLALAAAAAAVAAL 1248
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4595 AGVQGTRVTVTGERLLGGGSSIAAVQVAGVETRVIESSNNTHVVLRASNGTGSGDIELIADTGAKTVANVTFSYLELGVI 4674
Cdd:COG3321  1249 AAAAAALLAALAALALLAAAAGLAALAAAAAAAAAALALAAAAAAAAAALAALLAAAAAAAAAAAAAAAAAALAAALLAA 1328
                         490       500       510       520       530
                  ....*....|....*....|....*....|....*....|....*....|...
gi 514698100 4675 TAVRPAIGRVGTLVTIEGERLQSGGSAVARVDLGPAAPVVLQAFLDREQLHAE 4727
Cdd:COG3321  1329 ALAALAAAVAAALALAAAAAAAAAAAAAAAAAAALAAAAGAAAAAAALALAAL 1381
TNFRSF1A_teleost cd15834
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) in teleosts; also known as ...
5720-5839 1.88e-05

Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) in teleosts; also known as TNFR1; This subfamily of TNFRSF1 ((also known as type I TNFR, TNFR1, DR1, TNFRSF1A, CD120a, p55) is found in teleosts. It binds TNF-alpha, through the death domain (DD), and activates NF-kappaB, mediates apoptosis and activates signaling pathways controlling inflammatory, immune, and stress responses. It mediates signal transduction by interacting with antiapoptotic protein BCL2-associated athanogene 4 (BAG4/SODD) and adaptor proteins TRAF2 and TRADD that play regulatory roles. The human genetic disorder called tumor necrosis factor associated periodic syndrome (TRAPS), or periodic fever syndrome, is associated with germline mutations of the extracellular domains of this receptor, possibly due to impaired receptor clearance. Serum levels of TNFRSF1A are elevated in schizophrenia and bipolar disorder, and high levels are also associated with cognitive impairment and dementia. Knockout studies in zebrafish embryos have shown that a signaling balance between TNFRSF1A and TNFRSF1B is required for endothelial cell integrity. TNFRSF1A signals apoptosis through caspase-8, whereas TNFRSF1B signals survival via NF-kappaB in endothelial cells. Thus, this apoptotic pathway seems to be evolutionarily conserved, as TNFalpha promotes apoptosis of human endothelial cells and triggers caspase-2 and P53 activation in these cells via TNFRSF1A.


Pssm-ID: 276930 [Multi-domain]  Cd Length: 150  Bit Score: 48.64  E-value: 1.88e-05
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5720 VCVECAPGTFKATAG-DGTCRAHRTCE-DTEYETVAPTSSSDRKCkaltVCQDDEWESKAPTITtdRECSPCGRCTDGLT 5797
Cdd:cd15834    35 QCTPCPEGTYLEQINySPNCRRCTLCKvKNEEEVSPCKKSSNTVC----RCKKGYYKSRIDSET--RECLKCKTCGPGEI 108
                          90       100       110       120
                  ....*....|....*....|....*....|....*....|....*.
gi 514698100 5798 LDKACTDTSPTKCvgcdECASDEYTLS-SCTLSS--QTQCRQ-CTT 5839
Cdd:cd15834   109 EIQPCTPESNTVC----ECKDNYYRNNnKCKPCQkcSLDCQHlCTT 150
TNFRSF6 cd10579
Tumor necrosis factor receptor superfamily member 6 (TNFRSF6), also known as fas cell surface ...
5721-5858 1.94e-05

Tumor necrosis factor receptor superfamily member 6 (TNFRSF6), also known as fas cell surface death receptor (Fas); TNFRSF6 (also known as fas cell surface death receptor (FasR) or Fas, APT1, CD95, FAS1, APO-1, FASTM, ALPS1A) contains a death domain and plays a central role in the physiological regulation of programmed cell death. It has been implicated in the pathogenesis of various malignancies and diseases of the immune system. The receptor interactions with the Fas ligand (FasL), allowing the formation of a death-inducing signaling complex that includes Fas-associated death domain protein (FADD), caspase 8, and caspase 10; autoproteolytic processing of the caspases in the complex triggers a downstream caspase cascade, leading to apoptosis. This receptor has also been shown to activate NF-kappaB, MAPK3/ERK1, and MAPK8/JNK, and is involved in transducing the proliferating signals in normal diploid fibroblast and T cells. Of the several alternatively spliced transcript variants, some are candidates for nonsense-mediated mRNA decay (NMD). Isoforms lacking the transmembrane domain may negatively regulate the apoptosis mediated by the full length isoform.


Pssm-ID: 276905 [Multi-domain]  Cd Length: 129  Bit Score: 47.76  E-value: 1.94e-05
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5721 CVECAPGTFKATagdgTCrahrtCEDTEYETVAPtsssdrkckaltvCQD-DEWESKAPTITtdrECSPCGRCTD--GLT 5797
Cdd:cd10579    22 CQPCPPGTRKAI----DC-----TTNGGKPDCVP-------------CTEgKEYTDKKHYSD---KCRRCKICDEehGLE 76
                          90       100       110       120       130       140
                  ....*....|....*....|....*....|....*....|....*....|....*....|.
gi 514698100 5798 LDKACTDTSPTKCvgcdECASDEYtlssCTLSSQTQCRQCTTCGNDeyQTKACSVSQDTEC 5858
Cdd:cd10579    77 VEKNCTRTQNTKC----RCKSNFF----CNSSPCEHCDPCTTCEHG--IIEECTPTSNTKC 127
RoxA COG2850
Ribosomal protein L16 Arg81 hydroxylase, contains JmjC domain [Translation, ribosomal ...
4920-5090 2.01e-05

Ribosomal protein L16 Arg81 hydroxylase, contains JmjC domain [Translation, ribosomal structure and biogenesis];


Pssm-ID: 442098  Cd Length: 274  Bit Score: 50.58  E-value: 2.01e-05
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4920 PHTDPYDVLVIQLQGSKRW---TTCVPDAYVsdsndddddsanersnanstaadRPPSEAEVLAGFNAAQlgqlqeirsq 4996
Cdd:COG2850   121 PHFDSYDVFLLQGEGRRRWrigDQPDDDPEL-----------------------VPDLPLRILADFEPEI---------- 167
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4997 rqqgctgyqdsmlrgmrctNFTLREGDTMYMPKGIIHFALTEEqGSSHITI-----------------SLERKGLA--WA 5057
Cdd:COG2850   168 -------------------DWVLEPGDMLYLPPGFAHDGVALE-ECMTYSIgfrapswaellseladyLADDLLGDqrYR 227
                         170       180       190
                  ....*....|....*....|....*....|...
gi 514698100 5058 DALMYGATAAGSVLHNRLfqTRFKQAMLKLLSD 5090
Cdd:COG2850   228 DPDLQARADPGEIPAAAL--DRLRAMLLDLLDD 258
TNFRSF10 cd10580
Tumor necrosis factor receptor superfamily member 10 (TNFRSF10), includes TNFRSF10A (DR4), ...
6140-6237 2.39e-05

Tumor necrosis factor receptor superfamily member 10 (TNFRSF10), includes TNFRSF10A (DR4), TNFRSF10B (DR5), TNFRSF10C (DcR1) and TNFRSF10D (DcR2); TNFRSF10 family contains TNFRSF10A (also known as DR4, Apo2, TRAIL-R1, CD261), TNFRSF10B (also known as DR5, KILLER, TRICK2A, TRAIL-R2, TRICKB, CD262), TNFRSF10C (also known as DcR1, TRAIL-R3, LIT, TRID, CD263), and TNFRSF10D (also known as DcR2, TRUNDD, TRAIL-R4, CD264). Tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL) binds to all 4 receptors. DR4 (TRAIL-R1) and DR5 (TRAIL-R2) are membrane-bound and contain a death domain in their intracellular portion, which is able to transmit an apoptotic signal, thus often called death receptors. In contrast, DcR1 (TRAIL-R3), which lacks the complete intracellular portion and DcR2 (TRAIL-R4), which has a truncated cytoplasmic death domain, do not transmit an apoptotic signal, thus known as decoy receptors. Apoptosis mediated by DR4 and DR5 requires Fas (TNFRSF6)-associated via death domain (FADD), a death domain containing adaptor protein. Two transcript variants encoding different isoforms and one non-coding transcript have been found for TNFRSF10B/DR5. DcR1 appears to function as an antagonistic receptor that protects cells from TRAIL-induced apoptosis; it has been found to be a p53-regulated DNA damage-inducible gene. The expression of this gene is detected in many normal tissues but not in most cancer cell lines, which may explain the specific sensitivity of cancer cells to the apoptosis-inducing activity of TRAIL. DcR2 has been shown to play an inhibitory role in TRAIL-induced cell apoptosis. The membrane expression of all of these receptors (DR4, DR5, DcR1, and DcR2) is greater in normal endometrium (NE) than in endometrioid adenocarcinoma (EAC). In EAC patients, membrane expression of these receptors are not independent predictors of survival. DcR1 and DcR2 expression is critical in cell growth and apoptosis in cutaneous or uveal melanoma; DcR1 and DcR2 are frequently methylated in both, leading to loss of gene expression and melanomagenesis. On the other hand, DR4 and DR5 methylation is rare in cutaneous melanoma and frequent in uveal melanoma; their expression is wholly independent of the promoter methylation status. DcR1 and DcR2 genes are also reported to be hyper-methylated in prostate cancer. The TRAIL ligand, a potent and specific inducer of apoptosis in cancer cells, has been explored as a therapeutic drug; experimental data has shown that DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.


Pssm-ID: 276906 [Multi-domain]  Cd Length: 103  Bit Score: 46.87  E-value: 2.39e-05
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6140 CAECDRCDSGtQYETATCTATTNRVCAdltvcadteyesvaatdtsdrkcssCRECTSseylvsgCSESANAVCKAC-TE 6218
Cdd:cd10580    37 CLPCTVCKSD-EEELSPCTTTRNTECQ-------------------------CKPGTF-------CDPDSPEVCQKCsTR 83
                          90
                  ....*....|....*....
gi 514698100 6219 CPSGTFVSTACTPLADAEC 6237
Cdd:cd10580    84 CPEGMVEVSPCTPWSDLKC 102
TNFR_c6 pfam00020
TNFR/NGFR cysteine-rich region;
6219-6261 2.54e-05

TNFR/NGFR cysteine-rich region;


Pssm-ID: 459633 [Multi-domain]  Cd Length: 39  Bit Score: 44.61  E-value: 2.54e-05
                           10        20        30        40
                   ....*....|....*....|....*....|....*....|...
gi 514698100  6219 CPSGTFVSTACTPladaECTECTRCGSGYFVQSPCTSEADTTC 6261
Cdd:pfam00020    1 CPPGTYTDNWNGL----KCLPCTVCPPGQVVVRPCTPTSDTVC 39
TNFRSF5 cd13407
Tumor necrosis factor receptor superfamily member 5 (TNFRSF5), also known as CD40; TNFRSF5 ...
6074-6261 2.92e-05

Tumor necrosis factor receptor superfamily member 5 (TNFRSF5), also known as CD40; TNFRSF5 (commonly known as CD40 and also as CDW40, p50, Bp50) is widely expressed in diverse cell types including B lymphocytes, dendritic cells, platelets, monocytes, endothelial cells, and fibroblasts. It is essential in mediating a wide variety of immune and inflammatory responses, including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation. Its natural immunomodulating ligand is CD40L, and a primary defect in the CD40/CD40L system is associated with X-linked hyper-IgM (XHIM) syndrome. It is also involved in tumorigenesis; CD40 expression is significantly higher in gastric carcinomas and it is associated with the lymphatic metastasis of cancer cells and their tumor node metastasis (TNM) classification. Upregulated levels of CD40/CD40L on B cells and T cells may play an important role in the immune pathogenesis of breast cancer. Consequently, the CD40/CD40L system serves as a link between tumorigenesis, atherosclerosis, and the immune system, and offers a potential target for drug therapy for related diseases, such as cancer, atherosclerosis, diabetes mellitus, and immunological rejection.


Pssm-ID: 276912 [Multi-domain]  Cd Length: 161  Bit Score: 48.17  E-value: 2.92e-05
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6074 CSDEQYEtraptvnSDRECTGLttCGSGEYETRAPTATTDRKCASvtqCDSTQFvvsKPTATTDRDCAECDRCDSGTQYE 6153
Cdd:cd13407     1 CREKQYL-------HNGRCCSL--CPPGQKLVSDCTEATDTECLP---CEEGEF---QDTWNRERHCHQHRYCDPNLGLR 65
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6154 TAT-CTATTNRVCadltVCADTEYesvaatdTSDRKCSSCRECTSseylvsgCSESANAVCKA-------CTECPSGTF- 6224
Cdd:cd13407    66 VQTeGTAETDTTC----TCQEGQH-------CTSEACETCALHTS-------CKPGFGVKQIAtgvsdtiCEPCPVGFFs 127
                         170       180       190
                  ....*....|....*....|....*....|....*....
gi 514698100 6225 -VSTACTPladaeCTECTRCGS-GYFVQSPCTSEADTTC 6261
Cdd:cd13407   128 nVSSAFEK-----CHPWTSCETkGLVELQAGTNKTDVVC 161
TNFRSF10 cd10580
Tumor necrosis factor receptor superfamily member 10 (TNFRSF10), includes TNFRSF10A (DR4), ...
6216-6287 3.07e-05

Tumor necrosis factor receptor superfamily member 10 (TNFRSF10), includes TNFRSF10A (DR4), TNFRSF10B (DR5), TNFRSF10C (DcR1) and TNFRSF10D (DcR2); TNFRSF10 family contains TNFRSF10A (also known as DR4, Apo2, TRAIL-R1, CD261), TNFRSF10B (also known as DR5, KILLER, TRICK2A, TRAIL-R2, TRICKB, CD262), TNFRSF10C (also known as DcR1, TRAIL-R3, LIT, TRID, CD263), and TNFRSF10D (also known as DcR2, TRUNDD, TRAIL-R4, CD264). Tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL) binds to all 4 receptors. DR4 (TRAIL-R1) and DR5 (TRAIL-R2) are membrane-bound and contain a death domain in their intracellular portion, which is able to transmit an apoptotic signal, thus often called death receptors. In contrast, DcR1 (TRAIL-R3), which lacks the complete intracellular portion and DcR2 (TRAIL-R4), which has a truncated cytoplasmic death domain, do not transmit an apoptotic signal, thus known as decoy receptors. Apoptosis mediated by DR4 and DR5 requires Fas (TNFRSF6)-associated via death domain (FADD), a death domain containing adaptor protein. Two transcript variants encoding different isoforms and one non-coding transcript have been found for TNFRSF10B/DR5. DcR1 appears to function as an antagonistic receptor that protects cells from TRAIL-induced apoptosis; it has been found to be a p53-regulated DNA damage-inducible gene. The expression of this gene is detected in many normal tissues but not in most cancer cell lines, which may explain the specific sensitivity of cancer cells to the apoptosis-inducing activity of TRAIL. DcR2 has been shown to play an inhibitory role in TRAIL-induced cell apoptosis. The membrane expression of all of these receptors (DR4, DR5, DcR1, and DcR2) is greater in normal endometrium (NE) than in endometrioid adenocarcinoma (EAC). In EAC patients, membrane expression of these receptors are not independent predictors of survival. DcR1 and DcR2 expression is critical in cell growth and apoptosis in cutaneous or uveal melanoma; DcR1 and DcR2 are frequently methylated in both, leading to loss of gene expression and melanomagenesis. On the other hand, DR4 and DR5 methylation is rare in cutaneous melanoma and frequent in uveal melanoma; their expression is wholly independent of the promoter methylation status. DcR1 and DcR2 genes are also reported to be hyper-methylated in prostate cancer. The TRAIL ligand, a potent and specific inducer of apoptosis in cancer cells, has been explored as a therapeutic drug; experimental data has shown that DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.


Pssm-ID: 276906 [Multi-domain]  Cd Length: 103  Bit Score: 46.49  E-value: 3.07e-05
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6216 CTECPSGTFVSTA---CTPLADA-----------ECTECTRCGSGYFVQSPCTSEADTT----------------CKRCR 6265
Cdd:cd10580     2 CGLCPAGTYVSEDsgdCIPCKEGvdytehpnglpSCLPCTVCKSDEEELSPCTTTRNTEcqckpgtfcdpdspevCQKCS 81
                          90       100
                  ....*....|....*....|...
gi 514698100 6266 -SCASGEYLHTACTtplPIANVQ 6287
Cdd:cd10580    82 tRCPEGMVEVSPCT---PWSDLK 101
IPT_PCSR cd00603
IPT domain of Plexins and Cell Surface Receptors (PCSR) and related proteins . This subgroup ...
1504-1590 3.18e-05

IPT domain of Plexins and Cell Surface Receptors (PCSR) and related proteins . This subgroup contains IPT domains of plexins, receptors, like the plasminogen-related growth factor receptors, the hepatocyte growth factor-scatter factors, and the macrophage-stimulating receptors and of fibrocystin. Plexins are involved in the regulation of cell proliferation and of cellular adhesion and repulsion receptors. In general, there are three copies of the IPT_PCSR domain present preceeded by SEMA (semaphorin) and PSI (plexin, semaphorin, integrin) domains.


Pssm-ID: 238337 [Multi-domain]  Cd Length: 90  Bit Score: 46.29  E-value: 3.18e-05
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1504 VTDVSPPSG--QAGTLVTITGTGFPcTGSSVSTVSLGGVGASIRTQSATQIVVEAPSGSGQGDVVVtaddgSFAVSRGGW 1581
Cdd:cd00603     3 ITSISPSSGplSGGTRLTITGSNLG-SGSPRVRVTVGGVPCKVLNVSSTEIVCRTPAAATPGEGPV-----EVTVDGANV 76

                  ....*....
gi 514698100 1582 EFSRISSVT 1590
Cdd:cd00603    77 SARVLSNTT 85
IPT_plexin_repeat2 cd01179
Second repeat of the IPT domain of Plexins and Cell Surface Receptors (PCSR) . Plexins are ...
275-341 3.44e-05

Second repeat of the IPT domain of Plexins and Cell Surface Receptors (PCSR) . Plexins are involved in the regulation of cell proliferation and of cellular adhesion and repulsion receptors. In general, there are three copies of the IPT domain present preceeded by SEMA (semaphorin) and PSI (plexin, semaphorin, integrin) domains.


Pssm-ID: 238584  Cd Length: 85  Bit Score: 45.68  E-value: 3.44e-05
                          10        20        30        40        50        60        70
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|.
gi 514698100  275 TIAAVSPS----SGqvGTRVTITGTNLLGGGAAveRVTLAGVEASLVAQSATQIVVVASPSRERAAGPVVV 341
Cdd:cd01179     2 SITSLSPSygpqSG--GTRLTITGKHLNAGSSV--RVTVGGQPCKILSVSSSQIVCLTPPSASPGEAPVKV 68
TNFRSF10 cd10580
Tumor necrosis factor receptor superfamily member 10 (TNFRSF10), includes TNFRSF10A (DR4), ...
6188-6261 3.49e-05

Tumor necrosis factor receptor superfamily member 10 (TNFRSF10), includes TNFRSF10A (DR4), TNFRSF10B (DR5), TNFRSF10C (DcR1) and TNFRSF10D (DcR2); TNFRSF10 family contains TNFRSF10A (also known as DR4, Apo2, TRAIL-R1, CD261), TNFRSF10B (also known as DR5, KILLER, TRICK2A, TRAIL-R2, TRICKB, CD262), TNFRSF10C (also known as DcR1, TRAIL-R3, LIT, TRID, CD263), and TNFRSF10D (also known as DcR2, TRUNDD, TRAIL-R4, CD264). Tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL) binds to all 4 receptors. DR4 (TRAIL-R1) and DR5 (TRAIL-R2) are membrane-bound and contain a death domain in their intracellular portion, which is able to transmit an apoptotic signal, thus often called death receptors. In contrast, DcR1 (TRAIL-R3), which lacks the complete intracellular portion and DcR2 (TRAIL-R4), which has a truncated cytoplasmic death domain, do not transmit an apoptotic signal, thus known as decoy receptors. Apoptosis mediated by DR4 and DR5 requires Fas (TNFRSF6)-associated via death domain (FADD), a death domain containing adaptor protein. Two transcript variants encoding different isoforms and one non-coding transcript have been found for TNFRSF10B/DR5. DcR1 appears to function as an antagonistic receptor that protects cells from TRAIL-induced apoptosis; it has been found to be a p53-regulated DNA damage-inducible gene. The expression of this gene is detected in many normal tissues but not in most cancer cell lines, which may explain the specific sensitivity of cancer cells to the apoptosis-inducing activity of TRAIL. DcR2 has been shown to play an inhibitory role in TRAIL-induced cell apoptosis. The membrane expression of all of these receptors (DR4, DR5, DcR1, and DcR2) is greater in normal endometrium (NE) than in endometrioid adenocarcinoma (EAC). In EAC patients, membrane expression of these receptors are not independent predictors of survival. DcR1 and DcR2 expression is critical in cell growth and apoptosis in cutaneous or uveal melanoma; DcR1 and DcR2 are frequently methylated in both, leading to loss of gene expression and melanomagenesis. On the other hand, DR4 and DR5 methylation is rare in cutaneous melanoma and frequent in uveal melanoma; their expression is wholly independent of the promoter methylation status. DcR1 and DcR2 genes are also reported to be hyper-methylated in prostate cancer. The TRAIL ligand, a potent and specific inducer of apoptosis in cancer cells, has been explored as a therapeutic drug; experimental data has shown that DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.


Pssm-ID: 276906 [Multi-domain]  Cd Length: 103  Bit Score: 46.49  E-value: 3.49e-05
                          10        20        30        40        50        60        70
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*
gi 514698100 6188 KCSSCRECTSSEYLVSGCSESANAVCKacteCPSGTFvstaCTPLADAECTEC-TRCGSGYFVQSPCTSEADTTC 6261
Cdd:cd10580    36 SCLPCTVCKSDEEELSPCTTTRNTECQ----CKPGTF----CDPDSPEVCQKCsTRCPEGMVEVSPCTPWSDLKC 102
AidA COG3468
Autotransporter adhesin AidA [Cell wall/membrane/envelope biogenesis, Intracellular ...
1467-1918 3.51e-05

Autotransporter adhesin AidA [Cell wall/membrane/envelope biogenesis, Intracellular trafficking, secretion, and vesicular transport];


Pssm-ID: 442691 [Multi-domain]  Cd Length: 846  Bit Score: 51.10  E-value: 3.51e-05
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1467 LAAGNGSEPSSGDIVLIADTGAVVSRSGMWTYTEPCGVTDVSPPSGQAGTLVTITGTGFPCTGSSVSTVSLGGVGASIRT 1546
Cdd:COG3468     1 TASGGGGGATGLGGGGTGGGGGLGGTGGGNAGLGIGNGGGGGAASGSGAGGVAGNGGGGGGGAGGGGGGAGSGGGLAGAG 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1547 QSATQIVVEAPSGSGQGDVVVTADDGSFAVSRGGWefSRISSVTPASGQFGTAVTVAGQGLRLGFSSVTQVRLGDVAATI 1626
Cdd:COG3468    81 SGGTGGNSTGGGGGNSGTGGTGGGGGGGGSGNGGG--GGGGGGGGGTGGGGGGGTGSAGGGGGGGGGGTGVGGTGAAAAG 158
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1627 LSENNTHVVVRAGTGSLVGVPVDVQVISSGATTVQQSVAWTYLRDGVVSSVVPVQGQRGTRVTVRGERLLGGGSRLERVL 1706
Cdd:COG3468   159 GGTGSGGGGSGGGGGAGGGGGGGAGGSGGAGSTGSGAGGGGGGSGGGGGAAGTGGGGGGGGGAGGATGGAGSGGNTGGGV 238
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1707 LGDIAVDRILSYNDTVVVVEAGLSNSSAVVDVTLVSDTLAGVTGENVFTYVEPMTLYGLTRATGQAGTETTLLGRSLLGG 1786
Cdd:COG3468   239 GGGGGSAGGTGGGGLTGGGAAGTGGGGGGTGTGSGGGGGGGANGGGSGGGGGASGTGGGGTASTGGGGGGGGGNGGGGGG 318
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1787 SLAVTEVLLAGTGAQVIGFNDTHVTVRALAGTPGQGNVVIRTSNGAYLVAINGWSFSTPGAIAAVEPVSGQAGTRVTIVG 1866
Cdd:COG3468   319 GSNAGGGSGGGGGGGGGGGGGGTTLNGAGSAGGGTGAALAGTGGSGSGGGGGGGSGGGGGAGGGGANTGSDGVGTGLTTG 398
                         410       420       430       440       450       460
                  ....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1867 SRLLGGGSRVASVALGSVVHTSSVI------SGNDTQVVLDA-LAGPPGLSD-VIITSDT 1918
Cdd:COG3468   399 GTGNNGGGGVGGGGGGGLTLTGGTLtvngnyTGNNGTLVLNTvLGDDNSPTDrLVVNGNT 458
TNFRSF1B cd10577
Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B), also known as TNFR2; TNFRSF1B ...
5983-6117 3.52e-05

Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B), also known as TNFR2; TNFRSF1B (also known as TNFR2, type 2 TNFR, TNFBR, TNFR80, TNF-R75, TNF-R-II, p75, CD120b) binds TNF-alpha, but lacks the death domain (DD) that is associated with the cytoplasmic domain of TNFRSF1A (TNFR1). It is inducible and expressed exclusively by oligodendrocytes, astrocytes, T cells, thymocytes, myocytes, endothelial cells, and in human mesenchymal stem cells. TNFRSF1B protects oligodendrocyte progenitor cells (OLGs) against oxidative stress, and induces the up-regulation of cell survival genes. While pro-inflammatory and pathogen-clearing activities of TNF are mediated mainly through activation of TNFRSF1A, a strong activator of NF-kappaB, TNFRSF1B is more responsible for suppression of inflammation. Although the affinities of both receptors for soluble TNF are similar, TNFRSF1B is sometimes more abundantly expressed and thought to associate with TNF, thereby increasing its concentration near TNFRSF1A receptors, and making TNF available to activate TNFRSF1A (a ligand-passing mechanism).


Pssm-ID: 276903 [Multi-domain]  Cd Length: 163  Bit Score: 47.85  E-value: 3.52e-05
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5983 TACKLCEAGVNYAGSAGLTRCTSV-SECGAGEEETSAPTASTDRVCsTCASGKFKATTGQTPCE---AVSTCEEDEYVYR 6058
Cdd:cd10577    35 TVCAPCEESTYTQLWNWVPECLSCsSPCSSDQVETQACTRQQNRIC-SCKPGWYCVLKLQEGCRqcrPLKKCGPGFGVAR 113
                          90       100       110       120       130       140
                  ....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6059 AATVSTDTQCRaltACSDeqyETRAPTVNSDRECTGLTTCGSgeyeTRAP-TATTDRKCA 6117
Cdd:cd10577   114 PGTASSDVECK---PCAP---GTFSDTTSSTDTCRPHRICSS----VAIPgNASMDAVCA 163
AidA COG3468
Autotransporter adhesin AidA [Cell wall/membrane/envelope biogenesis, Intracellular ...
2572-3028 3.63e-05

Autotransporter adhesin AidA [Cell wall/membrane/envelope biogenesis, Intracellular trafficking, secretion, and vesicular transport];


Pssm-ID: 442691 [Multi-domain]  Cd Length: 846  Bit Score: 51.10  E-value: 3.63e-05
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2572 GTLVTIQGTSLLGGGTTAVSVMLAGSSALVLSSNATDVVVTAGPGAQSSGDVVIVSETGATVARGAAWTYvepGFIQRAS 2651
Cdd:COG3468     2 ASGGGGGATGLGGGGTGGGGGLGGTGGGNAGLGIGNGGGGGAASGSGAGGVAGNGGGGGGGAGGGGGGAG---SGGGLAG 78
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2652 PASGTAGTRVTITGASLLGGASTLARVTLAGVPVDSIDHQSNEVVIVTAASGAQRMGAIVLTADTGAVVqrLNFWDYIAT 2731
Cdd:COG3468    79 AGSGGTGGNSTGGGGGNSGTGGTGGGGGGGGSGNGGGGGGGGGGGGTGGGGGGGTGSAGGGGGGGGGGT--GVGGTGAAA 156
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2732 PVVGEIEPSSGQLGTVVTIRGSNLLAGGEALQLVTLAGVPAEAILSSNNSVVTVSSAQGSGATGPAVLVAAETGGRAVGT 2811
Cdd:COG3468   157 AGGGTGSGGGGSGGGGGAGGGGGGGAGGSGGAGSTGSGAGGGGGGSGGGGGAAGTGGGGGGGGGAGGATGGAGSGGNTGG 236
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2812 PSVNYTYLAGSSIASVQPASGQGGTFVDIVGERLLSGGSAVAAVSLAGVAAeVISGNDTFVRARAGPSAVTLTGDVVVTA 2891
Cdd:COG3468   237 GVGGGGGSAGGTGGGGLTGGGAAGTGGGGGGTGTGSGGGGGGGANGGGSGG-GGGASGTGGGGTASTGGGGGGGGGNGGG 315
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2892 DTGGRAELVNAWAYNTAGVVDAVVPGSGQRGTRVTIQGTRLLGEGTRAVRVSLGDVRAHIVESTATAVVVVYPGRVTLGV 2971
Cdd:COG3468   316 GGGGSNAGGGSGGGGGGGGGGGGGGTTLNGAGSAGGGTGAALAGTGGSGSGGGGGGGSGGGGGAGGGGANTGSDGVGTGL 395
                         410       420       430       440       450
                  ....*....|....*....|....*....|....*....|....*....|....*...
gi 514698100 2972 HDVEVESDTGSVVSAPAAWTALDNGVVHSVNPD-VGHGGTVVtIRGVrlLGGGDSVAD 3028
Cdd:COG3468   396 TTGGTGNNGGGGVGGGGGGGLTLTGGTLTVNGNyTGNNGTLV-LNTV--LGDDNSPTD 450
TNFRSF11B cd10581
Tumor necrosis factor receptor superfamily member 11B (TNFRSF11B), also known as ...
5813-5938 5.05e-05

Tumor necrosis factor receptor superfamily member 11B (TNFRSF11B), also known as Osteoprotegerin (OPG); TNFRSF11B (also known as Osteoprotegerin, OPG, TR1, OCIF) is a secreted glycoprotein that regulates bone resorption. It binds to two ligands, RANKL (receptor activator of nuclear factor kappaB ligand, also known as osteoprotegerin ligand, OPGL, TRANCE, TNF-related activation induced cytokine), a critical cytokine for osteoclast differentiation, and TRAIL (TNF-related apoptosis-inducing ligand), involved in immune surveillance. Therefore, acting as a decoy receptor for RANKL and TRAIL, OPG inhibits the regulatory effects of nuclear factor-kappaB on inflammation, skeletal, and vascular systems, and prevents TRAIL-induced apoptosis. Studies in mice counterparts suggest that this protein and its ligand also play a role in lymph-node organogenesis and vascular calcification. Circulating OPG levels have emerged as independent biomarkers of cardiovascular disease (CVD) in patients with acute or chronic heart disease. OPG has also been implicated in various inflammations and linked to diabetes and poor glycemic control. Alternatively spliced transcript variants of this gene have been reported, although their full length nature has not been determined.


Pssm-ID: 276907 [Multi-domain]  Cd Length: 147  Bit Score: 47.08  E-value: 5.05e-05
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5813 CDECASDEYTLSSCTLSSQTQCRQCTtcgnDEYQTKacSVSQDTECATLTT-CSSTQFEVEAPTATRDRRCKdltaCQPG 5891
Cdd:cd10581    36 CDQCPPGTYVKQHCSASRKTVCAPCP----DHHYAD--DWNSNDECQYCNTvCKELQYVKQECNSTHNRVCE----CVEG 105
                          90       100       110       120
                  ....*....|....*....|....*....|....*....|....*...
gi 514698100 5892 EYectaatltTDRE-CCGVTQCVPGSEETSAPTATSDRECRQCVAGTT 5938
Cdd:cd10581   106 RY--------LELEfCLKHTECPPGFGVVQPGTPESDTVCERCPEGFF 145
TNFRSF3 cd10578
Tumor necrosis factor receptor superfamily member 3 (TNFRSF3), also known as lymphotoxin beta ...
6207-6282 5.17e-05

Tumor necrosis factor receptor superfamily member 3 (TNFRSF3), also known as lymphotoxin beta receptor (LTBR); TNFRSF3 (also known as lymphotoxin beta receptor, LTbetaR, CD18, TNFCR, TNFR3, D12S370, TNFR-RP, TNFR2-RP, LT-BETA-R, TNF-R-III) plays a role in signaling during development of lymphoid and other organs, lipid metabolism, immune response, and programmed cell death. Its ligands include lymphotoxin (LT) alpha/beta membrane form (heterotrimer) and tumor necrosis factor ligand superfamily member 14 (also known as LIGHT). TNFRSF3 agonism by these ligands initiates canonical, as well as non-canonical nuclear factor-kappaB (NF-kappaB) signaling, and preferentially results in the translocation of p52-RELB complexes into the nucleus. While these ligands are often expressed by T and B cells, TNFRSF3 is conspicuous absence on T and B lymphocytes and NK cells, suggesting that signaling may be unidirectional for TNFRSF3. Activity of this receptor has also been linked to carcinogenesis; it helps trigger apoptosis and can also lead to release of the interleukin 8 (IL8). Alternatively spliced transcript variants encoding multiple isoforms have been observed.


Pssm-ID: 276904 [Multi-domain]  Cd Length: 158  Bit Score: 47.46  E-value: 5.17e-05
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6207 ESANAVCkaCTECPSGTFVSTACTPLADAECTECTR------------------CGS--GYFVQSPCTSEADTTCkRCR- 6265
Cdd:cd10578    42 EPRHQVC--CSRCPPGTHVSAECSRSQDTVCATCPEnsynehwnhlsicqlcrpCDPvlGFEEVAPCTSDRKTQC-RCQp 118
                          90       100
                  ....*....|....*....|.
gi 514698100 6266 --SCAsgeYLHTACT--TPLP 6282
Cdd:cd10578   119 gmFCV---HWDNECEhcEPLS 136
TNFRSF6_teleost cd13423
Tumor necrosis factor receptor superfamily member 6 (TNFRSF6) in teleosts; also known as fas ...
5789-5897 5.41e-05

Tumor necrosis factor receptor superfamily member 6 (TNFRSF6) in teleosts; also known as fas cell surface death receptor (FasR); This subfamily of TNFRSF6 (also known as fas cell surface death receptor (FasR) or Fas; APT1; CD95; FAS1; APO-1; FASTM; ALPS1A) is found in teleosts. It contains a death domain and plays a central role in the physiological regulation of programmed cell death. In humans, it has been implicated in the pathogenesis of various malignancies and diseases of the immune system. The receptor interactions with the Fas ligand (FasL), allowing the formation of a death-inducing signaling complex that includes Fas-associated death domain protein (FADD), caspase 8, and caspase 10; autoproteolytic processing of the caspases in the complex triggers a downstream caspase cascade, leading to apoptosis. This receptor has also been shown to activate NF-kappaB, MAPK3/ERK1, and MAPK8/JNK, and is involved in transducing the proliferating signals in normal diploid fibroblast and T cells. In channel catfish and the Japanese rice fish, medaka, homologs of Fas receptor (FasR), as well as FADD and caspase 8, have been identified and characterized, and likely constitute the teleost equivalent of the death-inducing signaling complex (DISC). FasL/FasR are involved in the initiation of apoptosis and suggest that mechanisms of cell-mediated cytotoxicity in teleosts are similar to those used by mammals; presumably, the mechanism of apoptosis induction via death receptors was evolutionarily established during the appearance of vertebrates.


Pssm-ID: 276928 [Multi-domain]  Cd Length: 103  Bit Score: 45.88  E-value: 5.41e-05
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5789 CGRCTDGLTLDKACTDT-SPTKCVGCDecasDEYTLSSCTlsSQTQCRQCTTCG-NDEYQT-KACSVSQDTECatlttcs 5865
Cdd:cd13423    14 CCLCPAGQHVEKHCTNNgTDGECEACE----DGTYNSHPN--SLDSCEPCTSCDpNANLEVeERCTPSSDTVC------- 80
                          90       100       110
                  ....*....|....*....|....*....|..
gi 514698100 5866 stqfeveaptatrdrRCKDLTACQPGEyECTA 5897
Cdd:cd13423    81 ---------------RCKEGHYCDKGE-ECKV 96
TNFRSF1A_teleost cd15834
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) in teleosts; also known as ...
7951-8021 5.92e-05

Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) in teleosts; also known as TNFR1; This subfamily of TNFRSF1 ((also known as type I TNFR, TNFR1, DR1, TNFRSF1A, CD120a, p55) is found in teleosts. It binds TNF-alpha, through the death domain (DD), and activates NF-kappaB, mediates apoptosis and activates signaling pathways controlling inflammatory, immune, and stress responses. It mediates signal transduction by interacting with antiapoptotic protein BCL2-associated athanogene 4 (BAG4/SODD) and adaptor proteins TRAF2 and TRADD that play regulatory roles. The human genetic disorder called tumor necrosis factor associated periodic syndrome (TRAPS), or periodic fever syndrome, is associated with germline mutations of the extracellular domains of this receptor, possibly due to impaired receptor clearance. Serum levels of TNFRSF1A are elevated in schizophrenia and bipolar disorder, and high levels are also associated with cognitive impairment and dementia. Knockout studies in zebrafish embryos have shown that a signaling balance between TNFRSF1A and TNFRSF1B is required for endothelial cell integrity. TNFRSF1A signals apoptosis through caspase-8, whereas TNFRSF1B signals survival via NF-kappaB in endothelial cells. Thus, this apoptotic pathway seems to be evolutionarily conserved, as TNFalpha promotes apoptosis of human endothelial cells and triggers caspase-2 and P53 activation in these cells via TNFRSF1A.


Pssm-ID: 276930 [Multi-domain]  Cd Length: 150  Bit Score: 47.10  E-value: 5.92e-05
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 7951 RNACTlSCGEGEYGDIDAWV--CRAVRPCDLSSEYMVAPETPTSNRVCETLT------------------VCRPSSKyET 8010
Cdd:cd15834    33 RSQCT-PCPEGTYLEQINYSpnCRRCTLCKVKNEEEVSPCKKSSNTVCRCKKgyyksridsetreclkckTCGPGEI-EI 110
                          90
                  ....*....|.
gi 514698100 8011 TAATPTSDRVC 8021
Cdd:cd15834   111 QPCTPESNTVC 121
IPT_plexin_repeat2 cd01179
Second repeat of the IPT domain of Plexins and Cell Surface Receptors (PCSR) . Plexins are ...
1941-2007 5.94e-05

Second repeat of the IPT domain of Plexins and Cell Surface Receptors (PCSR) . Plexins are involved in the regulation of cell proliferation and of cellular adhesion and repulsion receptors. In general, there are three copies of the IPT domain present preceeded by SEMA (semaphorin) and PSI (plexin, semaphorin, integrin) domains.


Pssm-ID: 238584  Cd Length: 85  Bit Score: 45.29  E-value: 5.94e-05
                          10        20        30        40        50        60
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*...
gi 514698100 1941 PQSGqvGTRITIVGSGLLGGSAfaREVVMGNsVPCSVLRGNDSVVVCVLADAGSPAAA-VDVTVVGAR 2007
Cdd:cd01179    12 PQSG--GTRLTITGKHLNAGSS--VRVTVGG-QPCKILSVSSSQIVCLTPPSASPGEApVKVLIDGAR 74
IPT_PCSR cd00603
IPT domain of Plexins and Cell Surface Receptors (PCSR) and related proteins . This subgroup ...
4496-4584 6.68e-05

IPT domain of Plexins and Cell Surface Receptors (PCSR) and related proteins . This subgroup contains IPT domains of plexins, receptors, like the plasminogen-related growth factor receptors, the hepatocyte growth factor-scatter factors, and the macrophage-stimulating receptors and of fibrocystin. Plexins are involved in the regulation of cell proliferation and of cellular adhesion and repulsion receptors. In general, there are three copies of the IPT_PCSR domain present preceeded by SEMA (semaphorin) and PSI (plexin, semaphorin, integrin) domains.


Pssm-ID: 238337 [Multi-domain]  Cd Length: 90  Bit Score: 45.14  E-value: 6.68e-05
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4496 VSSVVPSSG--QEGTRVTLSGTNLlGSGSGVDQVLLAGVSATVVSAASSEVVVITSALPGGVVGPVtgNVTVVSTSGALV 4573
Cdd:cd00603     3 ITSISPSSGplSGGTRLTITGSNL-GSGSPRVRVTVGGVPCKVLNVSSTEIVCRTPAAATPGEGPV--EVTVDGANVSAR 79
                          90
                  ....*....|.
gi 514698100 4574 HADTDSFTYVR 4584
Cdd:cd00603    80 VLSNTTFTYVE 90
TNFRSF11A cd13411
Tumor necrosis factor receptor superfamily member 11A (TNFRSF11A), also known as receptor ...
6141-6264 7.56e-05

Tumor necrosis factor receptor superfamily member 11A (TNFRSF11A), also known as receptor activator of nuclear factor-kappaB (RANK); TNFRSF11A (also known as RANK, FEO, OFE, ODFR, OSTS, PDB2, CD26, OPTB7, TRANCER, LOH18CR1) induces the activation of NF-kappa B and MAPK8/JNK through interactions with various TRAF adaptor proteins. This receptor and its ligand are important regulators of the interaction between T cells and dendritic cells. The receptor is also an essential mediator for osteoclast and lymph node development. Mutations at this locus have been associated with familial expansile osteolysis, autosomal recessive osteopetrosis, and Juvenile Paget's disease (JPD) of bone. Alternatively spliced transcript variants have been described for this locus. Mutation analysis may improve diagnosis, prognostication, recurrence risk assessment, and perhaps treatment selection among the monogenic disorders of RANKL/OPG/RANK activation.


Pssm-ID: 276916 [Multi-domain]  Cd Length: 163  Bit Score: 47.09  E-value: 7.56e-05
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6141 AECDRCDSGTqYETATCTATTNRVCADltvCADTEYESvaaTDTSDRKCSSCRECTSSEYLVSGcsESANAVCKACTECP 6220
Cdd:cd13411    13 RCCSKCEPGK-YMSSKCTVTSDSVCLP---CGPDEYLD---TWNEEDKCLLHKVCDAGKALVAV--DPGNSTAPRRCACT 83
                          90       100       110       120
                  ....*....|....*....|....*....|....*....|....
gi 514698100 6221 SGTFVSTACTPladaeCTECTRCGSGYFVQSPCTSEADTTCKRC 6264
Cdd:cd13411    84 AGYHWSEDCDC-----CRRNTECAPGFGAQHPVQLNKDTVCEPC 122
TNFRSF cd00185
Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) ...
5906-5989 7.59e-05

Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) interactions with TNF superfamily (TNFSF) ligands (TNFL) control key cellular processes such as differentiation, proliferation, apoptosis, and cell growth. Dysregulation of these pathways has been shown to result in a wide range of pathological conditions, including autoimmune diseases, inflammation, cancer, and viral infection. There are 29 very diverse family members of TNFRSF reported in humans: 22 are type I transmembrane receptors (single pass with the N terminus on extracellular side of the cell membrane) and have a clear signal peptide; the remaining 7 members are either type III transmembrane receptors (single pass with the N terminus on extracellular side of the membrane but no signal sequence; TNFR13B, TNFR13C, TNFR17, and XEDAR), or attached to the membrane via a glycosylphosphatidylinositol (GPI) linker (TNFR10C), or secreted as soluble receptors (TNFR11B and TNFR6B). All TNFRs contain relatively short cysteine-rich domains (CRDs) in the ectodomain, and are involved in interaction with the TNF homology domain (THD) of their ligands. TNFRs often have multiple CRDs (between one and six), with the most frequent configurations of three or four copies; most CRDs possess three disulfide bridges, but could have between one and four. Localized or genome-wide duplication and evolution of the TNFRSF members appear to have paralleled the emergence of the adaptive immune system; teleosts (i.e. ray-finned, bony fish), which possess an immune system with B and T cells, possess primary and secondary lymphoid organs, and are capable of adaptive responses to pathogens also display several characteristics that are different from the mammalian immune system, making teleost TNFSF orthologs and paralogs of interest to better understand immune system evolution and the immunological pathways elicited to pathogens.


Pssm-ID: 276900 [Multi-domain]  Cd Length: 87  Bit Score: 44.89  E-value: 7.59e-05
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5906 CCgvTQCVPGSEETSAPTATSDRECRQCVAGT-TDADGSGTT--PCVACSAGHYVPRgrtGGCAAF-----ECAAGHVDQ 5977
Cdd:cd00185     1 CC--QRCPPGEYLSSDCTATTDTVCSPCPPGTySESWNSLSKclPCTTCGGGNQVEK---TPCTATdnrccTCKPGFYCD 75
                          90
                  ....*....|..
gi 514698100 5978 DEDAATACKLCE 5989
Cdd:cd00185    76 EGTNVEECKPCT 87
TNFRSF1A cd10576
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A), also known as TNFR1; TNFRSF1A ...
5768-5891 7.71e-05

Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A), also known as TNFR1; TNFRSF1A (also known as type I TNFR, TNFR1, DR1, TNFRSF1A, CD120a, p55) binds TNF-alpha, through the death domain (DD), and activates NF-kappaB, mediates apoptosis and activates signaling pathways controlling inflammatory, immune, and stress responses. It mediates signal transduction by interacting with antiapoptotic protein BCL2-associated athanogene 4 (BAG4/SODD) and adaptor proteins TRAF2 and TRADD that play regulatory roles. The human genetic disorder called tumor necrosis factor associated periodic syndrome (TRAPS), or periodic fever syndrome, is associated with germline mutations of the extracellular domains of this receptor, possibly due to impaired receptor clearance. TNFRSF1A polymorphisms rs1800693 and rs4149584 are associated with elevated risk of multiple sclerosis. Serum levels of TNFRSF1A are elevated in schizophrenia and bipolar disorder, and high levels are also associated with cognitive impairment and dementia. Patients with idiopathic recurrent acute pericarditis (IRAP), presumed to be an autoimmune process, have also been shown to carry rare mutations (R104Q and D12E) in the TNFRSF1A gene.


Pssm-ID: 276902 [Multi-domain]  Cd Length: 130  Bit Score: 46.19  E-value: 7.71e-05
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5768 CQDDEWESKAPTIttdreCspCGRCTDGLTLDKACTdtSPTKCVGCDECASDEYTLSSCTLSsqtQCRQCTTCGNDEYQT 5847
Cdd:cd10576     1 CPQGKYLHPNNNH-----C--CTKCHKGTYLYNDCP--GPGQDTVCRECENGTFTASENYLR---KCLSCSRCRKEMGQV 68
                          90       100       110       120
                  ....*....|....*....|....*....|....*....|....*.
gi 514698100 5848 --KACSVSQDTECAtlttCSSTQFEVeapTATRDRRCKDLTACQPG 5891
Cdd:cd10576    69 eiSPCTVDQDTVCG----CRKNQYQH---YWSSLFQCKNCSLCLNG 107
TNFRSF6 cd10579
Tumor necrosis factor receptor superfamily member 6 (TNFRSF6), also known as fas cell surface ...
6143-6262 8.58e-05

Tumor necrosis factor receptor superfamily member 6 (TNFRSF6), also known as fas cell surface death receptor (Fas); TNFRSF6 (also known as fas cell surface death receptor (FasR) or Fas, APT1, CD95, FAS1, APO-1, FASTM, ALPS1A) contains a death domain and plays a central role in the physiological regulation of programmed cell death. It has been implicated in the pathogenesis of various malignancies and diseases of the immune system. The receptor interactions with the Fas ligand (FasL), allowing the formation of a death-inducing signaling complex that includes Fas-associated death domain protein (FADD), caspase 8, and caspase 10; autoproteolytic processing of the caspases in the complex triggers a downstream caspase cascade, leading to apoptosis. This receptor has also been shown to activate NF-kappaB, MAPK3/ERK1, and MAPK8/JNK, and is involved in transducing the proliferating signals in normal diploid fibroblast and T cells. Of the several alternatively spliced transcript variants, some are candidates for nonsense-mediated mRNA decay (NMD). Isoforms lacking the transmembrane domain may negatively regulate the apoptosis mediated by the full length isoform.


Pssm-ID: 276905 [Multi-domain]  Cd Length: 129  Bit Score: 46.22  E-value: 8.58e-05
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6143 CDRCDSGTqYETATCTATTNRvcADLTVCAD-TEYesvaaTDTSDR--KCSSCRECTSSEYL--VSGCSESANAVCKact 6217
Cdd:cd10579    22 CQPCPPGT-RKAIDCTTNGGK--PDCVPCTEgKEY-----TDKKHYsdKCRRCKICDEEHGLevEKNCTRTQNTKCR--- 90
                          90       100       110       120
                  ....*....|....*....|....*....|....*....|....*
gi 514698100 6218 eCPSGTFVSTACTpladAECTECTRCGSGyfVQSPCTSEADTTCK 6262
Cdd:cd10579    91 -CKSNFFCNSSPC----EHCDPCTTCEHG--IIEECTPTSNTKCK 128
TNFRSF6B cd10575
Tumor necrosis factor receptor superfamily member 6B (TNFRSF6B), also known as decoy receptor ...
5494-5557 8.93e-05

Tumor necrosis factor receptor superfamily member 6B (TNFRSF6B), also known as decoy receptor 3 (DcR3); The subfamily TNFRSF6B is also known as decoy receptor 3 (DcR3), M68, or TR6. This protein is a soluble receptor without death domain and cytoplasmic domain, and secreted by cells. It acts as a decoy receptor that competes with death receptors for ligand binding. It is a pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases, and cancer. Over-expression of this gene has been noted in several cancers, including pancreatic carcinoma, and gastrointestinal tract tumors. It can neutralize the biological effects of three tumor necrosis factor superfamily (TNFSF) members: TNFSF6 (Fas ligand/FasL/CD95L) and TNFSF14 (LIGHT) which are both involved in apoptosis and inflammation, and TNFSF15 (TNF-like molecule 1A/TL1A), which is a T cell co-stimulator and involved in gut inflammation. DcR3 is a novel inflammatory marker; higher DcR3 levels strongly correlate with inflammation and independently predict cardiovascular and all-cause mortality in chronic kidney disease (CKD) patients on hemodialysis. Increased synovial inflammatory cells infiltration in rheumatoid arthritis and ankylosing spondylitis is also associated with the elevated DcR3 expression. In cartilaginous fish, mRNA expression of DcR3 in the thymus and leydig, which are the representative lymphoid tissues of elasmobranchs, suggests that DcR3 may act as a modulator in the immune system. Interestingly, in banded dogfish (Triakis scyllia), DcR3 mRNA is strongly expressed in the gill, compared with human expression in the normal lung; both are respiratory organs, suggesting potential relevance of DcR3 to respiratory function.


Pssm-ID: 276901 [Multi-domain]  Cd Length: 163  Bit Score: 47.02  E-value: 8.93e-05
                          10        20        30        40        50        60        70
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*...
gi 514698100 5494 CDGPC-DSQYEKTAATATSDRVCR---GL----------TTCGAGEQEKVAPTASSDRVCEACPAGTTDANSDGSDAC 5557
Cdd:cd10575    58 CNVFCtERQVEKRQCNATHNRVCEckpGYymehgfclrhSSCPPGEGVIKLGTPYSDTQCEPCPPGFFSASSSSTEPC 135
RhsA COG3209
Uncharacterized conserved protein RhaS, contains 28 RHS repeats [General function prediction ...
2816-3632 9.40e-05

Uncharacterized conserved protein RhaS, contains 28 RHS repeats [General function prediction only];


Pssm-ID: 442442 [Multi-domain]  Cd Length: 1103  Bit Score: 49.75  E-value: 9.40e-05
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2816 YTYLAGSSIASVQPASGQGGTFVDIVGERLLSGGSAVAAVSLAGVAAEVISGNDTFVRARAGPSAVTLTGDVVVTADTGG 2895
Cdd:COG3209     1 ETSLGLVGGTTGASSTLLAATNAGGGTAVTNAGSTVLLAKGGLSTAAAAGGAATLTARSASTTDVVGTLTGAGGTSAGGV 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2896 RAELVNAWAYNTAGVVDAVVPGSGQRGTRVTIQGTRLLGEGTRAVRVSLGDVRAHIVESTATAVVVVYPGRVTLGVHDVE 2975
Cdd:COG3209    81 TALGDASAAGGGYVGGAAAGGGATLTGLAAATASAGRLVSTGAGAGGTVTAATGGTLGATAGSATTGSTDGGRGGVAVTG 160
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2976 VESDTGSVVSAPAAWTALDNGVVHSVNPDVGHGGTVVTIRGVRLLGGGDSVADVALAGVVTANVVSANNSVVVVVAELQA 3055
Cdd:COG3209   161 LAGGGASAYGLTLGGAAAGPATGVGTGAVTLATGLAGSALLALGSGAILGGLAGAYSGSATTATGTALGTPASVAATVTG 240
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3056 QAVTLGDVVVRADTNATVVSSTGLFDYVAPGEIVSVSPSSGQLGTVVTIEGRSLRGGSSAVVDVVLGGVSALDVVSENDT 3135
Cdd:COG3209   241 SATGAAGAGAAVATAATTLGGTTGAGTGASGAGLDASTGTGGAGGSNAAATAGGLGGAGLGSGGAGGGGTAGGTTTAAGT 320
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3136 RVVAVAGPSSGATGTESVQVVGQQGSVVARPSVWSYVAPAEVLDVAPQQGRAGTRVTVRGQGLLQGGGRIAQATVAGVTT 3215
Cdd:COG3209   321 TGTAAVSGAADAGTTTTTGTGTGGTTTTVGGGGSLTLGGYGAAGGLTTSVGAGGGGSTSGSTTTVGGGGTATGSGGGSST 400
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3216 ARIVDSNDTTVVLEAEVAPAGVTPVGDVQLVSDTGARVNASVTWQYLAAAVIDSVQPTSGQEGVFVELRGQHLLGGGSAI 3295
Cdd:COG3209   401 TGVGAGTTTTSTTGGDGGPATAAGALTAGGTATGTGTGGGGTTAGTDATTTTGGAGASGTLTTTGGAATGATTGGGTEAG 480
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3296 VDASLAGVAVERVVQSNDTFVRVVAGAKNASVVGDVVARGDTGALLRVVNGWQYAVPSVINSVVPASGQeGTLVTVSGVR 3375
Cdd:COG3209   481 TGGGTLTSGSAGATTLGTDTTLDDTLGGTTTTTAGARGLVVTTGTTLTLGTTTTATLSATDATGTGDTT-TTGTVGTGTS 559
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3376 LLGSLPGRITFVEVCGTEAEVVSESDTLVVARLRSNGGASQLGDVVVRADNGARTRAVNGFTYLSTsmiaavtpaeGQYG 3455
Cdd:COG3209   560 TGTGGTGTVTTTGDGTGGASTTTGTTGGTATTTTVTTTTTTSTAGTTTTTTSGYTRAGLTLTLGTG----------TASG 629
                         650       660       670       680       690       700       710       720
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3456 TRVTITGQRLLGGGAAVQAVELAGVAATVVSGSDTEVVVAAGNGTAGDVGDVVITSDSGAVSVDALAWRYLDASHITSVT 3535
Cdd:COG3209   630 LERATASTGSTTGGTTGTGVTTTGTTTTRATGTTGTGTGVTAGLTTLATGGTTVGGGTGTTSTATTGATTGGTETGTTVT 709
                         730       740       750       760       770       780       790       800
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3536 PRHGQKGTVVTINGTLLRGHGSGVAVVLLAGEAANVLSESDTSVVVAASAFGGSKSG-PVTIIASNGATAVSTPTAFEYR 3614
Cdd:COG3209   710 TLAGGTTTRLGTTTTGGGGGTTTDGTGTGGTTGTLTTTSTTTTTTAGALTYTYDALGrLTSETTPGGVTQGTYTTRYTYD 789
                         810
                  ....*....|....*...
gi 514698100 3615 APGAVSAIVPNSGHRGTY 3632
Cdd:COG3209   790 ALGRLTSVTYPDGETVTY 807
IPT smart00429
ig-like, plexins, transcription factors;
3087-3172 9.53e-05

ig-like, plexins, transcription factors;


Pssm-ID: 214657 [Multi-domain]  Cd Length: 90  Bit Score: 44.72  E-value: 9.53e-05
                            10        20        30        40        50        60        70        80
                    ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100   3087 EIVSVSPSSGQL--GTVVTIEGRSLRGGSSAVVDVVLGGVSAlDVVSENDTRVVAVAGPSSGATGTESVQVVGQQGS-VV 3163
Cdd:smart00429    3 VITRISPTSGPVsgGTEITLCGKNLKSISVVFVEVGVGEAPC-TFSPSSSTAIVCKTPPYHNIPGSVPVRTVGLRNGgVP 81

                    ....*....
gi 514698100   3164 ARPSVWSYV 3172
Cdd:smart00429   82 SSPQPFTYV 90
TNFRSF21 cd10583
Tumor necrosis factor receptor superfamily member 21 (TNFRSF21), also known as death receptor ...
6143-6264 9.62e-05

Tumor necrosis factor receptor superfamily member 21 (TNFRSF21), also known as death receptor (DR6); TNFRSF21 (also known as death receptor 6 (DR6), CD358, BM-018) is highly expressed in differentiating neurons as well as in the adult brain, and is upregulated in injured neurons. DR6 negatively regulates neurondendrocyte, axondendrocyte, and oligodendrocyte survival, hinders axondendrocyte and oligodendrocyte regeneration and its inhibition has a neuro-protective effect in nerve injury. It activates nuclear factor kappa-B (NFkB) and mitogen-activated protein kinase 8 (MAPK8, also called c-Jun N-terminal kinase 1), and induces cell apoptosis by associating with TNFRSF1A-associated via death domain (TRADD), which is known to mediate signal transduction of tumor necrosis factor receptors. TNFRSF21 plays a role in T-helper cell activation, and may be involved in inflammation and immune regulation. Its possible ligand is alpha-amyloid precursor protein (APP), hence probably involved in the development of Alzheimer's disease; when released, APP binds in an autocrine/paracrine manner to activate a caspase-dependent self-destruction program that removes unnecessary or connectionless axons. Increasing beta-catenin levels in brain endothelium upregulates TNFRSF21 and TNFRSF19, indicating that these death receptors are downstream target genes of Wnt/beta-catenin signaling, which has been shown to be required for blood-brain barrier development. DR6 is up-regulated in numerous solid tumors as well as in tumor vascular cells, including ovarian cancer and may be a clinically useful diagnostic and predictive serum biomarker for some adult sarcoma subtypes.


Pssm-ID: 276909 [Multi-domain]  Cd Length: 159  Bit Score: 46.67  E-value: 9.62e-05
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6143 CDRCDSGTqYETATCTATTNRVCadlTVCAD---TEYESvaatdtSDRKCSSCRE-CTSSEYLVSGCSESANAVCKacte 6218
Cdd:cd10583    15 CDKCPAGT-YVSKHCTETSLREC---SPCPNgtfTRHEN------GIEQCHRCRKpCPAPMIEKTPCTALTDRECT---- 80
                          90       100       110       120
                  ....*....|....*....|....*....|....*....|....*.
gi 514698100 6219 CPSGTFvstactpLADAECTECTRCGSGYFVQSPCTSEADTTCKRC 6264
Cdd:cd10583    81 CPPGTF-------LSNDTCVPHSVCPVGWGVRKKGTETEDVRCKPC 119
TNFRSF1B_teleost cd15835
Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B) in teleost; also known as ...
6007-6116 9.92e-05

Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B) in teleost; also known as TNFR2; This subfamily of TNFRSF1B (also known as TNFR2, type 2 TNFR, TNFBR, TNFR80, TNF-R75, TNF-R-II, p75, CD120b) is found in teleosts. It binds TNF-alpha, but lacks the death domain (DD) that is associated with the cytoplasmic domain of TNFRSF1A (TNFR1). It is inducible and expressed exclusively by oligodendrocytes, astrocytes, T cells, thymocytes, myocytes, endothelial cells, and in human mesenchymal stem cells. TNFRSF1B protects oligodendrocyte progenitor cells (OLGs) against oxidative stress, and induces the up-regulation of cell survival genes. While pro-inflammatory and pathogen-clearing activities of TNF are mediated mainly through activation of TNFRSF1A, a strong activator of NF-kappaB, TNFRSF1B is more responsible for suppression of inflammation. Although the affinities of both receptors for soluble TNF are similar, TNFRSF1B is sometimes more abundantly expressed and thought to associate with TNF, thereby increasing its concentration near TNFRSF1A receptors, and making TNF available to activate TNFRSF1A (a ligand-passing mechanism). Knockout studies in zebrafish embryos have shown that a signaling balance between TNFRSF1A and TNFRSF1B is required for endothelial cell integrity. TNFRSF1A signals apoptosis through caspase-8, whereas TNFRSF1B signals survival via NF-kB in endothelial cells. In goldfish (Carassius aurutus L.), TNFRSF1B expression is substantially higher than that of TNFRSF1 in tissues and various immune cell types. Both receptors are most robustly expressed in monocytes; mRNA levels of TNFRSF1B are lowest in peripheral blood leukocytes.


Pssm-ID: 276931 [Multi-domain]  Cd Length: 130  Bit Score: 45.89  E-value: 9.92e-05
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6007 SECGAGEEETSAPTASTDRVCSTCASGKFKATTGQTP-CEAVSTCEED---EYVyRAATVSTDTQCraltACSDEQYETR 6082
Cdd:cd15835    22 SKCRPGTRLKTKCSETSDTVCEPCPSGQYSENWNYYPnCFSCPKCKERkglQYA-QNCSSTTNAVC----VCKPGMYCIM 96
                          90       100       110
                  ....*....|....*....|....*....|....
gi 514698100 6083 APTVNSDRECTGLTTCGSGEYETRAPTATTDRKC 6116
Cdd:cd15835    97 GFDHPSCSECKKYRTCKPGYGVSVPGTPTSDVKC 130
TNFRSF1A_teleost cd15834
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) in teleosts; also known as ...
6171-6278 1.00e-04

Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) in teleosts; also known as TNFR1; This subfamily of TNFRSF1 ((also known as type I TNFR, TNFR1, DR1, TNFRSF1A, CD120a, p55) is found in teleosts. It binds TNF-alpha, through the death domain (DD), and activates NF-kappaB, mediates apoptosis and activates signaling pathways controlling inflammatory, immune, and stress responses. It mediates signal transduction by interacting with antiapoptotic protein BCL2-associated athanogene 4 (BAG4/SODD) and adaptor proteins TRAF2 and TRADD that play regulatory roles. The human genetic disorder called tumor necrosis factor associated periodic syndrome (TRAPS), or periodic fever syndrome, is associated with germline mutations of the extracellular domains of this receptor, possibly due to impaired receptor clearance. Serum levels of TNFRSF1A are elevated in schizophrenia and bipolar disorder, and high levels are also associated with cognitive impairment and dementia. Knockout studies in zebrafish embryos have shown that a signaling balance between TNFRSF1A and TNFRSF1B is required for endothelial cell integrity. TNFRSF1A signals apoptosis through caspase-8, whereas TNFRSF1B signals survival via NF-kappaB in endothelial cells. Thus, this apoptotic pathway seems to be evolutionarily conserved, as TNFalpha promotes apoptosis of human endothelial cells and triggers caspase-2 and P53 activation in these cells via TNFRSF1A.


Pssm-ID: 276930 [Multi-domain]  Cd Length: 150  Bit Score: 46.33  E-value: 1.00e-04
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6171 CADTEYESVAATdtsdrkCssCRECTSSEYLVSGCSESANAvcKACTECPSGTFVSTACTPLadaECTECTRCGSGYFVQ 6250
Cdd:cd15834     1 CLDSEYLSENGI------C--CNKCHPGYKLKEECTAPGER--SQCTPCPEGTYLEQINYSP---NCRRCTLCKVKNEEE 67
                          90       100       110       120
                  ....*....|....*....|....*....|....*....|....*..
gi 514698100 6251 -SPCTSEADTTCK------------------RCRSCASGEYLHTACT 6278
Cdd:cd15834    68 vSPCKKSSNTVCRckkgyyksridsetreclKCKTCGPGEIEIQPCT 114
COG4625 COG4625
Uncharacterized conserved protein, contains a C-terminal beta-barrel porin domain [Function ...
566-1073 1.01e-04

Uncharacterized conserved protein, contains a C-terminal beta-barrel porin domain [Function unknown];


Pssm-ID: 443664 [Multi-domain]  Cd Length: 900  Bit Score: 49.78  E-value: 1.01e-04
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  566 TALEAVTLGGVQAAAILSFNRTHVVVTAGDGPASTGPVVLTASNGSRVTGGAVWTQLERGAIGSVQPSSGHGGTRVTITG 645
Cdd:COG4625     1 GGGGGGGGGGGGGGGGTGGGGAGGGGGAGGGAGGGGAGGGGGGGGGGGGAGGGGGGGGTGGGGGGGGGGGGGGAGGGGGG 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  646 qrLLGGGAALASVELGGVLATEIAWANDTVAVVSAGASGSALAGGNVTLVADTGAVTTGSGLWAYVAPAVISSVAPTSGQ 725
Cdd:COG4625    81 --GGGGGGGGGTGGVGGGGGGGGGGGGGGGGGGGGGGGGSAGGGGGGAGGAGGGGGGGAGGGGGGGGGGGAGGGGGGGAG 158
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  726 AGTVVTIRGNNLSMGGAVREVFLAGIPAVSVSLVNDSFVVAHASGALSGRSSPAVVRNNFGAFVSSSVNWTYVPAGAVDI 805
Cdd:COG4625   159 GAGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGNGGGGGGGGGGGGGGGGGGGGAGGGGGGGGGGGGGGGGGGGGGGGG 238
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  806 TRPARAQFGTRVTVTGSNLLQGGAIIASASMAGVPcTVLSSNDTTVVVSVAGNFAATVASPSMTLVSDSGAVITFTSSTT 885
Cdd:COG4625   239 GGGGGGGGGAGGGGGGGGGNGGGGGAGGGGGGGGG-GSGGGGGGGGGGGSGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG 317
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  886 AEPSGVVTAISPSSGQYGTFVTLSGTQLLAHASNLRTVSLAGTQVLSIESATESEVIVRAGLGVNGTAGSPRLRASSGGV 965
Cdd:COG4625   318 GGGGGGGGGGGGGGGGAGGGGGSGGAGAGGGGAGGGGAGGGGGGGTGGGGGGGGGGGGGSGGGGAGGGGGSGGGGGGGAG 397
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  966 VAAATGVNFTYVRQGRIDTVSPLFGQLGTLVTISGEHLLSGGSSASRVLLAGLPAAVVSSNSSVVVARAPLSNSTSIRTG 1045
Cdd:COG4625   398 GGGGGGGAGGTGGGGAGGGGGAAGGGGGGTGAGGGGGGGGTGAGGGGATGGGGGGGGGAGGSGGGAGAGGGSGSGAGTLT 477
                         490       500
                  ....*....|....*....|....*...
gi 514698100 1046 SVVVLANTGALSAESSTTFTFRPAGFIA 1073
Cdd:COG4625   478 LTGNNTYTGTTTVNGGGNYTQSAGSTLA 505
TNFRSF16 cd13416
Tumor necrosis factor receptor superfamily member 16 (TNFRSF16), also known as p75 ...
5521-5679 1.05e-04

Tumor necrosis factor receptor superfamily member 16 (TNFRSF16), also known as p75 neurotrophin receptor (p75NTR) or CD271; TNFRSF16 (also known as nerve growth factor receptor (NGFR) or p75 neurotrophin receptor (p75NTR or p75(NTR)), CD271, Gp80-LNGFR) is a common receptor for both neurotrophins and proneurotrophins, and plays a diverse role in many tissues, including the nervous system. It has been shown to be expressed in various types of stem cells and has been used to prospectively isolate stem cells with different degrees of potency. p75NTR owes its signaling to the recruitment of intracellular binding proteins, leading to the activation of different signaling pathways. It binds nerve growth factor (NGF) and the complex can initiate a signaling cascade which has been associated with both neuronal apoptosis and neuronal survival of discrete populations of neurons, depending on the presence or absence of intracellular signaling molecules downstream of p75NTR (e.g. NF-kB, JNK, or p75NTR intracellular death domain). p75NTR can also bind NGF in concert with the neurotrophic tyrosine kinase receptor type 1 (TrkA) protein where it is thought to modulate the formation of the high-affinity neurotrophin binding complex. On melanoma cell, p75NTR is an immunosuppressive factor, induced by interferon (IFN)-gamma, and mediates down-regulation of melanoma antigens. It can interact with the aggregated form of amyloid beta (Abeta) peptides, and plays an important role in etiopathogenesis of Alzheimer's disease by influencing protein tau hyper-phosphorylation. p75(NTR) is involved in the formation and progression of retina diseases; its expression is induced in retinal pigment epithelium (RPE) cells and its knockdown rescues RPE cell proliferation activity and inhibits RPE apoptosis induced by hypoxia. It can therefore be a potential therapeutic target for RPE hypoxia or oxidative stress diseases.


Pssm-ID: 276921 [Multi-domain]  Cd Length: 159  Bit Score: 46.53  E-value: 1.05e-04
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5521 CGAGEQeKVAPTASSDRVCEACPAGTTDANSDG-SDACVTCgggTYVPAGSTGTCSqyeCsagTADTDsnagTACEACDG 5599
Cdd:cd13416    18 CPPGEG-VARPCGDNQTVCEPCLDGVTFSDVVShTEPCQPC---TRCPGLMSMRAP---C---TATHD----TVCECAYG 83
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5600 tttYQPSKGQERCLSVKTCGAGEEETTSPSATRNRVCQPCQLGsTFKAQSGQSTRCISVTTCGAGEEEIASPTLSTDRQC 5679
Cdd:cd13416    84 ---YYLDEDSGTCEPCTVCPPGQGVVQSCGPNQDTVCEACPEG-TYSDEDSSTDPCLPCTVCEDGEVELRECTPVSDTVC 159
TNFRSF1B_teleost cd15835
Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B) in teleost; also known as ...
5511-5608 1.06e-04

Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B) in teleost; also known as TNFR2; This subfamily of TNFRSF1B (also known as TNFR2, type 2 TNFR, TNFBR, TNFR80, TNF-R75, TNF-R-II, p75, CD120b) is found in teleosts. It binds TNF-alpha, but lacks the death domain (DD) that is associated with the cytoplasmic domain of TNFRSF1A (TNFR1). It is inducible and expressed exclusively by oligodendrocytes, astrocytes, T cells, thymocytes, myocytes, endothelial cells, and in human mesenchymal stem cells. TNFRSF1B protects oligodendrocyte progenitor cells (OLGs) against oxidative stress, and induces the up-regulation of cell survival genes. While pro-inflammatory and pathogen-clearing activities of TNF are mediated mainly through activation of TNFRSF1A, a strong activator of NF-kappaB, TNFRSF1B is more responsible for suppression of inflammation. Although the affinities of both receptors for soluble TNF are similar, TNFRSF1B is sometimes more abundantly expressed and thought to associate with TNF, thereby increasing its concentration near TNFRSF1A receptors, and making TNF available to activate TNFRSF1A (a ligand-passing mechanism). Knockout studies in zebrafish embryos have shown that a signaling balance between TNFRSF1A and TNFRSF1B is required for endothelial cell integrity. TNFRSF1A signals apoptosis through caspase-8, whereas TNFRSF1B signals survival via NF-kB in endothelial cells. In goldfish (Carassius aurutus L.), TNFRSF1B expression is substantially higher than that of TNFRSF1 in tissues and various immune cell types. Both receptors are most robustly expressed in monocytes; mRNA levels of TNFRSF1B are lowest in peripheral blood leukocytes.


Pssm-ID: 276931 [Multi-domain]  Cd Length: 130  Bit Score: 45.89  E-value: 1.06e-04
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5511 SDRVCRGLTT-------------CGAGEQEKVAPTASSDRVCEACPAGTTDANSDGSDACVTC------GGGTYVPAGST 5571
Cdd:cd15835     1 SDGNCRNTTTeyyndgsnlccskCRPGTRLKTKCSETSDTVCEPCPSGQYSENWNYYPNCFSCpkckerKGLQYAQNCSS 80
                          90       100       110
                  ....*....|....*....|....*....|....*..
gi 514698100 5572 GTCSQYECSAGTADTDSNAGTACEACDGTTTYQPSKG 5608
Cdd:cd15835    81 TTNAVCVCKPGMYCIMGFDHPSCSECKKYRTCKPGYG 117
TNFR smart00208
Tumor necrosis factor receptor / nerve growth factor receptor repeats; Repeats in growth ...
6195-6237 1.15e-04

Tumor necrosis factor receptor / nerve growth factor receptor repeats; Repeats in growth factor receptors that are involved in growth factor binding. TNF/TNFR


Pssm-ID: 214558  Cd Length: 39  Bit Score: 42.84  E-value: 1.15e-04
                            10        20        30        40
                    ....*....|....*....|....*....|....*....|...
gi 514698100   6195 CTSSEYlvsgCSESANAVCKACTECPSGTFVSTACTPLADAEC 6237
Cdd:smart00208    1 CKEGTY----CSDGNHSSCLRCRRCPPGLVVKQPCTATSDTVC 39
IPT cd00102
Immunoglobulin-like fold, Plexins, Transcription factors (IPT). IPTs are also known as ...
275-357 1.19e-04

Immunoglobulin-like fold, Plexins, Transcription factors (IPT). IPTs are also known as Transcription factor ImmunoGlobin (TIG) domains. They are present in intracellular transcription factors, cell surface receptors (such as plexins and scatter factor receptors), as well as, cyclodextrin glycosyltransferase and similar enzymes. Although they are involved in DNA binding in transcription factors, their function in other proteins is unknown. In these transcription factors, IPTs form homo- or heterodimers with the exception of the nuclear factor of activated Tcells (NFAT) transcription factors which are mainly monomers.


Pssm-ID: 238050 [Multi-domain]  Cd Length: 89  Bit Score: 44.37  E-value: 1.19e-04
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  275 TIAAVSPSSGQV--GTRVTITGTNLlgGGAAVERVTL-AGVEASLVAQSATQIVVVASPSRERAAGPVVVYSDTGAFARL 351
Cdd:cd00102     2 VITSISPSSGPVsgGTEVTITGSNF--GSGSNLRVTFgGGVPCSVLSVSSTAIVCTTPPYANPGPGPVEVTVDRGNGGIT 79

                  ....*...
gi 514698100  352 ESA--FAY 357
Cdd:cd00102    80 SSPltFTY 87
TNFRSF1B_teleost cd15835
Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B) in teleost; also known as ...
6098-6237 1.20e-04

Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B) in teleost; also known as TNFR2; This subfamily of TNFRSF1B (also known as TNFR2, type 2 TNFR, TNFBR, TNFR80, TNF-R75, TNF-R-II, p75, CD120b) is found in teleosts. It binds TNF-alpha, but lacks the death domain (DD) that is associated with the cytoplasmic domain of TNFRSF1A (TNFR1). It is inducible and expressed exclusively by oligodendrocytes, astrocytes, T cells, thymocytes, myocytes, endothelial cells, and in human mesenchymal stem cells. TNFRSF1B protects oligodendrocyte progenitor cells (OLGs) against oxidative stress, and induces the up-regulation of cell survival genes. While pro-inflammatory and pathogen-clearing activities of TNF are mediated mainly through activation of TNFRSF1A, a strong activator of NF-kappaB, TNFRSF1B is more responsible for suppression of inflammation. Although the affinities of both receptors for soluble TNF are similar, TNFRSF1B is sometimes more abundantly expressed and thought to associate with TNF, thereby increasing its concentration near TNFRSF1A receptors, and making TNF available to activate TNFRSF1A (a ligand-passing mechanism). Knockout studies in zebrafish embryos have shown that a signaling balance between TNFRSF1A and TNFRSF1B is required for endothelial cell integrity. TNFRSF1A signals apoptosis through caspase-8, whereas TNFRSF1B signals survival via NF-kB in endothelial cells. In goldfish (Carassius aurutus L.), TNFRSF1B expression is substantially higher than that of TNFRSF1 in tissues and various immune cell types. Both receptors are most robustly expressed in monocytes; mRNA levels of TNFRSF1B are lowest in peripheral blood leukocytes.


Pssm-ID: 276931 [Multi-domain]  Cd Length: 130  Bit Score: 45.50  E-value: 1.20e-04
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6098 CGSGEYETRAPTATTDRKCasvTQCDSTQFVVSKPTATtdrDCAECDRC--DSGTQYETaTCTATTNRVCAdltvcadte 6175
Cdd:cd15835    24 CRPGTRLKTKCSETSDTVC---EPCPSGQYSENWNYYP---NCFSCPKCkeRKGLQYAQ-NCSSTTNAVCV--------- 87
                          90       100       110       120       130       140
                  ....*....|....*....|....*....|....*....|....*....|....*....|..
gi 514698100 6176 yesvaatdtsdrkCSSCRECtSSEYLVSGCSEsanavCKACTECPSGTFVSTACTPLADAEC 6237
Cdd:cd15835    88 -------------CKPGMYC-IMGFDHPSCSE-----CKKYRTCKPGYGVSVPGTPTSDVKC 130
IPT cd00102
Immunoglobulin-like fold, Plexins, Transcription factors (IPT). IPTs are also known as ...
4496-4583 1.25e-04

Immunoglobulin-like fold, Plexins, Transcription factors (IPT). IPTs are also known as Transcription factor ImmunoGlobin (TIG) domains. They are present in intracellular transcription factors, cell surface receptors (such as plexins and scatter factor receptors), as well as, cyclodextrin glycosyltransferase and similar enzymes. Although they are involved in DNA binding in transcription factors, their function in other proteins is unknown. In these transcription factors, IPTs form homo- or heterodimers with the exception of the nuclear factor of activated Tcells (NFAT) transcription factors which are mainly monomers.


Pssm-ID: 238050 [Multi-domain]  Cd Length: 89  Bit Score: 44.37  E-value: 1.25e-04
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4496 VSSVVPSSG--QEGTRVTLSGTNlLGSGSGVDQVLLAGVSATVVSAASSEVVVITSALPGGVVGPVtgNVTVVSTSGALV 4573
Cdd:cd00102     3 ITSISPSSGpvSGGTEVTITGSN-FGSGSNLRVTFGGGVPCSVLSVSSTAIVCTTPPYANPGPGPV--EVTVDRGNGGIT 79
                          90
                  ....*....|
gi 514698100 4574 HADTDsFTYV 4583
Cdd:cd00102    80 SSPLT-FTYV 88
TNFRSF1B_teleost cd15835
Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B) in teleost; also known as ...
6192-6278 1.59e-04

Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B) in teleost; also known as TNFR2; This subfamily of TNFRSF1B (also known as TNFR2, type 2 TNFR, TNFBR, TNFR80, TNF-R75, TNF-R-II, p75, CD120b) is found in teleosts. It binds TNF-alpha, but lacks the death domain (DD) that is associated with the cytoplasmic domain of TNFRSF1A (TNFR1). It is inducible and expressed exclusively by oligodendrocytes, astrocytes, T cells, thymocytes, myocytes, endothelial cells, and in human mesenchymal stem cells. TNFRSF1B protects oligodendrocyte progenitor cells (OLGs) against oxidative stress, and induces the up-regulation of cell survival genes. While pro-inflammatory and pathogen-clearing activities of TNF are mediated mainly through activation of TNFRSF1A, a strong activator of NF-kappaB, TNFRSF1B is more responsible for suppression of inflammation. Although the affinities of both receptors for soluble TNF are similar, TNFRSF1B is sometimes more abundantly expressed and thought to associate with TNF, thereby increasing its concentration near TNFRSF1A receptors, and making TNF available to activate TNFRSF1A (a ligand-passing mechanism). Knockout studies in zebrafish embryos have shown that a signaling balance between TNFRSF1A and TNFRSF1B is required for endothelial cell integrity. TNFRSF1A signals apoptosis through caspase-8, whereas TNFRSF1B signals survival via NF-kB in endothelial cells. In goldfish (Carassius aurutus L.), TNFRSF1B expression is substantially higher than that of TNFRSF1 in tissues and various immune cell types. Both receptors are most robustly expressed in monocytes; mRNA levels of TNFRSF1B are lowest in peripheral blood leukocytes.


Pssm-ID: 276931 [Multi-domain]  Cd Length: 130  Bit Score: 45.12  E-value: 1.59e-04
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6192 CRECTSSEYLVSGCSESANAVCKActeCPSGTFVST-ACTPladaECTECTRCGSG---YFVQSpCTSEADTTCKrCRS- 6266
Cdd:cd15835    21 CSKCRPGTRLKTKCSETSDTVCEP---CPSGQYSENwNYYP----NCFSCPKCKERkglQYAQN-CSSTTNAVCV-CKPg 91
                          90
                  ....*....|....
gi 514698100 6267 --CASGEYlHTACT 6278
Cdd:cd15835    92 myCIMGFD-HPSCS 104
TNFRSF1A_teleost cd15834
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) in teleosts; also known as ...
5532-5640 1.69e-04

Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) in teleosts; also known as TNFR1; This subfamily of TNFRSF1 ((also known as type I TNFR, TNFR1, DR1, TNFRSF1A, CD120a, p55) is found in teleosts. It binds TNF-alpha, through the death domain (DD), and activates NF-kappaB, mediates apoptosis and activates signaling pathways controlling inflammatory, immune, and stress responses. It mediates signal transduction by interacting with antiapoptotic protein BCL2-associated athanogene 4 (BAG4/SODD) and adaptor proteins TRAF2 and TRADD that play regulatory roles. The human genetic disorder called tumor necrosis factor associated periodic syndrome (TRAPS), or periodic fever syndrome, is associated with germline mutations of the extracellular domains of this receptor, possibly due to impaired receptor clearance. Serum levels of TNFRSF1A are elevated in schizophrenia and bipolar disorder, and high levels are also associated with cognitive impairment and dementia. Knockout studies in zebrafish embryos have shown that a signaling balance between TNFRSF1A and TNFRSF1B is required for endothelial cell integrity. TNFRSF1A signals apoptosis through caspase-8, whereas TNFRSF1B signals survival via NF-kappaB in endothelial cells. Thus, this apoptotic pathway seems to be evolutionarily conserved, as TNFalpha promotes apoptosis of human endothelial cells and triggers caspase-2 and P53 activation in these cells via TNFRSF1A.


Pssm-ID: 276930 [Multi-domain]  Cd Length: 150  Bit Score: 45.56  E-value: 1.69e-04
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5532 TASSDR-VCEACPAGTTDANSDGSDACVTCGggtyvpagstgTCS---QYECSAGTADTDsnagTACEACDG-------T 5600
Cdd:cd15834    28 TAPGERsQCTPCPEGTYLEQINYSPNCRRCT-----------LCKvknEEEVSPCKKSSN----TVCRCKKGyyksridS 92
                          90       100       110       120
                  ....*....|....*....|....*....|....*....|
gi 514698100 5601 TTYQpskgqerCLSVKTCGAGEEETTSPSATRNRVCQpCQ 5640
Cdd:cd15834    93 ETRE-------CLKCKTCGPGEIEIQPCTPESNTVCE-CK 124
TNFRSF11B_teleost cd13412
Tumor necrosis factor receptor superfamily 11B (TNFRSF11B) in teleost; also known as ...
5789-5936 1.73e-04

Tumor necrosis factor receptor superfamily 11B (TNFRSF11B) in teleost; also known as Osteoprotegerin (OPG); This subfamily of TNFRSF11B (also known as Osteoprotegerin, OPG, TR1, OCIF) is found in teleosts. It is a secreted glycoprotein that regulates bone resorption. It binds to two ligands, RANKL (receptor activator of nuclear factor kappaB ligand, also known as osteoprotegerin ligand, OPGL, TRANCE, TNF-related activation induced cytokine), a critical cytokine for osteoclast differentiation, and TRAIL (TNF-related apoptosis-inducing ligand), involved in immune surveillance. Therefore, acting as a decoy receptor for RANKL and TRAIL, OPG inhibits the regulatory effects of nuclear factor-kappaB on inflammation, skeletal, and vascular systems, and prevents TRAIL-induced apoptosis. Studies in mice counterparts suggest that this protein and its ligand also play a role in lymph-node organogenesis and vascular calcification. Circulating OPG levels have emerged as independent biomarkers of cardiovascular disease (CVD) in patients with acute or chronic heart disease. OPG has also been implicated in various inflammations and linked to diabetes and poor glycemic control. Alternatively spliced transcript variants of this gene have been reported, although their full length nature has not been determined. Genetic analysis of the Japanese rice fish medaka (Oryzias latipes) has shown that entire networks for bone formation are conserved between teleosts and mammals; enabling medaka to be used as a genetic model to monitor bone homeostasis in vivo.


Pssm-ID: 276917 [Multi-domain]  Cd Length: 129  Bit Score: 45.17  E-value: 1.73e-04
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5789 CGRCTDGLTLDKACTDTSPTKCVgcdECASDEYTLSSCTLSsqtqcrQCTTCGNdeyqtkACSVSQDTEcatlTTCSstq 5868
Cdd:cd13412    22 CKKCPPGTHMAAHCTATTQTKCL---PCPAAHYTELWNYLP------RCLYCNN------FCSENQEVE----IECS--- 79
                          90       100       110       120       130       140
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*...
gi 514698100 5869 feveaptATRDRRCKdltaCQPGEYectaatlTTDRECCGVTQCVPGSEETSAPTATSDRECRQCVAG 5936
Cdd:cd13412    80 -------ATNNRVCR----CKEGYY-------MDSDFCIRHTECGPGYGVKTKGTTKQDTVCEKCPSG 129
TNFRSF9_teleost cd13424
Tumor necrosis factor receptor superfamily member 9 (TNFRSF9) in teleosts; also known as CD137; ...
6182-6265 1.74e-04

Tumor necrosis factor receptor superfamily member 9 (TNFRSF9) in teleosts; also known as CD137; This subfamily of TNFRSF9 (also known as CD137, ILA, 4-1BB) is found in teleosts. CD137 plays a role in the immunobiology of human cancer where it is preferentially expressed on tumor-reactive subset of tumor-infiltrating lymphocytes. It can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. It transduces signals that lead to the activation of NF-kappaB, mediated by the TRAF adaptor proteins. CD137 contributes to the clonal expansion, survival, and development of T cells. It can also induce proliferation in peripheral monocytes, enhance T cell apoptosis induced by TCR/CD3 triggered activation, and regulate CD28 co-stimulation to promote Th1 cell responses. CD137 is modulated by SAHA treatment in breast cancer cells, suggesting that the combination of SAHA with this receptor could be a new therapeutic approach for the treatment of tumors. Mostly, CD137 in teleosts have not been characterized.


Pssm-ID: 276929 [Multi-domain]  Cd Length: 150  Bit Score: 45.59  E-value: 1.74e-04
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6182 TDTSDRKCssCRECTSSEYLVSGCSESANAVCKACTecpSGTFVSTactPLaDAECTECTRCGSGYFVQSPCTSEADTTC 6261
Cdd:cd13424     6 PSGKNYVC--CESCHPGNRLVERCGPDPAELCKPCE---PGTYTVK---PL-DYSCYICTQCIGAQVLLKNCTPSSDTVC 76

                  ....
gi 514698100 6262 KrCR 6265
Cdd:cd13424    77 G-CK 79
TNFRSF_viral cd15839
Tumor necrosis factor receptor superfamily members, virus-encoded; This family contains viral ...
5675-5763 1.82e-04

Tumor necrosis factor receptor superfamily members, virus-encoded; This family contains viral TNFR homologs that include vaccinia virus (VACV) cytokine response modifier E (CrmE), an encoded TNFR that shares significant sequence similarity with mammalian type 2 TNF receptors (TNFSFR1B, p75, TNFR type 2), a cowpox virus encoded cytokine-response modifier B (crmB), which is a secreted form of TNF receptor that can contribute to the modification of TNF-mediated antiviral processes, and a myxoma virus (MYXV) T2 (M-T2) protein that binds and inhibits rabbit TNF-alpha. The CrmE structure confirms that the canonical TNFR fold is adopted, but only one of the two "ligand-binding" loops of TNFRSF1A is conserved, suggesting a mechanism for the higher affinity of poxvirus TNFRs for TNFalpha over lymphotoxin-alpha. CrmB protein specifically binds TNF-alpha and TNF-beta indicating that cowpox virus seeks to invade antiviral processes mediated by TNF. Intracellular M-T2 blocks virus-induced lymphocyte apoptosis via a highly conserved viral preligand assembly domain (vPLAD), which controls receptor signaling competency prior to ligand binding.


Pssm-ID: 276935 [Multi-domain]  Cd Length: 125  Bit Score: 44.86  E-value: 1.82e-04
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5675 TDRQCRTCASGTFKAAAGQSTTCIAV-STCAAGFTEDVAPTPSSDRVCvECAPGTFKATAGDGTCR--AHRTCEDTEYET 5751
Cdd:cd15839    32 SNTKCDPCPSDTFTSIPNHIPACLSCrGRCSSNQVETKSCSNTQNRIC-SCAPGYYCLLKGSDGCVacAPKTKCGVGYGV 110
                          90
                  ....*....|..
gi 514698100 5752 VAPTSSSDRKCK 5763
Cdd:cd15839   111 SGHTSTGDVICK 122
TNFRSF19L cd13419
tumor necrosis factor receptor superfamily member 19-like (TNFRSF19L), also known as receptor ...
5655-5734 1.91e-04

tumor necrosis factor receptor superfamily member 19-like (TNFRSF19L), also known as receptor expressed in lymphoid tissues (RELT); TNFRSF19L (also known as receptor expressed in lymphoid tissues (RELT)) is especially abundant in hematologic tissues and can stimulate the proliferation of T-cells. It serves as a substrate for the closely related kinases, odd-skipped related transcription factor 1 (OSR1) and STE20/SPS1-related proline/alanine-rich kinase (SPAK); RELT binds SPAK and uses it to mediate p38 and JNK activation, rather than rely on the canonical TRAF pathways for its function. RELT is capable of stimulating T-cell proliferation in the presence of CD3 signaling, which suggests its regulatory role in immune response. It interacts with phospholipid scramblase 1 (PLSCR1), an interferon-inducible protein that mediates antiviral activity against DNA and RNA viruses; PLSCR1 is a regulator of hepatitis B virus X (HBV X) protein. RELT and PLSCR1 co-localize in intracellular regions of human embryonic kidney-293 cells, with RELT over-expression appearing to alter the localization of PLSCR1.


Pssm-ID: 276924  Cd Length: 91  Bit Score: 43.94  E-value: 1.91e-04
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5655 CISVTTCGAGEEEIAS----PTLSTdrQCRTCASGTFKAAAGqSTTCIAVSTCAA-GFTEDVAPTPSSDRVCVECAPGTF 5729
Cdd:cd13419     1 CVPCLQCPPGQEPDRAcgqgQGLGV--LCRSCPPGTFSDSLG-SEPCRPHTSCEVlKRKVATSGTATSDAVCGDCLPGFH 77

                  ....*
gi 514698100 5730 KATAG 5734
Cdd:cd13419    78 SPAAP 82
AidA COG3468
Autotransporter adhesin AidA [Cell wall/membrane/envelope biogenesis, Intracellular ...
4218-4661 1.92e-04

Autotransporter adhesin AidA [Cell wall/membrane/envelope biogenesis, Intracellular trafficking, secretion, and vesicular transport];


Pssm-ID: 442691 [Multi-domain]  Cd Length: 846  Bit Score: 48.79  E-value: 1.92e-04
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4218 ATITALDAFTYNVAGDITDVSPSFGRVGTRVRLLGSNLLGGGTSAEVRFGGVTGAVTAVSETAIDVTVPAASGPSGLVNV 4297
Cdd:COG3468     1 TASGGGGGATGLGGGGTGGGGGLGGTGGGNAGLGIGNGGGGGAASGSGAGGVAGNGGGGGGGAGGGGGGAGSGGGLAGAG 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4298 SIVSDSGSHVlevagfrYTAPGSVAAVAPSSGHEGTVVTISGASLLAEEADAARVTLGGVNATVVFANDTRLVVVAGASS 4377
Cdd:COG3468    81 SGGTGGNSTG-------GGGGNSGTGGTGGGGGGGGSGNGGGGGGGGGGGGTGGGGGGGTGSAGGGGGGGGGGTGVGGTG 153
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4378 TAGLGDVFIETVGGARLLAANawmyVAQATITDVQPGSGQVGTRVTIRGTGLRCGGAAVTSVLLGSAVAPVVTEDDTTVI 4457
Cdd:COG3468   154 AAAAGGGTGSGGGGSGGGGGA----GGGGGGGAGGSGGAGSTGSGAGGGGGGSGGGGGAAGTGGGGGGGGGAGGATGGAG 229
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4458 AEAPARAVGASPVDVTVVADTGAYVTADDAWTFVTAGAVSSVVPSSGQEGTRVTLSGTNLLGSGSGVDQVLLAGVSATVV 4537
Cdd:COG3468   230 SGGNTGGGVGGGGGSAGGTGGGGLTGGGAAGTGGGGGGTGTGSGGGGGGGANGGGSGGGGGASGTGGGGTASTGGGGGGG 309
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4538 SAASSevvvitsalpGGVVGPVTGNVTVVSTSGALVHADTDSFTYVRAGAVTGVSPLAGVQGTRVTVTGERLLGGGSSIA 4617
Cdd:COG3468   310 GGNGG----------GGGGGSNAGGGSGGGGGGGGGGGGGGTTLNGAGSAGGGTGAALAGTGGSGSGGGGGGGSGGGGGA 379
                         410       420       430       440
                  ....*....|....*....|....*....|....*....|....
gi 514698100 4618 AVQVAGVETRVIESSNNTHVVLRASNGTGSGDIELIADTGAKTV 4661
Cdd:COG3468   380 GGGGANTGSDGVGTGLTTGGTGNNGGGGVGGGGGGGLTLTGGTL 423
TNFRSF25 cd13420
tumor necrosis factor receptor superfamily member 25 (TNFRSF25), also known as death receptor ...
6191-6267 1.96e-04

tumor necrosis factor receptor superfamily member 25 (TNFRSF25), also known as death receptor 3 (DR3); TNFRSF25 (also known as death receptor 3 (DR3), death domain receptor 3 (DDR3), apoptosis-mediating receptor, lymphocyte associated receptor of death (LARD), apoptosis inducing receptor (AIR), APO-3, translocating chain-association membrane protein (TRAMP), WSL-1, WSL-LR or TNFRSF12) is preferentially expressed in thymocytes and lymphocytes, and may play a role in regulating lymphocyte homeostasis. It has been detected in lymphocyte-rich tissues such as colon, intestine, thymus and spleen, as well as in the prostate. Various death domain containing adaptor proteins mediate the signal transduction of this receptor; it activates nuclear factor kappa-B (NFkB) and induces cell apoptosis by associating with TNFRSF1A-associated via death domain (TRADD), which is known to mediate signal transduction of tumor necrosis factor receptors. DR3 associates with tumor necrosis factor (TNF)-like cytokine 1A (TL1A also known as TNFSF15) on activated lymphocytes and induces pro-inflammatory signals; TL1A also binds decoy receptor DcR3 (also known as TNFRSF6B). DR3/DcR3/TL1A expression is increased in both serum and inflamed tissues in autoimmune diseases such as in several autoimmune diseases, including inflammatory bowel disease (IBD), rheumatoid arthritis (RA), allergic asthma, experimental autoimmune encephalomyelitis, type 1 diabetes, ankylosing spondylitis (AS), and primary biliary cirrhosis (PBC), making modulation of TL1A-DR3 interaction a potential therapeutic target.


Pssm-ID: 276925 [Multi-domain]  Cd Length: 114  Bit Score: 44.79  E-value: 1.96e-04
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6191 SCRECTSSEYLVSGCSESANAVckACTECPSGTFVS---------TAC---------TPLADAECTECTRCG--SGYFVQ 6250
Cdd:cd13420    16 CCRGCPAGHYLKAPCTEPCGNS--TCLPCPRGTFLArenhhktdcTRCqacdeqasqVALENCSAVSDTHCGceSGWFVE 93
                          90       100
                  ....*....|....*....|
gi 514698100 6251 ---SPCTSEADTTCKRCRSC 6267
Cdd:cd13420    94 csvKDCVSSSPFSCKPCLDC 113
COG4625 COG4625
Uncharacterized conserved protein, contains a C-terminal beta-barrel porin domain [Function ...
4025-4572 2.09e-04

Uncharacterized conserved protein, contains a C-terminal beta-barrel porin domain [Function unknown];


Pssm-ID: 443664 [Multi-domain]  Cd Length: 900  Bit Score: 48.62  E-value: 2.09e-04
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4025 SGGAGGSGDVVVESDTGAVVRLAAGFRYVPQAQILHLTRASGQVGTETTIVGEGLQMGDVIVSVLLAGVPAQVLSQSDVN 4104
Cdd:COG4625     6 GGGGGGGGGGGTGGGGAGGGGGAGGGAGGGGAGGGGGGGGGGGGAGGGGGGGGTGGGGGGGGGGGGGGAGGGGGGGGGGG 85
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4105 VTVRANTSTPATGDVMLVAGSGAFVELVNGWTYDDAGAIEDVQPAQGFAGNLVTISGRGLRGGSAAVTRVTLVGVLATEI 4184
Cdd:COG4625    86 GGGGTGGVGGGGGGGGGGGGGGGGGGGGGGGGSAGGGGGGAGGAGGGGGGGAGGGGGGGGGGGAGGGGGGGAGGAGGGGG 165
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4185 VHENDTVVVVRAGLPVDPFVMQTGRVVVMGSSGATITALDAFTYNVAGDITDVSPSFGRVGTRVRLLGSNLLGGGTSAEV 4264
Cdd:COG4625   166 GGGGGGGGGGGGGGGGGGGGGGGGGGGNGGGGGGGGGGGGGGGGGGGGAGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG 245
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4265 RFGGVTGAVTAVSETAIDVTVPAASGPSGLVNVSIVSDSGSHVLEVAGFRYTAPGSVAAVAPSSGHEGTVVTISGASLLA 4344
Cdd:COG4625   246 GGAGGGGGGGGGNGGGGGAGGGGGGGGGGSGGGGGGGGGGGSGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG 325
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4345 EEADAARVTLGGVNATVVFANDTRLVVVAGASSTAGLGDVFIETVGGARLLAANAWMYVAQATITDVQPGSGQVGTRVTI 4424
Cdd:COG4625   326 GGGGGGGGAGGGGGSGGAGAGGGGAGGGGAGGGGGGGTGGGGGGGGGGGGGSGGGGAGGGGGSGGGGGGGAGGGGGGGGA 405
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4425 RGTGLRCGGAAVTSVLLGSAVAPVVTEDDTTVIAEAPARAVGASPVDVTVVADTGAYVTADDAwTFVTAGAVSSVVPSSG 4504
Cdd:COG4625   406 GGTGGGGAGGGGGAAGGGGGGTGAGGGGGGGGTGAGGGGATGGGGGGGGGAGGSGGGAGAGGG-SGSGAGTLTLTGNNTY 484
                         490       500       510       520       530       540
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*...
gi 514698100 4505 QEGTRVTlSGTNLLGSGSGVDQVLLAGVSATVVSAASSEVVVITSALPGGVVGPVTGNVTVVSTSGAL 4572
Cdd:COG4625   485 TGTTTVN-GGGNYTQSAGSTLAVEVDAANSDRLVVTGTATLNGGTVVVLAGGYAPGTTYTILAVAAAL 551
TNFRSF9_teleost cd13424
Tumor necrosis factor receptor superfamily member 9 (TNFRSF9) in teleosts; also known as CD137; ...
5768-5937 2.14e-04

Tumor necrosis factor receptor superfamily member 9 (TNFRSF9) in teleosts; also known as CD137; This subfamily of TNFRSF9 (also known as CD137, ILA, 4-1BB) is found in teleosts. CD137 plays a role in the immunobiology of human cancer where it is preferentially expressed on tumor-reactive subset of tumor-infiltrating lymphocytes. It can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. It transduces signals that lead to the activation of NF-kappaB, mediated by the TRAF adaptor proteins. CD137 contributes to the clonal expansion, survival, and development of T cells. It can also induce proliferation in peripheral monocytes, enhance T cell apoptosis induced by TCR/CD3 triggered activation, and regulate CD28 co-stimulation to promote Th1 cell responses. CD137 is modulated by SAHA treatment in breast cancer cells, suggesting that the combination of SAHA with this receptor could be a new therapeutic approach for the treatment of tumors. Mostly, CD137 in teleosts have not been characterized.


Pssm-ID: 276929 [Multi-domain]  Cd Length: 150  Bit Score: 45.59  E-value: 2.14e-04
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5768 CQddEWESKaptiTTDRECspCGRCTDGLTLDKACtDTSPTKCvgCDECASDEYTLSSCTLSsqtqCRQCTTCGNDEYQT 5847
Cdd:cd13424     1 CK--KWEPS----GKNYVC--CESCHPGNRLVERC-GPDPAEL--CKPCEPGTYTVKPLDYS----CYICTQCIGAQVLL 65
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5848 KACSVSQDTECatlttcsstqfeveaptatrdrrckdltACQPGeYECtaatltTDRECcgvTQCVPGSEETSAPtaTSD 5927
Cdd:cd13424    66 KNCTPSSDTVC----------------------------GCKEG-LRC------GDAEC---SFCVTECGKGQEP--LGK 105
                         170
                  ....*....|
gi 514698100 5928 RECRQCVAGT 5937
Cdd:cd13424   106 RDCRQCPVGT 115
FhaB COG3210
Large exoprotein involved in heme utilization or adhesion [Intracellular trafficking, ...
3677-4711 3.08e-04

Large exoprotein involved in heme utilization or adhesion [Intracellular trafficking, secretion, and vesicular transport];


Pssm-ID: 442443 [Multi-domain]  Cd Length: 1698  Bit Score: 48.22  E-value: 3.08e-04
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3677 AVATPVDVVLTSRSGAQVAAAGAFTYLVEGSVADLLPAQGQRGTAVSLSGSNLCGGGTAIVAVTLGGVAASLKPTSTCNL 3756
Cdd:COG3210    33 GTSGLNILGSGGVGTAGGIASNAGTTASTSGGSGTAGGVGNTSASTGGIGAAAANTAGTLETGLTSNIGGGSVNGSNSTG 112
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3757 VQFVAGSRNNTAAEAVDVVLESNTGALIEGTGRWTYVVEGAISSVLPPGGVAGTLVTIrGSNLLGGGSTAAGVTLAGVSA 3836
Cdd:COG3210   113 NGTLTTTAASATTGNNTGGTTTSSTNTVTTLGGTTTGNTVLSTSGAGNNTNTNNSSSG-TNIGNSIPTTGGSLNVVAANP 191
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3837 SVEQANATHVIVTANRGTTAGDVVVTSDTGSNVVLQDGFTYSRISSVSPAEGQEGTRVRLDGVGFFTGGASVDRVEICGV 3916
Cdd:COG3210   192 TGVTGVGGALINATAGVLANAGGGTAGGVASANSTLTGGVVAAGTGAGVISTGGTDISSLSVAAGAGTGGAGGTGNAGNT 271
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3917 ASSVTNQSDSRLDVVVPAATTLVPPLRCDVEVVSAFGVSIVAADAFDYLEPGEIAAVTPTSGHEGTVVTVSGARLLGGGS 3996
Cdd:COG3210   272 TIGTTVTGTNATGSNTAGASSGDTTTNGTSSVTGAGGTGVLGGGTAAGITTTNTVGGNGDGNNTTANSGAGLVSGGTGGN 351
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3997 QVASVTFAGVEVHDVLTQSDSEIVAVLRSGGAGGSGDVVVESDTGAVVRLAAGFRYVPQAQILHLTRASGQVGTETTIVG 4076
Cdd:COG3210   352 NGTTGTGAGSGLTGTGNGGGLTTAGAGTVASTVGTATASTGNASSTTVLGSGSLATGNTGTTIAGNGGSANAGGFTTTGG 431
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4077 EGLQMGDVIVSVLLAGVPAQVLSQSDVNVTVRANTSTPATGDVMLVAGSGAFVELVNGWTYDDAGAIEDVQPAQGFAGNL 4156
Cdd:COG3210   432 VLGITGNGTVTGGTIGGLTGSGTTNGAGLSGNTDVSGTGTVTNSAGNTTSATTLAGGGIGTVTTNATISNNAGGDANGIA 511
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4157 VTISGRGLRGGSAAVTRVTLVGVLATEIVHENDTVVVVRAGLPVDPFVMQTGRVVVMGSSGATITALDAFTYNVAGDITD 4236
Cdd:COG3210   512 TGLTGITAGGGGGGNATSGGTGGDGTTLSGSGLTTTVSGGASGTTAASGSNTANTLGVLAATGGTSNATTAGNSTSATGG 591
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4237 VSPSFGRVGTRVRLLGSNLLGggtsaevrfGGVTGAVTAVSETAIDVTVPAASGPSGLVNVSIVSDSGSHVLEVAGFRYT 4316
Cdd:COG3210   592 TGTNSGGTVLSIGTGSAGATG---------TITLGAGTSGAGANATGGGAGLTGSAVGAALSGTGSGTTGTASANGSNTT 662
                         650       660       670       680       690       700       710       720
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4317 APGSVAAVAPSSGHEGTVVTISGASLLAEEADAARVTLGGVNATVVFANDTRLVVVAGASSTAGLGDVFIETVGGARLLA 4396
Cdd:COG3210   663 GVNTAGGTGGGTTGTVTSGATGGTTGTTLNAATGGTLNNAGNTLTISTGSITVTGQIGALANANGDTVTFGNLGTGATLT 742
                         730       740       750       760       770       780       790       800
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4397 ANAWMYVAQATITDVqpgSGQVGTRVTIRGTGLRCGGAAVTSVLlGSAVAPVVTEDDTTVIAEAPARAVGASPVDVTVva 4476
Cdd:COG3210   743 LNAGVTITSGNAGTL---SIGLTANTTASGTTLTLANANGNTSA-GATLDNAGAEISIDITADGTITAAGTTAINVTG-- 816
                         810       820       830       840       850       860       870       880
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4477 dtgayvtaddawtfvTAGAVSSVVPSSGQEGTRVTLSGTNLLGSGSGVDQVLLAGVSATVVSAASSEVVVITSALPGGVV 4556
Cdd:COG3210   817 ---------------SGGTITINTATTGLTGTGDTTSGAGGSNTTDTTTGTTSDGASGGGTAGANSGSLAATAASITVGS 881
                         890       900       910       920       930       940       950       960
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4557 GPVTGNVTVVSTSGALVHADTDSFTYVRAGAVTGVSPLAGVQGTRVTVTGERLLGGGSSIAAVQVAGVETRVIESSNNTH 4636
Cdd:COG3210   882 GGVATSTGTANAGTLTNLGTTTNAASGNGAVLATVTATGTGGGGLTGGNAAAGGTGAGNGTTALSGTQGNAGLSAASASD 961
                         970       980       990      1000      1010      1020      1030
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*
gi 514698100 4637 VVLRASNGTGSGDIELIADTGAKTVANVTFSYLELGVITAVRPAIGRVGTLVTIEGERLQSGGSAVARVDLGPAA 4711
Cdd:COG3210   962 GAGDTGASSAAGSSAVGTSANSAGSTGGVIAATGILVAGNSGTTASTTGGSGAIVAGGNGVTGTTGTASATGTGT 1036
TNFRSF cd00185
Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) ...
6048-6144 3.36e-04

Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) interactions with TNF superfamily (TNFSF) ligands (TNFL) control key cellular processes such as differentiation, proliferation, apoptosis, and cell growth. Dysregulation of these pathways has been shown to result in a wide range of pathological conditions, including autoimmune diseases, inflammation, cancer, and viral infection. There are 29 very diverse family members of TNFRSF reported in humans: 22 are type I transmembrane receptors (single pass with the N terminus on extracellular side of the cell membrane) and have a clear signal peptide; the remaining 7 members are either type III transmembrane receptors (single pass with the N terminus on extracellular side of the membrane but no signal sequence; TNFR13B, TNFR13C, TNFR17, and XEDAR), or attached to the membrane via a glycosylphosphatidylinositol (GPI) linker (TNFR10C), or secreted as soluble receptors (TNFR11B and TNFR6B). All TNFRs contain relatively short cysteine-rich domains (CRDs) in the ectodomain, and are involved in interaction with the TNF homology domain (THD) of their ligands. TNFRs often have multiple CRDs (between one and six), with the most frequent configurations of three or four copies; most CRDs possess three disulfide bridges, but could have between one and four. Localized or genome-wide duplication and evolution of the TNFRSF members appear to have paralleled the emergence of the adaptive immune system; teleosts (i.e. ray-finned, bony fish), which possess an immune system with B and T cells, possess primary and secondary lymphoid organs, and are capable of adaptive responses to pathogens also display several characteristics that are different from the mammalian immune system, making teleost TNFSF orthologs and paralogs of interest to better understand immune system evolution and the immunological pathways elicited to pathogens.


Pssm-ID: 276900 [Multi-domain]  Cd Length: 87  Bit Score: 42.97  E-value: 3.36e-04
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6048 STCEEDEYVYRAATVSTDTQCRAltaCSDEQYetrAPTVNSDRECTGLTTCGSGEYETRAP-TATTDRKCasvtQCDSTQ 6126
Cdd:cd00185     3 QRCPPGEYLSSDCTATTDTVCSP---CPPGTY---SESWNSLSKCLPCTTCGGGNQVEKTPcTATDNRCC----TCKPGF 72
                          90
                  ....*....|....*...
gi 514698100 6127 FvvsKPTATTDRDCAECD 6144
Cdd:cd00185    73 Y---CDEGTNVEECKPCT 87
TNFRSF10 cd10580
Tumor necrosis factor receptor superfamily member 10 (TNFRSF10), includes TNFRSF10A (DR4), ...
5784-5882 4.01e-04

Tumor necrosis factor receptor superfamily member 10 (TNFRSF10), includes TNFRSF10A (DR4), TNFRSF10B (DR5), TNFRSF10C (DcR1) and TNFRSF10D (DcR2); TNFRSF10 family contains TNFRSF10A (also known as DR4, Apo2, TRAIL-R1, CD261), TNFRSF10B (also known as DR5, KILLER, TRICK2A, TRAIL-R2, TRICKB, CD262), TNFRSF10C (also known as DcR1, TRAIL-R3, LIT, TRID, CD263), and TNFRSF10D (also known as DcR2, TRUNDD, TRAIL-R4, CD264). Tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL) binds to all 4 receptors. DR4 (TRAIL-R1) and DR5 (TRAIL-R2) are membrane-bound and contain a death domain in their intracellular portion, which is able to transmit an apoptotic signal, thus often called death receptors. In contrast, DcR1 (TRAIL-R3), which lacks the complete intracellular portion and DcR2 (TRAIL-R4), which has a truncated cytoplasmic death domain, do not transmit an apoptotic signal, thus known as decoy receptors. Apoptosis mediated by DR4 and DR5 requires Fas (TNFRSF6)-associated via death domain (FADD), a death domain containing adaptor protein. Two transcript variants encoding different isoforms and one non-coding transcript have been found for TNFRSF10B/DR5. DcR1 appears to function as an antagonistic receptor that protects cells from TRAIL-induced apoptosis; it has been found to be a p53-regulated DNA damage-inducible gene. The expression of this gene is detected in many normal tissues but not in most cancer cell lines, which may explain the specific sensitivity of cancer cells to the apoptosis-inducing activity of TRAIL. DcR2 has been shown to play an inhibitory role in TRAIL-induced cell apoptosis. The membrane expression of all of these receptors (DR4, DR5, DcR1, and DcR2) is greater in normal endometrium (NE) than in endometrioid adenocarcinoma (EAC). In EAC patients, membrane expression of these receptors are not independent predictors of survival. DcR1 and DcR2 expression is critical in cell growth and apoptosis in cutaneous or uveal melanoma; DcR1 and DcR2 are frequently methylated in both, leading to loss of gene expression and melanomagenesis. On the other hand, DR4 and DR5 methylation is rare in cutaneous melanoma and frequent in uveal melanoma; their expression is wholly independent of the promoter methylation status. DcR1 and DcR2 genes are also reported to be hyper-methylated in prostate cancer. The TRAIL ligand, a potent and specific inducer of apoptosis in cancer cells, has been explored as a therapeutic drug; experimental data has shown that DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.


Pssm-ID: 276906 [Multi-domain]  Cd Length: 103  Bit Score: 43.40  E-value: 4.01e-04
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5784 RECSPCgrcTDGLTLDKACTDTSptKCVGCDECASDEYTLSSCTLSSQTQCrQC---TTCGNDeyqtkACSVSQdtECAt 5860
Cdd:cd10580    16 GDCIPC---KEGVDYTEHPNGLP--SCLPCTVCKSDEEELSPCTTTRNTEC-QCkpgTFCDPD-----SPEVCQ--KCS- 81
                          90       100
                  ....*....|....*....|..
gi 514698100 5861 lTTCSSTQFEVEAPTATRDRRC 5882
Cdd:cd10580    82 -TRCPEGMVEVSPCTPWSDLKC 102
TNFRSF26 cd15837
Tumor necrosis factor receptor superfamily member 26 (TNFRSF26), also known as tumor necrosis ...
5682-5834 4.10e-04

Tumor necrosis factor receptor superfamily member 26 (TNFRSF26), also known as tumor necrosis factor receptor homolog 3 (TNFRH3); TNFRSF26 (also known as tumor necrosis factor receptor homolog 3 (TNFRH3) or TNFRSF24) is predominantly expressed in embryos and lymphoid cell types, along with its closely related TNFRSF22 and TNFRSF23 orthologs, and is developmentally regulated. Unlike TNFRSF22/23, TNFRSF26 does not serve as a TRAIL decoy receptor; it remains an orphan receptor.


Pssm-ID: 276933 [Multi-domain]  Cd Length: 118  Bit Score: 43.89  E-value: 4.10e-04
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5682 CASGTFKAAagqsttCIAVSTCAAG-FTEDVAPTPSSDRVCVECAPGTFkatagdgtcRAHRTCEDTeyetvaptsssdr 5760
Cdd:cd15837     1 CGPGEYKSA------NLCCQLCPAGhYVSEPCQENHGVGECAPCEPGTF---------TAHPNGETS------------- 52
                          90       100       110       120       130       140       150
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....
gi 514698100 5761 kCKALTVCQDDEWESKAPTITTDRECspcgRCTDGLTLDKACtdtSPTKCVGCDECASDEYTLSSCTLSSQTQC 5834
Cdd:cd15837    53 -CFPCSQCRDDQEVVAECSATSDRQC----QCKQGHFYCDEN---CLESCFRCSRCPGGRVVLQPCNATRDTVC 118
TNFRSF cd00185
Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) ...
5521-5598 4.16e-04

Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) interactions with TNF superfamily (TNFSF) ligands (TNFL) control key cellular processes such as differentiation, proliferation, apoptosis, and cell growth. Dysregulation of these pathways has been shown to result in a wide range of pathological conditions, including autoimmune diseases, inflammation, cancer, and viral infection. There are 29 very diverse family members of TNFRSF reported in humans: 22 are type I transmembrane receptors (single pass with the N terminus on extracellular side of the cell membrane) and have a clear signal peptide; the remaining 7 members are either type III transmembrane receptors (single pass with the N terminus on extracellular side of the membrane but no signal sequence; TNFR13B, TNFR13C, TNFR17, and XEDAR), or attached to the membrane via a glycosylphosphatidylinositol (GPI) linker (TNFR10C), or secreted as soluble receptors (TNFR11B and TNFR6B). All TNFRs contain relatively short cysteine-rich domains (CRDs) in the ectodomain, and are involved in interaction with the TNF homology domain (THD) of their ligands. TNFRs often have multiple CRDs (between one and six), with the most frequent configurations of three or four copies; most CRDs possess three disulfide bridges, but could have between one and four. Localized or genome-wide duplication and evolution of the TNFRSF members appear to have paralleled the emergence of the adaptive immune system; teleosts (i.e. ray-finned, bony fish), which possess an immune system with B and T cells, possess primary and secondary lymphoid organs, and are capable of adaptive responses to pathogens also display several characteristics that are different from the mammalian immune system, making teleost TNFSF orthologs and paralogs of interest to better understand immune system evolution and the immunological pathways elicited to pathogens.


Pssm-ID: 276900 [Multi-domain]  Cd Length: 87  Bit Score: 42.97  E-value: 4.16e-04
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5521 CGAGEQEKVAPTASSDRVCEACPAGT-TDANSDGSD--ACVTCGGGTYVPA--GSTGTCSQYECSAGTADTDSNAGTACE 5595
Cdd:cd00185     5 CPPGEYLSSDCTATTDTVCSPCPPGTySESWNSLSKclPCTTCGGGNQVEKtpCTATDNRCCTCKPGFYCDEGTNVEECK 84

                  ...
gi 514698100 5596 ACD 5598
Cdd:cd00185    85 PCT 87
TNFR_c6 pfam00020
TNFR/NGFR cysteine-rich region;
6195-6237 4.16e-04

TNFR/NGFR cysteine-rich region;


Pssm-ID: 459633 [Multi-domain]  Cd Length: 39  Bit Score: 41.14  E-value: 4.16e-04
                           10        20        30        40
                   ....*....|....*....|....*....|....*....|...
gi 514698100  6195 CTSSEYLVSGCSESanavCKACTECPSGTFVSTACTPLADAEC 6237
Cdd:pfam00020    1 CPPGTYTDNWNGLK----CLPCTVCPPGQVVVRPCTPTSDTVC 39
TNFRSF21 cd10583
Tumor necrosis factor receptor superfamily member 21 (TNFRSF21), also known as death receptor ...
5689-5840 4.56e-04

Tumor necrosis factor receptor superfamily member 21 (TNFRSF21), also known as death receptor (DR6); TNFRSF21 (also known as death receptor 6 (DR6), CD358, BM-018) is highly expressed in differentiating neurons as well as in the adult brain, and is upregulated in injured neurons. DR6 negatively regulates neurondendrocyte, axondendrocyte, and oligodendrocyte survival, hinders axondendrocyte and oligodendrocyte regeneration and its inhibition has a neuro-protective effect in nerve injury. It activates nuclear factor kappa-B (NFkB) and mitogen-activated protein kinase 8 (MAPK8, also called c-Jun N-terminal kinase 1), and induces cell apoptosis by associating with TNFRSF1A-associated via death domain (TRADD), which is known to mediate signal transduction of tumor necrosis factor receptors. TNFRSF21 plays a role in T-helper cell activation, and may be involved in inflammation and immune regulation. Its possible ligand is alpha-amyloid precursor protein (APP), hence probably involved in the development of Alzheimer's disease; when released, APP binds in an autocrine/paracrine manner to activate a caspase-dependent self-destruction program that removes unnecessary or connectionless axons. Increasing beta-catenin levels in brain endothelium upregulates TNFRSF21 and TNFRSF19, indicating that these death receptors are downstream target genes of Wnt/beta-catenin signaling, which has been shown to be required for blood-brain barrier development. DR6 is up-regulated in numerous solid tumors as well as in tumor vascular cells, including ovarian cancer and may be a clinically useful diagnostic and predictive serum biomarker for some adult sarcoma subtypes.


Pssm-ID: 276909 [Multi-domain]  Cd Length: 159  Bit Score: 44.74  E-value: 4.56e-04
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5689 AAAGQSTTCiavSTCAAGFTEDVAPTPSSDRVCVECAPGTF-KATAGDGTC-RAHRTCEDTEYETVAPTSSSDRKCkalt 5766
Cdd:cd10583     7 PATGTQLTC---DKCPAGTYVSKHCTETSLRECSPCPNGTFtRHENGIEQChRCRKPCPAPMIEKTPCTALTDREC---- 79
                          90       100       110       120       130       140       150
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....
gi 514698100 5767 VCQDDeweskapTITTDRECSPCGRCTDGLTLDKACTDTSPTKCVGCDECasdeyTLSSCTlSSQTQCRQCTTC 5840
Cdd:cd10583    80 TCPPG-------TFLSNDTCVPHSVCPVGWGVRKKGTETEDVRCKPCPRG-----TFSDVP-SSVLKCKTYTDC 140
TNFRSF6_teleost cd13423
Tumor necrosis factor receptor superfamily member 6 (TNFRSF6) in teleosts; also known as fas ...
6214-6279 6.17e-04

Tumor necrosis factor receptor superfamily member 6 (TNFRSF6) in teleosts; also known as fas cell surface death receptor (FasR); This subfamily of TNFRSF6 (also known as fas cell surface death receptor (FasR) or Fas; APT1; CD95; FAS1; APO-1; FASTM; ALPS1A) is found in teleosts. It contains a death domain and plays a central role in the physiological regulation of programmed cell death. In humans, it has been implicated in the pathogenesis of various malignancies and diseases of the immune system. The receptor interactions with the Fas ligand (FasL), allowing the formation of a death-inducing signaling complex that includes Fas-associated death domain protein (FADD), caspase 8, and caspase 10; autoproteolytic processing of the caspases in the complex triggers a downstream caspase cascade, leading to apoptosis. This receptor has also been shown to activate NF-kappaB, MAPK3/ERK1, and MAPK8/JNK, and is involved in transducing the proliferating signals in normal diploid fibroblast and T cells. In channel catfish and the Japanese rice fish, medaka, homologs of Fas receptor (FasR), as well as FADD and caspase 8, have been identified and characterized, and likely constitute the teleost equivalent of the death-inducing signaling complex (DISC). FasL/FasR are involved in the initiation of apoptosis and suggest that mechanisms of cell-mediated cytotoxicity in teleosts are similar to those used by mammals; presumably, the mechanism of apoptosis induction via death receptors was evolutionarily established during the appearance of vertebrates.


Pssm-ID: 276928 [Multi-domain]  Cd Length: 103  Bit Score: 42.80  E-value: 6.17e-04
                          10        20        30        40        50        60
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*...
gi 514698100 6214 KACTECPSGTFVSTACTPLADAecTECTRCGSGYFVQSPcTSEadTTCKRCRSCASGEYLHTA--CTT 6279
Cdd:cd13423    12 LTCCLCPAGQHVEKHCTNNGTD--GECEACEDGTYNSHP-NSL--DSCEPCTSCDPNANLEVEerCTP 74
IPT_plexin_repeat1 cd01180
First repeat of the IPT domain of Plexins and Cell Surface Receptors (PCSR) . Plexins are ...
1935-2014 6.51e-04

First repeat of the IPT domain of Plexins and Cell Surface Receptors (PCSR) . Plexins are involved in the regulation of cell proliferation and of cellular adhesion and repulsion receptors. In general, there are three copies of the IPT domain present preceeded by SEMA (semaphorin) and PSI (plexin, semaphorin, integrin) domains.


Pssm-ID: 238585  Cd Length: 94  Bit Score: 42.69  E-value: 6.51e-04
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1935 VIQSVDPQSGQV--GTRITIVGSGLlgGSAFA--REVVMGNSVPCSVLRGNDSVV---VCVLADAGSPAAAVDVTVVGAR 2007
Cdd:cd01180     2 VITEFFPLSGPLegGTRLTICGSNL--GLRKNdvRHGVRVGGVPCNPEPPEYSSSekiVCTTGPAGNPVFNGPVEVTVGH 79

                  ....*..
gi 514698100 2008 GSRVVAS 2014
Cdd:cd01180    80 GSFRTES 86
TNFRSF4 cd13406
Tumor necrosis factor receptor superfamily member 4 (TNFRSF4), also known as CD134 or OXO40; ...
5497-5574 6.56e-04

Tumor necrosis factor receptor superfamily member 4 (TNFRSF4), also known as CD134 or OXO40; TNFRSF4 (also known as OX40, ACT35, CD134, IMD16, TXGP1L) activates NF-kappaB through its interaction with adaptor proteins TRAF2 and TRAF5. It also promotes the expression of apoptosis inhibitors BCL2 and BCL2lL1/BCL2-XL, and thus suppresses apoptosis. It is primarily expressed on activated CD4+ and CD8+ T cells, where it is transiently expressed and upregulated on the most recently antigen-activated T cells within inflammatory lesions. This makes it an attractive target to modulate immune responses, i.e. TNFRSF4 (OX40) blocking agents to inhibit adverse inflammation or agonists to enhance immune responses. An artificially created biologic fusion protein, OX40-immunoglobulin (OX40-Ig), prevents OX40 from reaching the T-cell receptors, thus reducing the T-cell response. Some single nucleotide polymorphisms (SNPs) of its natural ligand OX40 ligand (OX40L, CD252), which is also found on activated T cells, have been associated with systemic lupus erythematosus.


Pssm-ID: 276911 [Multi-domain]  Cd Length: 142  Bit Score: 43.93  E-value: 6.56e-04
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5497 PCDSQYEKTAataTSDRVCRGLTTC--GAGEQEKVAPTASSDRVCeACPAGTT--DANSDGSDaCVTCGGGTYVPaGSTG 5572
Cdd:cd13406    38 PCEPGFYNEA---VNYEPCKPCTQCnqRSGSEEKQKCTKTSDTVC-RCRPGTQplDSYKPGVD-CVPCPPGHFSR-GDNQ 111

                  ..
gi 514698100 5573 TC 5574
Cdd:cd13406   112 AC 113
IPT cd00102
Immunoglobulin-like fold, Plexins, Transcription factors (IPT). IPTs are also known as ...
2732-2819 6.76e-04

Immunoglobulin-like fold, Plexins, Transcription factors (IPT). IPTs are also known as Transcription factor ImmunoGlobin (TIG) domains. They are present in intracellular transcription factors, cell surface receptors (such as plexins and scatter factor receptors), as well as, cyclodextrin glycosyltransferase and similar enzymes. Although they are involved in DNA binding in transcription factors, their function in other proteins is unknown. In these transcription factors, IPTs form homo- or heterodimers with the exception of the nuclear factor of activated Tcells (NFAT) transcription factors which are mainly monomers.


Pssm-ID: 238050 [Multi-domain]  Cd Length: 89  Bit Score: 42.45  E-value: 6.76e-04
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2732 PVVGEIEPSSGQL--GTVVTIRGSNLLAGGEALQLVTlAGVPAEAILSSNNSVVTVSSAQGSGATGPaVLVAAETGGRAV 2809
Cdd:cd00102     1 PVITSISPSSGPVsgGTEVTITGSNFGSGSNLRVTFG-GGVPCSVLSVSSTAIVCTTPPYANPGPGP-VEVTVDRGNGGI 78
                          90
                  ....*....|
gi 514698100 2810 GTPSVNYTYL 2819
Cdd:cd00102    79 TSSPLTFTYV 88
IPT_PCSR cd00603
IPT domain of Plexins and Cell Surface Receptors (PCSR) and related proteins . This subgroup ...
3530-3614 6.76e-04

IPT domain of Plexins and Cell Surface Receptors (PCSR) and related proteins . This subgroup contains IPT domains of plexins, receptors, like the plasminogen-related growth factor receptors, the hepatocyte growth factor-scatter factors, and the macrophage-stimulating receptors and of fibrocystin. Plexins are involved in the regulation of cell proliferation and of cellular adhesion and repulsion receptors. In general, there are three copies of the IPT_PCSR domain present preceeded by SEMA (semaphorin) and PSI (plexin, semaphorin, integrin) domains.


Pssm-ID: 238337 [Multi-domain]  Cd Length: 90  Bit Score: 42.44  E-value: 6.76e-04
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3530 HITSVTPRHG--QKGTVVTINGTLLrGHGSGVAVVLLAGEAANVLSESDTSVV--VAASAFGGSKSGPVTIIASNGATAV 3605
Cdd:cd00603     2 VITSISPSSGplSGGTRLTITGSNL-GSGSPRVRVTVGGVPCKVLNVSSTEIVcrTPAAATPGEGPVEVTVDGANVSARV 80

                  ....*....
gi 514698100 3606 STPTAFEYR 3614
Cdd:cd00603    81 LSNTTFTYV 89
TNFRSF1A cd10576
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A), also known as TNFR1; TNFRSF1A ...
5639-5768 7.19e-04

Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A), also known as TNFR1; TNFRSF1A (also known as type I TNFR, TNFR1, DR1, TNFRSF1A, CD120a, p55) binds TNF-alpha, through the death domain (DD), and activates NF-kappaB, mediates apoptosis and activates signaling pathways controlling inflammatory, immune, and stress responses. It mediates signal transduction by interacting with antiapoptotic protein BCL2-associated athanogene 4 (BAG4/SODD) and adaptor proteins TRAF2 and TRADD that play regulatory roles. The human genetic disorder called tumor necrosis factor associated periodic syndrome (TRAPS), or periodic fever syndrome, is associated with germline mutations of the extracellular domains of this receptor, possibly due to impaired receptor clearance. TNFRSF1A polymorphisms rs1800693 and rs4149584 are associated with elevated risk of multiple sclerosis. Serum levels of TNFRSF1A are elevated in schizophrenia and bipolar disorder, and high levels are also associated with cognitive impairment and dementia. Patients with idiopathic recurrent acute pericarditis (IRAP), presumed to be an autoimmune process, have also been shown to carry rare mutations (R104Q and D12E) in the TNFRSF1A gene.


Pssm-ID: 276902 [Multi-domain]  Cd Length: 130  Bit Score: 43.50  E-value: 7.19e-04
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5639 CQLGstfkaQSGQSTRCISVTTCGAGE---EEIASPTLSTDrqCRTCASGTFKAAAGQSTTCIAVSTCAAGFTE-DVAP- 5713
Cdd:cd10576     1 CPQG-----KYLHPNNNHCCTKCHKGTylyNDCPGPGQDTV--CRECENGTFTASENYLRKCLSCSRCRKEMGQvEISPc 73
                          90       100       110       120       130
                  ....*....|....*....|....*....|....*....|....*....|....*
gi 514698100 5714 TPSSDRVCvECAPGTFKATAGDgtCRAHRTCEDTEYETVAPTSSSDRKckalTVC 5768
Cdd:cd10576    74 TVDQDTVC-GCRKNQYQHYWSS--LFQCKNCSLCLNGTIRQPCQEKQD----TIC 121
TIG pfam01833
IPT/TIG domain; This family consists of a domain that has an immunoglobulin like fold. These ...
4496-4582 7.31e-04

IPT/TIG domain; This family consists of a domain that has an immunoglobulin like fold. These domains are found in cell surface receptors such as Met and Ron as well as in intracellular transcription factors where it is involved in DNA binding. CAUTION: This family does not currently recognize a significant number of members.


Pssm-ID: 460355 [Multi-domain]  Cd Length: 84  Bit Score: 42.05  E-value: 7.31e-04
                           10        20        30        40        50        60        70        80
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  4496 VSSVVPSSG--QEGTRVTLSGTNlLGSGSGVDQVLLAGVSATVVSAASSEVVVITsalPGGVVGPVTGNVTVVSTSGALv 4573
Cdd:pfam01833    3 ITSISPSSGpaSGGTTITITGSN-FGTDSSDLKVTIGGTPCTVISVSSTTIVCTT---PPGTSGLVNVSVTVGGGGISS- 77

                   ....*....
gi 514698100  4574 haDTDSFTY 4582
Cdd:pfam01833   78 --SPLTFTY 84
AidA COG3468
Autotransporter adhesin AidA [Cell wall/membrane/envelope biogenesis, Intracellular ...
585-1000 7.65e-04

Autotransporter adhesin AidA [Cell wall/membrane/envelope biogenesis, Intracellular trafficking, secretion, and vesicular transport];


Pssm-ID: 442691 [Multi-domain]  Cd Length: 846  Bit Score: 46.86  E-value: 7.65e-04
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  585 NRTHVVVTAGDGPASTGPVVLTASNGSRVTGGAVWTQLERGAIGSVQPSSGHGGTRVTITGQRLLGGGAALASVELGGVL 664
Cdd:COG3468    12 LGGGGTGGGGGLGGTGGGNAGLGIGNGGGGGAASGSGAGGVAGNGGGGGGGAGGGGGGAGSGGGLAGAGSGGTGGNSTGG 91
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  665 ATEIAWANDTVAVVSAGASGSALAGGNVTLVADTGAVTTGSGLWAYVAPAVISSVAPTSGQAGTVVTIRGNNLSMGGAVR 744
Cdd:COG3468    92 GGGNSGTGGTGGGGGGGGSGNGGGGGGGGGGGGTGGGGGGGTGSAGGGGGGGGGGTGVGGTGAAAAGGGTGSGGGGSGGG 171
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  745 EVFLAGIPAVSVSLVNDSFVVAHASGALSGRSSPAVVRNNFGAFVSSSVNWTYVPAGAVDITRPARAQFGTRVTVTGSNL 824
Cdd:COG3468   172 GGAGGGGGGGAGGSGGAGSTGSGAGGGGGGSGGGGGAAGTGGGGGGGGGAGGATGGAGSGGNTGGGVGGGGGSAGGTGGG 251
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  825 LQGGAIIASASMAGVPCTVLSSNDTTVVVSVAGNFAATVASPSMTLVSDSGAVITFTSSTTAEPSGVVTAISPSSGQYGT 904
Cdd:COG3468   252 GLTGGGAAGTGGGGGGTGTGSGGGGGGGANGGGSGGGGGASGTGGGGTASTGGGGGGGGGNGGGGGGGSNAGGGSGGGGG 331
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  905 FVTLSGTQLLAHASNLRTVSLAGTQVLSIESATESEVIVRAGLGVNGTAGSPRLRASSGGVVAAATGVNFTYVRQGRIDT 984
Cdd:COG3468   332 GGGGGGGGGTTLNGAGSAGGGTGAALAGTGGSGSGGGGGGGSGGGGGAGGGGANTGSDGVGTGLTTGGTGNNGGGGVGGG 411
                         410
                  ....*....|....*.
gi 514698100  985 VSPLFGQLGTLVTISG 1000
Cdd:COG3468   412 GGGGLTLTGGTLTVNG 427
TNFR smart00208
Tumor necrosis factor receptor / nerve growth factor receptor repeats; Repeats in growth ...
5816-5858 7.73e-04

Tumor necrosis factor receptor / nerve growth factor receptor repeats; Repeats in growth factor receptors that are involved in growth factor binding. TNF/TNFR


Pssm-ID: 214558  Cd Length: 39  Bit Score: 40.53  E-value: 7.73e-04
                            10        20        30        40
                    ....*....|....*....|....*....|....*....|...
gi 514698100   5816 CASDEYtlssCTLSSQTQCRQCTTCGNDEYQTKACSVSQDTEC 5858
Cdd:smart00208    1 CKEGTY----CSDGNHSSCLRCRRCPPGLVVKQPCTATSDTVC 39
TNFRSF6B cd10575
Tumor necrosis factor receptor superfamily member 6B (TNFRSF6B), also known as decoy receptor ...
5930-6098 7.96e-04

Tumor necrosis factor receptor superfamily member 6B (TNFRSF6B), also known as decoy receptor 3 (DcR3); The subfamily TNFRSF6B is also known as decoy receptor 3 (DcR3), M68, or TR6. This protein is a soluble receptor without death domain and cytoplasmic domain, and secreted by cells. It acts as a decoy receptor that competes with death receptors for ligand binding. It is a pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases, and cancer. Over-expression of this gene has been noted in several cancers, including pancreatic carcinoma, and gastrointestinal tract tumors. It can neutralize the biological effects of three tumor necrosis factor superfamily (TNFSF) members: TNFSF6 (Fas ligand/FasL/CD95L) and TNFSF14 (LIGHT) which are both involved in apoptosis and inflammation, and TNFSF15 (TNF-like molecule 1A/TL1A), which is a T cell co-stimulator and involved in gut inflammation. DcR3 is a novel inflammatory marker; higher DcR3 levels strongly correlate with inflammation and independently predict cardiovascular and all-cause mortality in chronic kidney disease (CKD) patients on hemodialysis. Increased synovial inflammatory cells infiltration in rheumatoid arthritis and ankylosing spondylitis is also associated with the elevated DcR3 expression. In cartilaginous fish, mRNA expression of DcR3 in the thymus and leydig, which are the representative lymphoid tissues of elasmobranchs, suggests that DcR3 may act as a modulator in the immune system. Interestingly, in banded dogfish (Triakis scyllia), DcR3 mRNA is strongly expressed in the gill, compared with human expression in the normal lung; both are respiratory organs, suggesting potential relevance of DcR3 to respiratory function.


Pssm-ID: 276901 [Multi-domain]  Cd Length: 163  Bit Score: 43.93  E-value: 7.96e-04
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5930 CRQCVAGTTDAD---GSGTTPCVACSAGHY------VPRGRTggCAAFeCAAGHVDQDEDAATACKLCEAGVNYAGSAGL 6000
Cdd:cd10575    16 CDQCPPGTFVAKhctRDRPTVCGPCPDLHYtqfwnyLEKCRY--CNVF-CTERQVEKRQCNATHNRVCECKPGYYMEHGF 92
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6001 trCTSVSECGAGEEETSAPTASTDRVCSTCASGKFkattgqtpceavstceedeyvyrAATVSTDTQCRALTACSDEQYE 6080
Cdd:cd10575    93 --CLRHSSCPPGEGVIKLGTPYSDTQCEPCPPGFF-----------------------SASSSSTEPCQPHTNCTQGGLE 147
                         170
                  ....*....|....*...
gi 514698100 6081 TRAPtvNSDRECTGLTTC 6098
Cdd:cd10575   148 TNVP--GNDYHDTLCTSC 163
TIG pfam01833
IPT/TIG domain; This family consists of a domain that has an immunoglobulin like fold. These ...
1586-1668 1.00e-03

IPT/TIG domain; This family consists of a domain that has an immunoglobulin like fold. These domains are found in cell surface receptors such as Met and Ron as well as in intracellular transcription factors where it is involved in DNA binding. CAUTION: This family does not currently recognize a significant number of members.


Pssm-ID: 460355 [Multi-domain]  Cd Length: 84  Bit Score: 41.66  E-value: 1.00e-03
                           10        20        30        40        50        60        70        80
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  1586 ISSVTPASGQF--GTAVTVAGQGLRLGfSSVTQVRLGDVAATILSENNTHVVVRagTGSLVGVPVDVQVISSGATTVQQS 1663
Cdd:pfam01833    3 ITSISPSSGPAsgGTTITITGSNFGTD-SSDLKVTIGGTPCTVISVSSTTIVCT--TPPGTSGLVNVSVTVGGGGISSSP 79

                   ....*
gi 514698100  1664 VAWTY 1668
Cdd:pfam01833   80 LTFTY 84
TNFRSF11A_teleost cd15836
Tumor necrosis factor receptor superfamily member 11A (TNFRSF11A) in teleost; also known as ...
5809-5895 1.00e-03

Tumor necrosis factor receptor superfamily member 11A (TNFRSF11A) in teleost; also known as RANK; TNFRSF11A (also known as RANK, FEO, OFE, ODFR, OSTS, PDB2, CD26, OPTB7, TRANCER, LOH18CR1) induces the activation of NF-kappa B and MAPK8/JNK through interactions with various TRAF adaptor proteins. This receptor and its ligand are important regulators of the interaction between T cells and dendritic cells. This receptor is also an essential mediator for osteoclast and lymph node development. Mutations at this locus have been associated with familial expansile osteolysis, autosomal recessive osteopetrosis, and Juvenile Paget's disease (JPD) of bone. Alternatively spliced transcript variants have been described for this locus. Mutation analysis may improve diagnosis, prognostication, recurrence risk assessment, and perhaps treatment selection among the monogenic disorders of RANKL/OPG/RANK activation.


Pssm-ID: 276932 [Multi-domain]  Cd Length: 122  Bit Score: 42.87  E-value: 1.00e-03
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5809 KCvgCDECASDEYTLSSCTLSSQTQCRQcttCGNDEYQTkacSVSQDTECATLTTCSSTQ-FEVEAP-TATRDRRCKdlt 5886
Cdd:cd15836    14 KC--CRKCEPGSFVFAHCSGSSDTICRD---CGRNEYQP---DWTSEMKCIPQKFCDEGKgFNRTRPhNPTALEPCQ--- 82

                  ....*....
gi 514698100 5887 aCQPGeYEC 5895
Cdd:cd15836    83 -CKPG-FQC 89
IPT_PCSR cd00603
IPT domain of Plexins and Cell Surface Receptors (PCSR) and related proteins . This subgroup ...
104-184 1.19e-03

IPT domain of Plexins and Cell Surface Receptors (PCSR) and related proteins . This subgroup contains IPT domains of plexins, receptors, like the plasminogen-related growth factor receptors, the hepatocyte growth factor-scatter factors, and the macrophage-stimulating receptors and of fibrocystin. Plexins are involved in the regulation of cell proliferation and of cellular adhesion and repulsion receptors. In general, there are three copies of the IPT_PCSR domain present preceeded by SEMA (semaphorin) and PSI (plexin, semaphorin, integrin) domains.


Pssm-ID: 238337 [Multi-domain]  Cd Length: 90  Bit Score: 41.67  E-value: 1.19e-03
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  104 VITAVRPAIG--RVGTLVTIEGERLQSGGSAVaRVDLGGVPATLLHGNDSTVVviCSAGSGA----GAVRVTSDVGGFVE 177
Cdd:cd00603     2 VITSISPSSGplSGGTRLTITGSNLGSGSPRV-RVTVGGVPCKVLNVSSTEIV--CRTPAAAtpgeGPVEVTVDGANVSA 78

                  ....*..
gi 514698100  178 GLLWTFV 184
Cdd:cd00603    79 RVLSNTT 85
TNFRSF11B_teleost cd13412
Tumor necrosis factor receptor superfamily 11B (TNFRSF11B) in teleost; also known as ...
5930-6033 1.23e-03

Tumor necrosis factor receptor superfamily 11B (TNFRSF11B) in teleost; also known as Osteoprotegerin (OPG); This subfamily of TNFRSF11B (also known as Osteoprotegerin, OPG, TR1, OCIF) is found in teleosts. It is a secreted glycoprotein that regulates bone resorption. It binds to two ligands, RANKL (receptor activator of nuclear factor kappaB ligand, also known as osteoprotegerin ligand, OPGL, TRANCE, TNF-related activation induced cytokine), a critical cytokine for osteoclast differentiation, and TRAIL (TNF-related apoptosis-inducing ligand), involved in immune surveillance. Therefore, acting as a decoy receptor for RANKL and TRAIL, OPG inhibits the regulatory effects of nuclear factor-kappaB on inflammation, skeletal, and vascular systems, and prevents TRAIL-induced apoptosis. Studies in mice counterparts suggest that this protein and its ligand also play a role in lymph-node organogenesis and vascular calcification. Circulating OPG levels have emerged as independent biomarkers of cardiovascular disease (CVD) in patients with acute or chronic heart disease. OPG has also been implicated in various inflammations and linked to diabetes and poor glycemic control. Alternatively spliced transcript variants of this gene have been reported, although their full length nature has not been determined. Genetic analysis of the Japanese rice fish medaka (Oryzias latipes) has shown that entire networks for bone formation are conserved between teleosts and mammals; enabling medaka to be used as a genetic model to monitor bone homeostasis in vivo.


Pssm-ID: 276917 [Multi-domain]  Cd Length: 129  Bit Score: 42.86  E-value: 1.23e-03
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5930 CRQCVAGT-TDADGSGTTP--CVACSAGH------YVPRGRTggCAAFeCAAGHVDQDEDAATACKLCEAGVNYAGSAGL 6000
Cdd:cd13412    22 CKKCPPGThMAAHCTATTQtkCLPCPAAHytelwnYLPRCLY--CNNF-CSENQEVEIECSATNNRVCRCKEGYYMDSDF 98
                          90       100       110
                  ....*....|....*....|....*....|...
gi 514698100 6001 trCTSVSECGAGEEETSAPTASTDRVCSTCASG 6033
Cdd:cd13412    99 --CIRHTECGPGYGVKTKGTTKQDTVCEKCPSG 129
TNFRSF4 cd13406
Tumor necrosis factor receptor superfamily member 4 (TNFRSF4), also known as CD134 or OXO40; ...
6143-6261 1.29e-03

Tumor necrosis factor receptor superfamily member 4 (TNFRSF4), also known as CD134 or OXO40; TNFRSF4 (also known as OX40, ACT35, CD134, IMD16, TXGP1L) activates NF-kappaB through its interaction with adaptor proteins TRAF2 and TRAF5. It also promotes the expression of apoptosis inhibitors BCL2 and BCL2lL1/BCL2-XL, and thus suppresses apoptosis. It is primarily expressed on activated CD4+ and CD8+ T cells, where it is transiently expressed and upregulated on the most recently antigen-activated T cells within inflammatory lesions. This makes it an attractive target to modulate immune responses, i.e. TNFRSF4 (OX40) blocking agents to inhibit adverse inflammation or agonists to enhance immune responses. An artificially created biologic fusion protein, OX40-immunoglobulin (OX40-Ig), prevents OX40 from reaching the T-cell receptors, thus reducing the T-cell response. Some single nucleotide polymorphisms (SNPs) of its natural ligand OX40 ligand (OX40L, CD252), which is also found on activated T cells, have been associated with systemic lupus erythematosus.


Pssm-ID: 276911 [Multi-domain]  Cd Length: 142  Bit Score: 43.16  E-value: 1.29e-03
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6143 CDRCDSGTQYEtATCTATTNRVCADltvCADTEYESVaatdTSDRKCSSCREC--TSSEYLVSGCSESANAVCK--ACTE 6218
Cdd:cd13406    15 CHECPPGEGME-SRCTGTQDTVCSP---CEPGFYNEA----VNYEPCKPCTQCnqRSGSEEKQKCTKTSDTVCRcrPGTQ 86
                          90       100       110       120       130
                  ....*....|....*....|....*....|....*....|....*....|....
gi 514698100 6219 CPSGTFVSTACTPLADAEC-----------TECTRcgSGYFVQSPCTSEADTTC 6261
Cdd:cd13406    87 PLDSYKPGVDCVPCPPGHFsrgdnqackpwTNCSL--AGKRTLRPGSSTSDAVC 138
TNFRSF3 cd10578
Tumor necrosis factor receptor superfamily member 3 (TNFRSF3), also known as lymphotoxin beta ...
5768-5906 1.36e-03

Tumor necrosis factor receptor superfamily member 3 (TNFRSF3), also known as lymphotoxin beta receptor (LTBR); TNFRSF3 (also known as lymphotoxin beta receptor, LTbetaR, CD18, TNFCR, TNFR3, D12S370, TNFR-RP, TNFR2-RP, LT-BETA-R, TNF-R-III) plays a role in signaling during development of lymphoid and other organs, lipid metabolism, immune response, and programmed cell death. Its ligands include lymphotoxin (LT) alpha/beta membrane form (heterotrimer) and tumor necrosis factor ligand superfamily member 14 (also known as LIGHT). TNFRSF3 agonism by these ligands initiates canonical, as well as non-canonical nuclear factor-kappaB (NF-kappaB) signaling, and preferentially results in the translocation of p52-RELB complexes into the nucleus. While these ligands are often expressed by T and B cells, TNFRSF3 is conspicuous absence on T and B lymphocytes and NK cells, suggesting that signaling may be unidirectional for TNFRSF3. Activity of this receptor has also been linked to carcinogenesis; it helps trigger apoptosis and can also lead to release of the interleukin 8 (IL8). Alternatively spliced transcript variants encoding multiple isoforms have been observed.


Pssm-ID: 276904 [Multi-domain]  Cd Length: 158  Bit Score: 43.22  E-value: 1.36e-03
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5768 CQDDEWESKAPTittDRECspCGRCTDGLTLDKACTDTSPTKCVGCDECASDEY--TLSSCTLssqtqCRQC-TTCGNDE 5844
Cdd:cd10578    33 CWDQEKEYYEPR---HQVC--CSRCPPGTHVSAECSRSQDTVCATCPENSYNEHwnHLSICQL-----CRPCdPVLGFEE 102
                          90       100       110       120       130       140
                  ....*....|....*....|....*....|....*....|....*....|....*....|...
gi 514698100 5845 yqTKACSVSQDTECatltTCSSTQFEVeaPTATRDRRCKDLTACQPG-EYECTAATLTTDREC 5906
Cdd:cd10578   103 --VAPCTSDRKTQC----RCQPGMFCV--HWDNECEHCEPLSDCPPGtEAELTDEVGEADNNC 157
IPT_CGTD cd00604
IPT domain (domain D) of cyclodextrin glycosyltransferase (CGTase) and similar enzymes. These ...
3354-3440 1.39e-03

IPT domain (domain D) of cyclodextrin glycosyltransferase (CGTase) and similar enzymes. These enzymes are involved in the enzymatic hydrolysis of alpha-1,4 linkages of starch polymers and belong to the glycosyl hydrolase family 13. Most consist of three domains (A,B,C) but CGTase is more complex and has two additional domains (D,E). The function of the IPT/D domain is unknown.


Pssm-ID: 238338 [Multi-domain]  Cd Length: 81  Bit Score: 41.18  E-value: 1.39e-03
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3354 VINSVVPASGQEGTLVTVSGvRLLGSLPGRITFvevCGTEAEVVSESDTLVVARLRSngGASQLGDVVVRADNGARTRAV 3433
Cdd:cd00604     2 LIGSVGPVMGKPGNTVTISG-EGFGSTGGTVYF---GGTAAEVLSWSDTSIVVEVPR--VAPGNYNISVTTVDGVTSNGY 75

                  ....*..
gi 514698100 3434 NgFTYLS 3440
Cdd:cd00604    76 N-FEVLT 81
IPT_plexin_repeat1 cd01180
First repeat of the IPT domain of Plexins and Cell Surface Receptors (PCSR) . Plexins are ...
1328-1393 1.43e-03

First repeat of the IPT domain of Plexins and Cell Surface Receptors (PCSR) . Plexins are involved in the regulation of cell proliferation and of cellular adhesion and repulsion receptors. In general, there are three copies of the IPT domain present preceeded by SEMA (semaphorin) and PSI (plexin, semaphorin, integrin) domains.


Pssm-ID: 238585  Cd Length: 94  Bit Score: 41.53  E-value: 1.43e-03
                          10        20        30        40        50        60        70
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*.
gi 514698100 1328 SVTSVSPSSG--QGGTRVTVLGANLRLGSSAVT-GVLLGSAACSLISE---NDTAVVCAAGVA----SAGSVPVTV 1393
Cdd:cd01180     2 VITEFFPLSGplEGGTRLTICGSNLGLRKNDVRhGVRVGGVPCNPEPPeysSSEKIVCTTGPAgnpvFNGPVEVTV 77
TNFRSF_viral cd15839
Tumor necrosis factor receptor superfamily members, virus-encoded; This family contains viral ...
6210-6279 1.44e-03

Tumor necrosis factor receptor superfamily members, virus-encoded; This family contains viral TNFR homologs that include vaccinia virus (VACV) cytokine response modifier E (CrmE), an encoded TNFR that shares significant sequence similarity with mammalian type 2 TNF receptors (TNFSFR1B, p75, TNFR type 2), a cowpox virus encoded cytokine-response modifier B (crmB), which is a secreted form of TNF receptor that can contribute to the modification of TNF-mediated antiviral processes, and a myxoma virus (MYXV) T2 (M-T2) protein that binds and inhibits rabbit TNF-alpha. The CrmE structure confirms that the canonical TNFR fold is adopted, but only one of the two "ligand-binding" loops of TNFRSF1A is conserved, suggesting a mechanism for the higher affinity of poxvirus TNFRs for TNFalpha over lymphotoxin-alpha. CrmB protein specifically binds TNF-alpha and TNF-beta indicating that cowpox virus seeks to invade antiviral processes mediated by TNF. Intracellular M-T2 blocks virus-induced lymphocyte apoptosis via a highly conserved viral preligand assembly domain (vPLAD), which controls receptor signaling competency prior to ligand binding.


Pssm-ID: 276935 [Multi-domain]  Cd Length: 125  Bit Score: 42.55  E-value: 1.44e-03
                          10        20        30        40        50        60        70
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|.
gi 514698100 6210 NAVCKACTECPSGTFVSTACTPLADaecTECTRCGSGYFVQSPCTSeadTTCKRCRS-CASGEYLHTACTT 6279
Cdd:cd15839     9 NSNNLCCKSCPPGTYASHLCDTTSN---TKCDPCPSDTFTSIPNHI---PACLSCRGrCSSNQVETKSCSN 73
TNFRSF cd00185
Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) ...
5721-5838 1.47e-03

Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) interactions with TNF superfamily (TNFSF) ligands (TNFL) control key cellular processes such as differentiation, proliferation, apoptosis, and cell growth. Dysregulation of these pathways has been shown to result in a wide range of pathological conditions, including autoimmune diseases, inflammation, cancer, and viral infection. There are 29 very diverse family members of TNFRSF reported in humans: 22 are type I transmembrane receptors (single pass with the N terminus on extracellular side of the cell membrane) and have a clear signal peptide; the remaining 7 members are either type III transmembrane receptors (single pass with the N terminus on extracellular side of the membrane but no signal sequence; TNFR13B, TNFR13C, TNFR17, and XEDAR), or attached to the membrane via a glycosylphosphatidylinositol (GPI) linker (TNFR10C), or secreted as soluble receptors (TNFR11B and TNFR6B). All TNFRs contain relatively short cysteine-rich domains (CRDs) in the ectodomain, and are involved in interaction with the TNF homology domain (THD) of their ligands. TNFRs often have multiple CRDs (between one and six), with the most frequent configurations of three or four copies; most CRDs possess three disulfide bridges, but could have between one and four. Localized or genome-wide duplication and evolution of the TNFRSF members appear to have paralleled the emergence of the adaptive immune system; teleosts (i.e. ray-finned, bony fish), which possess an immune system with B and T cells, possess primary and secondary lymphoid organs, and are capable of adaptive responses to pathogens also display several characteristics that are different from the mammalian immune system, making teleost TNFSF orthologs and paralogs of interest to better understand immune system evolution and the immunological pathways elicited to pathogens.


Pssm-ID: 276900 [Multi-domain]  Cd Length: 87  Bit Score: 41.43  E-value: 1.47e-03
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5721 CVECAPGTFkatagdgtCRAHRTCedteyetvaptsSSDRKCKAltvCQDDEWeskAPTITTDRECSPCGRCTDG-LTLD 5799
Cdd:cd00185     2 CQRCPPGEY--------LSSDCTA------------TTDTVCSP---CPPGTY---SESWNSLSKCLPCTTCGGGnQVEK 55
                          90       100       110
                  ....*....|....*....|....*....|....*....
gi 514698100 5800 KACTDTSPTKCvgcdECASDEYTLSSctlSSQTQCRQCT 5838
Cdd:cd00185    56 TPCTATDNRCC----TCKPGFYCDEG---TNVEECKPCT 87
TNFRSF6B cd10575
Tumor necrosis factor receptor superfamily member 6B (TNFRSF6B), also known as decoy receptor ...
6050-6192 1.47e-03

Tumor necrosis factor receptor superfamily member 6B (TNFRSF6B), also known as decoy receptor 3 (DcR3); The subfamily TNFRSF6B is also known as decoy receptor 3 (DcR3), M68, or TR6. This protein is a soluble receptor without death domain and cytoplasmic domain, and secreted by cells. It acts as a decoy receptor that competes with death receptors for ligand binding. It is a pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases, and cancer. Over-expression of this gene has been noted in several cancers, including pancreatic carcinoma, and gastrointestinal tract tumors. It can neutralize the biological effects of three tumor necrosis factor superfamily (TNFSF) members: TNFSF6 (Fas ligand/FasL/CD95L) and TNFSF14 (LIGHT) which are both involved in apoptosis and inflammation, and TNFSF15 (TNF-like molecule 1A/TL1A), which is a T cell co-stimulator and involved in gut inflammation. DcR3 is a novel inflammatory marker; higher DcR3 levels strongly correlate with inflammation and independently predict cardiovascular and all-cause mortality in chronic kidney disease (CKD) patients on hemodialysis. Increased synovial inflammatory cells infiltration in rheumatoid arthritis and ankylosing spondylitis is also associated with the elevated DcR3 expression. In cartilaginous fish, mRNA expression of DcR3 in the thymus and leydig, which are the representative lymphoid tissues of elasmobranchs, suggests that DcR3 may act as a modulator in the immune system. Interestingly, in banded dogfish (Triakis scyllia), DcR3 mRNA is strongly expressed in the gill, compared with human expression in the normal lung; both are respiratory organs, suggesting potential relevance of DcR3 to respiratory function.


Pssm-ID: 276901 [Multi-domain]  Cd Length: 163  Bit Score: 43.16  E-value: 1.47e-03
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6050 CEEDEYVYRAATVSTDTQCralTACSDEQYETRAPTVNSDRECTGLttCGSGEYETRAPTATTDRKCASV---------- 6119
Cdd:cd10575    19 CPPGTFVAKHCTRDRPTVC---GPCPDLHYTQFWNYLEKCRYCNVF--CTERQVEKRQCNATHNRVCECKpgyymehgfc 93
                          90       100       110       120       130       140       150
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*..
gi 514698100 6120 ---TQCDSTQFVVSKPTATTDRDCAECdrcdsgtQYETATCTATTNRVCADLTVCADTEYE-SVAATDTSDRKCSSC 6192
Cdd:cd10575    94 lrhSSCPPGEGVIKLGTPYSDTQCEPC-------PPGFFSASSSSTEPCQPHTNCTQGGLEtNVPGNDYHDTLCTSC 163
TNFRSF7 cd13408
Tumor necrosis factor receptor superfamily member 7 (TNFRSF7), also known as CD27; TNFRSF7 ...
6185-6240 1.73e-03

Tumor necrosis factor receptor superfamily member 7 (TNFRSF7), also known as CD27; TNFRSF7 (also known as CD27, T14, S152, Tp55, S152, LPFS2) has a key role in the generation of immunological memory via effects on T-cell expansion and survival, and B cell development. It binds to ligand CD70, and plays a key role in regulating B-cell activation and immunoglobulin synthesis. CD27 transduces signals that lead to the activation of NF-kappaB and MAPK8/JNK, and mediates the signaling process through adaptor proteins TRAF2 and TRAF5. CD27-binding protein (SIVA), a pro-apoptotic protein, can bind to CD27 and may play an important role in the apoptosis induced by this receptor. The potential role of the CD27/CD70 pathway in the course of inflammatory diseases, such as arthritis, and inflammatory bowel disease, suggests that CD70 may be a target for immune intervention. The expression of CD27 and CD44 molecules correlates with the differentiation stage of B cell precursors and has been shown to have a biological significance in acute lymphoblastic leukemia.


Pssm-ID: 276913 [Multi-domain]  Cd Length: 121  Bit Score: 42.10  E-value: 1.73e-03
                          10        20        30        40        50
                  ....*....|....*....|....*....|....*....|....*....|....*.
gi 514698100 6185 SDRKCSSCRECTSSeYLVSGCSESANAVCKacteCPSGtfvsTACTplaDAECTEC 6240
Cdd:cd13408    74 ARPHCESCRHCNSG-LLIRNCTITANTECA----CPKG----WQCR---DKECTEC 117
VSP pfam03302
Giardia variant-specific surface protein;
5789-6221 1.73e-03

Giardia variant-specific surface protein;


Pssm-ID: 146106 [Multi-domain]  Cd Length: 397  Bit Score: 44.96  E-value: 1.73e-03
                           10        20        30        40        50        60        70        80
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  5789 CGRCTDG--LTLDKA-CTDTSPTKCVGCDECASDEYTL-----SSCTLSSQTQCRQ---------CTTCGNDEYQTKACS 5851
Cdd:pfam03302    1 CDECKPGyeLSADKTkCTSSAPCKTENCKACSNDKREVceecnSNNYLTPTSQCIDdcakignyyYTTNANNKKICKECT 80
                           90       100       110       120       130       140       150       160
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  5852 VSQDTECATLTTCSstqfeveaptatrdrrckdltACQPGEYEctaatlttdreccgvtqcvpgSEETSAPtatSDRECR 5931
Cdd:pfam03302   81 VANCKTCEDQGQCQ---------------------ACNDGFYK---------------------SGDACSP---CHESCK 115
                          170       180       190       200       210       220       230       240
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  5932 QCVAGTTdadgSGTTPCVACSAGHYVPRGRTGGCAAfECAAGHVdqdedaATACKLCeaGVNYAGSAGLTRC---TSVSE 6008
Cdd:pfam03302  116 TCSGGTA----SDCTECLTGKALRYGNDGTKGTCGE-GCTTGTG------AGACKTC--GLTIDGTSYCSECateTEYPQ 182
                          250       260       270       280       290       300       310       320
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  6009 CGAGEEETSAPTAS------TDRVCSTCASGKFKATTGqtpceavstCEEdeyvyraatvstdtqcraltacsdeqyETR 6082
Cdd:pfam03302  183 NGVCTSTAARATATckassvANGMCSSCANGYFRMNGG---------CYE---------------------------TTK 226
                          330       340       350       360       370       380       390       400
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  6083 APtvnsdrectGLTTCgsgeyeTRAPTATTDRKCASVTQCDSTQFVVSKPTATTDRDCAECDRCDSGTQYETATCTattn 6162
Cdd:pfam03302  227 FP---------GKSVC------EEANSGGTCQKEAPGYKLNNGDLVTCSPGCKTCTSNTVCTTCMDGYVKTSDSCT---- 287
                          410       420       430       440       450       460
                   ....*....|....*....|....*....|....*....|....*....|....*....|....
gi 514698100  6163 rvcadltvcadteyesvaatdtsdrKC-SSCRECTSSEYLVSGCS----ESANAvCKACTECPS 6221
Cdd:pfam03302  288 -------------------------KCdSSCETCTGATTTCKTCAtgyyKSGTG-CVSCTSSES 325
TNFRSF4 cd13406
Tumor necrosis factor receptor superfamily member 4 (TNFRSF4), also known as CD134 or OXO40; ...
5715-5836 1.77e-03

Tumor necrosis factor receptor superfamily member 4 (TNFRSF4), also known as CD134 or OXO40; TNFRSF4 (also known as OX40, ACT35, CD134, IMD16, TXGP1L) activates NF-kappaB through its interaction with adaptor proteins TRAF2 and TRAF5. It also promotes the expression of apoptosis inhibitors BCL2 and BCL2lL1/BCL2-XL, and thus suppresses apoptosis. It is primarily expressed on activated CD4+ and CD8+ T cells, where it is transiently expressed and upregulated on the most recently antigen-activated T cells within inflammatory lesions. This makes it an attractive target to modulate immune responses, i.e. TNFRSF4 (OX40) blocking agents to inhibit adverse inflammation or agonists to enhance immune responses. An artificially created biologic fusion protein, OX40-immunoglobulin (OX40-Ig), prevents OX40 from reaching the T-cell receptors, thus reducing the T-cell response. Some single nucleotide polymorphisms (SNPs) of its natural ligand OX40 ligand (OX40L, CD252), which is also found on activated T cells, have been associated with systemic lupus erythematosus.


Pssm-ID: 276911 [Multi-domain]  Cd Length: 142  Bit Score: 42.39  E-value: 1.77e-03
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5715 PSSDRVCVECAPG---TFKATAG-DGTCRAhrtCEDTEYETvaPTSSSdrKCKALTVC-QDDEWESKAP-TITTDRECS- 5787
Cdd:cd13406     9 PSGEKCCHECPPGegmESRCTGTqDTVCSP---CEPGFYNE--AVNYE--PCKPCTQCnQRSGSEEKQKcTKTSDTVCRc 81
                          90       100       110       120       130
                  ....*....|....*....|....*....|....*....|....*....|
gi 514698100 5788 -PCGRCTDGLTLDKACTDTSPTKCVGCDECASDEYTlsSCTLSSQTQCRQ 5836
Cdd:cd13406    82 rPGTQPLDSYKPGVDCVPCPPGHFSRGDNQACKPWT--NCSLAGKRTLRP 129
RhsA COG3209
Uncharacterized conserved protein RhaS, contains 28 RHS repeats [General function prediction ...
3981-4775 1.83e-03

Uncharacterized conserved protein RhaS, contains 28 RHS repeats [General function prediction only];


Pssm-ID: 442442 [Multi-domain]  Cd Length: 1103  Bit Score: 45.52  E-value: 1.83e-03
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3981 GTVVTVSGARLLGGGSQVASVTFAGVEVHDVLTQSDSEIVAVLRSGGAGGSGDVVVESDTGAVVRLAAGFRYVPQAQILH 4060
Cdd:COG3209     3 SLGLVGGTTGASSTLLAATNAGGGTAVTNAGSTVLLAKGGLSTAAAAGGAATLTARSASTTDVVGTLTGAGGTSAGGVTA 82
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4061 LTRASGQVGTETTIVGEGLQMGDVIVSVLLAGVPAQVLSQSDVNVTVRANTSTPATGDVMLVAGSGAFVELVNGWTYDDA 4140
Cdd:COG3209    83 LGDASAAGGGYVGGAAAGGGATLTGLAAATASAGRLVSTGAGAGGTVTAATGGTLGATAGSATTGSTDGGRGGVAVTGLA 162
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4141 GAIEDVQPAQGFAGNLVTISGRGLRGGSAAVTRVTLVGVLATEIVHENDTVVVVRAGLPVDPFVMQTGRVVVMGSSGATI 4220
Cdd:COG3209   163 GGGASAYGLTLGGAAAGPATGVGTGAVTLATGLAGSALLALGSGAILGGLAGAYSGSATTATGTALGTPASVAATVTGSA 242
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4221 TALDAFTYNVAGDITDVSPSFGRVGTRVRLLGSNLLGGGTSAEVRFGGVTGAVTAVSETAIDVTVPAASGPSGLVNVSIV 4300
Cdd:COG3209   243 TGAAGAGAAVATAATTLGGTTGAGTGASGAGLDASTGTGGAGGSNAAATAGGLGGAGLGSGGAGGGGTAGGTTTAAGTTG 322
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4301 SDSGSHVLEVAGFRYTAPGSVAAVAPSSGHEGTVVTISGASLLAEEADAARVTLGGVNATVVFANDTRLVVVAGASSTAG 4380
Cdd:COG3209   323 TAAVSGAADAGTTTTTGTGTGGTTTTVGGGGSLTLGGYGAAGGLTTSVGAGGGGSTSGSTTTVGGGGTATGSGGGSSTTG 402
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4381 LGDVFIETVGGARLLAANAWMYVAQATITDVQPGSGQVGTRVTIRGTGLRCGGAAVTSVLLGSAVAPVVTEDDTTVIAEA 4460
Cdd:COG3209   403 VGAGTTTTSTTGGDGGPATAAGALTAGGTATGTGTGGGGTTAGTDATTTTGGAGASGTLTTTGGAATGATTGGGTEAGTG 482
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4461 PARAVGASPVDVTVVADTGAYVTADDAWTFVTAGAVSSVVPSSGQEGTRVTLSGTNLLGSGSGVDQVLLAGVSATVVSAA 4540
Cdd:COG3209   483 GGTLTSGSAGATTLGTDTTLDDTLGGTTTTTAGARGLVVTTGTTLTLGTTTTATLSATDATGTGDTTTTGTVGTGTSTGT 562
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4541 SSEVVVITSALPGGVVGPVTGNVTVVSTSGALVHADTDSFTYVRAGAVTGVSPLAGVQGTRVTVTGerllgGGSSIAAVQ 4620
Cdd:COG3209   563 GGTGTVTTTGDGTGGASTTTGTTGGTATTTTVTTTTTTSTAGTTTTTTSGYTRAGLTLTLGTGTAS-----GLERATAST 637
                         650       660       670       680       690       700       710       720
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4621 VAGVETRVIESSNNTHVVLRASNGTGSGDIELIADTGAKTVANVTFSYLELGVITAVRPAIGRVGTLVTIEGERLQSGGS 4700
Cdd:COG3209   638 GSTTGGTTGTGVTTTGTTTTRATGTTGTGTGVTAGLTTLATGGTTVGGGTGTTSTATTGATTGGTETGTTVTTLAGGTTT 717
                         730       740       750       760       770       780       790
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*
gi 514698100 4701 AVARVDLGPAAPVVLQAFLDREQLHAESSSPDAARTGTTFVGTDHDALHHDMQGDGHRQQQQPQQGAHQQWDAED 4775
Cdd:COG3209   718 RLGTTTTGGGGGTTTDGTGTGGTTGTLTTTSTTTTTTAGALTYTYDALGRLTSETTPGGVTQGTYTTRYTYDALG 792
IPT_plexin_repeat1 cd01180
First repeat of the IPT domain of Plexins and Cell Surface Receptors (PCSR) . Plexins are ...
2732-2818 1.94e-03

First repeat of the IPT domain of Plexins and Cell Surface Receptors (PCSR) . Plexins are involved in the regulation of cell proliferation and of cellular adhesion and repulsion receptors. In general, there are three copies of the IPT domain present preceeded by SEMA (semaphorin) and PSI (plexin, semaphorin, integrin) domains.


Pssm-ID: 238585  Cd Length: 94  Bit Score: 41.15  E-value: 1.94e-03
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2732 PVVGEIEPSSGQL--GTVVTIRGSNL-LAGGEALQLVTLAGVPAEAIL---SSNNSVVTVSSAQGSGATGPAVLVAAeTG 2805
Cdd:cd01180     1 PVITEFFPLSGPLegGTRLTICGSNLgLRKNDVRHGVRVGGVPCNPEPpeySSSEKIVCTTGPAGNPVFNGPVEVTV-GH 79
                          90
                  ....*....|...
gi 514698100 2806 GRAVGTPSVNYTY 2818
Cdd:cd01180    80 GSFRTESSEGFSF 92
TNFR smart00208
Tumor necrosis factor receptor / nerve growth factor receptor repeats; Repeats in growth ...
6138-6165 2.33e-03

Tumor necrosis factor receptor / nerve growth factor receptor repeats; Repeats in growth factor receptors that are involved in growth factor binding. TNF/TNFR


Pssm-ID: 214558  Cd Length: 39  Bit Score: 39.37  E-value: 2.33e-03
                            10        20
                    ....*....|....*....|....*...
gi 514698100   6138 RDCAECDRCDSGtQYETATCTATTNRVC 6165
Cdd:smart00208   13 SSCLRCRRCPPG-LVVKQPCTATSDTVC 39
COG4625 COG4625
Uncharacterized conserved protein, contains a C-terminal beta-barrel porin domain [Function ...
2518-3025 2.33e-03

Uncharacterized conserved protein, contains a C-terminal beta-barrel porin domain [Function unknown];


Pssm-ID: 443664 [Multi-domain]  Cd Length: 900  Bit Score: 45.15  E-value: 2.33e-03
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2518 VHAVVVTAKAGNVSASPEPIRIVADTGAVVTLNDTWSYVQAGRVASVNPASGHQGTLVTIQGTSLLGGGTTAVSVMLAGS 2597
Cdd:COG4625     1 GGGGGGGGGGGGGGGGTGGGGAGGGGGAGGGAGGGGAGGGGGGGGGGGGAGGGGGGGGTGGGGGGGGGGGGGGAGGGGGG 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2598 SALVLSSNATDVVVTAGPGAQSSGDVVIVSETGATVARGAAWTYVEPGFIQRASPASGTAGTRVTITGASLLGGASTLAR 2677
Cdd:COG4625    81 GGGGGGGGGTGGVGGGGGGGGGGGGGGGGGGGGGGGGSAGGGGGGAGGAGGGGGGGAGGGGGGGGGGGAGGGGGGGAGGA 160
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2678 VTLAGVPVDSIDHQSNEVVIVTAASGAQRMGAIVLTADTGAVVQRLNFWDYIATPVVGEIEPSSGQLGTVVTIRGSNLLA 2757
Cdd:COG4625   161 GGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGNGGGGGGGGGGGGGGGGGGGGAGGGGGGGGGGGGGGGGGGGGGGGGGG 240
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2758 GGEALQLVTLAGVPAEAILSSNNSVVTVSSAQGSGATGPAVLVAAETGGRAVGTPSVNYTYLAGSSIASVQPASGQGGTF 2837
Cdd:COG4625   241 GGGGGGGAGGGGGGGGGNGGGGGAGGGGGGGGGGSGGGGGGGGGGGSGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG 320
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2838 VDIVGERLLSGGSAVAAVSLAGVAAEVISGNDTFVRARAGPSAVTLTGDVVVTADTGGRAELVNAWAYNTAGVVDAVVPG 2917
Cdd:COG4625   321 GGGGGGGGGGGGGAGGGGGSGGAGAGGGGAGGGGAGGGGGGGTGGGGGGGGGGGGGSGGGGAGGGGGSGGGGGGGAGGGG 400
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2918 S--GQRGTRVTIQGTRLLGEGTRAVRVSLGDVRAHIVESTATAVVVVYPGRVTLGVHDVEVESDTGSVVSAPAAWTALDN 2995
Cdd:COG4625   401 GggGAGGTGGGGAGGGGGAAGGGGGGTGAGGGGGGGGTGAGGGGATGGGGGGGGGAGGSGGGAGAGGGSGSGAGTLTLTG 480
                         490       500       510
                  ....*....|....*....|....*....|
gi 514698100 2996 GVVHSVNPDVGHGGTVVTIRGVRLLGGGDS 3025
Cdd:COG4625   481 NNTYTGTTTVNGGGNYTQSAGSTLAVEVDA 510
IPT_PCSR cd00603
IPT domain of Plexins and Cell Surface Receptors (PCSR) and related proteins . This subgroup ...
4588-4670 2.55e-03

IPT domain of Plexins and Cell Surface Receptors (PCSR) and related proteins . This subgroup contains IPT domains of plexins, receptors, like the plasminogen-related growth factor receptors, the hepatocyte growth factor-scatter factors, and the macrophage-stimulating receptors and of fibrocystin. Plexins are involved in the regulation of cell proliferation and of cellular adhesion and repulsion receptors. In general, there are three copies of the IPT_PCSR domain present preceeded by SEMA (semaphorin) and PSI (plexin, semaphorin, integrin) domains.


Pssm-ID: 238337 [Multi-domain]  Cd Length: 90  Bit Score: 40.90  E-value: 2.55e-03
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4588 VTGVSPLAGVQ--GTRVTVTGERlLGGGSSIAAVQVAGVETRVIESSNNTHV-VLRASNGTGSGDIEL---IADTGAKTV 4661
Cdd:cd00603     3 ITSISPSSGPLsgGTRLTITGSN-LGSGSPRVRVTVGGVPCKVLNVSSTEIVcRTPAAATPGEGPVEVtvdGANVSARVL 81

                  ....*....
gi 514698100 4662 ANVTFSYLE 4670
Cdd:cd00603    82 SNTTFTYVE 90
TNFR_c6 pfam00020
TNFR/NGFR cysteine-rich region;
6140-6165 2.57e-03

TNFR/NGFR cysteine-rich region;


Pssm-ID: 459633 [Multi-domain]  Cd Length: 39  Bit Score: 39.22  E-value: 2.57e-03
                           10        20
                   ....*....|....*....|....*.
gi 514698100  6140 CAECDRCDSGtQYETATCTATTNRVC 6165
Cdd:pfam00020   15 CLPCTVCPPG-QVVVRPCTPTSDTVC 39
COG4625 COG4625
Uncharacterized conserved protein, contains a C-terminal beta-barrel porin domain [Function ...
2343-2884 2.60e-03

Uncharacterized conserved protein, contains a C-terminal beta-barrel porin domain [Function unknown];


Pssm-ID: 443664 [Multi-domain]  Cd Length: 900  Bit Score: 45.15  E-value: 2.60e-03
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2343 TSSGAAGTSVRIVLVADTGARVETATVQFDFVPPGDIQAVGPASGQEGTLVTIRGERLLGNGTALAYTYIGGVAAQIVSA 2422
Cdd:COG4625     2 GGGGGGGGGGGGGGGTGGGGAGGGGGAGGGAGGGGAGGGGGGGGGGGGAGGGGGGGGTGGGGGGGGGGGGGGAGGGGGGG 81
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2423 SNDEVVVVAGRSSNRFTLDQHPVISDIVLVADNGAEVVAASSFTYLRPGVISSVFPLSGQAGTRVGISGVRLFGGGSRIV 2502
Cdd:COG4625    82 GGGGGGGGTGGVGGGGGGGGGGGGGGGGGGGGGGGGSAGGGGGGAGGAGGGGGGGAGGGGGGGGGGGAGGGGGGGAGGAG 161
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2503 SVYLGATQAQVITQTVHAVVVTAKAGNVSASPEPIRIVADTGAVVTLNDTWSYVQAGRVASVNPASGHQGTLVTIQGTSL 2582
Cdd:COG4625   162 GGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGNGGGGGGGGGGGGGGGGGGGGAGGGGGGGGGGGGGGGGGGGGGGGGGGG 241
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2583 LGGGTTAVSVMLAGSSALVLSSNATDVVVTAGPGAQSSGDVVIVSETGATVARGAAWTYVEPGFIQRASPASGTAGTRVT 2662
Cdd:COG4625   242 GGGGGGAGGGGGGGGGNGGGGGAGGGGGGGGGGSGGGGGGGGGGGSGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG 321
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2663 ITGASLLGGASTLARVTLAGVPVDSIDHQSNEVVIVTAASGAQRMGAIVLTADTGAVVQRLNFWDYIATPVVGEIEPSSG 2742
Cdd:COG4625   322 GGGGGGGGGGGGAGGGGGSGGAGAGGGGAGGGGAGGGGGGGTGGGGGGGGGGGGGSGGGGAGGGGGSGGGGGGGAGGGGG 401
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2743 QLGTVVTIRGSNLLAGGEALQLVTLAGVPAEAILSSNNSVVTVSSAQGSGATGPAVLVAAETGGRAVGTPSVNYTYLAGS 2822
Cdd:COG4625   402 GGGAGGTGGGGAGGGGGAAGGGGGGTGAGGGGGGGGTGAGGGGATGGGGGGGGGAGGSGGGAGAGGGSGSGAGTLTLTGN 481
                         490       500       510       520       530       540
                  ....*....|....*....|....*....|....*....|....*....|....*....|..
gi 514698100 2823 SIASVQPASGQGGTFVDIVGERLLSGGSAVAAVSLAGVAAEVISGNDTFVRARAGPSAVTLT 2884
Cdd:COG4625   482 NTYTGTTTVNGGGNYTQSAGSTLAVEVDAANSDRLVVTGTATLNGGTVVVLAGGYAPGTTYT 543
TNFRSF11B_teleost cd13412
Tumor necrosis factor receptor superfamily 11B (TNFRSF11B) in teleost; also known as ...
5594-5727 2.74e-03

Tumor necrosis factor receptor superfamily 11B (TNFRSF11B) in teleost; also known as Osteoprotegerin (OPG); This subfamily of TNFRSF11B (also known as Osteoprotegerin, OPG, TR1, OCIF) is found in teleosts. It is a secreted glycoprotein that regulates bone resorption. It binds to two ligands, RANKL (receptor activator of nuclear factor kappaB ligand, also known as osteoprotegerin ligand, OPGL, TRANCE, TNF-related activation induced cytokine), a critical cytokine for osteoclast differentiation, and TRAIL (TNF-related apoptosis-inducing ligand), involved in immune surveillance. Therefore, acting as a decoy receptor for RANKL and TRAIL, OPG inhibits the regulatory effects of nuclear factor-kappaB on inflammation, skeletal, and vascular systems, and prevents TRAIL-induced apoptosis. Studies in mice counterparts suggest that this protein and its ligand also play a role in lymph-node organogenesis and vascular calcification. Circulating OPG levels have emerged as independent biomarkers of cardiovascular disease (CVD) in patients with acute or chronic heart disease. OPG has also been implicated in various inflammations and linked to diabetes and poor glycemic control. Alternatively spliced transcript variants of this gene have been reported, although their full length nature has not been determined. Genetic analysis of the Japanese rice fish medaka (Oryzias latipes) has shown that entire networks for bone formation are conserved between teleosts and mammals; enabling medaka to be used as a genetic model to monitor bone homeostasis in vivo.


Pssm-ID: 276917 [Multi-domain]  Cd Length: 129  Bit Score: 41.71  E-value: 2.74e-03
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5594 CEAcDGTTTYQ---PSKGQerCLSVKTCGAGEEETTSPSATRNRVCQPCQlgstfkaqSGQST-------RCISVTTCGA 5663
Cdd:cd13412     1 CGA-DAAPTYEhrdPSTGK--ILTCKKCPPGTHMAAHCTATTQTKCLPCP--------AAHYTelwnylpRCLYCNNFCS 69
                          90       100       110       120       130       140
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*..
gi 514698100 5664 GEEEIA---SPTlsTDRQCRtCASGTFKAaagqSTTCIAVSTCAAGFTEDVAPTPSSDRVCVECAPG 5727
Cdd:cd13412    70 ENQEVEiecSAT--NNRVCR-CKEGYYMD----SDFCIRHTECGPGYGVKTKGTTKQDTVCEKCPSG 129
IPT_plexin_repeat2 cd01179
Second repeat of the IPT domain of Plexins and Cell Surface Receptors (PCSR) . Plexins are ...
2732-2818 2.75e-03

Second repeat of the IPT domain of Plexins and Cell Surface Receptors (PCSR) . Plexins are involved in the regulation of cell proliferation and of cellular adhesion and repulsion receptors. In general, there are three copies of the IPT domain present preceeded by SEMA (semaphorin) and PSI (plexin, semaphorin, integrin) domains.


Pssm-ID: 238584  Cd Length: 85  Bit Score: 40.29  E-value: 2.75e-03
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2732 PVVGEIEPSSGQL--GTVVTIRGSNLLAGGEalQLVTLAGVPAEaILSSNNSVVT-VSSAQGSGATGP-AVLVaaetgGR 2807
Cdd:cd01179     1 PSITSLSPSYGPQsgGTRLTITGKHLNAGSS--VRVTVGGQPCK-ILSVSSSQIVcLTPPSASPGEAPvKVLI-----DG 72
                          90
                  ....*....|.
gi 514698100 2808 AVGTPSVNYTY 2818
Cdd:cd01179    73 ARRLAPLVFTY 83
IPT cd00102
Immunoglobulin-like fold, Plexins, Transcription factors (IPT). IPTs are also known as ...
1504-1567 2.76e-03

Immunoglobulin-like fold, Plexins, Transcription factors (IPT). IPTs are also known as Transcription factor ImmunoGlobin (TIG) domains. They are present in intracellular transcription factors, cell surface receptors (such as plexins and scatter factor receptors), as well as, cyclodextrin glycosyltransferase and similar enzymes. Although they are involved in DNA binding in transcription factors, their function in other proteins is unknown. In these transcription factors, IPTs form homo- or heterodimers with the exception of the nuclear factor of activated Tcells (NFAT) transcription factors which are mainly monomers.


Pssm-ID: 238050 [Multi-domain]  Cd Length: 89  Bit Score: 40.52  E-value: 2.76e-03
                          10        20        30        40        50        60
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*..
gi 514698100 1504 VTDVSPPSGQA--GTLVTITGTGFpcTGSSVSTVSLGG-VGASIRTQSATQIVVEAPSGSGQGDVVV 1567
Cdd:cd00102     3 ITSISPSSGPVsgGTEVTITGSNF--GSGSNLRVTFGGgVPCSVLSVSSTAIVCTTPPYANPGPGPV 67
TNFR_c6 pfam00020
TNFR/NGFR cysteine-rich region;
5724-5762 2.86e-03

TNFR/NGFR cysteine-rich region;


Pssm-ID: 459633 [Multi-domain]  Cd Length: 39  Bit Score: 38.83  E-value: 2.86e-03
                           10        20        30
                   ....*....|....*....|....*....|....*....
gi 514698100  5724 CAPGTFKATAGDGTCRAHRTCEDTEYETVAPTSSSDRKC 5762
Cdd:pfam00020    1 CPPGTYTDNWNGLKCLPCTVCPPGQVVVRPCTPTSDTVC 39
IPT cd00102
Immunoglobulin-like fold, Plexins, Transcription factors (IPT). IPTs are also known as ...
3087-3172 2.93e-03

Immunoglobulin-like fold, Plexins, Transcription factors (IPT). IPTs are also known as Transcription factor ImmunoGlobin (TIG) domains. They are present in intracellular transcription factors, cell surface receptors (such as plexins and scatter factor receptors), as well as, cyclodextrin glycosyltransferase and similar enzymes. Although they are involved in DNA binding in transcription factors, their function in other proteins is unknown. In these transcription factors, IPTs form homo- or heterodimers with the exception of the nuclear factor of activated Tcells (NFAT) transcription factors which are mainly monomers.


Pssm-ID: 238050 [Multi-domain]  Cd Length: 89  Bit Score: 40.52  E-value: 2.93e-03
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3087 EIVSVSPSSGQL--GTVVTIEGRSLrgGSSAVVDVVLGGVSALDVVSENDTRVVAVAGPS-SGATGTESVQVVGQQGSVV 3163
Cdd:cd00102     2 VITSISPSSGPVsgGTEVTITGSNF--GSGSNLRVTFGGGVPCSVLSVSSTAIVCTTPPYaNPGPGPVEVTVDRGNGGIT 79

                  ....*....
gi 514698100 3164 ARPSVWSYV 3172
Cdd:cd00102    80 SSPLTFTYV 88
TIG pfam01833
IPT/TIG domain; This family consists of a domain that has an immunoglobulin like fold. These ...
4407-4475 3.02e-03

IPT/TIG domain; This family consists of a domain that has an immunoglobulin like fold. These domains are found in cell surface receptors such as Met and Ron as well as in intracellular transcription factors where it is involved in DNA binding. CAUTION: This family does not currently recognize a significant number of members.


Pssm-ID: 460355 [Multi-domain]  Cd Length: 84  Bit Score: 40.51  E-value: 3.02e-03
                           10        20        30        40        50        60        70
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|.
gi 514698100  4407 TITDVQPGSGQV--GTRVTIRGTGLRcGGAAVTSVLLGSAVAPVVTEDDTTVIAEAPARAVGASPVDVTVV 4475
Cdd:pfam01833    2 VITSISPSSGPAsgGTTITITGSNFG-TDSSDLKVTIGGTPCTVISVSSTTIVCTTPPGTSGLVNVSVTVG 71
TNFRSF_viral cd15839
Tumor necrosis factor receptor superfamily members, virus-encoded; This family contains viral ...
5888-6030 3.09e-03

Tumor necrosis factor receptor superfamily members, virus-encoded; This family contains viral TNFR homologs that include vaccinia virus (VACV) cytokine response modifier E (CrmE), an encoded TNFR that shares significant sequence similarity with mammalian type 2 TNF receptors (TNFSFR1B, p75, TNFR type 2), a cowpox virus encoded cytokine-response modifier B (crmB), which is a secreted form of TNF receptor that can contribute to the modification of TNF-mediated antiviral processes, and a myxoma virus (MYXV) T2 (M-T2) protein that binds and inhibits rabbit TNF-alpha. The CrmE structure confirms that the canonical TNFR fold is adopted, but only one of the two "ligand-binding" loops of TNFRSF1A is conserved, suggesting a mechanism for the higher affinity of poxvirus TNFRs for TNFalpha over lymphotoxin-alpha. CrmB protein specifically binds TNF-alpha and TNF-beta indicating that cowpox virus seeks to invade antiviral processes mediated by TNF. Intracellular M-T2 blocks virus-induced lymphocyte apoptosis via a highly conserved viral preligand assembly domain (vPLAD), which controls receptor signaling competency prior to ligand binding.


Pssm-ID: 276935 [Multi-domain]  Cd Length: 125  Bit Score: 41.39  E-value: 3.09e-03
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5888 CQPGEYECTAATLttdreCCgvTQCVPGSEETSAPTATSDRECRQCVAGTTDADGSGTTPCVACsaghyvpRGRtggcaa 5967
Cdd:cd15839     1 CNGNDYNSNSNNL-----CC--KSCPPGTYASHLCDTTSNTKCDPCPSDTFTSIPNHIPACLSC-------RGR------ 60
                          90       100       110       120       130       140
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*..
gi 514698100 5968 feCAAGHVDQDEDAATACKLCEAGVNY----AGSAGLTRCTSVSECGAGeEETSAPTASTDRVCSTC 6030
Cdd:cd15839    61 --CSSNQVETKSCSNTQNRICSCAPGYycllKGSDGCVACAPKTKCGVG-YGVSGHTSTGDVICKKC 124
COG4625 COG4625
Uncharacterized conserved protein, contains a C-terminal beta-barrel porin domain [Function ...
1193-1703 3.44e-03

Uncharacterized conserved protein, contains a C-terminal beta-barrel porin domain [Function unknown];


Pssm-ID: 443664 [Multi-domain]  Cd Length: 900  Bit Score: 44.77  E-value: 3.44e-03
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1193 VAGSDPRVTAAGIEVSAPGGAAGVRNITVVANTGAYFTVARAFTVIAEPNVTAITPSSGQAGAYVTVSGTELLGGGAFAE 1272
Cdd:COG4625     1 GGGGGGGGGGGGGGGGTGGGGAGGGGGAGGGAGGGGAGGGGGGGGGGGGAGGGGGGGGTGGGGGGGGGGGGGGAGGGGGG 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1273 RVFLAGVEADVVTSSPSSVVVRAPVSVAKVGPTVIVADTGATTTSLLNFTFTPQLSVTSVSPSSGQGGTRVTVLGANLRL 1352
Cdd:COG4625    81 GGGGGGGGGTGGVGGGGGGGGGGGGGGGGGGGGGGGGSAGGGGGGAGGAGGGGGGGAGGGGGGGGGGGAGGGGGGGAGGA 160
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1353 GSSAVTGVLLGSAAcsliseNDTAVVCAAGVASAGSVPVTVEASSGAFASVGGVLAFEYLDAGVINSVEPGSGQQGTRVV 1432
Cdd:COG4625   161 GGGGGGGGGGGGGG------GGGGGGGGGGGGGGGGGGNGGGGGGGGGGGGGGGGGGGGAGGGGGGGGGGGGGGGGGGGG 234
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1433 VSGLRLLGGGIRVDQAFLGGVEATIRSSSAFAVTLAAGNGSEPSSGDIVLIADTGAVVSRSGMWTYTEPCGVTDVSPPSG 1512
Cdd:COG4625   235 GGGGGGGGGGGGGAGGGGGGGGGNGGGGGAGGGGGGGGGGSGGGGGGGGGGGSGGGGGGGGGGGGGGGGGGGGGGGGGGG 314
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1513 QAGTLVTITGTGFPCTGSSVSTVSLGGVGASIRTQSATQIVVEAPSGSGQGDVVVTADDGSFAVSRGGWEFSRISSVTPA 1592
Cdd:COG4625   315 GGGGGGGGGGGGGGGGGGGAGGGGGSGGAGAGGGGAGGGGAGGGGGGGTGGGGGGGGGGGGGSGGGGAGGGGGSGGGGGG 394
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1593 SGQFGTAVTVAGQGLRLGFSSVTQVRLGDVAATILSENNTHVVVRAGTGSLVGVPVDVQVISSGATTVQQSVAWTYLRDG 1672
Cdd:COG4625   395 GAGGGGGGGGAGGTGGGGAGGGGGAAGGGGGGTGAGGGGGGGGTGAGGGGATGGGGGGGGGAGGSGGGAGAGGGSGSGAG 474
                         490       500       510
                  ....*....|....*....|....*....|.
gi 514698100 1673 VVSSVVPVQGQRGTRVTVRGERLLGGGSRLE 1703
Cdd:COG4625   475 TLTLTGNNTYTGTTTVNGGGNYTQSAGSTLA 505
COG4625 COG4625
Uncharacterized conserved protein, contains a C-terminal beta-barrel porin domain [Function ...
4015-4571 3.58e-03

Uncharacterized conserved protein, contains a C-terminal beta-barrel porin domain [Function unknown];


Pssm-ID: 443664 [Multi-domain]  Cd Length: 900  Bit Score: 44.77  E-value: 3.58e-03
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4015 SDSEIVAVLRSGGAGGSGDVVVESDTGAVVRLAAGFRYVPQAQILHLTRASGQVGTETTIVGEGLQMGDVIVSVLLAGVP 4094
Cdd:COG4625     1 GGGGGGGGGGGGGGGGTGGGGAGGGGGAGGGAGGGGAGGGGGGGGGGGGAGGGGGGGGTGGGGGGGGGGGGGGAGGGGGG 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4095 AQVLSQSDVNVTVRANTSTPATGDVMLVAGSGAFVELVNGWTYDDAGAIEDVQPAQGFAGNLVTISGRGLRGGSAAVTRV 4174
Cdd:COG4625    81 GGGGGGGGGTGGVGGGGGGGGGGGGGGGGGGGGGGGGSAGGGGGGAGGAGGGGGGGAGGGGGGGGGGGAGGGGGGGAGGA 160
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4175 TLVGVLATEIVHENDTVVVVRAGLPVDPFVMQTGRVVVMGSSGATITALDAFTYNVAGDITDVSPSFGRVGTRVRLLGSN 4254
Cdd:COG4625   161 GGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGNGGGGGGGGGGGGGGGGGGGGAGGGGGGGGGGGGGGGGGGGGGGGGGG 240
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4255 LLGGGTSAEVRFGGVTGAVTAVSETAIDVTVPAASGPSGLVNVSIVSDSGSHVLEVAGFRYTAPGSVAAVAPSSGHEGTV 4334
Cdd:COG4625   241 GGGGGGGAGGGGGGGGGNGGGGGAGGGGGGGGGGSGGGGGGGGGGGSGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG 320
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4335 VTISGASLLAEEADAARVTLGGVNATVVFANDTRLVVVAGASSTAGLGDVFIETVGGARLLAANAWMYVAQATITDVQPG 4414
Cdd:COG4625   321 GGGGGGGGGGGGGAGGGGGSGGAGAGGGGAGGGGAGGGGGGGTGGGGGGGGGGGGGSGGGGAGGGGGSGGGGGGGAGGGG 400
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4415 SGQVGTRVTIRGTGLRCGGAAVTSVLLGSAVAPVVTEDDTTVIAEAPARAVGASPVDVTVVADTGAYVTADDAWTFVTAG 4494
Cdd:COG4625   401 GGGGAGGTGGGGAGGGGGAAGGGGGGTGAGGGGGGGGTGAGGGGATGGGGGGGGGAGGSGGGAGAGGGSGSGAGTLTLTG 480
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 4495 AVSSVVPSSGQEGTRVTLSGTNLL----------------------GSGSGVDQVLLAGVSATVVSAASsevvVITSALP 4552
Cdd:COG4625   481 NNTYTGTTTVNGGGNYTQSAGSTLavevdaansdrlvvtgtatlngGTVVVLAGGYAPGTTYTILAVAA----ALDALAG 556
                         570
                  ....*....|....*....
gi 514698100 4553 GGVVGPVTGNVTVVSTSGA 4571
Cdd:COG4625   557 NGDLSALYNALAALDAAAA 575
TNFR smart00208
Tumor necrosis factor receptor / nerve growth factor receptor repeats; Repeats in growth ...
6171-6213 4.08e-03

Tumor necrosis factor receptor / nerve growth factor receptor repeats; Repeats in growth factor receptors that are involved in growth factor binding. TNF/TNFR


Pssm-ID: 214558  Cd Length: 39  Bit Score: 38.60  E-value: 4.08e-03
                            10        20        30        40
                    ....*....|....*....|....*....|....*....|...
gi 514698100   6171 CADTEYESvaatDTSDRKCSSCRECTSSEYLVSGCSESANAVC 6213
Cdd:smart00208    1 CKEGTYCS----DGNHSSCLRCRRCPPGLVVKQPCTATSDTVC 39
TNFRSF_viral cd15839
Tumor necrosis factor receptor superfamily members, virus-encoded; This family contains viral ...
5988-6143 4.17e-03

Tumor necrosis factor receptor superfamily members, virus-encoded; This family contains viral TNFR homologs that include vaccinia virus (VACV) cytokine response modifier E (CrmE), an encoded TNFR that shares significant sequence similarity with mammalian type 2 TNF receptors (TNFSFR1B, p75, TNFR type 2), a cowpox virus encoded cytokine-response modifier B (crmB), which is a secreted form of TNF receptor that can contribute to the modification of TNF-mediated antiviral processes, and a myxoma virus (MYXV) T2 (M-T2) protein that binds and inhibits rabbit TNF-alpha. The CrmE structure confirms that the canonical TNFR fold is adopted, but only one of the two "ligand-binding" loops of TNFRSF1A is conserved, suggesting a mechanism for the higher affinity of poxvirus TNFRs for TNFalpha over lymphotoxin-alpha. CrmB protein specifically binds TNF-alpha and TNF-beta indicating that cowpox virus seeks to invade antiviral processes mediated by TNF. Intracellular M-T2 blocks virus-induced lymphocyte apoptosis via a highly conserved viral preligand assembly domain (vPLAD), which controls receptor signaling competency prior to ligand binding.


Pssm-ID: 276935 [Multi-domain]  Cd Length: 125  Bit Score: 41.01  E-value: 4.17e-03
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5988 CEAGVNYAGSAGLTrCTSvseCGAGEEETSAPTASTDRVCSTCASGKFKATTGQTPceavsTCeedeyvyraatvstdTQ 6067
Cdd:cd15839     1 CNGNDYNSNSNNLC-CKS---CPPGTYASHLCDTTSNTKCDPCPSDTFTSIPNHIP-----AC---------------LS 56
                          90       100       110       120       130       140       150
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*..
gi 514698100 6068 CRAltACSDEQYETRAPTVNSDRECtgltTCGSGEY-ETRAPTATtdRKCASVTQCDSTqFVVSKPTATTDRDCAEC 6143
Cdd:cd15839    57 CRG--RCSSNQVETKSCSNTQNRIC----SCAPGYYcLLKGSDGC--VACAPKTKCGVG-YGVSGHTSTGDVICKKC 124
COG4625 COG4625
Uncharacterized conserved protein, contains a C-terminal beta-barrel porin domain [Function ...
2613-3129 4.28e-03

Uncharacterized conserved protein, contains a C-terminal beta-barrel porin domain [Function unknown];


Pssm-ID: 443664 [Multi-domain]  Cd Length: 900  Bit Score: 44.38  E-value: 4.28e-03
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2613 AGPGAQSSGDVVIVSETGATVARGAAWTYVEPGFIQRASPASGTAGTRVTITGASLLGGASTLARVTLAGVPVDSIDHQS 2692
Cdd:COG4625     1 GGGGGGGGGGGGGGGGTGGGGAGGGGGAGGGAGGGGAGGGGGGGGGGGGAGGGGGGGGTGGGGGGGGGGGGGGAGGGGGG 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2693 NEVVIVTAASGAQRMGAIVLTADTGAVVQRLNFWDYIATPVVGEIEPSSGQLGTVVTIRGSNLLAGGEALQLVTLAGVPA 2772
Cdd:COG4625    81 GGGGGGGGGTGGVGGGGGGGGGGGGGGGGGGGGGGGGSAGGGGGGAGGAGGGGGGGAGGGGGGGGGGGAGGGGGGGAGGA 160
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2773 EAILSSNNSVVTVSSAQGSGATGPAVLVAAETGGRAVGTPSVNYTYLAGSSIASVQPASGQGGTFVDIVGERLLSGGSAV 2852
Cdd:COG4625   161 GGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGNGGGGGGGGGGGGGGGGGGGGAGGGGGGGGGGGGGGGGGGGGGGGGGG 240
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2853 AAVSLAGVAAEVISGNDTFVRARAGPSAVTLTGDVVVTADTGGRAELVNAWAYNTAGVVDAVVPGSGQRGTRVTIQGTRL 2932
Cdd:COG4625   241 GGGGGGGAGGGGGGGGGNGGGGGAGGGGGGGGGGSGGGGGGGGGGGSGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG 320
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2933 LGEGTRAVRVSLGDVRAHIVESTATAVVVVYPGRVTLGVHDVEVESDTGSVVSAPAAWTALDNGVVHSVNPDVGHGGTVV 3012
Cdd:COG4625   321 GGGGGGGGGGGGGAGGGGGSGGAGAGGGGAGGGGAGGGGGGGTGGGGGGGGGGGGGSGGGGAGGGGGSGGGGGGGAGGGG 400
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3013 TIRGVRLLGGGDSVADVALAGVVTANVVSANNSVVVVVAELQAQAVTLGDVVVRADTNATVVSSTGLFDYVAPGEIVSVS 3092
Cdd:COG4625   401 GGGGAGGTGGGGAGGGGGAAGGGGGGTGAGGGGGGGGTGAGGGGATGGGGGGGGGAGGSGGGAGAGGGSGSGAGTLTLTG 480
                         490       500       510
                  ....*....|....*....|....*....|....*...
gi 514698100 3093 PSSGQLGTVVTIEGR-SLRGGSSAVVDVVLGGVSALDV 3129
Cdd:COG4625   481 NNTYTGTTTVNGGGNyTQSAGSTLAVEVDAANSDRLVV 518
COG4625 COG4625
Uncharacterized conserved protein, contains a C-terminal beta-barrel porin domain [Function ...
3400-3860 4.58e-03

Uncharacterized conserved protein, contains a C-terminal beta-barrel porin domain [Function unknown];


Pssm-ID: 443664 [Multi-domain]  Cd Length: 900  Bit Score: 44.38  E-value: 4.58e-03
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3400 SDTLVVARLRSNGGASQLGDVVVRADNGARTRAVNGFTYLSTSMIAAVTPAEGQYGTRVTITGQRLLGGGAAVQAVELAG 3479
Cdd:COG4625    53 GGGGGGTGGGGGGGGGGGGGGAGGGGGGGGGGGGGGGTGGVGGGGGGGGGGGGGGGGGGGGGGGGSAGGGGGGAGGAGGG 132
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3480 VAATVVSGSDTEVVVAAGNGTAGDVGDVVITSDSGAVSVDALAWRYLDASHITSVTPRHGQKGTVVTINGTLLRGHGSGV 3559
Cdd:COG4625   133 GGGGAGGGGGGGGGGGAGGGGGGGAGGAGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGNGGGGGGGGGGGGGGGGGGG 212
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3560 AVVLLAGEAANVLSESDTSVVVAASAFGGSKSGPVTIIASNGATAVSTPTAFEYRAPGAVSAIVPNSGHRGTYVTIKGSN 3639
Cdd:COG4625   213 GAGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGAGGGGGGGGGNGGGGGAGGGGGGGGGGSGGGGGGGGGGGSGGGGG 292
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3640 LRGHGPTVMSVTLGGVAGHIVSENSSSVVVRVERLSVAVATPVDVVLTSRSGAQVAAAGAFTYLVEGSVADLLPAQGQRG 3719
Cdd:COG4625   293 GGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGAGGGGGSGGAGAGGGGAGGGGAGGGGGGGTGGGGGGGGG 372
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3720 TAVSLSGSNLCGGGTAIVAVTLGGVAASLKPTSTCNLVQFVAGSRNNTAAEAVDVVLESNTGALIEGTGRWTYVVEGAIS 3799
Cdd:COG4625   373 GGGGSGGGGAGGGGGSGGGGGGGAGGGGGGGGAGGTGGGGAGGGGGAAGGGGGGTGAGGGGGGGGTGAGGGGATGGGGGG 452
                         410       420       430       440       450       460
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*.
gi 514698100 3800 SVLPPGGVAGTLVTIRGSN-----LLGGGSTAAGVTLAGVSASVEQANATHVIVTANRGTTAGDVV 3860
Cdd:COG4625   453 GGGAGGSGGGAGAGGGSGSgagtlTLTGNNTYTGTTTVNGGGNYTQSAGSTLAVEVDAANSDRLVV 518
PHA02714 PHA02714
CD-30-like protein; Provisional
6193-6280 4.70e-03

CD-30-like protein; Provisional


Pssm-ID: 165087 [Multi-domain]  Cd Length: 110  Bit Score: 40.77  E-value: 4.70e-03
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6193 RECTSSEYLvsgcsESANAVCKACTECPSGTFVSTACTPLADAECtectRCGSGYfvqsPCTSEADTTCKRCRSCASGEY 6272
Cdd:PHA02714   22 KTCPKDYYL-----EPEDGLCTACVTCLSNMVEKQSCGPDKPRKC----QCGPGL----KCTVPAVNSCARCTPDTTTKK 88
                          90
                  ....*....|
gi 514698100 6273 LHT--ACTTP 6280
Cdd:PHA02714   89 IEPeqCCTTP 98
TNFR_c6 pfam00020
TNFR/NGFR cysteine-rich region;
6030-6068 4.82e-03

TNFR/NGFR cysteine-rich region;


Pssm-ID: 459633 [Multi-domain]  Cd Length: 39  Bit Score: 38.45  E-value: 4.82e-03
                           10        20        30
                   ....*....|....*....|....*....|....*....
gi 514698100  6030 CASGKFKATTGQTPCEAVSTCEEDEYVYRAATVSTDTQC 6068
Cdd:pfam00020    1 CPPGTYTDNWNGLKCLPCTVCPPGQVVVRPCTPTSDTVC 39
IPT_plexin_repeat2 cd01179
Second repeat of the IPT domain of Plexins and Cell Surface Receptors (PCSR) . Plexins are ...
104-183 5.25e-03

Second repeat of the IPT domain of Plexins and Cell Surface Receptors (PCSR) . Plexins are involved in the regulation of cell proliferation and of cellular adhesion and repulsion receptors. In general, there are three copies of the IPT domain present preceeded by SEMA (semaphorin) and PSI (plexin, semaphorin, integrin) domains.


Pssm-ID: 238584  Cd Length: 85  Bit Score: 39.51  E-value: 5.25e-03
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  104 VITAVRPAIGRV--GTLVTIEGERLQSGGSavARVDLGGVPATLLHGNDSTVVVICSAGSGAGAVRVTSDVGGFVEGLLW 181
Cdd:cd01179     2 SITSLSPSYGPQsgGTRLTITGKHLNAGSS--VRVTVGGQPCKILSVSSSQIVCLTPPSASPGEAPVKVLIDGARRLAPL 79

                  ..
gi 514698100  182 TF 183
Cdd:cd01179    80 VF 81
RhsA COG3209
Uncharacterized conserved protein RhaS, contains 28 RHS repeats [General function prediction ...
2708-3535 5.25e-03

Uncharacterized conserved protein RhaS, contains 28 RHS repeats [General function prediction only];


Pssm-ID: 442442 [Multi-domain]  Cd Length: 1103  Bit Score: 43.98  E-value: 5.25e-03
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2708 GAIVLTADTGAVVQRLNFWDYIATPVVGEIEPSSGQLGTVVTIRGSNLLAGGEALQLVTLAGVPAEAILSSNNSVVTVSS 2787
Cdd:COG3209     8 GGTTGASSTLLAATNAGGGTAVTNAGSTVLLAKGGLSTAAAAGGAATLTARSASTTDVVGTLTGAGGTSAGGVTALGDAS 87
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2788 AQGSGATGPAVLVAAETGGRAVGTPSVNYTYLAGSSIASVQPASGQGGTFVDIVGERLLSGGSAVAAVSLAGVAAEVISG 2867
Cdd:COG3209    88 AAGGGYVGGAAAGGGATLTGLAAATASAGRLVSTGAGAGGTVTAATGGTLGATAGSATTGSTDGGRGGVAVTGLAGGGAS 167
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2868 NDTFVRARAGPSAVTLTGDVVVTADTGGRAELVNAWAYNTAGVVDAVVPGSGQRGTRVTIQGTRLLGEGTRAVRVSLGDV 2947
Cdd:COG3209   168 AYGLTLGGAAAGPATGVGTGAVTLATGLAGSALLALGSGAILGGLAGAYSGSATTATGTALGTPASVAATVTGSATGAAG 247
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 2948 RAHIVESTATAVVVVYPGRVTLGVHDVEVESDTGSVVSAPAAWTALDNGVVHSVNPDVGHGGTVVTIRGVRLLGGGDSVA 3027
Cdd:COG3209   248 AGAAVATAATTLGGTTGAGTGASGAGLDASTGTGGAGGSNAAATAGGLGGAGLGSGGAGGGGTAGGTTTAAGTTGTAAVS 327
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3028 DVALAGVVTANVVSANNSVVVVVAELQAQAVTLGDVVVRADTNATVVSSTGLFDYVAPGEIVSVSPSSGQLGTVVTIEGR 3107
Cdd:COG3209   328 GAADAGTTTTTGTGTGGTTTTVGGGGSLTLGGYGAAGGLTTSVGAGGGGSTSGSTTTVGGGGTATGSGGGSSTTGVGAGT 407
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3108 SLRGGSSAVVDVVLGGVSALDVVSENDTRVVAVAGPSSGATGTESVQVVGQQGSVVARPSVWSYVAPAEVLDVAPQQGRA 3187
Cdd:COG3209   408 TTTSTTGGDGGPATAAGALTAGGTATGTGTGGGGTTAGTDATTTTGGAGASGTLTTTGGAATGATTGGGTEAGTGGGTLT 487
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3188 GTRVTVRGQGLLQGGGRIAQATVAGVTTARIVDSNDTTVVLEAEVAPAGVTPVGDVQLVSDTGARVNASVTWQYLAAAVI 3267
Cdd:COG3209   488 SGSAGATTLGTDTTLDDTLGGTTTTTAGARGLVVTTGTTLTLGTTTTATLSATDATGTGDTTTTGTVGTGTSTGTGGTGT 567
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3268 DSVQPTSGQEGVFVELRGQHLLGGGSAIVDASLAGVAVERVVQSNDTFVRVVAGAKNASVVGDVVARGDTGALLRVVNGW 3347
Cdd:COG3209   568 VTTTGDGTGGASTTTGTTGGTATTTTVTTTTTTSTAGTTTTTTSGYTRAGLTLTLGTGTASGLERATASTGSTTGGTTGT 647
                         650       660       670       680       690       700       710       720
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3348 QYAVPSVINSVVPASGQEGTLVTVSGVRLLGSLPGRITFVEVCGTEAEVVSESDTLVVARLRSNGGASQLGDVVVRADNG 3427
Cdd:COG3209   648 GVTTTGTTTTRATGTTGTGTGVTAGLTTLATGGTTVGGGTGTTSTATTGATTGGTETGTTVTTLAGGTTTRLGTTTTGGG 727
                         730       740       750       760       770       780       790       800
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 3428 ARTRAVNGFTYLSTSMIAAVTPAEGQYGTRVTITGQRLLGGGAAVQAVELAGVAATVVSGSD-----TEVVVAAGNGT-- 3500
Cdd:COG3209   728 GGTTTDGTGTGGTTGTLTTTSTTTTTTAGALTYTYDALGRLTSETTPGGVTQGTYTTRYTYDalgrlTSVTYPDGETVty 807
                         810       820       830
                  ....*....|....*....|....*....|....*....
gi 514698100 3501 ----AGDVGDVVITSDSGAVSVDALAWRYLDASHITSVT 3535
Cdd:COG3209   808 tydaLGRLTSVITVGSGGGTDLQDRTYTYDAAGNITSIT 846
IPT smart00429
ig-like, plexins, transcription factors;
1935-2014 5.55e-03

ig-like, plexins, transcription factors;


Pssm-ID: 214657 [Multi-domain]  Cd Length: 90  Bit Score: 39.71  E-value: 5.55e-03
                            10        20        30        40        50        60        70        80
                    ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100   1935 VIQSVDPQSGQV--GTRITIVGSGLLGGSAFaREVVMGNSVPCSVLRGNDSVVVCVLADAGSPAAAVDVTVVGARGSRVV 2012
Cdd:smart00429    3 VITRISPTSGPVsgGTEITLCGKNLKSISVV-FVEVGVGEAPCTFSPSSSTAIVCKTPPYHNIPGSVPVRTVGLRNGGVP 81

                    ..
gi 514698100   2013 AS 2014
Cdd:smart00429   82 SS 83
TNFRSF9_teleost cd13424
Tumor necrosis factor receptor superfamily member 9 (TNFRSF9) in teleosts; also known as CD137; ...
6019-6143 5.65e-03

Tumor necrosis factor receptor superfamily member 9 (TNFRSF9) in teleosts; also known as CD137; This subfamily of TNFRSF9 (also known as CD137, ILA, 4-1BB) is found in teleosts. CD137 plays a role in the immunobiology of human cancer where it is preferentially expressed on tumor-reactive subset of tumor-infiltrating lymphocytes. It can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. It transduces signals that lead to the activation of NF-kappaB, mediated by the TRAF adaptor proteins. CD137 contributes to the clonal expansion, survival, and development of T cells. It can also induce proliferation in peripheral monocytes, enhance T cell apoptosis induced by TCR/CD3 triggered activation, and regulate CD28 co-stimulation to promote Th1 cell responses. CD137 is modulated by SAHA treatment in breast cancer cells, suggesting that the combination of SAHA with this receptor could be a new therapeutic approach for the treatment of tumors. Mostly, CD137 in teleosts have not been characterized.


Pssm-ID: 276929 [Multi-domain]  Cd Length: 150  Bit Score: 41.35  E-value: 5.65e-03
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6019 PTASTDRVCSTCASGKFKAT-TGQTPCEAVSTCEEDEYVyraaTVSTDTQCRALTACSDEQYETRAPTVNSDREC---TG 6094
Cdd:cd13424     6 PSGKNYVCCESCHPGNRLVErCGPDPAELCKPCEPGTYT----VKPLDYSCYICTQCIGAQVLLKNCTPSSDTVCgckEG 81
                          90       100       110       120       130
                  ....*....|....*....|....*....|....*....|....*....|
gi 514698100 6095 LtTCGSGEyetraptattdrkCA-SVTQCDSTQfvvsKPTAttDRDCAEC 6143
Cdd:cd13424    82 L-RCGDAE-------------CSfCVTECGKGQ----EPLG--KRDCRQC 111
TNFRSF6 cd10579
Tumor necrosis factor receptor superfamily member 6 (TNFRSF6), also known as fas cell surface ...
5802-5906 5.70e-03

Tumor necrosis factor receptor superfamily member 6 (TNFRSF6), also known as fas cell surface death receptor (Fas); TNFRSF6 (also known as fas cell surface death receptor (FasR) or Fas, APT1, CD95, FAS1, APO-1, FASTM, ALPS1A) contains a death domain and plays a central role in the physiological regulation of programmed cell death. It has been implicated in the pathogenesis of various malignancies and diseases of the immune system. The receptor interactions with the Fas ligand (FasL), allowing the formation of a death-inducing signaling complex that includes Fas-associated death domain protein (FADD), caspase 8, and caspase 10; autoproteolytic processing of the caspases in the complex triggers a downstream caspase cascade, leading to apoptosis. This receptor has also been shown to activate NF-kappaB, MAPK3/ERK1, and MAPK8/JNK, and is involved in transducing the proliferating signals in normal diploid fibroblast and T cells. Of the several alternatively spliced transcript variants, some are candidates for nonsense-mediated mRNA decay (NMD). Isoforms lacking the transmembrane domain may negatively regulate the apoptosis mediated by the full length isoform.


Pssm-ID: 276905 [Multi-domain]  Cd Length: 129  Bit Score: 40.82  E-value: 5.70e-03
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5802 CTDTSPTKCVGCDEcaSDEYTLSSCTLSsqtQCRQCTTCgnDEYQ----TKACSVSQDTECatltTCSSTQFeveaPTAT 5877
Cdd:cd10579    36 TTNGGKPDCVPCTE--GKEYTDKKHYSD---KCRRCKIC--DEEHglevEKNCTRTQNTKC----RCKSNFF----CNSS 100
                          90       100       110
                  ....*....|....*....|....*....|
gi 514698100 5878 RDRRCKDLTACQPG-EYECTAatlTTDREC 5906
Cdd:cd10579   101 PCEHCDPCTTCEHGiIEECTP---TSNTKC 127
TIG pfam01833
IPT/TIG domain; This family consists of a domain that has an immunoglobulin like fold. These ...
4588-4668 5.77e-03

IPT/TIG domain; This family consists of a domain that has an immunoglobulin like fold. These domains are found in cell surface receptors such as Met and Ron as well as in intracellular transcription factors where it is involved in DNA binding. CAUTION: This family does not currently recognize a significant number of members.


Pssm-ID: 460355 [Multi-domain]  Cd Length: 84  Bit Score: 39.35  E-value: 5.77e-03
                           10        20        30        40        50        60        70        80
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  4588 VTGVSPLAGVQ--GTRVTVTGERlLGGGSSIAAVQVAGVETRVIESSNNTHVVLRASNGTGSGDIELIADTGAKTVANVT 4665
Cdd:pfam01833    3 ITSISPSSGPAsgGTTITITGSN-FGTDSSDLKVTIGGTPCTVISVSSTTIVCTTPPGTSGLVNVSVTVGGGGISSSPLT 81

                   ...
gi 514698100  4666 FSY 4668
Cdd:pfam01833   82 FTY 84
IPT_PCSR cd00603
IPT domain of Plexins and Cell Surface Receptors (PCSR) and related proteins . This subgroup ...
715-799 6.04e-03

IPT domain of Plexins and Cell Surface Receptors (PCSR) and related proteins . This subgroup contains IPT domains of plexins, receptors, like the plasminogen-related growth factor receptors, the hepatocyte growth factor-scatter factors, and the macrophage-stimulating receptors and of fibrocystin. Plexins are involved in the regulation of cell proliferation and of cellular adhesion and repulsion receptors. In general, there are three copies of the IPT_PCSR domain present preceeded by SEMA (semaphorin) and PSI (plexin, semaphorin, integrin) domains.


Pssm-ID: 238337 [Multi-domain]  Cd Length: 90  Bit Score: 39.75  E-value: 6.04e-03
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  715 VISSVAPTSG--QAGTVVTIRGNNLSMGGAVREVFLAGIPAVSVSlVNDSFVVAHASGALSGRSSPAVV---RNNFGAFV 789
Cdd:cd00603     2 VITSISPSSGplSGGTRLTITGSNLGSGSPRVRVTVGGVPCKVLN-VSSTEIVCRTPAAATPGEGPVEVtvdGANVSARV 80
                          90
                  ....*....|
gi 514698100  790 SSSVNWTYVP 799
Cdd:cd00603    81 LSNTTFTYVE 90
TNFRSF9_teleost cd13424
Tumor necrosis factor receptor superfamily member 9 (TNFRSF9) in teleosts; also known as CD137; ...
5922-6050 6.28e-03

Tumor necrosis factor receptor superfamily member 9 (TNFRSF9) in teleosts; also known as CD137; This subfamily of TNFRSF9 (also known as CD137, ILA, 4-1BB) is found in teleosts. CD137 plays a role in the immunobiology of human cancer where it is preferentially expressed on tumor-reactive subset of tumor-infiltrating lymphocytes. It can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. It transduces signals that lead to the activation of NF-kappaB, mediated by the TRAF adaptor proteins. CD137 contributes to the clonal expansion, survival, and development of T cells. It can also induce proliferation in peripheral monocytes, enhance T cell apoptosis induced by TCR/CD3 triggered activation, and regulate CD28 co-stimulation to promote Th1 cell responses. CD137 is modulated by SAHA treatment in breast cancer cells, suggesting that the combination of SAHA with this receptor could be a new therapeutic approach for the treatment of tumors. Mostly, CD137 in teleosts have not been characterized.


Pssm-ID: 276929 [Multi-domain]  Cd Length: 150  Bit Score: 41.35  E-value: 6.28e-03
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 5922 PTATSDRECRQCVAGTTDADGSGTTP---CVACSAGHYVPRGRTGGCA-AFECAAGHVDQDE---DAATACKlCEAGVNy 5994
Cdd:cd13424     6 PSGKNYVCCESCHPGNRLVERCGPDPaelCKPCEPGTYTVKPLDYSCYiCTQCIGAQVLLKNctpSSDTVCG-CKEGLR- 83
                          90       100       110       120       130
                  ....*....|....*....|....*....|....*....|....*....|....*.
gi 514698100 5995 AGSAGLTRCtsVSECGAGEEETSaptastDRVCSTCASGKFKATTGQTPCEAVSTC 6050
Cdd:cd13424    84 CGDAECSFC--VTECGKGQEPLG------KRDCRQCPVGTFNDQIHSKCKEWSTSC 131
TNFRSF9_teleost cd13424
Tumor necrosis factor receptor superfamily member 9 (TNFRSF9) in teleosts; also known as CD137; ...
5781-5848 6.46e-03

Tumor necrosis factor receptor superfamily member 9 (TNFRSF9) in teleosts; also known as CD137; This subfamily of TNFRSF9 (also known as CD137, ILA, 4-1BB) is found in teleosts. CD137 plays a role in the immunobiology of human cancer where it is preferentially expressed on tumor-reactive subset of tumor-infiltrating lymphocytes. It can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. It transduces signals that lead to the activation of NF-kappaB, mediated by the TRAF adaptor proteins. CD137 contributes to the clonal expansion, survival, and development of T cells. It can also induce proliferation in peripheral monocytes, enhance T cell apoptosis induced by TCR/CD3 triggered activation, and regulate CD28 co-stimulation to promote Th1 cell responses. CD137 is modulated by SAHA treatment in breast cancer cells, suggesting that the combination of SAHA with this receptor could be a new therapeutic approach for the treatment of tumors. Mostly, CD137 in teleosts have not been characterized.


Pssm-ID: 276929 [Multi-domain]  Cd Length: 150  Bit Score: 40.97  E-value: 6.46e-03
                          10        20        30        40        50        60        70
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....
gi 514698100 5781 TTDRECSPCGRCTDGLTLDKACTDTSPTKCvGCDE---CASDE--YTLSSCTLSSQ-TQCRQCTTCGNDEYQTK 5848
Cdd:cd13424    47 PLDYSCYICTQCIGAQVLLKNCTPSSDTVC-GCKEglrCGDAEcsFCVTECGKGQEpLGKRDCRQCPVGTFNDQ 119
TNFRSF4 cd13406
Tumor necrosis factor receptor superfamily member 4 (TNFRSF4), also known as CD134 or OXO40; ...
6008-6116 7.14e-03

Tumor necrosis factor receptor superfamily member 4 (TNFRSF4), also known as CD134 or OXO40; TNFRSF4 (also known as OX40, ACT35, CD134, IMD16, TXGP1L) activates NF-kappaB through its interaction with adaptor proteins TRAF2 and TRAF5. It also promotes the expression of apoptosis inhibitors BCL2 and BCL2lL1/BCL2-XL, and thus suppresses apoptosis. It is primarily expressed on activated CD4+ and CD8+ T cells, where it is transiently expressed and upregulated on the most recently antigen-activated T cells within inflammatory lesions. This makes it an attractive target to modulate immune responses, i.e. TNFRSF4 (OX40) blocking agents to inhibit adverse inflammation or agonists to enhance immune responses. An artificially created biologic fusion protein, OX40-immunoglobulin (OX40-Ig), prevents OX40 from reaching the T-cell receptors, thus reducing the T-cell response. Some single nucleotide polymorphisms (SNPs) of its natural ligand OX40 ligand (OX40L, CD252), which is also found on activated T cells, have been associated with systemic lupus erythematosus.


Pssm-ID: 276911 [Multi-domain]  Cd Length: 142  Bit Score: 40.84  E-value: 7.14e-03
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6008 ECGAGEEETSAPTASTDRVCSTCASGKFKATTGQTPCEAVSTCEEDE--YVYRAATVSTDT--QCRALTACSDEQYETR- 6082
Cdd:cd13406    17 ECPPGEGMESRCTGTQDTVCSPCEPGFYNEAVNYEPCKPCTQCNQRSgsEEKQKCTKTSDTvcRCRPGTQPLDSYKPGVd 96
                          90       100       110       120
                  ....*....|....*....|....*....|....*....|..
gi 514698100 6083 ----APTVNS---DRECTGLTTCGSGEYETRAP-TATTDRKC 6116
Cdd:cd13406    97 cvpcPPGHFSrgdNQACKPWTNCSLAGKRTLRPgSSTSDAVC 138
RhsA COG3209
Uncharacterized conserved protein RhaS, contains 28 RHS repeats [General function prediction ...
910-1691 7.17e-03

Uncharacterized conserved protein RhaS, contains 28 RHS repeats [General function prediction only];


Pssm-ID: 442442 [Multi-domain]  Cd Length: 1103  Bit Score: 43.59  E-value: 7.17e-03
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  910 GTQLLAHASNLRTVSLAGTQVLSIESATESEVIVRAGLGVNGTAGSPRLRASSGGVVAAATGVNFTYVRQGRIDTVSPLF 989
Cdd:COG3209     1 ETSLGLVGGTTGASSTLLAATNAGGGTAVTNAGSTVLLAKGGLSTAAAAGGAATLTARSASTTDVVGTLTGAGGTSAGGV 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  990 GQLGTLVTISGEHLLSGGSSASRVLLAGLPAAVVSSNSSVVVARAPLSNSTSIRTGSVVVLANTGALSAESSTTFTFRPA 1069
Cdd:COG3209    81 TALGDASAAGGGYVGGAAAGGGATLTGLAAATASAGRLVSTGAGAGGTVTAATGGTLGATAGSATTGSTDGGRGGVAVTG 160
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1070 GFIASVSPSFGQRGTYVEIAGNRLLDGSGLREVLLADVPAEVLSANDTFALVRAQASLPRVGDVVVRSDSGYEVVSSQAF 1149
Cdd:COG3209   161 LAGGGASAYGLTLGGAAAGPATGVGTGAVTLATGLAGSALLALGSGAILGGLAGAYSGSATTATGTALGTPASVAATVTG 240
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1150 VYIAPQHPDTVVPASGQFGTRVTINGTGLLGGGATVQTVQFDAVAGSDPRVTAAGIEVSAPGGAAGVRNITVVANTGAYF 1229
Cdd:COG3209   241 SATGAAGAGAAVATAATTLGGTTGAGTGASGAGLDASTGTGGAGGSNAAATAGGLGGAGLGSGGAGGGGTAGGTTTAAGT 320
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1230 TVARA---FTVIAEPNVTAITPSSGQAGAYVTVSGTELLGGGAFAERVFLAGVEADVVTSSPSSVVVRAPVSVAKVGPTV 1306
Cdd:COG3209   321 TGTAAvsgAADAGTTTTTGTGTGGTTTTVGGGGSLTLGGYGAAGGLTTSVGAGGGGSTSGSTTTVGGGGTATGSGGGSST 400
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1307 IVADTGATTTSLLNFTFTPQLSVTSVSPSSGQGGTRVTVLGANLRLGSSAVTGVLLGSAACSLISENDTAVVCAAGVASA 1386
Cdd:COG3209   401 TGVGAGTTTTSTTGGDGGPATAAGALTAGGTATGTGTGGGGTTAGTDATTTTGGAGASGTLTTTGGAATGATTGGGTEAG 480
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1387 GSVPVTVEASSGAFASVGGVLAFEYLDAGVINSVEPGSGQQGTRVVVSGLRLLGGGIRVDQAFLGGVEATIRSSSAFAVT 1466
Cdd:COG3209   481 TGGGTLTSGSAGATTLGTDTTLDDTLGGTTTTTAGARGLVVTTGTTLTLGTTTTATLSATDATGTGDTTTTGTVGTGTST 560
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1467 LAAGNGSEPSSGDIVLIADTGAVVSRSGMWTYTEPCGVTDVSPPSGQAGTLVTITGTGFPCTGSSVSTVSLGGVGASIRT 1546
Cdd:COG3209   561 GTGGTGTVTTTGDGTGGASTTTGTTGGTATTTTVTTTTTTSTAGTTTTTTSGYTRAGLTLTLGTGTASGLERATASTGST 640
                         650       660       670       680       690       700       710       720
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1547 QSATQIVVEAPSGSGQGDVVVTADDGSFAVSRGGWEFSRISSVTPASGQFGTAVTVAGQGLRLGFSSVTQVRLGDVAATI 1626
Cdd:COG3209   641 TGGTTGTGVTTTGTTTTRATGTTGTGTGVTAGLTTLATGGTTVGGGTGTTSTATTGATTGGTETGTTVTTLAGGTTTRLG 720
                         730       740       750       760       770       780
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*
gi 514698100 1627 LSENNTHVVVRAGTGSLVGVPVDVQVISSGATTVQQSVAWTYLRDGVVSSVVPVQGQRGTRVTVR 1691
Cdd:COG3209   721 TTTTGGGGGTTTDGTGTGGTTGTLTTTSTTTTTTAGALTYTYDALGRLTSETTPGGVTQGTYTTR 785
IPT_PCSR cd00603
IPT domain of Plexins and Cell Surface Receptors (PCSR) and related proteins . This subgroup ...
814-852 7.94e-03

IPT domain of Plexins and Cell Surface Receptors (PCSR) and related proteins . This subgroup contains IPT domains of plexins, receptors, like the plasminogen-related growth factor receptors, the hepatocyte growth factor-scatter factors, and the macrophage-stimulating receptors and of fibrocystin. Plexins are involved in the regulation of cell proliferation and of cellular adhesion and repulsion receptors. In general, there are three copies of the IPT_PCSR domain present preceeded by SEMA (semaphorin) and PSI (plexin, semaphorin, integrin) domains.


Pssm-ID: 238337 [Multi-domain]  Cd Length: 90  Bit Score: 39.36  E-value: 7.94e-03
                          10        20        30
                  ....*....|....*....|....*....|....*....
gi 514698100  814 GTRVTVTGSNLLQGGAIIAsASMAGVPCTVLSSNDTTVV 852
Cdd:cd00603    16 GTRLTITGSNLGSGSPRVR-VTVGGVPCKVLNVSSTEIV 53
TIG pfam01833
IPT/TIG domain; This family consists of a domain that has an immunoglobulin like fold. These ...
2732-2818 8.21e-03

IPT/TIG domain; This family consists of a domain that has an immunoglobulin like fold. These domains are found in cell surface receptors such as Met and Ron as well as in intracellular transcription factors where it is involved in DNA binding. CAUTION: This family does not currently recognize a significant number of members.


Pssm-ID: 460355 [Multi-domain]  Cd Length: 84  Bit Score: 38.97  E-value: 8.21e-03
                           10        20        30        40        50        60        70        80
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  2732 PVVGEIEPSSGQL--GTVVTIRGSNLLAGGEALQlVTLAGVPAEAILSSNNSVVTVSsaqGSGATGPaVLVAAETGGRAV 2809
Cdd:pfam01833    1 PVITSISPSSGPAsgGTTITITGSNFGTDSSDLK-VTIGGTPCTVISVSSTTIVCTT---PPGTSGL-VNVSVTVGGGGI 75

                   ....*....
gi 514698100  2810 GTPSVNYTY 2818
Cdd:pfam01833   76 SSSPLTFTY 84
AidA COG3468
Autotransporter adhesin AidA [Cell wall/membrane/envelope biogenesis, Intracellular ...
373-735 8.55e-03

Autotransporter adhesin AidA [Cell wall/membrane/envelope biogenesis, Intracellular trafficking, secretion, and vesicular transport];


Pssm-ID: 442691 [Multi-domain]  Cd Length: 846  Bit Score: 43.40  E-value: 8.55e-03
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  373 AGTVVELTGFNLLGGGSALSSLSVHGVEVEQVTFASDALIAFVVPLTSVQGLGDVRIVSASGATVEAGDAFTLLEPGRIV 452
Cdd:COG3468    69 GAGSGGGLAGAGSGGTGGNSTGGGGGNSGTGGTGGGGGGGGSGNGGGGGGGGGGGGTGGGGGGGTGSAGGGGGGGGGGTG 148
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  453 GVAPERGQEGTFVTIVGeRLLGGGETIARAVLGATAAEAVVSSSDARVVVRAGAAVTFGPVGVTLWADTGAVVNTSAGLF 532
Cdd:COG3468   149 VGGTGAAAAGGGTGSGG-GGSGGGGGAGGGGGGGAGGSGGAGSTGSGAGGGGGGSGGGGGAAGTGGGGGGGGGAGGATGG 227
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  533 EYLAPGMVASVLPVSGQAGTQVVIEGmeLLGHETALEAVTLGGVQAAAILSFNRTHVVVTAGDGPASTGPVVLTASNGSR 612
Cdd:COG3468   228 AGSGGNTGGGVGGGGGSAGGTGGGGL--TGGGAAGTGGGGGGTGTGSGGGGGGGANGGGSGGGGGASGTGGGGTASTGGG 305
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  613 VTGGAVWTQLERGAIGSVQPSSGHGGTRVTITGQRLLGGGAALASVELGGVLATEIAWANDTVAVVSAGASGSALAGGNV 692
Cdd:COG3468   306 GGGGGGNGGGGGGGSNAGGGSGGGGGGGGGGGGGGTTLNGAGSAGGGTGAALAGTGGSGSGGGGGGGSGGGGGAGGGGAN 385
                         330       340       350       360
                  ....*....|....*....|....*....|....*....|...
gi 514698100  693 TLVADTGAVTTGSGLWAYVAPAVISSVAPTSGQAGTVVTIRGN 735
Cdd:COG3468   386 TGSDGVGTGLTTGGTGNNGGGGVGGGGGGGLTLTGGTLTVNGN 428
TIG pfam01833
IPT/TIG domain; This family consists of a domain that has an immunoglobulin like fold. These ...
4143-4228 8.88e-03

IPT/TIG domain; This family consists of a domain that has an immunoglobulin like fold. These domains are found in cell surface receptors such as Met and Ron as well as in intracellular transcription factors where it is involved in DNA binding. CAUTION: This family does not currently recognize a significant number of members.


Pssm-ID: 460355 [Multi-domain]  Cd Length: 84  Bit Score: 38.97  E-value: 8.88e-03
                           10        20        30        40        50        60        70        80
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  4143 IEDVQPAQGFA--GNLVTISGRGLrGGSAAVTRVTLVGVLATEIVHENDTVVVVraglpVDPFVMQTGRVVVMGSSGATI 4220
Cdd:pfam01833    3 ITSISPSSGPAsgGTTITITGSNF-GTDSSDLKVTIGGTPCTVISVSSTTIVCT-----TPPGTSGLVNVSVTVGGGGIS 76

                   ....*...
gi 514698100  4221 TALDAFTY 4228
Cdd:pfam01833   77 SSPLTFTY 84
TNFRSF27 cd15838
Tumor necrosis factor receptor superfamily member 27 (TNFRSF27), also known as ectodysplasin ...
6171-6264 9.29e-03

Tumor necrosis factor receptor superfamily member 27 (TNFRSF27), also known as ectodysplasin A2 receptor (EDA2R) or X-linked ectodermal dysplasia receptor (XEDAR); TNFRSF27 (also known as ectodysplasin A2 receptor (EDA2R), X-linked ectodermal dysplasia receptor (XEDAR), EDAA2R, EDA-A2R) has two isoforms, EDA-A1 and EDA-A2, that are encoded by the anhidrotic ectodermal dysplasia (EDA) gene. It is highly expressed during embryonic development and binds to ectodysplasin-A2 (EDA-A2), playing a crucial role in the p53-signaling pathway. EDA2R is a direct p53 target that is frequently down-regulated in colorectal cancer tissues due to its epigenetic alterations or through the p53 gene mutations. Mutations in the EDA-A2/XEDAR signaling give rise to ectodermal dysplasia, characterized by loss of hair, sweat glands, and teeth. A non-synonymous SNP on EDA2R, along with genetic variants in human androgen receptor is associated with androgenetic alopecia (AGA).


Pssm-ID: 276934  Cd Length: 116  Bit Score: 39.88  E-value: 9.29e-03
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 6171 CADTEYEsvaatdTSDRKCSSCRECTSSEYLVSGC--SESANAvckACTECPSGTFVSTactpLADAECTECTRCGSGYF 6248
Cdd:cd15838     1 CQEKEYL------DEHGKCVPCRECGPGQELSKDCgyGEGGDA---YCTACPPRRFKDS----WGHHGCKTCLSCALINR 67
                          90
                  ....*....|....*..
gi 514698100 6249 VQ-SPCTSEADTTCKRC 6264
Cdd:cd15838    68 VQkSNCTATSNAVCGDC 84
COG4625 COG4625
Uncharacterized conserved protein, contains a C-terminal beta-barrel porin domain [Function ...
343-911 9.61e-03

Uncharacterized conserved protein, contains a C-terminal beta-barrel porin domain [Function unknown];


Pssm-ID: 443664 [Multi-domain]  Cd Length: 900  Bit Score: 43.23  E-value: 9.61e-03
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  343 SDTGAFARLESAFAYQIPGRISTLSPSSGQAGTVVELTGFNLLGGGSALSSLSVHGVEVEQVTFASDALIAFVVPLTSVQ 422
Cdd:COG4625    20 GGAGGGGGAGGGAGGGGAGGGGGGGGGGGGAGGGGGGGGTGGGGGGGGGGGGGGAGGGGGGGGGGGGGGGTGGVGGGGGG 99
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  423 GLGDVRIVSASGATVEAGDAFTLLEPGRIVGVAPERGQEGTFVTIVGERLLGGGETIARAVLGATAAEAVVSSSDARVVV 502
Cdd:COG4625   100 GGGGGGGGGGGGGGGGGGSAGGGGGGAGGAGGGGGGGAGGGGGGGGGGGAGGGGGGGAGGAGGGGGGGGGGGGGGGGGGG 179
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  503 RAGAAVTFGPVGVTLWADTGAVVNTSAGLFEYLAPGMVASVLPVSGQAGTQVVIEGMELLGHETALEAVTLGGVQAAAIL 582
Cdd:COG4625   180 GGGGGGGGGGGGGNGGGGGGGGGGGGGGGGGGGGAGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGAGGGGGGGGGNG 259
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  583 SFNRTHVVVTAGDGPASTGPVVLTASNGSRVTGGAVWTQLERGAIGSVQPSSGHGGTRVTITGqrllGGGAALASVELGG 662
Cdd:COG4625   260 GGGGAGGGGGGGGGGSGGGGGGGGGGGSGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG----GGGGGGGGGGGAG 335
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  663 VLATEIAWANDTVAVVSAGASGSALAGGNVTLVADTGAVTTGSGLWAYVAPAVISSVAPTSGQAGTVVTIRGNNLSMGGA 742
Cdd:COG4625   336 GGGGSGGAGAGGGGAGGGGAGGGGGGGTGGGGGGGGGGGGGSGGGGAGGGGGSGGGGGGGAGGGGGGGGAGGTGGGGAGG 415
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  743 VREVFLAGIPAVSVSLVNDSFVVAHASGALSGRSSPAVVRNNFGAFVSSSVNWTYVPAGAVDITrparaqfgTRVTVTGS 822
Cdd:COG4625   416 GGGAAGGGGGGTGAGGGGGGGGTGAGGGGATGGGGGGGGGAGGSGGGAGAGGGSGSGAGTLTLT--------GNNTYTGT 487
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100  823 NLLQGGAIIASASMAGVPCTVLSSNDTTVVVSVAGNFAATvaspsmTLVSDSGAVITFTSSTTAEPSGVVTAISPSSGQY 902
Cdd:COG4625   488 TTVNGGGNYTQSAGSTLAVEVDAANSDRLVVTGTATLNGG------TVVVLAGGYAPGTTYTILAVAAALDALAGNGDLS 561

                  ....*....
gi 514698100  903 GTFVTLSGT 911
Cdd:COG4625   562 ALYNALAAL 570
IPT cd00102
Immunoglobulin-like fold, Plexins, Transcription factors (IPT). IPTs are also known as ...
1585-1669 9.65e-03

Immunoglobulin-like fold, Plexins, Transcription factors (IPT). IPTs are also known as Transcription factor ImmunoGlobin (TIG) domains. They are present in intracellular transcription factors, cell surface receptors (such as plexins and scatter factor receptors), as well as, cyclodextrin glycosyltransferase and similar enzymes. Although they are involved in DNA binding in transcription factors, their function in other proteins is unknown. In these transcription factors, IPTs form homo- or heterodimers with the exception of the nuclear factor of activated Tcells (NFAT) transcription factors which are mainly monomers.


Pssm-ID: 238050 [Multi-domain]  Cd Length: 89  Bit Score: 38.98  E-value: 9.65e-03
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 514698100 1585 RISSVTPASG--QFGTAVTVAGQGlrLGFSSVTQVRL-GDVAATILSENNTHVVVRAGTGSLVG-VPVDVQVISSGATTV 1660
Cdd:cd00102     2 VITSISPSSGpvSGGTEVTITGSN--FGSGSNLRVTFgGGVPCSVLSVSSTAIVCTTPPYANPGpGPVEVTVDRGNGGIT 79

                  ....*....
gi 514698100 1661 QQSVAWTYL 1669
Cdd:cd00102    80 SSPLTFTYV 88
TNFRSF cd00185
Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) ...
7982-8046 9.71e-03

Tumor necrosis factor receptor superfamily (TNFRSF); Members of TNFR superfamily (TNFRSF) interactions with TNF superfamily (TNFSF) ligands (TNFL) control key cellular processes such as differentiation, proliferation, apoptosis, and cell growth. Dysregulation of these pathways has been shown to result in a wide range of pathological conditions, including autoimmune diseases, inflammation, cancer, and viral infection. There are 29 very diverse family members of TNFRSF reported in humans: 22 are type I transmembrane receptors (single pass with the N terminus on extracellular side of the cell membrane) and have a clear signal peptide; the remaining 7 members are either type III transmembrane receptors (single pass with the N terminus on extracellular side of the membrane but no signal sequence; TNFR13B, TNFR13C, TNFR17, and XEDAR), or attached to the membrane via a glycosylphosphatidylinositol (GPI) linker (TNFR10C), or secreted as soluble receptors (TNFR11B and TNFR6B). All TNFRs contain relatively short cysteine-rich domains (CRDs) in the ectodomain, and are involved in interaction with the TNF homology domain (THD) of their ligands. TNFRs often have multiple CRDs (between one and six), with the most frequent configurations of three or four copies; most CRDs possess three disulfide bridges, but could have between one and four. Localized or genome-wide duplication and evolution of the TNFRSF members appear to have paralleled the emergence of the adaptive immune system; teleosts (i.e. ray-finned, bony fish), which possess an immune system with B and T cells, possess primary and secondary lymphoid organs, and are capable of adaptive responses to pathogens also display several characteristics that are different from the mammalian immune system, making teleost TNFSF orthologs and paralogs of interest to better understand immune system evolution and the immunological pathways elicited to pathogens.


Pssm-ID: 276900 [Multi-domain]  Cd Length: 87  Bit Score: 39.11  E-value: 9.71e-03
                          10        20        30        40        50        60
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*
gi 514698100 7982 EYMVAPETPTSNRVCETltvCrPSSKYettAATPTSDRVCTPLTRCHPTQEFVSVNATATTDRVC 8046
Cdd:cd00185     9 EYLSSDCTATTDTVCSP---C-PPGTY---SESWNSLSKCLPCTTCGGGNQVEKTPCTATDNRCC 66
 
Blast search parameters
Data Source: Precalculated data, version = cdd.v.3.21
Preset Options:Database: CDSEARCH/cdd   Low complexity filter: no  Composition Based Adjustment: yes   E-value threshold: 0.01

References:

  • Wang J et al. (2023), "The conserved domain database in 2023", Nucleic Acids Res.51(D)384-8.
  • Lu S et al. (2020), "The conserved domain database in 2020", Nucleic Acids Res.48(D)265-8.
  • Marchler-Bauer A et al. (2017), "CDD/SPARCLE: functional classification of proteins via subfamily domain architectures.", Nucleic Acids Res.45(D)200-3.
Help | Disclaimer | Write to the Help Desk
NCBI | NLM | NIH